<!DOCTYPE html>
 <!--[if lt IE 7]> <html dir="ltr" lang="en-US" class="aui ltr no-js lt-ie9 lt-ie8 lt-ie7"> <![endif]--> <!--[if IE 7]> <html dir="ltr" lang="en-US" class="aui ltr no-js lt-ie9 lt-ie8"> <![endif]--> <!--[if IE 8]> <html dir="ltr" lang="en-US" class="aui ltr no-js lt-ie9"> <![endif]--> <!--[if gt IE 8]><!--> <html class="aui ltr" dir="ltr" lang="en-US" prefix="og: http://ogp.me/ns#"> <!--<![endif]--> <head> <title>Maintenance agonist treatments for opiate‐dependent pregnant women - Minozzi, S - 2020 | Cochrane Library</title> <meta content="Maintenance agonist treatments for opiate‐dependent pregnant women - Minozzi, S - 2020 | Cochrane Library" property="og:title"/> <meta content="https://www.cochranelibrary.com/cdsr/doi/10.1002/14651858.CD006318.pub4/full" property="og:url"/> <meta content="article" property="og:type"/> <meta content="https://www.cochranelibrary.com/cochrane-theme/images/cochrane_circulargraphic.png" property="og:image"/> <meta content="summary_large_image" name="twitter:card"/> <meta content="Maintenance agonist treatments for opiate‐dependent pregnant women - Minozzi, S - 2020 | Cochrane Library" name="twitter:title"/> <meta content="https://www.cochranelibrary.com/cdsr/doi/10.1002/14651858.CD006318.pub4/full" name="twitter:url"/> <meta content="https://www.cochranelibrary.com/cochrane-theme/images/cochrane_circulargraphic.png" name="twitter:image"/> <meta content="initial-scale=1.0, width=device-width" name="viewport"/> <meta content="10.1002/14651858.CD006318.pub4" name="dc.identifier" scheme="DOI"/> <meta content="Maintenance agonist treatments for opiate‐dependent pregnant women" name="citation_title"/> <meta content="Silvia Minozzi" name="citation_author"/> <meta content="Lazio Regional Health Service" name="citation_author_institution"/> <meta content="minozzi.silvia@gmail.com" name="citation_author_email"/> <meta content="Laura Amato" name="citation_author"/> <meta content="Lazio Regional Health Service" name="citation_author_institution"/> <meta content="Shayesteh Jahanfar" name="citation_author"/> <meta content="Cristina Bellisario" name="citation_author"/> <meta content="AO Città della Salute e della Scienza di Torino Via San Francesco da Paola 31" name="citation_author_institution"/> <meta content="Marica Ferri" name="citation_author"/> <meta content="European Monitoring Centre for Drugs and Drug Addiction" name="citation_author_institution"/> <meta content="Marina Davoli" name="citation_author"/> <meta content="Lazio Regional Health Service" name="citation_author_institution"/> <meta content="Cochrane Database of Systematic Reviews" name="citation_journal_title"/> <meta content="John Wiley &amp; Sons, Ltd" name="citation_publisher"/> <meta content="11" name="citation_issue"/> <meta content="10.1002/14651858.CD006318.pub4" name="citation_doi"/> <meta content="2020" name="citation_date"/> <meta content="2020/11/09" name="citation_online_date"/> <meta content="https://www.cochranelibrary.com/cdsr/doi/10.1002/14651858.CD006318.pub4/abstract" name="citation_abstract_html_url"/> <meta content="https://www.cochranelibrary.com/cdsr/doi/10.1002/14651858.CD006318.pub4/full" name="citation_fulltext_html_url"/> <meta content="https://www.cochranelibrary.com/cdsr/doi/10.1002/14651858.CD006318.pub4/pdf/full" name="citation_pdf_url"/> <meta content="1465-1858" name="citation_issn"/> <meta content="en" name="citation_language"/> <meta content="Birth Weight [drug effects]; Buprenorphine [adverse effects, therapeutic use]; Delayed-Action Preparations [adverse effects, therapeutic use]; Methadone [adverse effects, therapeutic use]; Morphine [adverse effects, therapeutic use]; Narcotics [adverse effects, agonists, *therapeutic use]; *Opiate Substitution Treatment; Opioid-Related Disorders [*rehabilitation]; Patient Dropouts [statistics &amp; numerical data]; Pregnancy Complications [*rehabilitation]; Randomized Controlled Trials as Topic" name="citation_keywords"/> <link href="https://fonts.googleapis.com/css?family=Source+Sans+Pro:400,700,600,900" rel="stylesheet"/> <script src="https://cmp.osano.com/AzZdRbSORDOOzF9W/d594efc1-9663-477d-9528-6576640e64fd/osano.js"></script> <style> .osano-cm-widget{display: none;} </style> <script src="https://static.addtoany.com/menu/page.js"></script> <script async="" charset="utf-8" src="https://platform.twitter.com/widgets.js"></script> <script async="async" src="//script.crazyegg.com/pages/scripts/0056/6375.js" type="text/javascript"></script> <script type="text/javascript">window.dataLayer={};var xtend=function(){var a={};var b=false;var c=0;var d=arguments.length;if(Object.prototype.toString.call(arguments[0])==="[object Boolean]"){b=arguments[0];c++}var f=function(g){for(var h in g){if(Object.prototype.hasOwnProperty.call(g,h)){if(b&&Object.prototype.toString.call(g[h])==="[object Object]"){a[h]=xtend(true,a[h],g[h])}else{a[h]=g[h]}}}};for(;c<d;c++){var e=arguments[c];f(e)}return a};</script> <!-- Global site tag (gtag.js) - Google Analytics --> <script src="https://www.googletagmanager.com/gtag/js?id=UA-189672-63&amp;l=gDataLayer"></script> <script>window.gDataLayer=window.gDataLayer||[];function gtag(){gDataLayer.push(arguments)}gtag("js",new Date());gtag("config","UA-189672-63");</script> <script type="text/javascript">var o={auth:{customerIds:[],individualId:null,brandedCustomer:null,roles:["Guest"]}};window.dataLayer=xtend(true,window.dataLayer,o);</script> <script type="text/javascript">var o={page:{siteSection:"Content",languageCode:"en",cms:{pageTitle:"Content"}}};window.dataLayer=xtend(true,window.dataLayer,o);</script> <meta content="text/html; charset=utf-8" http-equiv="content-type"/> <link href="https://www.cochranelibrary.com/cochrane-theme/images/favicon.ico" rel="Shortcut Icon"/> <link href="https://www.cochranelibrary.com/web/cochrane/content?templateType=full&amp;urlTitle=/cdsr/doi/10.1002/14651858.CD006318.pub4&amp;doi=10.1002/14651858.CD006318.pub4&amp;type=cdsr&amp;contentLanguage=" rel="canonical"/> <link href="https://www.cochranelibrary.com/zh/web/cochrane/content?templateType=full&amp;urlTitle=/cdsr/doi/10.1002/14651858.CD006318.pub4&amp;doi=10.1002/14651858.CD006318.pub4&amp;type=cdsr&amp;contentLanguage=" hreflang="zh-HANS" rel="alternate"/> <link href="https://www.cochranelibrary.com/zh_HANT/web/cochrane/content?templateType=full&amp;urlTitle=/cdsr/doi/10.1002/14651858.CD006318.pub4&amp;doi=10.1002/14651858.CD006318.pub4&amp;type=cdsr&amp;contentLanguage=" hreflang="zh-HANT" rel="alternate"/> <link href="https://www.cochranelibrary.com/hr/web/cochrane/content?templateType=full&amp;urlTitle=/cdsr/doi/10.1002/14651858.CD006318.pub4&amp;doi=10.1002/14651858.CD006318.pub4&amp;type=cdsr&amp;contentLanguage=" hreflang="hr-HR" rel="alternate"/> <link href="https://www.cochranelibrary.com/nl/web/cochrane/content?templateType=full&amp;urlTitle=/cdsr/doi/10.1002/14651858.CD006318.pub4&amp;doi=10.1002/14651858.CD006318.pub4&amp;type=cdsr&amp;contentLanguage=" hreflang="nl-NL" rel="alternate"/> <link href="https://www.cochranelibrary.com/web/cochrane/content?templateType=full&amp;urlTitle=/cdsr/doi/10.1002/14651858.CD006318.pub4&amp;doi=10.1002/14651858.CD006318.pub4&amp;type=cdsr&amp;contentLanguage=" hreflang="x-default" rel="alternate"/> <link href="https://www.cochranelibrary.com/web/cochrane/content?templateType=full&amp;urlTitle=/cdsr/doi/10.1002/14651858.CD006318.pub4&amp;doi=10.1002/14651858.CD006318.pub4&amp;type=cdsr&amp;contentLanguage=" hreflang="en-US" rel="alternate"/> <link href="https://www.cochranelibrary.com/fr/web/cochrane/content?templateType=full&amp;urlTitle=/cdsr/doi/10.1002/14651858.CD006318.pub4&amp;doi=10.1002/14651858.CD006318.pub4&amp;type=cdsr&amp;contentLanguage=" hreflang="fr-FR" rel="alternate"/> <link href="https://www.cochranelibrary.com/de/web/cochrane/content?templateType=full&amp;urlTitle=/cdsr/doi/10.1002/14651858.CD006318.pub4&amp;doi=10.1002/14651858.CD006318.pub4&amp;type=cdsr&amp;contentLanguage=" hreflang="de-DE" rel="alternate"/> <link href="https://www.cochranelibrary.com/hi/web/cochrane/content?templateType=full&amp;urlTitle=/cdsr/doi/10.1002/14651858.CD006318.pub4&amp;doi=10.1002/14651858.CD006318.pub4&amp;type=cdsr&amp;contentLanguage=" hreflang="hi-HI" rel="alternate"/> <link href="https://www.cochranelibrary.com/hu/web/cochrane/content?templateType=full&amp;urlTitle=/cdsr/doi/10.1002/14651858.CD006318.pub4&amp;doi=10.1002/14651858.CD006318.pub4&amp;type=cdsr&amp;contentLanguage=" hreflang="hu-HU" rel="alternate"/> <link href="https://www.cochranelibrary.com/in/web/cochrane/content?templateType=full&amp;urlTitle=/cdsr/doi/10.1002/14651858.CD006318.pub4&amp;doi=10.1002/14651858.CD006318.pub4&amp;type=cdsr&amp;contentLanguage=" hreflang="in-ID" rel="alternate"/> <link href="https://www.cochranelibrary.com/ja/web/cochrane/content?templateType=full&amp;urlTitle=/cdsr/doi/10.1002/14651858.CD006318.pub4&amp;doi=10.1002/14651858.CD006318.pub4&amp;type=cdsr&amp;contentLanguage=" hreflang="ja-JP" rel="alternate"/> <link href="https://www.cochranelibrary.com/ko/web/cochrane/content?templateType=full&amp;urlTitle=/cdsr/doi/10.1002/14651858.CD006318.pub4&amp;doi=10.1002/14651858.CD006318.pub4&amp;type=cdsr&amp;contentLanguage=" hreflang="ko-KR" rel="alternate"/> <link href="https://www.cochranelibrary.com/ms/web/cochrane/content?templateType=full&amp;urlTitle=/cdsr/doi/10.1002/14651858.CD006318.pub4&amp;doi=10.1002/14651858.CD006318.pub4&amp;type=cdsr&amp;contentLanguage=" hreflang="ms-MY" rel="alternate"/> <link href="https://www.cochranelibrary.com/fa/web/cochrane/content?templateType=full&amp;urlTitle=/cdsr/doi/10.1002/14651858.CD006318.pub4&amp;doi=10.1002/14651858.CD006318.pub4&amp;type=cdsr&amp;contentLanguage=" hreflang="fa-IR" rel="alternate"/> <link href="https://www.cochranelibrary.com/pl/web/cochrane/content?templateType=full&amp;urlTitle=/cdsr/doi/10.1002/14651858.CD006318.pub4&amp;doi=10.1002/14651858.CD006318.pub4&amp;type=cdsr&amp;contentLanguage=" hreflang="pl-PL" rel="alternate"/> <link href="https://www.cochranelibrary.com/pt/web/cochrane/content?templateType=full&amp;urlTitle=/cdsr/doi/10.1002/14651858.CD006318.pub4&amp;doi=10.1002/14651858.CD006318.pub4&amp;type=cdsr&amp;contentLanguage=" hreflang="pt-PT" rel="alternate"/> <link href="https://www.cochranelibrary.com/ro/web/cochrane/content?templateType=full&amp;urlTitle=/cdsr/doi/10.1002/14651858.CD006318.pub4&amp;doi=10.1002/14651858.CD006318.pub4&amp;type=cdsr&amp;contentLanguage=" hreflang="ro-RO" rel="alternate"/> <link href="https://www.cochranelibrary.com/ru/web/cochrane/content?templateType=full&amp;urlTitle=/cdsr/doi/10.1002/14651858.CD006318.pub4&amp;doi=10.1002/14651858.CD006318.pub4&amp;type=cdsr&amp;contentLanguage=" hreflang="ru-RU" rel="alternate"/> <link href="https://www.cochranelibrary.com/es/web/cochrane/content?templateType=full&amp;urlTitle=/cdsr/doi/10.1002/14651858.CD006318.pub4&amp;doi=10.1002/14651858.CD006318.pub4&amp;type=cdsr&amp;contentLanguage=" hreflang="es-ES" rel="alternate"/> <link href="https://www.cochranelibrary.com/ta/web/cochrane/content?templateType=full&amp;urlTitle=/cdsr/doi/10.1002/14651858.CD006318.pub4&amp;doi=10.1002/14651858.CD006318.pub4&amp;type=cdsr&amp;contentLanguage=" hreflang="ta-IN" rel="alternate"/> <link href="https://www.cochranelibrary.com/th/web/cochrane/content?templateType=full&amp;urlTitle=/cdsr/doi/10.1002/14651858.CD006318.pub4&amp;doi=10.1002/14651858.CD006318.pub4&amp;type=cdsr&amp;contentLanguage=" hreflang="th-TH" rel="alternate"/> <link class="lfr-css-file" href="https://www.cochranelibrary.com/cochrane-theme/css/main.css?browserId=other&amp;themeId=cochrane_WAR_cochranetheme&amp;minifierType=css&amp;languageId=en_US&amp;b=6210&amp;t=1738734064000" rel="stylesheet" type="text/css"/> <link class="lfr-css-file" href="https://www.cochranelibrary.com/cochrane-theme/css/aui.css?browserId=other&amp;themeId=cochrane_WAR_cochranetheme&amp;minifierType=css&amp;languageId=en_US&amp;b=6210&amp;t=1738734064000" rel="stylesheet" type="text/css"/> <link href="/html/css/main.css?browserId=other&amp;themeId=cochrane_WAR_cochranetheme&amp;minifierType=css&amp;languageId=en_US&amp;b=6210&amp;t=1739772874000" rel="stylesheet" type="text/css"/> <link href="https://www.cochranelibrary.com/scolaris-content-display/css/main.css?browserId=other&amp;themeId=cochrane_WAR_cochranetheme&amp;minifierType=css&amp;languageId=en_US&amp;b=6210&amp;t=1739772750000" rel="stylesheet" type="text/css"/> <link href="https://www.cochranelibrary.com/notifications-portlet/notifications/css/main.css?browserId=other&amp;themeId=cochrane_WAR_cochranetheme&amp;minifierType=css&amp;languageId=en_US&amp;b=6210&amp;t=1739772751000" rel="stylesheet" type="text/css"/> <link href="https://www.cochranelibrary.com/html/portlet/login/css/main.css?browserId=other&amp;themeId=cochrane_WAR_cochranetheme&amp;minifierType=css&amp;languageId=en_US&amp;b=6210&amp;t=1739772901000" rel="stylesheet" type="text/css"/> <script type="text/javascript">var Liferay={Browser:{acceptsGzip:function(){return false},getMajorVersion:function(){return 80},getRevision:function(){return"537.36"},getVersion:function(){return"80.0"},isAir:function(){return false},isChrome:function(){return true},isFirefox:function(){return false},isGecko:function(){return true},isIe:function(){return false},isIphone:function(){return false},isLinux:function(){return true},isMac:function(){return false},isMobile:function(){return false},isMozilla:function(){return false},isOpera:function(){return false},isRtf:function(){return true},isSafari:function(){return true},isSun:function(){return false},isWap:function(){return false},isWapXhtml:function(){return false},isWebKit:function(){return true},isWindows:function(){return false},isWml:function(){return false}},Data:{NAV_SELECTOR:"#navigation",isCustomizationView:function(){return false},notices:[null]},ThemeDisplay:{getLayoutId:function(){return"7"},getLayoutURL:function(){return"https://www.cochranelibrary.com/en/content"},getParentLayoutId:function(){return"0"},isPrivateLayout:function(){return"false"},isVirtualLayout:function(){return false},getBCP47LanguageId:function(){return"en-US"},getCDNBaseURL:function(){return"https://www.cochranelibrary.com"},getCDNDynamicResourcesHost:function(){return""},getCDNHost:function(){return""},getCompanyId:function(){return"20155"},getCompanyGroupId:function(){return"20195"},getDefaultLanguageId:function(){return"en_US"},getDoAsUserIdEncoded:function(){return""},getLanguageId:function(){return"en_US"},getParentGroupId:function(){return"20182"},getPathContext:function(){return""},getPathImage:function(){return"/image"},getPathJavaScript:function(){return"/html/js"},getPathMain:function(){return"/en/c"},getPathThemeImages:function(){return"https://www.cochranelibrary.com/cochrane-theme/images"},getPathThemeRoot:function(){return"/cochrane-theme"},getPlid:function(){return"20757"},getPortalURL:function(){return"https://www.cochranelibrary.com"},getPortletSetupShowBordersDefault:function(){return true},getScopeGroupId:function(){return"20182"},getScopeGroupIdOrLiveGroupId:function(){return"20182"},getSessionId:function(){return""},getSiteGroupId:function(){return"20182"},getURLControlPanel:function(){return"/group/control_panel?refererPlid=20757"},getURLHome:function(){return"https\x3a\x2f\x2fwww\x2ecochranelibrary\x2ecom\x2fweb\x2fcochrane"},getUserId:function(){return"20159"},getUserName:function(){return""},isAddSessionIdToURL:function(){return false},isFreeformLayout:function(){return false},isImpersonated:function(){return false},isSignedIn:function(){return false},isStateExclusive:function(){return false},isStateMaximized:function(){return false},isStatePopUp:function(){return false}},PropsValues:{NTLM_AUTH_ENABLED:false}};var themeDisplay=Liferay.ThemeDisplay;Liferay.AUI={getAvailableLangPath:function(){return"available_languages.jsp?browserId=other&themeId=cochrane_WAR_cochranetheme&colorSchemeId=01&minifierType=js&languageId=en_US&b=6210&t=1513679709000"},getCombine:function(){return true},getComboPath:function(){return"/combo/?browserId=other&minifierType=&languageId=en_US&b=6210&t=1513679709000&"},getFilter:function(){return"min"},getJavaScriptRootPath:function(){return"/html/js"},getLangPath:function(){return"aui_lang.jsp?browserId=other&themeId=cochrane_WAR_cochranetheme&colorSchemeId=01&minifierType=js&languageId=en_US&b=6210&t=1513679709000"},getStaticResourceURLParams:function(){return"?browserId=other&minifierType=&languageId=en_US&b=6210&t=1513679709000"}};Liferay.authToken="Xx9QLps0";Liferay.currentURL="\x2fweb\x2fcochrane\x2fcontent\x3ftemplateType\x3dfull\x26urlTitle\x3d\x2fcdsr\x2fdoi\x2f10\x2e1002\x2f14651858\x2eCD006318\x2epub4\x26doi\x3d10\x2e1002\x2f14651858\x2eCD006318\x2epub4\x26type\x3dcdsr\x26contentLanguage\x3d";Liferay.currentURLEncoded="\x252Fweb\x252Fcochrane\x252Fcontent\x253FtemplateType\x253Dfull\x2526urlTitle\x253D\x252Fcdsr\x252Fdoi\x252F10\x2e1002\x252F14651858\x2eCD006318\x2epub4\x2526doi\x253D10\x2e1002\x252F14651858\x2eCD006318\x2epub4\x2526type\x253Dcdsr\x2526contentLanguage\x253D";</script> <script src="/html/js/barebone.jsp?browserId=other&amp;themeId=cochrane_WAR_cochranetheme&amp;colorSchemeId=01&amp;minifierType=js&amp;minifierBundleId=javascript.barebone.files&amp;languageId=en_US&amp;b=6210&amp;t=1513679709000" type="text/javascript"></script> <script type="text/javascript"></script> <script type="text/javascript">var o={database:"CDSR",page:{pageType:"Article Full Text HTML"},article:{availableLanguage:["en","es","zh_HANS","de","zh_HANT","ru","ko","ms","ja","fa","fr","pl"],languageCode:"en",accessStatus:"delayed-free",doi:"10.1002/14651858.CD006318.pub4",title:"Maintenance agonist treatments for opiate\\u2010dependent pregnant women",firstPublishedDate:"Nov 9, 2020 12:00:00 AM",isCurrentVersion:true,editorialGroup:"Cochrane Drugs and Alcohol Group",availableParts:["PDF Full","PDF Standard","PDF Abstract","HTML","Comments","Information","References","Stats","Related Content"]}};window.dataLayer=xtend(true,window.dataLayer,o);</script> <link class="lfr-css-file" href="https://www.cochranelibrary.com/cochrane-theme/css/custom.css?browserId=other&amp;themeId=cochrane_WAR_cochranetheme&amp;minifierType=css&amp;languageId=en_US&amp;b=6210&amp;t=1738734064000" rel="stylesheet" type="text/css"/> <style type="text/css"></style> <script async="" src="https://assets.adobedtm.com/59640f9fa510/7cad07cf7779/launch-a215d9c51521.min.js"></script> <!--[if lt IE 9]> <script src="/cochrane-theme/vendor/respond/dest/respond.min.js?t=1738734064000" type="text/javascript"></script> <![endif]--> </head> <body class="yui3-skin-sam controls-visible guest-site signed-out public-page site"> <div class="site-container"> <a href="#main-content" id="skip-to-content">Skip to Content</a> <div class="cookie-message cookie-message--hidden system-message-container" id="js-cookie-message"> <div class="container"> <a aria-label="Close cookies message" class="fa fa-times js-cookie-close pull-right" href="#"></a> <div class="system-message-wrapper container"> <i aria-hidden="true" class="fa fa-exclamation-triangle"></i> <div class="system-message-title">Cookies</div> <div class="system-message-description"> <p> Our site uses cookies to improve your experience. You can find out more about our use of cookies in About Cookies, including instructions on how to turn off cookies if you wish to do so. By continuing to browse this site you agree to us using cookies as described in <a href="http://olabout.wiley.com/WileyCDA/Section/id-813473.html">About Cookies</a>. </p> <a class="btn secondary js-cookie-close js-cookie-accept" href="#">I accept</a> </div> </div> </div> </div> <script>document.body.className=document.body.className+" js_enabled";</script><header> <div class="container"> <div class="branding"> <h1 class="brand-container"> <a href="https://www.cochranelibrary.com/en/"> <span class="brand-name">The Cochrane Library</span> <img alt="Cochrane Library logo" class="brand-logo" src="https://www.cochranelibrary.com/cochrane-theme/images/en-US_logo.png" title="Cochrane Library"/> </a> </h1> <span class="additional-branding"> <p class="brand-message"> <em>Trusted evidence.</em> <em>Informed decisions.</em> <em>Better health.</em> </p> </span> </div> <div class="desktop-search basic-search-container"> <div class="desktop-search-form"> <div class="portlet-boundary portlet-boundary_scolarissearchportlet_WAR_scolarissearch_ portlet-static portlet-static-end" id="p_p_id_scolarissearchportlet_WAR_scolarissearch_"> <span id="p_scolarissearchportlet_WAR_scolarissearch"></span> <section class="portlet" id="portlet_scolarissearchportlet_WAR_scolarissearch"> <header class="portlet-topper"> <h1 class="portlet-title"> <span class="" onmouseover="Liferay.Portal.ToolTip.show(this, 'Scolaris\x20Search\x20Portlet')"> <img alt="" id="owel__null__null" src="/scolaris-search/icon.png"/> <span class="taglib-text hide-accessible">Scolaris Search Portlet</span> </span> <span class="portlet-title-text">Scolaris Search Portlet</span> </h1> <menu class="portlet-topper-toolbar" id="portlet-topper-toolbar_scolarissearchportlet_WAR_scolarissearch" type="toolbar"> </menu> </header> <div class="portlet-content"> <div class="portlet-content-container"> <div class="portlet-body"> <div class="header-search"> <form action="https://www.cochranelibrary.com/en/content?p_auth=Xx9QLps0&amp;p_p_id=scolarissearchportlet_WAR_scolarissearch&amp;p_p_lifecycle=1&amp;p_p_state=normal&amp;p_p_mode=view&amp;_scolarissearchportlet_WAR_scolarissearch_scolarisAction=redirectSearchResult" method="post"> <input name="searchType" type="hidden" value="basic"/> <input name="facetDisplayName" type="hidden" value=""/> <input name="facetQueryTerm" type="hidden" value=""/> <input name="facetQueryField" type="hidden" value=""/> <input name="facetCategory" type="hidden" value=""/> <fieldset class="fieldset"> <legend class="sr-only">Basic Search</legend> <div class="select search-by"> <select aria-label="Search by options" class="custom-select-enabled search-type" name="searchBy" title="Search by options"> <option value="1">Title Abstract Keyword</option> <option value="2">Record Title</option> <option value="3">Abstract</option> <option value="4">Author</option> <option value="5">Keyword</option> <option value="6">All Text</option> <option value="7">Publication Type</option> <option value="8">Source</option> <option value="9">DOI</option> <option value="14">Language</option> <option value="10">Accession Number</option> <option value="11">Trial Registry Number</option> <option value="12">Cochrane Group</option> <option value="13">Cochrane Topic</option> </select> </div> <div class="search-select-crg-container select" style="display: none;"> <select class="search-select-crg-list"></select> </div> <div class="search-select-topic-container select" data-topic-list-url="https://www.cochranelibrary.com/en/content?p_p_id=scolaristopics_WAR_scolaristopics&amp;p_p_lifecycle=2&amp;p_p_state=normal&amp;p_p_mode=view&amp;p_p_resource_id=topics-list&amp;p_p_cacheability=cacheLevelPage" style="display: none;"> <select class="search-select-topic-list"></select> </div> <div class="search-select-cl-container select" style="display: none;"> <select class="search-select-cl-list"></select> </div> <div class="search-text-container"> <div class="control-group control-group-inline search-input-wrapper"> <input aria-label="Enter search term" class="field browser-search search-text ui-autocomplete-input" id="searchText" name="searchText" placeholder="Search" size="30" type="text" value=""/>
<div id="autocomplete-results"></div>
</div>
<div class="control-group control-group-inline search-button-wrapper">
<button aria-label="Search" class="searchByBtn" type="submit">
<i aria-hidden="true" class="fa fa-search"></i>
</button>
</div>
</div>
</fieldset>
</form>
</div>
<script>
    window.displayResultURL = 'https://www.cochranelibrary.com/en/content?p_p_id=scolarissearchportlet_WAR_scolarissearch&p_p_lifecycle=2&p_p_state=normal&p_p_mode=view&p_p_resource_id=getSuggestions&p_p_cacheability=cacheLevelPage&_scolarissearchportlet_WAR_scolarissearch_templateType=full&_scolarissearchportlet_WAR_scolarissearch_urlTitle=%2Fcdsr%2Fdoi%2F10.1002%2F14651858.CD006318.pub4&_scolarissearchportlet_WAR_scolarissearch_contentLanguage=&_scolarissearchportlet_WAR_scolarissearch_type=cdsr&_scolarissearchportlet_WAR_scolarissearch_doi=10.1002%2F14651858.CD006318.pub4';
    window.searchByOption = '';
</script>
</div>
</div>
</div>
<div style="display:none">
<input id="freelabel" name="freelabel" type="hidden" value="Free access"/>
<input id="openlabel" name="openlabel" type="hidden" value="Open access"/>
</div>
</section>
</div>
</div>
<div class="search-tools-nav">
<a class="btn secondary" href="/en/browse-by-topic">Browse</a>
<a class="btn primary advanced-search-button" href="/en/advanced-search">Advanced search</a>
</div>
</div>
<a class="toggle-menu-switch" href="#"><i aria-hidden="true" class="fa fa-bars"></i> <div class="toggle-menu-text">Open menu</div></a>
</div>
<div class="auxiliary-container">
<div class="container">
<div class="header-auxiliary-menu">
<div class="auxiliary-menu-item language-selector">
<div class="portlet-boundary portlet-boundary_scolarislanguageselector_WAR_scolarislanguageportlet_ portlet-static portlet-static-end" id="p_p_id_scolarislanguageselector_WAR_scolarislanguageportlet_INSTANCE_header_">
<span id="p_scolarislanguageselector_WAR_scolarislanguageportlet_INSTANCE_header"></span>
<section class="portlet" id="portlet_scolarislanguageselector_WAR_scolarislanguageportlet_INSTANCE_header">
<header class="portlet-topper">
<h1 class="portlet-title">
<span class="" onmouseover="Liferay.Portal.ToolTip.show(this, 'Scolaris\x20Language\x20Selector')">
<img alt="" id="bvrs__null__null" src="/scolaris-language-portlet/icon.png"/> <span class="taglib-text hide-accessible">Scolaris Language Selector</span> </span> <span class="portlet-title-text">Scolaris Language Selector</span> </h1> <menu class="portlet-topper-toolbar" id="portlet-topper-toolbar_scolarislanguageselector_WAR_scolarislanguageportlet_INSTANCE_header" type="toolbar"> </menu> </header> <div class="portlet-content"> <div class="portlet-content-container"> <div class="portlet-body"> <div class="language-display" data-content-languages="[de, en, es, fa, fr, hi, hr, id, ja, ko, hu, ms, nl, pl, pt, ru, ro, ta, th, zh_HANT, zh_HANS]"> <a class="open-language-modal" href="#" title="Select your preferred language"> <i class="fa fa-file-text"></i> Review language : English </a> <a class="open-language-modal" href="#" title="Select your preferred language"> <i class="fa fa-globe"></i> Website language : English </a> </div> <div class="language-selector-modal-content" data-modal-title="Language selection" data-size="large" style="display: none;"> <div class="form-content language-selector-modal"> <div class="row-fluid"> <div> <table class="mytable" style="border: 1px solid #f0f0f0" width="90%"> <tbody> <tr class="row-box"> <td><i class="fa fa-file-text icon-size"></i></td> <td><h3>Cochrane review language</h3> <p>Select your preferred language for Cochrane reviews and other content. Sections without translation will be in English.</p> </td> <td> <div> <select id="contentLanguageSelector" onchange="updateLang(this.value)"> <option class="content-language-option" data-languagecode="de" value="de"> Deutsch </option> <option class="content-language-option" data-languagecode="en" selected="" value="en"> English </option> <option class="content-language-option" data-languagecode="es" value="es"> Español </option> <option class="content-language-option" data-languagecode="fa" value="fa"> فارسی </option> <option class="content-language-option" data-languagecode="fr" value="fr"> Français </option> <option class="content-language-option" data-languagecode="hi" value="hi"> हिन्दी </option> <option class="content-language-option" data-languagecode="hr" value="hr"> Hrvatski </option> <option class="content-language-option" data-languagecode="id" value="id"> Bahasa Indonesia </option> <option class="content-language-option" data-languagecode="ja" value="ja"> 日本語 </option> <option class="content-language-option" data-languagecode="ko" value="ko"> 한국어 </option> <option class="content-language-option" data-languagecode="hu" value="hu"> Magyar </option> <option class="content-language-option" data-languagecode="ms" value="ms"> Bahasa Malaysia </option> <option class="content-language-option" data-languagecode="nl" value="nl"> Nederlands </option> <option class="content-language-option" data-languagecode="pl" value="pl"> Polski </option> <option class="content-language-option" data-languagecode="pt" value="pt"> Português </option> <option class="content-language-option" data-languagecode="ru" value="ru"> Русский </option> <option class="content-language-option" data-languagecode="ro" value="ro"> Română </option> <option class="content-language-option" data-languagecode="ta" value="ta"> தமிழ் </option> <option class="content-language-option" data-languagecode="th" value="th"> ภาษาไทย </option> <option class="content-language-option" data-languagecode="zh_HANT" value="zh_HANT"> 繁體中文 </option> <option class="content-language-option" data-languagecode="zh_HANS" value="zh_HANS"> 简体中文 </option> </select> </div> </td> </tr> <tr> <td colspan="1" style="height: 10px"></td> </tr> <tr class="row-box"> <td><i class="fa fa-globe icon-size"></i></td> <td> <div class="language-info"> <h3>Website language</h3> <p>Select your preferred language for the Cochrane Library website.</p> </div> </td> <td> <div class="language-dropdown"> <select id="portalLanguageSelector"> <option class="portal-language-selector" data-portallanguage="en" selected="" value="/en/cdsr/doi/10.1002/14651858.CD006318.pub4/full/en"> English </option> <option class="portal-language-selector" data-portallanguage="es" value="/es/cdsr/doi/10.1002/14651858.CD006318.pub4/full/es"> Español </option> </select> </div> </td> </tr> <tr> <td colspan="1" style="height: 10px"></td> </tr> </tbody> </table> </div> </div> <div style="text-align: right;"> <button class="btn primary btn-cancel" style="margin-left: 10px;" type="button">Cancel</button> <a class="btn secondary ok-btn" href="https://www.cochranelibrary.com/en/content?p_p_id=scolariscontentlanguagebanner_WAR_scolarislanguageportlet&amp;p_p_lifecycle=2&amp;p_p_state=normal&amp;p_p_mode=view&amp;p_p_resource_id=set-content-language&amp;p_p_cacheability=cacheLevelPage">Save</a> </div> </div> </div> </div> </div> </div> <div style="display:none"> <input id="freelabel" name="freelabel" type="hidden" value="Free access"/>
<input id="openlabel" name="openlabel" type="hidden" value="Open access"/>
</div>
</section>
</div>
</div>
<a class="auxiliary-menu-item signin last" href="https://www.cochranelibrary.com/c/portal/login?p_l_id=20757&amp;redirect=%2Fcdsr%2Fdoi%2F10.1002%2F14651858.CD006318.pub4%2Ffull" rel="nofollow">
<i class="icon fa fa-user"></i> Sign In
    </a>
<span class="auxiliary-container-extended"></span>
</div>
</div>
</div>
</header>
<div class="main-nav-wrapper">
<span class="main-nav-left-extended"></span>
<nav class="main container">
<ul>
<li class="nav-root-item parent">
<a href="#">Cochrane reviews<span class="icon fa fa-caret-down"></span></a>
<ul class="child">
<li class="child-nav-item" id="layout_nav_child_attr_14" role="presentation">
<a aria-labelledby="layout_14" href="https://www.cochranelibrary.com/en/cdsr/reviews" role="menuitem">
            Search reviews (CDSR)
        </a>
</li>
<li class="child-nav-item" id="layout_nav_child_attr_15" role="presentation">
<a aria-labelledby="layout_15" href="https://www.cochranelibrary.com/en/cdsr/reviews/topics" role="menuitem">
            Browse reviews
        </a>
</li>
<li class="child-nav-item" id="layout_nav_child_attr_18" role="presentation">
<a aria-labelledby="layout_18" href="https://www.cochranelibrary.com/en/cdsr/table-of-contents" role="menuitem">
            Issues
        </a>
</li>
<li class="child-nav-item" id="layout_nav_child_attr_17" role="presentation">
<a aria-labelledby="layout_17" href="https://www.cochranelibrary.com/en/cdsr/editorials" role="menuitem">
            Editorials
        </a>
</li>
<li class="child-nav-item" id="layout_nav_child_attr_19" role="presentation">
<a aria-labelledby="layout_19" href="https://www.cochranelibrary.com/en/special-collections" role="menuitem">
            Special Collections
        </a>
</li>
<li class="child-nav-item" id="layout_nav_child_attr_20" role="presentation">
<a aria-labelledby="layout_20" href="https://www.cochranelibrary.com/en/cdsr/supplements" role="menuitem">
            Supplements
        </a>
</li>
<li class="child-nav-item" id="layout_nav_child_attr_121" role="presentation">
<a aria-labelledby="layout_121" href="https://www.cochranelibrary.com/en/about/about-cochrane-reviews" role="menuitem">
            About Cochrane reviews
        </a>
</li>
</ul>
</li>
<li class="nav-root-item parent">
<a href="#">Searching for trials<span class="icon fa fa-caret-down"></span></a>
<ul class="child">
<li class="child-nav-item" id="layout_nav_child_attr_254" role="presentation">
<a aria-labelledby="layout_254" href="https://www.cochranelibrary.com/en/search/releases" role="menuitem">
            What's new (search and CENTRAL)
        </a>
</li>
<li class="child-nav-item" id="layout_nav_child_attr_266" role="presentation">
<a aria-labelledby="layout_266" href="https://www.cochranelibrary.com/en/search-help" role="menuitem">
            Search help
        </a>
</li>
<li class="child-nav-item" id="layout_nav_child_attr_252" role="presentation">
<a aria-labelledby="layout_252" href="https://www.cochranelibrary.com/en/search-help-quick-guides" role="menuitem">
            Search help quick guides
        </a>
</li>
<li class="child-nav-item" id="layout_nav_child_attr_251" role="presentation">
<a aria-labelledby="layout_251" href="https://www.cochranelibrary.com/en/search-faqs" role="menuitem">
            Search FAQs
        </a>
</li>
<li class="child-nav-item" id="layout_nav_child_attr_114" role="presentation">
<a aria-labelledby="layout_114" href="https://www.cochranelibrary.com/en/central/about-central" role="menuitem">
            About CENTRAL
        </a>
</li>
<li class="child-nav-item" id="layout_nav_child_attr_115" role="presentation">
<a aria-labelledby="layout_115" href="https://www.cochranelibrary.com/en/central/central-creation" role="menuitem">
            How CENTRAL is created
        </a>
</li>
<li class="child-nav-item" id="layout_nav_child_attr_241" role="presentation">
<a aria-labelledby="layout_241" href="https://www.cochranelibrary.com/en/retracted-trials" role="menuitem">
            Retracted publications in CENTRAL
        </a>
</li>
</ul>
</li>
<li class="nav-root-item parent">
<a href="#">Clinical Answers<span class="icon fa fa-caret-down"></span></a>
<ul class="child">
<li class="child-nav-item" id="layout_nav_child_attr_29" role="presentation">
<a aria-labelledby="layout_29" href="https://www.cochranelibrary.com/en/cca" role="menuitem">
            Browse Clinical Answers
        </a>
</li>
<li class="child-nav-item" id="layout_nav_child_attr_91" role="presentation">
<a aria-labelledby="layout_91" href="https://www.cochranelibrary.com/en/cca/about" role="menuitem">
            About Clinical Answers
        </a>
</li>
</ul>
</li>
<li class="nav-root-item parent">
<a href="#">About<span class="icon fa fa-caret-down"></span></a>
<ul class="child">
<li class="child-nav-item" id="layout_nav_child_attr_116" role="presentation">
<a aria-labelledby="layout_116" href="https://www.cochranelibrary.com/en/about/about-cochrane-library" role="menuitem">
            About the Cochrane Library
        </a>
</li>
<li class="child-nav-item" id="layout_nav_child_attr_13" role="presentation">
<a aria-labelledby="layout_13" href="https://www.cochranelibrary.com/en/cdsr/about-cdsr" role="menuitem">
            Cochrane Database of Systematic reviews
        </a>
</li>
<li class="child-nav-item" id="layout_nav_child_attr_198" role="presentation">
<a aria-labelledby="layout_198" href="https://www.cochranelibrary.com/en/cdsr/editorial-policies" role="menuitem">
            Editorial policies
        </a>
</li>
<li class="child-nav-item" id="layout_nav_child_attr_92" role="presentation">
<a aria-labelledby="layout_92" href="https://www.cochranelibrary.com/en/about/author-information" role="menuitem">
            Information for authors
        </a>
</li>
<li class="child-nav-item" id="layout_nav_child_attr_212" role="presentation">
<a aria-labelledby="layout_212" href="https://www.cochranelibrary.com/en/about-pico" role="menuitem">
            About PICO
        </a>
</li>
<li class="child-nav-item" id="layout_nav_child_attr_207" role="presentation">
<a aria-labelledby="layout_207" href="https://www.cochranelibrary.com/en/about/about-translations" role="menuitem">
            About translations
        </a>
</li>
<li class="child-nav-item" id="layout_nav_child_attr_188" role="presentation">
<a aria-labelledby="layout_188" href="https://www.cochranelibrary.com/en/about/releases" role="menuitem">
            What's new
        </a>
</li>
<li class="child-nav-item" id="layout_nav_child_attr_216" role="presentation">
<a aria-labelledby="layout_216" href="https://www.cochranelibrary.com/en/data" role="menuitem">
            Data reuse
        </a>
</li>
<li class="child-nav-item" id="layout_nav_child_attr_235" role="presentation">
<a aria-labelledby="layout_235" href="https://www.cochranelibrary.com/en/about/about-cochrane-library/editorial-board" role="menuitem">
            Cochrane Library Editorial Board
        </a>
</li>
</ul>
</li>
<li class="nav-root-item parent">
<a href="#">Help<span class="icon fa fa-caret-down"></span></a>
<ul class="child">
<li class="child-nav-item" id="layout_nav_child_attr_259" role="presentation">
<a aria-labelledby="layout_259" href="https://m.info.wiley.com/webApp/cochranenewsletter?id=0" role="menuitem">
            Newsletter
        </a>
</li>
<li class="child-nav-item" id="layout_nav_child_attr_177" role="presentation">
<a aria-labelledby="layout_177" href="https://www.wiley.com/en-us/customer-success/cochrane-library-training-hub" role="menuitem">
            Cochrane Library Training
        </a>
</li>
<li class="child-nav-item" id="layout_nav_child_attr_44" role="presentation">
<a aria-labelledby="layout_44" href="https://www.cochranelibrary.com/en/help/access" role="menuitem">
            Access
        </a>
</li>
<li class="child-nav-item" id="layout_nav_child_attr_150" role="presentation">
<a aria-labelledby="layout_150" href="https://www.cochranelibrary.com/en/help/permissions" role="menuitem">
            Permissions and reprints
        </a>
</li>
<li class="child-nav-item" id="layout_nav_child_attr_93" role="presentation">
<a aria-labelledby="layout_93" href="https://www.cochranelibrary.com/en/help/media" role="menuitem">
            Media information
        </a>
</li>
<li class="child-nav-item" id="layout_nav_child_attr_97" role="presentation">
<a aria-labelledby="layout_97" href="https://www.cochranelibrary.com/en/help/contact-us" role="menuitem">
            Contact us
        </a>
</li>
<li class="child-nav-item" id="layout_nav_child_attr_125" role="presentation">
<a aria-labelledby="layout_125" href="https://www.cochranelibrary.com/en/about/terms-and-conditions" role="menuitem">
            Terms and conditions
        </a>
</li>
<li class="child-nav-item" id="layout_nav_child_attr_176" role="presentation">
<a aria-labelledby="layout_176" href="https://cochranesupport.wiley.com/s/article/cochrane-library-known-issues" role="menuitem">
            Known issues
        </a>
</li>
<li class="child-nav-item" id="layout_nav_child_attr_270" role="presentation">
<a aria-labelledby="layout_270" href="https://www.cochranelibrary.com/search-help" role="menuitem">
            Search help
        </a>
</li>
</ul>
</li>
<li class="about-link"><a href="https://www.cochrane.org/about-us" target="_blank"><span>About Cochrane</span><i class="fa fa-caret-right"></i></a></li>
</ul>
</nav>
</div>
<div class="portlet-boundary portlet-boundary_scolariscontentlanguagebanner_WAR_scolarislanguageportlet_ portlet-static portlet-static-end" id="p_p_id_scolariscontentlanguagebanner_WAR_scolarislanguageportlet_">
<span id="p_scolariscontentlanguagebanner_WAR_scolarislanguageportlet"></span>
<section class="portlet" id="portlet_scolariscontentlanguagebanner_WAR_scolarislanguageportlet">
<header class="portlet-topper">
<h1 class="portlet-title">
<span class="" onmouseover="Liferay.Portal.ToolTip.show(this, 'Scolaris\x20Content\x20Language\x20Banner\x20Portlet')">
<img alt="" id="etlj__null__null" src="/scolaris-language-portlet/icon.png"/> <span class="taglib-text hide-accessible">Scolaris Content Language Banner Portlet</span> </span> <span class="portlet-title-text">Scolaris Content Language Banner Portlet</span> </h1> <menu class="portlet-topper-toolbar" id="portlet-topper-toolbar_scolariscontentlanguagebanner_WAR_scolarislanguageportlet" type="toolbar"> </menu> </header> <div class="portlet-content"> <div class="portlet-content-container"> <div class="portlet-body"> </div> </div> </div> <div style="display:none"> <input id="freelabel" name="freelabel" type="hidden" value="Free access"/>
<input id="openlabel" name="openlabel" type="hidden" value="Open access"/>
</div>
</section>
</div>
<div class="" id="content">
<div class="columns-1" id="main-content" role="main">
<div class="portlet-layout row-fluid">
<div class="portlet-column portlet-column-only span12" id="column-1">
<div class="portlet-dropzone portlet-column-content portlet-column-content-only" id="layout-column_column-1">
<div class="portlet-boundary portlet-boundary_scolariscontentdisplay_WAR_scolariscontentdisplay_ portlet-static portlet-static-end scolaris-content-display-portlet" id="p_p_id_scolariscontentdisplay_WAR_scolariscontentdisplay_">
<span id="p_scolariscontentdisplay_WAR_scolariscontentdisplay"></span>
<section class="portlet" id="portlet_scolariscontentdisplay_WAR_scolariscontentdisplay">
<header class="portlet-topper">
<h1 class="portlet-title">
<span class="" onmouseover="Liferay.Portal.ToolTip.show(this, 'Scolaris\x20Content\x20Display')">
<img alt="" id="rjus__column1__0" src="/scolaris-content-display/icon.png"/> <span class="taglib-text hide-accessible">Scolaris Content Display</span> </span> <span class="portlet-title-text">Scolaris Content Display</span> </h1> <menu class="portlet-topper-toolbar" id="portlet-topper-toolbar_scolariscontentdisplay_WAR_scolariscontentdisplay" type="toolbar"> </menu> </header> <div class="portlet-content"> <div class="portlet-content-container"> <div class="portlet-body"> <div class="publication cdsr container"> <div class="article-navigation-container" id="cdsr-nav"> <nav class="article-navigation"> <ul class="tools-row"> <li> <li class="tools pdf pulldown-menu readcube-menu closed en_US"> <a class="pulldown-menu-trigger" href="#0"> <span class="pdf-icon"> <i class="icon fa fa-file-pdf-o"></i> <span>Download PDF</span> </span> <i aria-hidden="true" class="fa fa-caret-down"></i> </a> <ul class="pulldown-menu-items"> <li class=""> <a class="download media pdf-link-full pdf-link" href="/cdsr/doi/10.1002/14651858.CD006318.pub4/pdf/full/en" title="Article in PDF format"> <span class="readcube-label"> Full </span> <span class="readcube-description"> All content </span> </a> <a class="download media pdf-link-full readcube-epdf-link" href="/cdsr/doi/10.1002/14651858.CD006318.pub4/epdf/full/en" title="Article in PDF format"> <span class="readcube-label"> Full </span> <span class="readcube-description"> All content </span> </a> </li> <li class=""> <a class="download media pdf-link-abstract pdf-link" href="/cdsr/doi/10.1002/14651858.CD006318.pub4/pdf/abstract/en" title="Article in PDF format"> <span class="readcube-label"> Summary </span> <span class="readcube-description"> Abstract and plain language summary only </span> </a> <a class="download media pdf-link-abstract readcube-epdf-link" href="/cdsr/doi/10.1002/14651858.CD006318.pub4/epdf/abstract/en" title="Article in PDF format"> <span class="readcube-label"> Summary </span> <span class="readcube-description"> Abstract and plain language summary only </span> </a> </li> </ul> </li> <li class="tools cite cite-article-link" data-article-id="CD006318.PUB4" data-modal-title="Cite this review"> <span><i aria-hidden="true" class="icon fa fa-share"></i></span> <span>Cite this review</span> </li> </li> </ul> <ul class="tools-row tools-secondary"> <li> <li class="tools print print-cdsr-link" data-content-language="en" data-indicator-tooltip="scolaris.print.modal.language.tooltip.en" data-print-options="[{&quot;param&quot;: &quot;abstract&quot;,&quot;titles&quot;:[{&quot;language&quot;:&quot;en&quot;,&quot;title&quot;:&quot;Abstract&quot;},{&quot;language&quot;:&quot;es&quot;,&quot;title&quot;:&quot;Resumen&quot;},{&quot;language&quot;:&quot;fa&quot;,&quot;title&quot;:&quot;چکیده&quot;},{&quot;language&quot;:&quot;fr&quot;,&quot;title&quot;:&quot;Résumé scientifique&quot;},{&quot;language&quot;:&quot;ko&quot;,&quot;title&quot;:&quot;초록&quot;},{&quot;language&quot;:&quot;zh_HANS&quot;,&quot;title&quot;:&quot;摘要&quot;}]},{&quot;param&quot;: &quot;pls&quot;,&quot;titles&quot;:[{&quot;language&quot;:&quot;en&quot;,&quot;title&quot;:&quot;Plain language summary&quot;},{&quot;language&quot;:&quot;de&quot;,&quot;title&quot;:&quot;Zusammenfassung in einfacher Sprache&quot;},{&quot;language&quot;:&quot;es&quot;,&quot;title&quot;:&quot;Resumen en términos sencillos&quot;},{&quot;language&quot;:&quot;fa&quot;,&quot;title&quot;:&quot;خلاصه به زبان ساده&quot;},{&quot;language&quot;:&quot;fr&quot;,&quot;title&quot;:&quot;Résumé simplifié&quot;},{&quot;language&quot;:&quot;ja&quot;,&quot;title&quot;:&quot;一般語訳&quot;},{&quot;language&quot;:&quot;ko&quot;,&quot;title&quot;:&quot;쉬운 말 요약&quot;},{&quot;language&quot;:&quot;ms&quot;,&quot;title&quot;:&quot;Ringkasan bahasa mudah&quot;},{&quot;language&quot;:&quot;pl&quot;,&quot;title&quot;:&quot;Streszczenie prostym językiem&quot;},{&quot;language&quot;:&quot;ru&quot;,&quot;title&quot;:&quot;Резюме на простом языке&quot;},{&quot;language&quot;:&quot;zh_HANS&quot;,&quot;title&quot;:&quot;简语概要&quot;},{&quot;language&quot;:&quot;zh_HANT&quot;,&quot;title&quot;:&quot;淺顯易懂的口語結論&quot;}]},{&quot;param&quot;: &quot;conclusions&quot;,&quot;titles&quot;:[{&quot;language&quot;:&quot;en&quot;,&quot;title&quot;:&quot;Authors' conclusions&quot;}]},{&quot;param&quot;: &quot;summaryOfFindings&quot;,&quot;titles&quot;:[{&quot;language&quot;:&quot;en&quot;,&quot;title&quot;:&quot;Summary of findings&quot;}]},{&quot;param&quot;: &quot;background&quot;,&quot;titles&quot;:[{&quot;language&quot;:&quot;en&quot;,&quot;title&quot;:&quot;Background&quot;}]},{&quot;param&quot;: &quot;objectives&quot;,&quot;titles&quot;:[{&quot;language&quot;:&quot;en&quot;,&quot;title&quot;:&quot;Objectives&quot;}]},{&quot;param&quot;: &quot;methods&quot;,&quot;titles&quot;:[{&quot;language&quot;:&quot;en&quot;,&quot;title&quot;:&quot;Methods&quot;}]},{&quot;param&quot;: &quot;results&quot;,&quot;titles&quot;:[{&quot;language&quot;:&quot;en&quot;,&quot;title&quot;:&quot;Results&quot;}]},{&quot;param&quot;: &quot;discussion&quot;,&quot;titles&quot;:[{&quot;language&quot;:&quot;en&quot;,&quot;title&quot;:&quot;Discussion&quot;}]},{&quot;param&quot;: &quot;references&quot;,&quot;titles&quot;:[{&quot;language&quot;:&quot;en&quot;,&quot;title&quot;:&quot;References&quot;}]},{&quot;param&quot;: &quot;appendices&quot;,&quot;titles&quot;:[{&quot;language&quot;:&quot;en&quot;,&quot;title&quot;:&quot;Appendices&quot;},{&quot;language&quot;:&quot;en&quot;,&quot;title&quot;:&quot;Search strategies&quot;}]},{&quot;param&quot;: &quot;characteristics&quot;,&quot;titles&quot;:[{&quot;language&quot;:&quot;en&quot;,&quot;title&quot;:&quot;Characteristics of studies&quot;}]},{&quot;param&quot;: &quot;data&quot;,&quot;titles&quot;:[{&quot;language&quot;:&quot;en&quot;,&quot;title&quot;:&quot;Analyses&quot;}]},{&quot;param&quot;: &quot;information&quot;,&quot;titles&quot;:[{&quot;language&quot;:&quot;en&quot;,&quot;title&quot;:&quot;Information&quot;}]},{&quot;param&quot;: &quot;authors&quot;,&quot;titles&quot;:[{&quot;language&quot;:&quot;en&quot;,&quot;title&quot;:&quot;Authors&quot;}]},{&quot;param&quot;: &quot;history&quot;,&quot;titles&quot;:[{&quot;language&quot;:&quot;en&quot;,&quot;title&quot;:&quot;History&quot;},{&quot;language&quot;:&quot;en&quot;,&quot;title&quot;:&quot;History&quot;}]}]" data-print-urlbase="/cdsr/doi/10.1002/14651858.CD006318.pub4/print"> <span><i class="icon fa fa-print"></i></span> <span>Print</span> </li> <li class="js-old-version-modal-trigger tools comments comment-on-review" data-article-id="CD006318.PUB4" data-english-only-message="Please note, that commenting is available in English only. Apologies for any inconvenience." data-href="/cdsr/doi/10.1002/14651858.CD006318.pub4/read-comments" data-new-version="" id="comment-on-review"> <span class="comment-icon"><i class="icon fa fa-comment"></i></span> <span class="comments-count">0</span> <span>Comment</span> </li> <li class="tools share-cdsr-link" data-share-url="/cdsr/doi/10.1002/14651858.CD006318.pub4/full"> <span><i class="icon fa fa-share-alt"></i></span> <span>Share</span> </li> <li class="tools follow"> <span class="article-not-followed cochrane-link signin follow-wrapper"> <span> <i class="icon fa fa-plus"></i> </span> <span> Follow </span> </span> </li> </li> </ul> <div class="metrics-wrapper"> <div class="metrics-count"> <span>Full text views: </span> <span>5819 <i class="icon fa fa-info-circle custom-tooltip" style="padding-left: 2px;color: #962d91;" title="Usage represents full text views on Cochrane Library since January 2022 or 2023. For articles published after this date, the usage represents views since the article was first published on Cochrane Library."> </i> </span> </div> </div> <div class="metrics-wrapper nav-link-section"> <div class="altmetric-embed" data-badge-type="1" data-condensed="true" data-doi="10.1002/14651858.CD006318.pub4" data-link-target="_blank"></div> <div class="inline-status-wrapper guidelines-count" data-count-plural="Cited in $1 guidelines" data-count-single="Cited in 1 guideline"> <a href="related-content#guidelines_data" title="Guidelines"></a> </div> </div> <ul class="nav-section-header"> <li> <h3>Contents</h3> </li> </ul> <ul class="nav-long-form nav-link-section"> <li class="cdsr-nav-link bold-nav-link" lang="en"> <a href="/cdsr/doi/10.1002/14651858.CD006318.pub4/full"> Abstract </a> </li> <li class="cdsr-nav-link bold-nav-link" lang="en"> <a href="/cdsr/doi/10.1002/14651858.CD006318.pub4/full#pico"> PICOs </a> </li> <li class="cdsr-nav-link bold-nav-link" lang="en"> <a href="/cdsr/doi/10.1002/14651858.CD006318.pub4/full#CD006318-abs-0002"> Plain language summary </a> </li> <li class="cdsr-nav-link bold-nav-link" lang="en"> <a href="/cdsr/doi/10.1002/14651858.CD006318.pub4/full#CD006318-sec-0118"> Authors' conclusions </a> </li> <li class="cdsr-nav-link bold-nav-link" lang="en"> <a href="/cdsr/doi/10.1002/14651858.CD006318.pub4/full#CD006318-sec-0008"> Summary of findings </a> </li> <li class="cdsr-nav-link" lang="en"> <a href="/cdsr/doi/10.1002/14651858.CD006318.pub4/full#CD006318-sec-0009"> Background </a> </li> <li class="cdsr-nav-link" lang="en"> <a href="/cdsr/doi/10.1002/14651858.CD006318.pub4/full#CD006318-sec-0014"> Objectives </a> </li> <li class="cdsr-nav-link" lang="en"> <a href="/cdsr/doi/10.1002/14651858.CD006318.pub4/full#CD006318-sec-0015"> Methods </a> </li> <li class="cdsr-nav-link" lang="en"> <a href="/cdsr/doi/10.1002/14651858.CD006318.pub4/full#CD006318-sec-0042"> Results </a> </li> <li class="cdsr-nav-link" lang="en"> <a href="/cdsr/doi/10.1002/14651858.CD006318.pub4/full#CD006318-sec-0112"> Discussion </a> </li> <li class="cdsr-nav-link"> <a class="figures-and-tables-link" href="/cdsr/doi/10.1002/14651858.CD006318.pub4/#"> Figures and tables </a> </li> <li class="cdsr-nav-link" lang="en"> <a href="/cdsr/doi/10.1002/14651858.CD006318.pub4/references"> References </a> </li> </ul> <div class="nav-section-header"> <h3>Supplementary materials</h3> </div> <ul class="nav-long-form nav-link-section"> <li class="cdsr-nav-link" lang="en"> <a href="/cdsr/doi/10.1002/14651858.CD006318.pub4/appendices#CD006318-sec-0123"> Search strategies </a> </li> <li class="cdsr-nav-link" lang="en"> <a href="/cdsr/doi/10.1002/14651858.CD006318.pub4/references#characteristicStudies"> Characteristics of studies </a> </li> <li class="cdsr-nav-link" lang="en"> <a href="/cdsr/doi/10.1002/14651858.CD006318.pub4/references#dataAndAnalyses"> Analyses </a> </li> <li class="cdsr-nav-link download-stats-data-link" data-download-href="/cdsr/doi/10.1002/14651858.CD006318.pub4/media/CDSR/CD006318/supinfo/CD006318StatsDataOnly.rm5?content-disposition=attachment&amp;mime-type=application/octet-stream"> <a href="/cdsr/doi/10.1002/14651858.CD006318.pub4/media/CDSR/CD006318/supinfo/CD006318StatsDataOnly.rm5?content-disposition=attachment&amp;mime-type=application/octet-stream"> Download data </a> </li> </ul> <ul class="tools-row"> <li> </li> </ul> <ul class="nav-section-header"> <li><h3>Related</h3></li> </ul> <ul class="linked-content linked-content-dropdown" id="linked-content-articles" tabindex="0"> <li class="linked-cca" data-type="cca"> <div class="linked-content-section"> <span class="linked-type">Cochrane Clinical Answers<span class="count"></span></span> <i aria-hidden="true" class="fa fa-caret-down"></i> </div> <div class="articles"></div> </li> <li class="linked-editorials" data-type="editorial"> <div class="linked-content-section"> <span class="linked-type">Editorials<span class="count"></span></span> <i aria-hidden="true" class="fa fa-caret-down"></i> </div> <div class="articles"></div> </li> <li class="linked-podcasts" data-type="podcast"> <div class="linked-content-section"> <span class="linked-type">Podcasts<span class="count"></span></span> <i aria-hidden="true" class="fa fa-caret-down"></i> </div> <div class="articles"></div> </li> <li class="linked-sc" data-type="sc"> <div class="linked-content-section"> <span class="linked-type">Special Collections<span class="count"></span></span> <i aria-hidden="true" class="fa fa-caret-down"></i> </div> <div class="articles"></div> </li> </ul> <div class="nav-section-header"> <h3>About this review</h3> </div> <ul class="nav-long-form nav-info nav-link-section"> <li class="cdsr-nav-link" lang="en"> <a href="/cdsr/doi/10.1002/14651858.CD006318.pub4/information"> <i> <svg viewbox="0 0 24 24"> <path d="M11,9H13V7H11M12,20C7.59,20 4,16.41 4,12C4,7.59 7.59,4 12,4C16.41,4 20,7.59 20,12C20,16.41 16.41,20 12,20M12,2A10,10 0 0,0 2,12A10,10 0 0,0 12,22A10,10 0 0,0 22,12A10,10 0 0,0 12,2M11,17H13V11H11V17Z"></path> </svg> </i> Information </a> </li> <li class="cdsr-nav-link" lang="en"> <a href="/cdsr/doi/10.1002/14651858.CD006318.pub4/information#authors"> <i> <svg viewbox="0 0 24 24"> <path d="M12,5.5A3.5,3.5 0 0,1 15.5,9A3.5,3.5 0 0,1 12,12.5A3.5,3.5 0 0,1 8.5,9A3.5,3.5 0 0,1 12,5.5M5,8C5.56,8 6.08,8.15 6.53,8.42C6.38,9.85 6.8,11.27 7.66,12.38C7.16,13.34 6.16,14 5,14A3,3 0 0,1 2,11A3,3 0 0,1 5,8M19,8A3,3 0 0,1 22,11A3,3 0 0,1 19,14C17.84,14 16.84,13.34 16.34,12.38C17.2,11.27 17.62,9.85 17.47,8.42C17.92,8.15 18.44,8 19,8M5.5,18.25C5.5,16.18 8.41,14.5 12,14.5C15.59,14.5 18.5,16.18 18.5,18.25V20H5.5V18.25M0,20V18.5C0,17.11 1.89,15.94 4.45,15.6C3.86,16.28 3.5,17.22 3.5,18.25V20H0M24,20H20.5V18.25C20.5,17.22 20.14,16.28 19.55,15.6C22.11,15.94 24,17.11 24,18.5V20Z"></path> </svg> </i> Authors </a> </li> <li class="cdsr-nav-link" lang="en"> <a href="/cdsr/doi/10.1002/14651858.CD006318.pub4/information#history"> <i> <svg viewbox="0 0 24 24"> <path d="M13.5,8H12V13L16.28,15.54L17,14.33L13.5,12.25V8M13,3A9,9 0 0,0 4,12H1L4.96,16.03L9,12H6A7,7 0 0,1 13,5A7,7 0 0,1 20,12A7,7 0 0,1 13,19C11.07,19 9.32,18.21 8.06,16.94L6.64,18.36C8.27,20 10.5,21 13,21A9,9 0 0,0 22,12A9,9 0 0,0 13,3"></path> </svg> </i> Version history </a> </li> <li class="cdsr-nav-link"> <a href="/cdsr/doi/10.1002/14651858.CD006318.pub4/information#keywords"> <i> <svg viewbox="0 0 24 24"> <path d="M11 3C10.18 3 9.44 3.5 9.14 4.27L3.64 18.27C3.12 19.58 4.09 21 5.5 21H7.75C8.59 21 9.33 20.5 9.62 19.7L10.26 18H13.74L14.38 19.7C14.67 20.5 15.42 21 16.25 21H18.5C19.91 21 20.88 19.58 20.36 18.27L14.86 4.27C14.56 3.5 13.82 3 13 3M11 5H13L18.5 19H16.25L15.12 16H8.87L7.75 19H5.5M12 7.67L9.62 14H14.37Z"></path> </svg> </i> Keywords (MeSH, PICOs) </a> </li> <li class="cdsr-nav-link"> <a href="/cdsr/doi/10.1002/14651858.CD006318.pub4/related-content"> <i class="icon fa fa-sitemap fa-rotate-270"></i> Related content </a> </li> <li class="cdsr-nav-link translation-notes-link"> <a href="/cdsr/doi/10.1002/14651858.CD006318.pub4/#"> <i> <svg viewbox="0 0 24 24"> <path d="M12.87,15.07L10.33,12.56L10.36,12.53C12.1,10.59 13.34,8.36 14.07,6H17V4H10V2H8V4H1V6H12.17C11.5,7.92 10.44,9.75 9,11.35C8.07,10.32 7.3,9.19 6.69,8H4.69C5.42,9.63 6.42,11.17 7.67,12.56L2.58,17.58L4,19L9,14L12.11,17.11L12.87,15.07M18.5,10H16.5L12,22H14L15.12,19H19.87L21,22H23L18.5,10M15.88,17L17.5,12.67L19.12,17H15.88Z"></path> </svg> </i> Translation notes </a> </li> <li class="cdsr-nav-link"> <a class="request-permissions" data-copyright="Copyright © 2020 The Cochrane Collaboration. Published by John Wiley &amp; Sons, Ltd." data-creative-commons="false" href="/cdsr/doi/10.1002/14651858.CD006318.pub4/#"> <span class="request-permissions-icon"></span> Request permissions </a> </li> <li class="cdsr-nav-link"> <a href="/data"> <i class="icon fa fa-database"></i> Request data reuse </a> </li> </ul> </nav> </div> <article> <div class="cdsr-header-top"> <div class="cdsr-header-left"> <a class="publish-database" href="/">Cochrane Database of Systematic reviews</a> <span class="publish-type">Review - Intervention</span> </div> <div class="cdsr-header-right"> <div class="inline-status-wrapper"> <ul class="cochrane-status"> <li aria-label="A new search for studies has been conducted." class="status-item up-to-date custom-tooltip" data-status="newsearch" title="A new search for studies has been conducted."> <a class="btn secondary" href="information#history">New search</a> </li> </ul> </div> </div> </div> <header class="publication-header"> <h1 class="publication-title" lang="en">Maintenance agonist treatments for opiate‐dependent pregnant women</h1> <div class="publication-metadata-block"> <div class="publication-authors"> <div class="publish-meta-wrapper"> <ul class="authors"> <li class="author"><a href="/cdsr/doi/10.1002/14651858.CD006318.pub4/information#CD006318-cr-0004"><i class="icon corresponding-author fa fa-envelope"></i>Silvia Minozzi</a></li> <li class="author"><a href="/cdsr/doi/10.1002/14651858.CD006318.pub4/information#CD006318-cr-0005">Laura Amato</a></li> <li class="author"><a href="/cdsr/doi/10.1002/14651858.CD006318.pub4/information#CD006318-cr-0006">Shayesteh Jahanfar</a></li> <li class="author"><a href="/cdsr/doi/10.1002/14651858.CD006318.pub4/information#CD006318-cr-0007">Cristina Bellisario</a></li> <li class="author"><a href="/cdsr/doi/10.1002/14651858.CD006318.pub4/information#CD006318-cr-0008">Marica Ferri</a></li> <li class="author"><a href="/cdsr/doi/10.1002/14651858.CD006318.pub4/information#CD006318-cr-0009">Marina Davoli</a></li> </ul> <span class="author declaration"> <a class="declarationsOfInterestLink" href="/cdsr/doi/10.1002/14651858.CD006318.pub4/information/en#CD006318-sec-0135">Authors' declarations of interest</a> </span> </div> </div> </div> <div class="publication-metadata-block"> <p> <span class="publish-date">Version published: 09 November 2020 </span> <a class="whatsNewLink" href="/cdsr/doi/10.1002/14651858.CD006318.pub4/information/en#versionTable">Version history</a> </p> <div class="doi-header"> <a href="https://doi.org/10.1002/14651858.CD006318.pub4">https://doi.org/10.1002/14651858.CD006318.pub4</a> </div> </div> </header> <div class="publication-control-bar"> <span class="publication-control-button publication-control-collapse"> Collapse all </span> <span class="publication-control-button publication-control-expand"> Expand all </span> </div> <section class="abstract"> <div class="section-header section-collapse-header" id="CD006318-abs-0001" lang="en"> <h2 class="title section-collapse-title"> Abstract <i aria-hidden="true" class="fa fa-caret-up section-collapse-icon"></i> </h2> <div class="section-language-toggles"> <span class="section-languages-legend">available in</span> <nav class="section-languages"> <li class="section-language"> <a class="is-active" href="full/en#CD006318-abs-0001">English</a> </li> <li class="section-language"> <a class="" href="full/es#CD006318-abs-0017">Español</a> </li> <li class="section-language"> <a class="" href="full/fa#CD006318-abs-0012">فارسی</a> </li> <li class="section-language"> <a class="" href="full/fr#CD006318-abs-0014">Français</a> </li> <li class="section-language"> <a class="" href="full/ko#CD006318-abs-0008">한국어</a> </li> <li class="section-language"> <a class="" href="full/zh_HANS#CD006318-abs-0003">简体中文</a> </li> </nav> </div> </div> <div class="abstract full_abstract" id="CD006318-abs-0001" lang="en"> <section id="CD006318-sec-0001"> <h3 class="title" id="CD006318-sec-0001">Background</h3> <p>The prevalence of opiate use among pregnant women can range from 1% to 2% to as high as 21%. Just in the United States alone, among pregnant women with hospital delivery, a fourfold increase in opioid use is reported from 1999 to 2014 (Haight 2018). Heroin crosses the placenta, and pregnant, opiate‐dependent women experience a six‐fold increase in maternal obstetric complications such as low birth weight, toxaemia, third trimester bleeding, malpresentation, puerperal morbidity, fetal distress and meconium aspiration. Neonatal complications include narcotic withdrawal, postnatal growth deficiency, microcephaly, neuro‐behavioural problems, increased neonatal mortality and a 74‐fold increase in sudden infant death syndrome. This is an updated version of the original Cochrane Review first published in 2008 and last updated in 2013. </p> </section> <section id="CD006318-sec-0002"> <h3 class="title" id="CD006318-sec-0002">Objectives</h3> <p>To assess the effectiveness of any maintenance treatment alone or in combination with a psychosocial intervention compared to no intervention, other pharmacological intervention or psychosocial interventions alone for child health status, neonatal mortality, retaining pregnant women in treatment, and reducing the use of substances. </p> </section> <section id="CD006318-sec-0003"> <h3 class="title" id="CD006318-sec-0003">Search methods</h3> <p>We updated our searches of the following databases to February 2020: the Cochrane Drugs and Alcohol Group Specialised Register, CENTRAL, MEDLINE, Embase, PsycINFO, CINAHL, and Web of Science. We also searched two trials registers and checked the reference lists of included studies for further references to relevant randomised controlled trials (RCTs). </p> </section> <section id="CD006318-sec-0004"> <h3 class="title" id="CD006318-sec-0004">Selection criteria</h3> <p>Randomised controlled trials which assessed the efficacy of any pharmacological maintenance treatment for opiate‐dependent pregnant women. </p> </section> <section id="CD006318-sec-0005"> <h3 class="title" id="CD006318-sec-0005">Data collection and analysis</h3> <p>We used the standard methodological procedures expected by Cochrane.</p> </section> <section id="CD006318-sec-0006"> <h3 class="title" id="CD006318-sec-0006">Main results</h3> <p>We found four trials with 271 pregnant women. Three compared methadone with buprenorphine and one methadone with oral slow‐release morphine. Three out of four studies had adequate allocation concealment and were double‐blind. The major flaw in the included studies was attrition bias: three out of four had a high dropout rate (30% to 40%), and this was unbalanced between groups. </p> <p><b>Methadone versus buprenorphine:</b> </p> <p>There was probably no evidence of a difference in the dropout rate from treatment (risk ratio (RR) 0.66, 95% confidence interval (CI) 0.37 to 1.20, three studies, 223 participants, moderate‐quality evidence). There may be no evidence of a difference in the use of primary substances between methadone and buprenorphine (RR 1.81, 95% CI 0.70 to 4.68, two studies, 151 participants, low‐quality evidence). Birth weight may be higher in the buprenorphine group in the two trials that reported data MD;‐530.00 g, 95%CI ‐662.78 to ‐397.22 (one study, 19 particpants) and MD: ‐215.00 g, 95%CI ‐238.93 to ‐191.07 (one study, 131 participants) although the results could not be pooled due to very high heterogeneity (very low‐quality of evidence). The third study reported that there was no evidence of a difference. We found there may be no evidence of a difference in the APGAR score (MD: 0.00, 95% CI ‐0.03 to 0.03, two studies,163 participants, low‐quality evidence). Many measures were used in the studies to assess neonatal abstinence syndrome. The number of newborns treated for neonatal abstinence syndrome, which is the most critical outcome, may not differ between groups (RR 1.19, 95% CI 0.87 to1.63, three studies, 166 participants, low‐quality evidence). </p> <p>Only one study which compared methadone with buprenorphine reported side effects. We found there may be no evidence of a difference in the number of mothers with serious adverse events (AEs) (RR 1.69, 95% CI 0.75 to 3.83, 175 participants, low‐quality evidence) and we found there may be no difference in the numbers of newborns with serious AEs (RR 4.77, 95% CI 0.59, 38.49,131 participants, low‐quality evidence). </p> <p><b>Methadone versus slow‐release morphine:</b> </p> <p>There were no dropouts in either treatment group. Oral slow‐release morphine may be superior to methadone for abstinence from heroin use during pregnancy (RR 2.40, 95% CI 1.00 to 5.77, one study, 48 participants, low‐quality evidence). </p> <p>In the comparison between methadone and slow‐release morphine, no side effects were reported for the mother. In contrast, one child in the methadone group had central apnoea, and one child in the morphine group had obstructive apnoea (low‐quality evidence). </p> </section> <section id="CD006318-sec-0007"> <h3 class="title" id="CD006318-sec-0007">Authors' conclusions</h3> <p>Methadone and buprenorphine may be similar in efficacy and safety for the treatment of opioid‐dependent pregnant women and their babies. There is not enough evidence to make conclusions for the comparison between methadone and slow‐release morphine. Overall, the body of evidence is too small to make firm conclusions about the equivalence of the treatments compared. There is still a need for randomised controlled trials of adequate sample size comparing different maintenance treatments. </p> </section> </div> </section> <section class="pico-section" id="pico"> <h2 class="title section-collapse-title">PICOs <i class="icon fa fa-info-circle" title="The PICO model is widely used and taught in evidence-based health care as a strategy for formulating questions and search strategies and for characterizing clinical studies or meta-analyses. PICO stands for four different potential components of a clinical question: Patient, Population or Problem; Intervention; Comparison; Outcome."></i> <i aria-hidden="true" class="fa fa-caret-up section-collapse-icon"></i> </h2> <div class="section-content" style="display: block;"> <h3 class="keyword-heading">PICOs</h3> <div class="pico-table"> <div class="pico-column Population"> <h6>Population<span class="pico-count"></span></h6> <ul class="pico-terms"> </ul> </div> <div class="pico-column Intervention"> <h6>Intervention<span class="pico-count"></span></h6> <ul class="pico-terms"> </ul> </div> <div class="pico-column Comparison"> <h6>Comparison<span class="pico-count"></span></h6> <ul class="pico-terms"> </ul> </div> <div class="pico-column Outcome"> <h6>Outcome<span class="pico-count"></span></h6> <ul class="pico-terms"> </ul> </div> </div> <div class="pico-information"> <p><i class="icon fa fa-info-circle"></i> The PICO model is widely used and taught in evidence-based health care as a strategy for formulating questions and search strategies and for characterizing clinical studies or meta-analyses. PICO stands for four different potential components of a clinical question: Patient, Population or Problem; Intervention; Comparison; Outcome.</p> <p>See more on using PICO in the <a href="https://training.cochrane.org/handbook/current/chapter-02#section-2-3">Cochrane Handbook</a>.</p> </div> </div> </section> <section class="pls"> <div class="section-header section-collapse-header" id="CD006318-abs-0002" lang="en"> <h2 class="title section-collapse-title"> Plain language summary <i aria-hidden="true" class="fa fa-caret-up section-collapse-icon"></i> </h2> <div class="section-language-toggles"> <span class="section-languages-legend">available in</span> <nav class="section-languages"> <li class="section-language"> <a class="is-active" href="full/en#CD006318-abs-0002">English</a> </li> <li class="section-language"> <a class="" href="full/de#CD006318-abs-0005">Deutsch</a> </li> <li class="section-language"> <a class="" href="full/es#CD006318-abs-0018">Español</a> </li> <li class="section-language"> <a class="" href="full/fa#CD006318-abs-0013">فارسی</a> </li> <li class="section-language"> <a class="" href="full/fr#CD006318-abs-0015">Français</a> </li> <li class="section-language"> <a class="" href="full/ja#CD006318-abs-0011">日本語</a> </li> <li class="section-language"> <a class="" href="full/ko#CD006318-abs-0009">한국어</a> </li> <li class="section-language"> <a class="" href="full/ms#CD006318-abs-0010">Bahasa Malaysia</a> </li> <li class="section-language"> <a class="" href="full/pl#CD006318-abs-0016">Polski</a> </li> <li class="section-language"> <a class="" href="full/ru#CD006318-abs-0007">Русский</a> </li> <li class="section-language"> <a class="" href="full/zh_HANS#CD006318-abs-0004">简体中文</a> </li> <li class="section-language"> <a class="" href="full/zh_HANT#CD006318-abs-0006">繁體中文</a> </li> </nav> </div> </div> <div class="abstract abstract_plainLanguageSummary" id="CD006318-abs-0002" lang="en"> <h3>Maintenance treatments for opiate‐dependent pregnant women</h3> <p><b>Review question</b> </p> <p>This review summarised research studies comparing different types of pharmacologic maintenance treatments for pregnant women with opioid dependence </p> <p><b>Key messages</b>: </p> <p>Methadone and buprenorphine may be substantially similar in efficacy and safety for the treatment of opioid‐dependent pregnant women and their babies. There is not enough evidence to make conclusions for the comparison between methadone and slow‐release morphine. Overall, the body of evidence is too small to make firm conclusions. </p> <p><b>Background</b> </p> <p>Some women continue to use opiates when they are pregnant, yet heroin readily crosses the placenta. Opiate‐dependent women experience a sixfold increase in maternal obstetric complications and may give birth to low‐weight babies. The newborn may experience narcotic withdrawal (neonatal abstinence syndrome) and have development problems. There is also increased neonatal mortality and a 74‐fold increase in the risk of sudden infant death syndrome. Maintenance treatment with methadone provides a steady concentration of opiate in the pregnant woman's blood, and so prevents the adverse effects on the fetus of repeated withdrawals. Buprenorphine is also used. </p> <p><b>Search date</b> </p> <p>The evidence is current to 18 February 2020.</p> <p><b>Study characteristics</b> </p> <p>Only four randomised controlled trials with 271 participants satisfied the inclusion criteria for the review: two from Austria (outpatients), one from the USA (inpatients) and the fourth a multicentre, international study conducted in Austria, Canada and the USA. The trials continued for 15 to 18 weeks. Three compared methadone with buprenorphine (223 participants) and one compared methadone with oral slow‐release morphine (48 participants). </p> <p><b>Study funding sources</b> </p> <p>The National Institute on Drug Abuse funded two studies, one received a grant from the Mayor of Vienna, and in the fourth study Schering Plough provided an educational grant to the first author to employ personnel required to conduct this study. </p> <p><b>Key results</b> </p> <p>This review found few differences in newborn or maternal outcomes for pregnant, opiate‐addicted women who were maintained on methadone, buprenorphine or oral slow‐release morphine from a mean gestational age of 23 weeks to delivery. </p> <p>Comparing methadone with buprenorphine, there is probably little or no difference in the number of women who dropped out of treatment. There may be little or no difference in the use of a primary substance and the number of newborns treated for neonatal abstinence syndrome between the methadone and buprenorphine groups. We are very uncertain whether newborns with mothers receiving buprenorphine could have a heavier birth weight. </p> <p>Comparing methadone with oral slow‐release morphine, there were no dropouts in the only study included. The use of heroin in the third trimester may be lower with slow‐release morphine. However, there may be little or no difference in infant birth weight or duration of neonatal abstinence syndrome. </p> <p>The number of participants in the trials was small and may not be sufficient to draw firm conclusions. All the included studies ended immediately after the baby was born. No severe complications were noted. </p> <p><b>Quality of evidence</b> </p> <p>In the comparison of methadone with buprenorphine, the quality of the evidence ranged from moderate to very low because of inconsistency in the results of the studies for some outcomes, high rates of participants who dropped out from the studies, and small sample sizes of the included studies. In the comparison of methadone with slow‐release morphine, the quality of the evidence was low because of the small sample size of the study. </p> </div> </section> <section id="vls" style="display: none"> <div class="section-header section-collapse-header"> <h2 class="title section-collapse-title">Visual summary<i aria-hidden="true" class="fa fa-caret-up section-collapse-icon"></i></h2> </div> <a href="" target="_blank"><img alt="visual summary" src=""/></a> </section> <section class="conclusions"> <div class="section-header section-collapse-header" id="CD006318-sec-0118" lang="en"> <h2 class="title section-collapse-title"> Authors' conclusions <i aria-hidden="true" class="fa fa-caret-up section-collapse-icon"></i> </h2> </div> <section class="authorsConclusions" lang="en"> <div class="section-header" id="CD006318-sec-0118"></div> <h3 class="title" id="CD006318-sec-0119">Implications for practice</h3> <section id="CD006318-sec-0119"> <p>Methadone and buprenorphine may be substantially similar in efficacy and safety for the treatment of opioid‐dependent pregnant women and their babies. There is not enough evidence to make conclusions for the comparison between methadone and slow‐release morphine. Overall, the body of evidence is too small to draw firm conclusions. about the equivalence of the treatments compared. Many questions remain unanswered. Which is the most effective drug treatment and at what dosage? What is the most appropriate type of setting? In particular, is it useful or not to associate any type of psychosocial intervention with pharmacological treatment? </p> </section> <h3 class="title" id="CD006318-sec-0120">Implications for research</h3> <section id="CD006318-sec-0120"> <p>Large randomised controlled trials which compare different pharmacological maintenance treatments are still needed, with longer follow‐up periods (ideally up to one year) and which also consider as relevant outcomes the level of nicotine exposure, concomitant use during pregnancy of other prescribed medications (such as selective serotonin reuptake inhibitors and benzodiazepines) and use of non‐prescribed drugs such as cocaine, alcohol and marijuana. Moreover, studies assessing the effectiveness of psychosocial treatments in addition to pharmacological treatments versus pharmacological treatments alone should be conducted. </p> </section> </section> </section> <section class="summaryOfFindings"> <div class="section-header section-collapse-header" id="CD006318-sec-0008" lang="en"> <h2 class="title section-collapse-title"> Summary of findings <i aria-hidden="true" class="fa fa-caret-up section-collapse-icon"></i> </h2> </div> <section class="summaryOfFindings" lang="en"> <div class="section-header" id="CD006318-sec-0008"></div> <div class="table" id="CD006318-tbl-0001"> <table class="summary-of-findings framed"><a class="open-table-viewer open-in-figure-viewer" href="#0">Open in table viewer</a><div class="table-heading"><span class="table-label">Summary of findings 1.</span> <span class="table-title">Methadone compared to buprenorphine for opiate‐dependent pregnant women</span></div> <tbody> <tr class="separated"> <td align="left" bgcolor="#ffffff" colspan="7" rowspan="1" valign="top"> <p><b>Methadone compared to buprenorphine for opiate‐dependent pregnant women</b> </p> </td> </tr> <tr class="separated"> <td align="left" bgcolor="#ffffff" colspan="7" rowspan="1" valign="top"> <p><b>Patient or population:</b> opiate‐dependent pregnant women<br/><b>Setting:</b> outpatients<br/><b>Intervention:</b> methadone<br/><b>Comparison:</b> buprenorphine </p> </td> </tr> <tr class="separated"> <th align="left" class="headercell" colspan="1" rowspan="2" scope="col" valign="top"> <p><b>Outcomes</b> </p> </th> <th align="left" class="headercell table-tint" colspan="2" rowspan="1" scope="col" valign="top"> <p><b>Anticipated absolute effects<sup>*</sup> (95% CI)</b> </p> </th> <th align="left" class="headercell" colspan="1" rowspan="2" scope="col" valign="top"> <p><b>Relative effect<br/>(95% CI)</b> </p> </th> <th align="left" class="headercell" colspan="1" rowspan="2" scope="col" valign="top"> <p><b>№ of participants<br/>(studies)</b> </p> </th> <th align="left" class="headercell" colspan="1" rowspan="2" scope="col" valign="top"> <p><b>Certainty of the evidence<br/>(GRADE)</b> </p> </th> <th align="left" class="headercell" colspan="1" rowspan="2" scope="col" valign="top"> <p><b>Comments</b> </p> </th> </tr> <tr class="separated"> <th align="left" class="headercell table-tint" colspan="1" rowspan="1" scope="col" valign="top"> <p><b>Risk with buprenorphine</b> </p> </th> <th align="left" class="headercell table-tint" colspan="1" rowspan="1" scope="col" valign="top"> <p><b>Risk with methadone</b> </p> </th> </tr> <tr class="separated"> <td align="left" bgcolor="#ffffff" colspan="1" rowspan="2" valign="top"> <p>Dropout rate<br/>follow‐up: range 15 weeks to 18 weeks </p> </td> <td align="left" class="table-tint table-highlight" colspan="2" rowspan="1" valign="top"> <p>Study population</p> </td> <td align="left" bgcolor="#ffffff" colspan="1" rowspan="2" valign="top"> <p>RR 0.66<br/>(0.37 to 1.20) </p> </td> <td align="left" bgcolor="#ffffff" colspan="1" rowspan="2" valign="top"> <p>223<br/>(3 RCTs) </p> </td> <td align="left" bgcolor="#ffffff" colspan="1" rowspan="2" valign="top"> <p>⊕⊕⊕⊝<br/>MODERATE <sup>1</sup> </p> </td> <td align="left" bgcolor="#ffffff" colspan="1" rowspan="2" valign="top"></td> </tr> <tr class="separated"> <td align="left" class="table-tint table-highlight" colspan="1" rowspan="1" valign="top"> <p>318 per 1000</p> </td> <td align="left" class="table-tint table-highlight" colspan="1" rowspan="1" valign="top"> <p>210 per 1000<br/>(118 to 382) </p> </td> </tr> <tr class="separated"> <td align="left" bgcolor="#ffffff" colspan="1" rowspan="2" valign="top"> <p>Use of primary substance<br/>follow‐up: range 15 weeks to 18 weeks </p> </td> <td align="left" class="table-tint table-highlight" colspan="2" rowspan="1" valign="top"> <p>Study population</p> </td> <td align="left" bgcolor="#ffffff" colspan="1" rowspan="2" valign="top"> <p>RR 1.81<br/>(0.70 to 4.68) </p> </td> <td align="left" bgcolor="#ffffff" colspan="1" rowspan="2" valign="top"> <p>151<br/>(2 RCTs) </p> </td> <td align="left" bgcolor="#ffffff" colspan="1" rowspan="2" valign="top"> <p>⊕⊕⊝⊝<br/>LOW <sup>1 2</sup> </p> </td> <td align="left" bgcolor="#ffffff" colspan="1" rowspan="2" valign="top"></td> </tr> <tr class="separated"> <td align="left" class="table-tint table-highlight" colspan="1" rowspan="1" valign="top"> <p>75 per 1000</p> </td> <td align="left" class="table-tint table-highlight" colspan="1" rowspan="1" valign="top"> <p>135 per 1000<br/>(52 to 349) </p> </td> </tr> <tr class="separated"> <td align="left" bgcolor="#ffffff" colspan="1" rowspan="1" valign="top"> <p>Birth weight<br/>follow‐up: mean 18 weeks </p> </td> <td align="left" class="table-tint table-highlight" colspan="1" rowspan="1" valign="top"> <p>The mean birth weight ranged from 3.093 g to 3530 gr</p> </td> <td align="left" class="table-tint table-highlight" colspan="1" rowspan="1" valign="top"> <p>MD ranged from ‐530.00 gr (662.78,lower to 397.22 lower) to ‐215.00 gr (238.93, lower to 191.07 lower) </p> </td> <td align="left" bgcolor="#ffffff" colspan="1" rowspan="1" valign="top"> <p>‐</p> </td> <td align="left" bgcolor="#ffffff" colspan="1" rowspan="1" valign="top"> <p>19 and 131 participants <br/>(2 RCTs) </p> </td> <td align="left" bgcolor="#ffffff" colspan="1" rowspan="1" valign="top"> <p>⊕⊝⊝⊝<br/>VERY LOW <sup>2 3 4</sup> </p> </td> <td align="left" bgcolor="#ffffff" colspan="1" rowspan="1" valign="top"></td> </tr> <tr class="separated"> <td align="left" bgcolor="#ffffff" colspan="1" rowspan="1" valign="top"> <p>APGAR score<br/>Scale from: 0 to 10<br/>follow‐up: mean 18 weeks </p> </td> <td align="left" class="table-tint table-highlight" colspan="1" rowspan="1" valign="top"> <p>The mean APGAR score was 8.95</p> </td> <td align="left" class="table-tint table-highlight" colspan="1" rowspan="1" valign="top"> <p>MD 0<br/>(0.03 lower to 0.03 higher) </p> </td> <td align="left" bgcolor="#ffffff" colspan="1" rowspan="1" valign="top"> <p>‐</p> </td> <td align="left" bgcolor="#ffffff" colspan="1" rowspan="1" valign="top"> <p>163<br/>(2 RCTs) </p> </td> <td align="left" bgcolor="#ffffff" colspan="1" rowspan="1" valign="top"> <p>⊕⊕⊝⊝<br/>LOW <sup>2 4</sup> </p> </td> <td align="left" bgcolor="#ffffff" colspan="1" rowspan="1" valign="top"></td> </tr> <tr class="separated"> <td align="left" bgcolor="#ffffff" colspan="1" rowspan="2" valign="top"> <p>Number treated for NAS<br/>follow‐up: range 15 weeks to 18 weeks </p> </td> <td align="left" class="table-tint table-highlight" colspan="2" rowspan="1" valign="top"> <p>Study population</p> </td> <td align="left" bgcolor="#ffffff" colspan="1" rowspan="2" valign="top"> <p>RR 1.19<br/>(0.87 to 1.63) </p> </td> <td align="left" bgcolor="#ffffff" colspan="1" rowspan="2" valign="top"> <p>166<br/>(3 RCTs) </p> </td> <td align="left" bgcolor="#ffffff" colspan="1" rowspan="2" valign="top"> <p>⊕⊕⊝⊝<br/>LOW <sup>1 2</sup> </p> </td> <td align="left" bgcolor="#ffffff" colspan="1" rowspan="2" valign="top"></td> </tr> <tr class="separated"> <td align="left" class="table-tint table-highlight" colspan="1" rowspan="1" valign="top"> <p>447 per 1000</p> </td> <td align="left" class="table-tint table-highlight" colspan="1" rowspan="1" valign="top"> <p>532 per 1000<br/>(389 to 729) </p> </td> </tr> <tr class="separated"> <td align="left" bgcolor="#ffffff" colspan="1" rowspan="2" valign="top"> <p>Serious adverse events for the mother</p> </td> <td align="left" class="table-tint table-highlight" colspan="2" rowspan="1" valign="top"> <p>Study population</p> </td> <td align="left" bgcolor="#ffffff" colspan="1" rowspan="2" valign="top"> <p>RR 1.69<br/>(0.75 to 3.83) </p> </td> <td align="left" bgcolor="#ffffff" colspan="1" rowspan="2" valign="top"> <p>175<br/>(1 RCT) </p> </td> <td align="left" bgcolor="#ffffff" colspan="1" rowspan="2" valign="top"> <p>⊕⊕⊝⊝<br/>LOW <sup>1 2</sup> </p> </td> <td align="left" bgcolor="#ffffff" colspan="1" rowspan="2" valign="top"></td> </tr> <tr class="separated"> <td align="left" class="table-tint table-highlight" colspan="1" rowspan="1" valign="top"> <p>93 per 1000</p> </td> <td align="left" class="table-tint table-highlight" colspan="1" rowspan="1" valign="top"> <p>157 per 1000<br/>(70 to 356) </p> </td> </tr> <tr class="separated"> <td align="left" bgcolor="#ffffff" colspan="1" rowspan="2" valign="top"> <p>Serious adverse events for the child</p> </td> <td align="left" class="table-tint table-highlight" colspan="2" rowspan="1" valign="top"> <p>Study population</p> </td> <td align="left" bgcolor="#ffffff" colspan="1" rowspan="2" valign="top"> <p>RR 4.77<br/>(0.59 to 38.49) </p> </td> <td align="left" bgcolor="#ffffff" colspan="1" rowspan="2" valign="top"> <p>131<br/>(1 RCT) </p> </td> <td align="left" bgcolor="#ffffff" colspan="1" rowspan="2" valign="top"> <p>⊕⊕⊝⊝<br/>LOW <sup>1 2</sup> </p> </td> <td align="left" bgcolor="#ffffff" colspan="1" rowspan="2" valign="top"></td> </tr> <tr class="separated"> <td align="left" class="table-tint table-highlight" colspan="1" rowspan="1" valign="top"> <p>17 per 1000</p> </td> <td align="left" class="table-tint table-highlight" colspan="1" rowspan="1" valign="top"> <p>82 per 1000<br/>(10 to 664) </p> </td> </tr> <tr class="separated"> <td align="" bgcolor="#ffffff" colspan="7" rowspan="1" valign=""> <p>*<b>The risk in the intervention group</b> (and its 95% confidence interval) is based on the assumed risk in the comparison group and the <b>relative effect</b> of the intervention (and its 95% CI).<br/><br/><b>CI:</b> Confidence interval; <b>RR:</b> Risk ratio; <b>OR:</b> Odds ratio; </p> </td> </tr> <tr class="separated"> <td align="" bgcolor="#ffffff" colspan="7" rowspan="1" valign=""> <p><b>GRADE Working Group grades of evidence</b> <br/><b>High certainty:</b> We are very confident that the true effect lies close to that of the estimate of the effect<br/><b>Moderate certainty:</b> We are moderately confident in the effect estimate: The true effect is likely to be close to the estimate of the effect, but there is a possibility that it is substantially different<br/><b>Low certainty:</b> Our confidence in the effect estimate is limited: The true effect may be substantially different from the estimate of the effect<br/><b>Very low certainty:</b> We have very little confidence in the effect estimate: The true effect is likely to be substantially different from the estimate of effect </p> </td> </tr> </tbody> <tfoot> <tr> <td colspan="7"> <div class="table-footnote"> <p><sup>1</sup> downgraded one level due to imprecision: optimal information size not met </p> <p><sup>2</sup> downgraded one level due to study limitations: high risk of attrition bias </p> <p><sup>3</sup> downgraded one level due to inconsistency: high heterogeneity: I<sup>2</sup> 95% </p> <p><sup>4</sup> downgraded one level due to imprecision: fewer than 400 participants </p> </div> </td> </tr> </tfoot> </table> </div> <div class="table" id="CD006318-tbl-0002"> <table class="summary-of-findings framed"><a class="open-table-viewer open-in-figure-viewer" href="#0">Open in table viewer</a><div class="table-heading"><span class="table-label">Summary of findings 2.</span> <span class="table-title">Methadone compared to oral slow‐release morphine for opiate‐dependent pregnant women</span></div> <tbody> <tr class="separated"> <td align="left" bgcolor="#ffffff" colspan="7" rowspan="1" valign="top"> <p><b>Methadone compared to oral slow‐release morphine for opiate‐dependent pregnant women</b> </p> </td> </tr> <tr class="separated"> <td align="left" bgcolor="#ffffff" colspan="7" rowspan="1" valign="top"> <p><b>Patient or population:</b> opiate‐dependent pregnant women<br/><b>Setting:</b> <br/><b>Intervention:</b> methadone<br/><b>Comparison:</b> oral slow‐release morphine </p> </td> </tr> <tr class="separated"> <th align="left" class="headercell" colspan="1" rowspan="2" scope="col" valign="top"> <p><b>Outcomes</b> </p> </th> <th align="left" class="headercell table-tint" colspan="2" rowspan="1" scope="col" valign="top"> <p><b>Anticipated absolute effects<sup>*</sup> (95% CI)</b> </p> </th> <th align="left" class="headercell" colspan="1" rowspan="2" scope="col" valign="top"> <p><b>Relative effect<br/>(95% CI)</b> </p> </th> <th align="left" class="headercell" colspan="1" rowspan="2" scope="col" valign="top"> <p><b>№ of participants<br/>(studies)</b> </p> </th> <th align="left" class="headercell" colspan="1" rowspan="2" scope="col" valign="top"> <p><b>Certainty of the evidence<br/>(GRADE)</b> </p> </th> <th align="left" class="headercell" colspan="1" rowspan="2" scope="col" valign="top"> <p><b>Comments</b> </p> </th> </tr> <tr class="separated"> <th align="left" class="headercell table-tint" colspan="1" rowspan="1" scope="col" valign="top"> <p><b>Risk with oral slow‐release morphine</b> </p> </th> <th align="left" class="headercell table-tint" colspan="1" rowspan="1" scope="col" valign="top"> <p><b>Risk with methadone</b> </p> </th> </tr> <tr class="separated"> <td align="left" bgcolor="#ffffff" colspan="1" rowspan="1" valign="top"> <p>Dropout rate from treatment<br/>follow‐up: mean 15 weeks </p> </td> <td align="left" class="table-tint table-highlight" colspan="2" rowspan="1" valign="top"> <p>No dropouts from either group</p> </td> <td align="left" bgcolor="#ffffff" colspan="1" rowspan="1" valign="top"></td> <td align="left" bgcolor="#ffffff" colspan="1" rowspan="1" valign="top"> <p>48<br/>(1 RCT) </p> </td> <td align="left" bgcolor="#ffffff" colspan="1" rowspan="1" valign="top"> <p>⊕⊕⊝⊝<br/>LOW <sup>1 2</sup> </p> </td> <td align="left" bgcolor="#ffffff" colspan="1" rowspan="1" valign="top"></td> </tr> <tr class="separated"> <td align="left" bgcolor="#ffffff" colspan="1" rowspan="2" valign="top"> <p>Use of substance<br/>follow‐up: mean 15 weeks </p> </td> <td align="left" class="table-tint table-highlight" colspan="2" rowspan="1" valign="top"> <p>Study population</p> </td> <td align="left" bgcolor="#ffffff" colspan="1" rowspan="2" valign="top"> <p>RR 2.40<br/>(1.00 to 5.77) </p> </td> <td align="left" bgcolor="#ffffff" colspan="1" rowspan="2" valign="top"> <p>48<br/>(1 RCT) </p> </td> <td align="left" bgcolor="#ffffff" colspan="1" rowspan="2" valign="top"> <p>⊕⊕⊝⊝<br/>LOW <sup>1 3</sup> </p> </td> <td align="left" bgcolor="#ffffff" colspan="1" rowspan="2" valign="top"></td> </tr> <tr class="separated"> <td align="left" class="table-tint table-highlight" colspan="1" rowspan="1" valign="top"> <p>208 per 1000</p> </td> <td align="left" class="table-tint table-highlight" colspan="1" rowspan="1" valign="top"> <p>500 per 1000<br/>(208 to 1000) </p> </td> </tr> <tr class="separated"> <td align="left" bgcolor="#ffffff" colspan="1" rowspan="1" valign="top"> <p>Birth weight<br/>follow‐up: mean 15 weeks </p> </td> <td align="left" class="table-tint table-highlight" colspan="1" rowspan="1" valign="top"> <p>The mean birth weight was 2912 g</p> </td> <td align="left" class="table-tint table-highlight" colspan="1" rowspan="1" valign="top"> <p>MD 124 higher<br/>(186.94 lower to 434.94 higher) </p> </td> <td align="left" bgcolor="#ffffff" colspan="1" rowspan="1" valign="top"> <p>‐</p> </td> <td align="left" bgcolor="#ffffff" colspan="1" rowspan="1" valign="top"> <p>48<br/>(1 RCT) </p> </td> <td align="left" bgcolor="#ffffff" colspan="1" rowspan="1" valign="top"> <p>⊕⊕⊝⊝<br/>LOW <sup>1 2</sup> </p> </td> <td align="left" bgcolor="#ffffff" colspan="1" rowspan="1" valign="top"></td> </tr> <tr class="separated"> <td align="left" bgcolor="#ffffff" colspan="1" rowspan="1" valign="top"> <p>APGAR score (APGAR score )<br/>follow‐up: mean 15 weeks </p> </td> <td align="left" class="table-tint table-highlight" colspan="2" rowspan="1" valign="top"> <p>The study did not assess this outcome</p> </td> <td align="left" bgcolor="#ffffff" colspan="1" rowspan="1" valign="top"> <p>‐</p> </td> <td align="left" bgcolor="#ffffff" colspan="1" rowspan="1" valign="top"></td> <td align="left" bgcolor="#ffffff" colspan="1" rowspan="1" valign="top"></td> <td align="left" bgcolor="#ffffff" colspan="1" rowspan="1" valign="top"></td> </tr> <tr class="separated"> <td align="" bgcolor="#ffffff" colspan="1" rowspan="1" valign=""> <p>Adverse events for the mother</p> <p>follow‐up: mean 15 weeks</p> </td> <td align="" class="table-tint table-highlight" colspan="2" rowspan="1" valign=""> <p>No side effects for the mother were reported</p> </td> <td align="" bgcolor="#ffffff" colspan="1" rowspan="1" valign=""></td> <td align="" bgcolor="#ffffff" colspan="1" rowspan="1" valign=""> <p>48<br/>(1 RCT) </p> </td> <td align="" bgcolor="#ffffff" colspan="1" rowspan="1" valign=""> <p>⊕⊕⊝⊝<br/>LOW <sup>1 2</sup> </p> </td> <td align="" bgcolor="#ffffff" colspan="1" rowspan="1" valign=""></td> </tr> <tr class="separated"> <td align="" bgcolor="#ffffff" colspan="1" rowspan="1" valign=""> <p>Serious adverse events for the child</p> <p>follow‐up: mean 15 weeks</p> </td> <td align="" class="table-tint table-highlight" colspan="2" rowspan="1" valign=""> <p>No severe complications were noted in any of the neonates as monitored by polysomnography, although one child in the methadone group had central apnoea and one child in the morphine group had obstructive apnoea. </p> </td> <td align="" bgcolor="#ffffff" colspan="1" rowspan="1" valign=""></td> <td align="" bgcolor="#ffffff" colspan="1" rowspan="1" valign=""> <p>48<br/>(1 RCT) </p> </td> <td align="" bgcolor="#ffffff" colspan="1" rowspan="1" valign=""> <p>⊕⊕⊝⊝<br/>LOW <sup>1 2</sup> </p> </td> <td align="" bgcolor="#ffffff" colspan="1" rowspan="1" valign=""></td> </tr> <tr class="separated"> <td align="" bgcolor="#ffffff" colspan="7" rowspan="1" valign=""> <p>*<b>The risk in the intervention group</b> (and its 95% confidence interval) is based on the assumed risk in the comparison group and the <b>relative effect</b> of the intervention (and its 95% CI).<br/><br/><b>CI:</b> Confidence interval; <b>RR:</b> Risk ratio; <b>OR:</b> Odds ratio; </p> </td> </tr> <tr class="separated"> <td align="" bgcolor="#ffffff" colspan="7" rowspan="1" valign=""> <p><b>GRADE Working Group grades of evidence</b> <br/><b>High certainty:</b> We are very confident that the true effect lies close to that of the estimate of the effect<br/><b>Moderate certainty:</b> We are moderately confident in the effect estimate: The true effect is likely to be close to the estimate of the effect, but there is a possibility that it is substantially different<br/><b>Low certainty:</b> Our confidence in the effect estimate is limited: The true effect may be substantially different from the estimate of the effect<br/><b>Very low certainty:</b> We have very little confidence in the effect estimate: The true effect is likely to be substantially different from the estimate of effect </p> </td> </tr> </tbody> <tfoot> <tr> <td colspan="7"> <div class="table-footnote"> <p><sup>1</sup> not applicable </p> <p><sup>2</sup> downgraded two levels: fewer than 100 participants </p> <p><sup>3</sup> downgraded two level: optimal information size not met </p> </div> </td> </tr> </tfoot> </table> </div> </section> </section> <section class="background"> <div class="section-header section-collapse-header" id="CD006318-sec-0009" lang="en"> <h2 class="title section-collapse-title"> Background <i aria-hidden="true" class="fa fa-caret-up section-collapse-icon"></i> </h2> </div> <section class="background" lang="en"> <div class="section-header" id="CD006318-sec-0009"></div> <section id="CD006318-sec-0010"> <h3 class="title" id="CD006318-sec-0010">Description of the condition</h3> <p>Prenatal opioid use has increased dramatically since 2000. In the United States, the trend of current illegal drug use among pregnant women remained relatively stable from 2007 to 2008 (5.1%) up to 2009 to 2010 (4.4%) (<a href="./references#CD006318-bbs2-0030" title="BehnkeM , SmithVC . Prenatal substance abuse: short- and long-term effects on the exposed fetus. Pediatrics2013;131:e1009-24. [DOI: 10.1542/peds.2012-3931]">Behnke 2013</a>). However, the nationwide use of opioids during pregnancy has increased and more than quadrupled between 1999 and 2014 (<a href="./references#CD006318-bbs2-0041" title="HaightSC , KoJY , TongVT , BohmMK , CallaghanWM . Opioid use disorder documented at delivery hospitalization - United States, 1999-2014. Morbidity and Mortality Weekly Report2018;67(31):845-9. [PMID: 30091969]">Haight 2018</a>). </p> <p>The prevalence of opioid abuse is also increasing in other countries. In Australia, the National Drug Strategy Household Survey in 2013 found that among pregnant women, a small minority had used illicit substances; 2.4% before knowledge of their pregnancy and 1.6% after they knew they were pregnant (<a href="./references#CD006318-bbs2-0028" title="Australian Institute of Health and Welfare. National Drug Strategy Household Survey detailed report 2013. www.aihw.gov.au/reports/illicit-use-of-drugs/2013-ndshs-detailed/contents/table-of-contents (accessed 23 March 2020).">AIHW 2014</a>). In the older version of the same survey conducted in 2010, it was reported that less than one in 20 women (4.2%) who were pregnant and breastfeeding in the past 12 months used any illicit drug while they were pregnant. This included those who used illicit drugs in the time before they knew they were pregnant (<a href="./references#CD006318-bbs2-0027" title="Australian Institute of Health and Welfare. National Drug Strategy Household Survey detailed report 2010. Canberra: Australian Institute of Health and Welfare. www.aihw.gov.au/reports/illicit-use-of-drugs/2010-ndshs/contents/table-of-contents (accessed 23 March 2020).">AIHW 2011</a>). </p> <p>The Canadian Maternity Experiences Survey found that 7% of women reported street drug use in the three months before pregnancy, which was then reduced to 1% once aware of pregnancy (<a href="./references#CD006318-bbs2-0059" title="OrdeanA . Opioid agonist treatment during pregnancy: review of methadone and buprenorphine. In: Best Start Resource Centre Annual Conference; 2018 February 7. en.beststart.org/2018-bsrc-conference-handouts, 2018.">Ordean 2018</a>). The European Monitoring Centre for Drug &amp; Drug Addiction (<a href="./references#CD006318-bbs2-0036" title="European Monitoring Centre for Drugs and Drug Addiction. Pregnancy and opioid use: strategies for treatment. In: EMCDDA Papers. Luxembourg: Publications Office of the European Union, 2014.">EMCDDA 2014</a>) report indicates that the actual prevalence of drug use among pregnant women in Europe is difficult to ascertain. In many European countries, the data are simply not available due to a lack of scheduled antenatal visits among drug users. An isolated study conducted in a maternity hospital in Dublin, Ireland, found that 4% of prenatal and 6% of postnatal women tested positive for drug metabolites. Prevalence data of opioid use among pregnant women in other important data resources are limited (sources searched: World Health Organization (<a href="./references#CD006318-bbs2-0067" title="World Health Organization. Guidelines for the Identification and Management of Substance Use and Substance Use Disorders in Pregnancy. Geneva, Switzerland: World Health Organization, 2014.">WHO 2014</a>), United Nations Office on Drug and Crime ‐ World Drug Report (<a href="./references#CD006318-bbs2-0064" title="UNODC/WHO. World Drug Report 2018. www.unodc.org/wdr2018/ (accessed prior to 8 October 2020).">UNODC 2018</a>), Office of National Drug Control Policy, USA (<a href="./references#CD006318-bbs2-0058" title="Office of National Drug Control Policy. National Drug Control Strategy. Washington, D.C: Office of National Drug Control Policy, Executive Office of the President, 2020.">ONDCP 2020</a>), Monitoring the Future 2019 Survey (<a href="./references#CD006318-bbs2-0056" title="National Institute of Drug Abuse. Monitoring the future: treating opioid use disorder during pregnancy. www.drugabuse.gov/publications/treating-opioid-use-disorder-during-pregnancy (accessed prior to 8 October 2020).">Monitoring the future 2017</a>). </p> <p>Heroin readily crosses the placenta, and untreated opiate dependence in pregnant women is associated with many environmental and medical factors that contribute to poor maternal and child outcomes. It causes a six‐fold increase in obstetric complications, such as low birth weight, toxaemia, third trimester bleeding, malpresentation, puerperal morbidity, fetal distress and meconium aspiration. Neonatal complications include neonatal abstinence syndrome (NAS), postnatal growth deficiency, microcephaly, neurobehavioural problems, increased neonatal mortality and a 74‐fold increase in sudden infant death syndrome (<a href="./references#CD006318-bbs2-0033" title="DattelB . Substance abuse in pregnancy. Seminars in Perinatology1990;14(2):179-87.">Dattel 1990</a>; <a href="./references#CD006318-bbs2-0038" title="Fajemirokun-OdudeyiO , SinhaC , TuttyS , PairaudeauP , ArmstrongD , PhillipsT , et al. Pregnancy outcome in women who use opiates. European Journal of Obstetrics, Gynecology, and Reproductive Biology2006;126(2):170-5.">Fajemirokun 2006</a>; <a href="./references#CD006318-bbs2-0051" title="LudlowJP , EvansSF , HulseG . Obstetric and perinatal outcomes in pregnancies associated with illicit substance abuse. Australian and New Zealand Journal of Obstetrics and Gynaecology2004;44(4):301-6.">Ludlow 2004</a>; <a href="./references#CD006318-bbs2-0061" title="ReddyUM , DavisJM , RenZ , GreeneMF , Opioid Use in Pregnancy, Neonatal Abstinence Syndrome, and Childhood Outcomes Workshop invited speakers. Opioid use in pregnancy, neonatal abstinence syndrome, and childhood outcomes: executive summary of a joint workshop by the Eunice Kennedy Shriver National Institute of Child Health and Human Development, American Congress of Obstetricians and Gynecologists, American Academy of Pediatrics, Society for Maternal-Fetal Medicine, Centers for Disease Control and Prevention, and the March of Dimes Foundation. Obstetrics and Gynecology2017;130(1):10-28.">Reddy 2017</a>). </p> <p>All of the commonly used opioids, including heroin and methadone, can produce neonatal abstinence syndrome in infants born to opiate‐dependent mothers. Neonatal abstinence syndrome combines all the symptoms of an adult withdrawal syndrome with irritability, poorly co‐ordinated sucking and, in the most severe cases, seizures and death (<a href="./references#CD006318-bbs2-0048" title="KaltenbachK , BerghellaV , FinneganL . Opioid dependence during pregnancy: effects and management. Obstetrics and Gynecology Clinics of North America1998;25:139-51.">Kaltenbach 1998</a>). </p> </section> <section id="CD006318-sec-0011"> <h3 class="title" id="CD006318-sec-0011">Description of the intervention</h3> <p>Since the early 1970s, treatment with methadone has been the standard of care for pregnant women addicted to opiates. Despite its ability to induce fetal dependence and withdrawal, maintenance treatment provides a steady concentration in the maternal blood plasma. It thus prevents the adverse effects of repeated withdrawal on the fetus (<a href="./references#CD006318-bbs2-0045" title="JarvisMA , SchnollSH . Methadone treatment during pregnancy. Journal of Psychoactive Drugs1994;26(2):155-61.">Jarvis 1994</a>). </p> <p>Buprenorphine has also been administered to opioid‐dependent pregnant women as a maintenance treatment. Placental transfer of buprenorphine may be less than with methadone, reducing fetal exposure and development of neonatal abstinence syndrome (<a href="./references#CD006318-bbs2-0060" title="RayburnW , BogenschutzMP . Pharmacotherapy for pregnant women with addiction. American Journal of Obstetrics and Gynecology2004;191:1885-97.">Rayburn 2004</a>). </p> </section> <section id="CD006318-sec-0012"> <h3 class="title" id="CD006318-sec-0012">How the intervention might work</h3> <p>Methadone maintenance treatment given during pregnancy reduces maternal illicit opiate use and fetal exposure, enhances compliance with obstetric care, and is associated with improved neonatal outcomes such as heavier birth weight (<a href="./references#CD006318-bbs2-0038" title="Fajemirokun-OdudeyiO , SinhaC , TuttyS , PairaudeauP , ArmstrongD , PhillipsT , et al. Pregnancy outcome in women who use opiates. European Journal of Obstetrics, Gynecology, and Reproductive Biology2006;126(2):170-5.">Fajemirokun 2006</a>; <a href="./references#CD006318-bbs2-0048" title="KaltenbachK , BerghellaV , FinneganL . Opioid dependence during pregnancy: effects and management. Obstetrics and Gynecology Clinics of North America1998;25:139-51.">Kaltenbach 1998</a>). Additional benefits include a potential reduction in drug‐seeking behaviours, including commercial sex, to gain money for drugs. This reduction may decrease a woman's chance of acquiring sexually transmitted diseases such as human immunodeficiency virus (HIV) and hepatitis. For all these reasons, methadone treatment has become the 'gold standard' for the management of pregnant heroin users (<a href="./references#CD006318-bbs2-0057" title="National Institutes of Health Consensus Development Panel. Effective medical treatment of opiate addiction. JAMA1998;280(22):1936-43.">NIH 1998</a>) and many guidelines, in the UK (<a href="./references#CD006318-bbs2-0063" title="Department of Health (England), The Scottish Government, Welsh Assembly Government and Northern Ireland Executive. Drug Misuse and Dependence: UK Guidelines on Clinical Management. www.smmgp.org.uk2007.">UK Guidelines 2007</a>), USA (<a href="./references#CD006318-bbs2-0032" title="Center for Substance Abuse Treatment. Medication-assisted treatment for opioid addiction in opioid treatment programs. (Treatment Improvement Protocol Series 43). www.ncbi. nlm.nih.gov2005.">CSAT 2005</a>) and Australia (<a href="./references#CD006318-bbs2-0034" title="DunlopAJ , PanjariM , O'SullivanH , HenschkeP , Love V et al. Clinical guidelines for the use of buprenorphine in pregnancy. Turning Point Alcohol and Drug Centre, Fitzroy, Australia2003.">Dunlop 2003</a>), support the use of methadone during pregnancy. </p> <p>Previous studies have been performed in centres that offered methadone and comprehensive services, including obstetric, health, psychiatric care, individual, group and family therapy. Consequently, it is difficult to evaluate the results of these studies and to distinguish the benefits of methadone itself from other measures of psychosocial and obstetric care (<a href="./references#CD006318-bbs2-0065" title="WangEC . Methadone treatment during pregnancy. Journal of Obstetric, Gynecologic, and Neonatal Nursing1999;28:615-22.">Wang 1999</a>). </p> <p>The available clinical literature suggests that buprenorphine maintenance is also associated with reduced maternal illicit opiate use and fetal exposure, enhanced compliance with obstetric care, and improved neonatal outcomes such as heavier birth weight (<a href="./references#CD006318-bbs2-0046" title="JohnsonRE , JonesHE , FisherG . Use of buprenorphine in pregnancy: patient management and effects on the neonate. Drug and Alcohol Dependence2003;70:S87-101.">Johnson 2003</a>; <a href="./references#CD006318-bbs2-0050" title="LejueneC , Simmat-DurandL , GourarierL , Aubisson S for the Groupe d'Etudes Grossesses et Addictions (GEGA). Prospective multicenter observational study of 260 infants born to 259 opiate-dependent mothers on methadone or high-dose buprenorphine substitution. Drug and Alcohol Dependence2006;82(3):250-7.">Lejuene 2006</a>). </p> </section> <section id="CD006318-sec-0013"> <h3 class="title" id="CD006318-sec-0013">Why it is important to do this review</h3> <p>The Cochrane Drugs and Alcohol Group has conducted several systematic reviews on maintenance treatment: methadone (<a href="./references#CD006318-bbs2-0037" title="FaggianoF , Vigna-TagliantiF , VersinoE , LemmaP . Methadone maintenance at different dosages for opioid dependence. Cochrane Database of Systematic Reviews2003, Issue 3. Art. No: CD002208. [DOI: 10.1002/14651858.CD002208]">Faggiano 2003</a>; <a href="./references#CD006318-bbs2-0053" title="MattickRP , BreenC , KimberJ , DavoliM . Methadone maintenance therapy versus no opioid replacement therapy for opioid dependence. Cochrane Database of Systematic Reviews2009, Issue 3. Art. No: CD002209. [DOI: 10.1002/14651858.CD002209.pub2]">Mattick 2009</a>), heroin (<a href="./references#CD006318-bbs2-0039" title="FerriM , DavoliM , PerucciCA . Heroin maintenance for chronic heroin-dependent individuals. Cochrane Database of Systematic Reviews2011, Issue 12. Art. No: CD003410. [DOI: 10.1002/14651858.CD003410.pub4]">Ferri 2011</a>), levomethadyl acetate hydrochloride (LAAM) (<a href="./references#CD006318-bbs2-0031" title="ClarkNC , LintzerisN , GijsbersA , WhelanG , DunlopA , RitterA , et al. LAAM maintenance vs methadone maintenance for heroin dependence. Cochrane Database of Systematic Reviews2002, Issue 2. Art. No: CD002210. [DOI: 10.1002/14651858.CD002210]">Clark 2002</a>), buprenorphine (<a href="./references#CD006318-bbs2-0052" title="MattickRP , KimberJ , BreenC , DavoliM . Buprenorphine maintenance versus placebo or methadone maintenance for opioid dependence. Cochrane Database of Systematic Reviews2008, Issue 2. Art. No: CD002207. [DOI: 10.1002/14651858.CD002207.pub3]">Mattick 2008</a>), naltrexone (<a href="./references#CD006318-bbs2-0055" title="MinozziS , AmatoL , VecchiS , DavoliM , KirchmayerU , VersterA . Oral naltrexone maintenance treatment for opioid dependence. Cochrane Database of Systematic Reviews2011, Issue 4. Art. No: CD001333. [DOI: 10.1002/14651858.CD001333.pub4]">Minozzi 2011</a>), psychosocial treatment alone (<a href="./references#CD006318-bbs2-0054" title="MayetS , FarrellM , FerriM , AmatoL , DavoliM . Psychosocial treatment for opiate abuse and dependence. Cochrane Database of Systematic Reviews2004, Issue 4. Art. No: CD004330. [DOI: 10.1002/14651858.CD004330.pub2]">Mayet 2004</a>) and psychosocial treatment combined with maintenance treatment (<a href="./references#CD006318-bbs2-0029" title="AmatoL , MinozziS , DavoliM , VecchiS , FerriM , MayetS . Psychosocial combined with agonist maintenance treatments versus agonist maintenance treatments alone for treatment of opioid dependence. Cochrane Database of Systematic Reviews2011, Issue 10. Art. No: CD004147. [DOI: 10.1002/14651858.CD004147.pub4]">Amato 2011</a>). However, none of these reviews include studies on pregnant, opiate‐dependent women. </p> <p>Two narrative reviews have discussed the risks and benefits of maintenance treatment in opiate‐dependent women (<a href="./references#CD006318-bbs2-0060" title="RayburnW , BogenschutzMP . Pharmacotherapy for pregnant women with addiction. American Journal of Obstetrics and Gynecology2004;191:1885-97.">Rayburn 2004</a>; <a href="./references#CD006318-bbs2-0065" title="WangEC . Methadone treatment during pregnancy. Journal of Obstetric, Gynecologic, and Neonatal Nursing1999;28:615-22.">Wang 1999</a>); however, neither specified the inclusion criteria for the studies. They also described the studies and the results in a very generic way and did not draw firm conclusions about the superiority of one drug treatment over another. Two other out‐of‐date reviews also included observational studies and assessed the relationship between maternal opiate use and infant birth weight (<a href="./references#CD006318-bbs2-0043" title="HulseGK , MilneE , EnglishDR , HolmanCD . The relationship between maternal use of heroin and methadone and infant birth weight. Addiction1997;92(11):1571-9.">Hulse 1997</a>) and neonatal mortality (<a href="./references#CD006318-bbs2-0044" title="HulseGK , MilneE , EnglishDR , HolmanCD . The relationship between maternal opiate use and neonatal mortality. Addiction1998;93(7):1033-42.">Hulse 1998</a>). They found better results in patients taking methadone in terms of birth weight but no reduction in mortality. A more recent observational systematic review was conducted on the efficacy and safety of detoxification from opioids compared to maintenance with methadone or buprenorphine to treat opioid‐dependent pregnant women (<a href="./references#CD006318-bbs2-0066" title="WangM . Opioid detoxification during pregnancy: systematic review and meta-analysis of maternal and neonatal outcomes. Obstetrics &amp; Gynecology2018;131:197s.">Wang 2018</a>). They included 235 pregnant women from three cohort studies in the meta‐analysis. Maternal maintenance therapy was associated with increased risk of relapse (RR 1.91, 95% confidence interval (CI)  1.14 to 3.21) but no treatment differences were observed for rates of NAS (RR 0.99, 95% CI 0.38 to 2.53) or preterm birth (RR 0.39, 95% CI 0.10 to 1.60). Another narrative review was conducted (including 75 articles from 1975 to 2015) and concluded that women with opioid use addiction during pregnancy could be treated with methadone or buprenorphine (<a href="./references#CD006318-bbs2-0049" title="KlamanSL , IsaacsK , LeopoldA , PerpichJ , HayashiS , VenderJ , et al. Treating women who are pregnant and parenting for opioid use disorder and the concurrent care of their infants and children: literature review to support national guidance. Journal of Addiction Medicine2017;11:178-90.">Klaman 2017</a>). </p> </section> </section> </section> <section class="objectives"> <div class="section-header section-collapse-header" id="CD006318-sec-0014" lang="en"> <h2 class="title section-collapse-title"> Objectives <i aria-hidden="true" class="fa fa-caret-up section-collapse-icon"></i> </h2> </div> <section class="objectives" lang="en"> <div class="section-header" id="CD006318-sec-0014"></div> <p>To assess the effectiveness of any opioid agonist maintenance treatment alone or in combination with a psychosocial intervention compared to no intervention, other pharmacological intervention or psychosocial interventions for child health status, neonatal mortality, retaining pregnant women in treatment, and reducing the use of substances. </p> </section> </section> <section class="methods"> <div class="section-header section-collapse-header" id="CD006318-sec-0015" lang="en"> <h2 class="title section-collapse-title"> Methods <i aria-hidden="true" class="fa fa-caret-up section-collapse-icon"></i> </h2> </div> <section class="methods" lang="en"> <div class="section-header" id="CD006318-sec-0015"></div> <section id="CD006318-sec-0016"> <h3 class="title">Criteria for considering studies for this review</h3> <section id="CD006318-sec-0017"> <h4 class="title">Types of studies</h4> <p>Randomised controlled trials which enrolled pregnant women were eligible. Studies starting after the delivery were excluded. </p> </section> <section id="CD006318-sec-0018"> <h4 class="title">Types of participants</h4> <p>Opiate‐addicted according to the "Diagnostic and Statistical Manual of mental disorders" (DSM‐IV or DSM‐V) criteria pregnant women of any age irrespective of the duration of pregnancy. There was no restriction concerning the physical or psychological illness. </p> </section> <section id="CD006318-sec-0019"> <h4 class="title">Types of interventions</h4> <section id="CD006318-sec-0020"> <h5 class="title">Experimental intervention</h5> <p> <ul id="CD006318-list-0001"> <li> <p>Any pharmacological intervention (methadone, buprenorphine, LAAM, heroin, morphine, codeine) alone or combined with psychosocial intervention(s) for maintenance treatment </p> </li> </ul> </p> </section> <section id="CD006318-sec-0021"> <h5 class="title">Control intervention</h5> <p> <ul id="CD006318-list-0002"> <li> <p>No intervention</p> </li> <li> <p>Other pharmacological interventions</p> </li> <li> <p>Psychosocial intervention alone</p> </li> </ul> </p> </section> </section> <section id="CD006318-sec-0022"> <h4 class="title">Types of outcome measures</h4> <section id="CD006318-sec-0023"> <h5 class="title">For the woman</h5> <p>1. <b>Dropout</b> from treatment, as measured by the number of women who had dropped out at the end of the intervention </p> <p>2. <b>Use of primary substance of abuse</b> </p> <p>2.1 Use of primary substance as measured by the number of women using heroin during or at the end of treatment (self‐report or urine analysis results) </p> <p>2.2. Use of primary substance at follow‐up as measured by the number of women using heroin at the end of follow‐up (after childbirth) </p> <p>3. <b>Obstetric outcomes</b> </p> <p>3.1 Third trimester bleeding</p> <p>3.2 Fetal distress and meconium aspiration</p> <p>3.3 Caesarean section</p> <p>3.4 Abnormal presentation</p> <p>3.5 Medical complications at delivery</p> <p>3.6 Breastfeeding following delivery</p> <p>3.7 Puerperal morbidity</p> </section> <section id="CD006318-sec-0024"> <h5 class="title">For the child</h5> <p>4. <b>Health status</b> measured as: </p> <p>4.1 Birth weight</p> <p>4.2 APGAR score (Activity, Pulse, Grimace, Appearance and Respiration score)</p> <p>4.3 Neonatal abstinence syndrome</p> <p>4.4 Prenatal and neonatal mortality </p> </section> <section id="CD006318-sec-0025"> <h5 class="title">Secondary outcomes</h5> <p>5. Nicotine consumption<br/>6. Use of other substances<br/>7. Side effects for the mother<br/>8. Side effects for the child </p> </section> </section> </section> <section id="CD006318-sec-0026"> <h3 class="title">Search methods for identification of studies</h3> <section id="CD006318-sec-0027"> <h4 class="title">Electronic searches</h4> <p>For this update, we revised all our search strategies in line with current Cochrane Drugs and Alcohol Group practices. We searched the following databases up to 18 February 2020: </p> <p> <ul id="CD006318-list-0003"> <li> <p>Cochrane Drugs and Alcohol Group (CDAG) Specialised Register (searched 18 February 2020) <a href="./appendices#CD006318-sec-0124">Appendix 1</a>; </p> </li> <li> <p>Cochrane Central Register of Controlled Trials (CENTRAL) via the Cochrane Register of Studies (CRS‐Web); (searched 18 February 2020) <a href="./appendices#CD006318-sec-0125">Appendix 2</a>; </p> </li> <li> <p>MEDLINE (OVID) (2013 to 18 February 2020) <a href="./appendices#CD006318-sec-0126">Appendix 3</a>; </p> </li> <li> <p>Embase (OVID) (2013 to 18 February 2020) <a href="./appendices#CD006318-sec-0127">Appendix 4</a>; </p> </li> <li> <p>PsycINFO (Ovid) (2013 to 18 February 2020) <a href="./appendices#CD006318-sec-0128">Appendix 5</a>; </p> </li> <li> <p>CINAHL (EBSCO Host) (2013 to 18 February 2020) <a href="./appendices#CD006318-sec-0129">Appendix 6</a>; </p> </li> <li> <p>Web of Science (2013 to 18 February 2020) <a href="./appendices#CD006318-sec-0130">Appendix 7</a>. </p> </li> </ul> </p> <p>We searched the following trials registries on 18 February 2020:</p> <p> <ol id="CD006318-list-0004"> <li> <p>ClinicalTrials.gov (<a href="http://clinicaltrials.gov/" target="_blank">clinicaltrials.gov</a>); </p> </li> <li> <p>World Health Organization (WHO) International Clinical Trials Registry Platform (ICTRP) (<a href="http://apps.who.int/trialsearch/" target="_blank">apps.who.int/trialsearch/</a>). </p> </li> </ol> </p> <p>Details of the previous search strategies are available in <a href="./references#CD006318-bbs2-0070" title="MinozziS , AmatoL , BellisarioC , FerriM , DavoliM . Maintenance agonist treatments for opiate-dependent pregnant women. Cochrane Database of Systematic Reviews2013, Issue 12. Art. No: CD006318. [DOI: 10.1002/14651858.CD006318.pub3]">Minozzi 2013</a>. </p> </section> <section id="CD006318-sec-0028"> <h4 class="title">Searching other resources</h4> <p>We checked the bibliographies of included studies and relevant reviews for further references to relevant trials. </p> <p>We contacted the authors of included studies and experts in the field in various countries to find out if they knew any other published or unpublished controlled trials. </p> <p>We did not apply any language restrictions.</p> </section> </section> <section id="CD006318-sec-0029"> <h3 class="title" id="CD006318-sec-0029">Data collection and analysis</h3> <section id="CD006318-sec-0030"> <h4 class="title">Selection of studies</h4> <p>Two authors (Minozzi, Bellisario) independently inspected the search hits by reading titles and abstracts. We obtained each potentially relevant study located by the search in full text and the two authors assessed each for inclusion independently. Doubts were resolved by discussion between the authors. </p> </section> <section id="CD006318-sec-0031"> <h4 class="title">Data extraction and management</h4> <p>Two authors (Minozzi, Bellisario) independently extracted data from studies using a standardised checklist. Any disagreement was resolved by discussion. </p> </section> <section id="CD006318-sec-0032"> <h4 class="title">Assessment of risk of bias in included studies</h4> <p>Two authors (Minozzi, Bellisario) independently performed the 'Risk of bias' assessment for RCTs and "Controlled Clinical Trials"(CCTs) using the criteria recommended in the <i>Cochrane Handbook for Systematic Reviews of Interventions</i> (<a href="./references#CD006318-bbs2-0042" title="HigginsJPT , GreenS , editors. Cochrane Handbook for Systematic Reviews of Interventions 5.1.0 [updated March 2011]. The Cochrane Collaboration, 2011. Available from handbook.cochrane.org.">Higgins 2011</a>). The recommended approach for assessing the risk of bias in studies included in Cochrane Reviews is a two‐part tool, addressing six specific domains, namely: sequence generation and allocation concealment (selection bias), blinding of participants and providers (performance bias), blinding of outcome assessor (detection bias), incomplete outcome data (attrition bias), selective outcome reporting (reporting bias). The first part of the tool involves describing what was reported to have happened in the study. The second part of the tool consists of assigning a judgement relating to the risk of bias for that entry in terms of low, high or unclear risk. To make these judgements, we used the criteria indicated in the <i>Cochrane Handbook for Systematic Reviews of Interventions</i> adapted to the addiction field. See <a href="./appendices#CD006318-sec-0131">Appendix 8</a> for details. </p> <p>We considered blinding of participants, personnel and outcome assessors (avoidance of performance bias and detection bias) separately for objective outcomes (e.g. dropouts, use of the substance of abuse measured by urine analysis, participants relapsed at the end of follow‐up, participants engaged in further treatment) and subjective outcomes (e.g. duration and severity of signs and symptoms of withdrawal, patient self‐reported use of the substance, side effects). </p> <p>We considered incomplete outcome data (avoidance of attrition bias) for all outcomes except for dropout from the treatment, which is very often the primary outcome measure in trials on addiction. </p> <section id="CD006318-sec-0033"> <h5 class="title">Grading of evidence</h5> <p>We assessed the overall quality of the evidence for the primary outcomes and the secondary outcome "side effects" using the GRADE system. The Grading of Recommendation, Assessment, Development and Evaluation Working Group (GRADE) developed a method for grading the quality of evidence (<a href="./references#CD006318-bbs2-0062" title="SchunemannH , BrozekJ , GuyattG , OxmanA , editor(s). Handbook for grading the quality of evidence and the strength of recommendations using the GRADE approach (updated October 2013). GRADE Working Group, 2013. Available from gdt.guidelinedevelopment.org/app/handbook/handbook.html.">Schunemann 2013</a>), which takes into account issues not only related to internal validity but also external validity, such as directness of results. The 'Summary of findings' tables presents the main findings of a review in a transparent and straightforward tabular format. In particular, they provide crucial information concerning the quality of evidence, the magnitude of the effect of the interventions examined and the sum of available data on the primary outcomes. </p> <p>The GRADE system uses the following criteria for assigning grades of evidence:</p> <p> <ul id="CD006318-list-0005"> <li> <p>High: further research is very unlikely to change our confidence in the estimate of effect. </p> </li> <li> <p>Moderate: Further research is likely to have an important impact on our confidence in the estimate of effect and may change the estimate. </p> </li> <li> <p>Low: Further research is very likely to have an important impact on our confidence in the estimate of effect and is likely to change the estimate. </p> </li> <li> <p>Very low: any estimate of effect is very uncertain.</p> </li> </ul> </p> <p>Grading is decreased for the following reasons:</p> <p> <ul id="CD006318-list-0006"> <li> <p>Serious (‐1) or very serious (‐2) limitation to study quality.</p> </li> <li> <p>Important inconsistency (‐1).</p> </li> <li> <p>Some (‐1) or major (‐2) uncertainty about directness.</p> </li> <li> <p>Imprecise or sparse data (‐1).</p> </li> <li> <p>High probability of reporting bias (‐1).</p> </li> </ul> </p> </section> </section> <section id="CD006318-sec-0034"> <h4 class="title">Measures of treatment effect</h4> <p>We analysed dichotomous outcomes by calculating the risk ratio (RR) for each trial with the uncertainty in each result being expressed by its confidence interval. We analysed continuous outcomes by calculating the mean difference (MD) or the standardised mean difference (SMD) with 95% CI. For nicotine use, we compared the contrast of the mean number of cigarettes smoked from baseline to end of treatment in the experimental and control groups. In the case of missing standard deviations (SDs) for the difference from baseline to the end of treatment, we imputed the SD using the SD of the mean at the end of treatment for each group. </p> <p>We did not use data presented as the number of positive urine tests over the total number of tests in the experimental and control group as a measure of substance abuse. This is because using tests instead of participants as the unit of analysis violates the hypothesis of independence among observations. In fact, the results of tests done in each participant are not independent. </p> </section> <section id="CD006318-sec-0035"> <h4 class="title">Unit of analysis issues</h4> <p>If multi‐arm studies were included in the meta‐analyses and one arm was considered more than once in the same comparisons (e.g. two different dosages of drugs compared with the same control group), we combined all the relevant experimental groups into a single group and we compared it with the control to avoid double counting of participants in the control groups. No cross‐over or cluster‐randomised trials were expected to be found because these study desings are not adequate with these types of participants and of interventions . </p> </section> <section id="CD006318-sec-0036"> <h4 class="title">Dealing with missing data</h4> <p>For the analysis of binary outcome data (number of women using heroin), all randomised patients were included in the statistical analysis, with those who dropped out or were lost to follow‐up assigned to the 'using drug' category. For continuous outcomes, only the available data were considered. </p> </section> <section id="CD006318-sec-0037"> <h4 class="title">Assessment of heterogeneity</h4> <p>We analysed heterogeneity by means of the I<sup>2</sup> statistic and the Chi<sup>2</sup> test for heterogeneity. The cut points were an I<sup>2</sup> value &gt; 50% and a P‐value of the Chi<sup>2</sup> test of &lt; 0.1. </p> </section> <section id="CD006318-sec-0038"> <h4 class="title">Assessment of reporting biases</h4> <p>We intended to use funnel plots (plots of the effect estimate from each study against the standard error) to assess the potential for bias related to the size of the trials, which could indicate possible publication bias, if a sufficient number of studies (i.e. at least ten studies) were included. If asymmetry had been found, we would have conducted the Egger test (<a href="./references#CD006318-bbs2-0035" title="EggerM , Davey SmithG , SchneiderM , MinderC . Bias in meta-analysis detected by a simple, graphical test. BMJ1997;315:629-34.">Egger 1997</a>). </p> </section> <section id="CD006318-sec-0039"> <h4 class="title">Data synthesis</h4> <p>We combined the outcome measures from the individual trials through meta‐analysis where possible (good comparability of intervention and outcomes between trials). We used the random‐effect model because we expected a certain degree of heterogeneity among trials </p> </section> <section id="CD006318-sec-0040"> <h4 class="title">Subgroup analysis and investigation of heterogeneity</h4> <p>No subgroup analyses were planned. In case of substantial heterogeneity (i.e. I<sup>2</sup> value &gt; 90%) and inconsistency in the direction of effect, meta‐analysis was not done. </p> </section> <section id="CD006318-sec-0041"> <h4 class="title">Sensitivity analysis</h4> <p>To incorporate the assessment of risk of bias into the review process, we first plotted the intervention effect estimates against the evaluation of risk of bias. We inspected the results stratified for risk of bias. If we found significant associations between the measure of effect and risk of bias, we excluded studies with a high risk of bias from the analysis. The items considered in the sensitivity analysis were: random sequence generation, allocation concealment and blinding of personnel and outcome assessors. </p> </section> </section> </section> </section> <section class="results"> <div class="section-header section-collapse-header" id="CD006318-sec-0042" lang="en"> <h2 class="title section-collapse-title"> Results <i aria-hidden="true" class="fa fa-caret-up section-collapse-icon"></i> </h2> </div> <section class="results" lang="en"> <div class="section-header" id="CD006318-sec-0042"></div> <section id="CD006318-sec-0043"> <h3 class="title">Description of studies</h3> <section id="CD006318-sec-0044"> <h4 class="title">Results of the search</h4> <p>In the previous version of our review (<a href="./references#CD006318-bbs2-0070" title="MinozziS , AmatoL , BellisarioC , FerriM , DavoliM . Maintenance agonist treatments for opiate-dependent pregnant women. Cochrane Database of Systematic Reviews2013, Issue 12. Art. No: CD006318. [DOI: 10.1002/14651858.CD006318.pub3]">Minozzi 2013</a>), we retrieved a total of 1385 records. Once duplicates had been removed, we had a total of 968 records. We excluded 933 records based on titles and abstracts. We obtained the full text of the remaining 35 records. We excluded 20 studies. We included four studies reported in 15 references (see <a href="./references#CD006318-sec-0141" title="">Characteristics of included studies</a>). For a further description of our screening process, see the study flow diagram (<a href="#CD006318-fig-0001">Figure 1</a>). </p> <div class="figure" id="CD006318-fig-0001"> <div class="figure-caption-wrapper-top"> <nav class="inline-nav-list has-dividers"> <ul> <li><a class="open-in-figure-viewer" href="#0">Open in figure viewer</a></li> </ul> </nav> <div class="figure-label">Figure 1</div> </div> <hr class="top"/><img alt="Study flow diagram September 2013." data-id="CD006318-fig-0001" src="/cdsr/doi/10.1002/14651858.CD006318.pub4/media/CDSR/CD006318/image_n/nCD006318-FIG-01.png"/><hr class="bottom"/> <div class="figure-caption-wrapper-bottom"> <div class="figure-caption"> <p>Study flow diagram September 2013.</p> </div> </div> </div> <p>As shown in <a href="#CD006318-fig-0002">Figure 2</a>, our update searches identified 633 records. Once duplicates had been removed, we had a total of 467 records. We screened out 462 references based on titles and abstracts. We examined the remaining five records in full text and excluded one (see <a href="./references#CD006318-sec-0142" title="">Characteristics of excluded studies</a>). We did not include new studies; the remaining four records are new reposts of a previously included study (<a href="./references#CD006318-bbs2-0004" title="ChisolmMS , FitzsimonsH , LeoutsakosJM , AcquavitaSP , HeilSH , Wilson-MurphyM , et al. A comparison of cigarette smoking profiles in opioid-dependent pregnant patients receiving methadone or buprenorphine. Nicotine Tobacco Research2013;15(7):1297-304. CoyleMG , SalisburyAL , LesterBM , JonesHE , LinH , Graf-RohrmeisterK , et al. Neonatal neurobehavior effects following buprenorphine versus methadone exposure. Addiction2012;107(Suppl 1):63-73. GaalemaDE , ScottTL , HeilSH , CoyleMG , KaltenbachK , BadgerGJ , et al. Differences in the profile of neonatal abstinence syndrome signs in methadone- versus buprenorphine-exposed neonates. Addiction2012;107(Suppl 1):53-62. HolbrookAM , BaxterJK , JonesHE , HeilSH , CoyleMG , MartinPR , et al. Infections and obstetric outcomes in opioid-dependent pregnant women maintained on methadone or buprenorphine. Addiction2012;107(Suppl 1):83-90. HolbrookAM , JonesHE , HeilSH , MartinPR , StineSM , FischerG , et al. Induction of pregnant women onto opioid-agonist maintenance medication: an analysis of withdrawal symptoms and study retention. Drug and Alcohol Dependence2013;132(0):329-34. JanssonLM , DipietroJA , VelezM , ElkoA , WilliamsE , MilioL , et al. Fetal neurobehavioral effects of exposure to methadone or buprenorphine. Neurotoxicology and Teratology2011;33(2):240-3. JonesHE , DenglerE , GarrisondA , O'GradyeKE , SeashoreC , HortonE , et al. Neonatal outcomes and their relationship to maternal buprenorphine dose during pregnancy. Drug and Alcohol Dependence2014;134:414-7. JonesHE , FischerG , HeilSH , KaltenbachK , MartinPR , CoyleMG , et al. Maternal Opioid Treatment: Human Experimental Research (MOTHER) - approach, issues and lessons learned. Addiction2012;107(Suppl 1):28-35. JonesHE , JanssonLM , O’GradycKE , KaltenbachK . The relationship between maternal methadone dose at delivery and neonatal outcome: methodological and design considerations. Neurotoxicology and Teratology2013:110-5. [DOI: 10.1016/j.ntt.2013.05.003]JonesHE , JohnsonRE , JasinskiDR , TutenM , MilioL . Dosing pre to postpartum with either buprenorphine or methadone. In: 69th Annual Scientific Meeting of the College on Problems of Drug Dependence. Quebec City, Canada, 2007:16-21. JonesHE , JohnsonRE , O'GradyKE , JasinskiDR , TutenM , MilioL . Dosing adjustments in postpartum patients maintained on buprenorphine or methadone. Journal of Addiction Medicine2008;2(2):103-7. JonesHE , KaltenbachK , HeilSH , StineSM , CoyleMG , ArriaAM , et al. Neonatal abstinence syndrome after methadone or buprenorphine exposure. New England Journal of Medicine2010;363:2320-31. KaltenbachK , O’GradyKE , HeilSH , SalisburyAL , CoyleMG , FischerG , et al. Prenatal exposure to methadone or buprenorphine: early childhood developmental outcomes. Drug and Alcohol Dependence2018;185:40-9. UngerA , JagschR , BäwertA , WinklbaurB , RohrmeisterK , MartinPR , et al. Are male neonates more vulnerable to neonatal abstinence syndrome than female neonates?Gender Medicine2011;8(6):355-64. Wilson-MurphyMM , ChisolmMS , LeoutsakosJS , KaltenbachK , HeilSH , MartinPR . Treatment completion in opioid-dependent pregnant patients randomised to agonist treatment: the role of intravenous drug use. In: 73rd Annual Scientific Meeting of the College on Problems of Drug Dependence. 2011:195, Abstract no: 778. Winklbaur-HausknostB , JagschR , Graf-RohrmeisterK , UngerA , BaewertA , LangerM , et al. Lessons learned from a comparison of evidence-based research in pregnant opioid-dependent women. Human Psychopharmacology2013;28(1):15-24. ">MOTHER Study</a>). We identified one ongoing study (<a href="./references#CD006318-bbs2-0026" title="NCT03098407. Opioid dependence treatment therapies in pregnancy [A pilot randomized comparative effectiveness clinical trial of buprenorphine vs. methadone for the treatment of opioid dependence in pregnancy]. clinicaltrials.gov/show/NCT03098407 (first received 31 March 2017). ">NCT 03098407</a>). </p> <div class="figure" id="CD006318-fig-0002"> <div class="figure-caption-wrapper-top"> <nav class="inline-nav-list has-dividers"> <ul> <li><a class="open-in-figure-viewer" href="#0">Open in figure viewer</a></li> </ul> </nav> <div class="figure-label">Figure 2</div> </div> <hr class="top"/><img alt="Study flow diagram February 2020." data-id="CD006318-fig-0002" src="/cdsr/doi/10.1002/14651858.CD006318.pub4/media/CDSR/CD006318/image_n/nCD006318-FIG-02.png"/><hr class="bottom"/> <div class="figure-caption-wrapper-bottom"> <div class="figure-caption"> <p>Study flow diagram February 2020.</p> </div> </div> </div> </section> <section id="CD006318-sec-0045"> <h4 class="title">Included studies</h4> <p>Four studies with 271 participants met the inclusion criteria for this review.</p> <section id="CD006318-sec-0046"> <h5 class="title">Duration of trials</h5> <p>The mean duration of the trials was 16.3 weeks (range 15 to 18 weeks).</p> </section> <section id="CD006318-sec-0047"> <h5 class="title">Treatment regimens and settings</h5> <p>Two trials were conducted in Austria (<a href="./references#CD006318-bbs2-0001" title="FischerG , JagschR , EderH , GombasW , EtzerdorferP , Schmidl-MohlK , et al. Comparison of methadone and slow-release morphine maintenance in pregnant addicts. Addiction1999;94(2):231-9. ">Fischer 1999</a>; <a href="./references#CD006318-bbs2-0002" title="FischerG , OrtnerR , RohrmeisterK , JagschR , BaewertA , LangerM , et al. Methadone versus buprenorphine in pregnant addicts: a double-blind, double dummy comparison study. Addiction2006;101(2):275-81. ">Fischer 2006</a>) and one in the USA (<a href="./references#CD006318-bbs2-0003" title="JonesHE , JohnsonRE , JasinskiDR , O'GradyKE , ChisholmCA , ChooRE , et al. Buprenorphine versus methadone in the treatment of pregnant opioid-dependent patients: effects on the neonatal abstinence syndrome. Drug and Alcohol Dependence2005;79(1):1-10. ">Jones 2005</a>). The <a href="./references#CD006318-bbs2-0004" title="ChisolmMS , FitzsimonsH , LeoutsakosJM , AcquavitaSP , HeilSH , Wilson-MurphyM , et al. A comparison of cigarette smoking profiles in opioid-dependent pregnant patients receiving methadone or buprenorphine. Nicotine Tobacco Research2013;15(7):1297-304. CoyleMG , SalisburyAL , LesterBM , JonesHE , LinH , Graf-RohrmeisterK , et al. Neonatal neurobehavior effects following buprenorphine versus methadone exposure. Addiction2012;107(Suppl 1):63-73. GaalemaDE , ScottTL , HeilSH , CoyleMG , KaltenbachK , BadgerGJ , et al. Differences in the profile of neonatal abstinence syndrome signs in methadone- versus buprenorphine-exposed neonates. Addiction2012;107(Suppl 1):53-62. HolbrookAM , BaxterJK , JonesHE , HeilSH , CoyleMG , MartinPR , et al. Infections and obstetric outcomes in opioid-dependent pregnant women maintained on methadone or buprenorphine. Addiction2012;107(Suppl 1):83-90. HolbrookAM , JonesHE , HeilSH , MartinPR , StineSM , FischerG , et al. Induction of pregnant women onto opioid-agonist maintenance medication: an analysis of withdrawal symptoms and study retention. Drug and Alcohol Dependence2013;132(0):329-34. JanssonLM , DipietroJA , VelezM , ElkoA , WilliamsE , MilioL , et al. Fetal neurobehavioral effects of exposure to methadone or buprenorphine. Neurotoxicology and Teratology2011;33(2):240-3. JonesHE , DenglerE , GarrisondA , O'GradyeKE , SeashoreC , HortonE , et al. Neonatal outcomes and their relationship to maternal buprenorphine dose during pregnancy. Drug and Alcohol Dependence2014;134:414-7. JonesHE , FischerG , HeilSH , KaltenbachK , MartinPR , CoyleMG , et al. Maternal Opioid Treatment: Human Experimental Research (MOTHER) - approach, issues and lessons learned. Addiction2012;107(Suppl 1):28-35. JonesHE , JanssonLM , O’GradycKE , KaltenbachK . The relationship between maternal methadone dose at delivery and neonatal outcome: methodological and design considerations. Neurotoxicology and Teratology2013:110-5. [DOI: 10.1016/j.ntt.2013.05.003]JonesHE , JohnsonRE , JasinskiDR , TutenM , MilioL . Dosing pre to postpartum with either buprenorphine or methadone. In: 69th Annual Scientific Meeting of the College on Problems of Drug Dependence. Quebec City, Canada, 2007:16-21. JonesHE , JohnsonRE , O'GradyKE , JasinskiDR , TutenM , MilioL . Dosing adjustments in postpartum patients maintained on buprenorphine or methadone. Journal of Addiction Medicine2008;2(2):103-7. JonesHE , KaltenbachK , HeilSH , StineSM , CoyleMG , ArriaAM , et al. Neonatal abstinence syndrome after methadone or buprenorphine exposure. New England Journal of Medicine2010;363:2320-31. KaltenbachK , O’GradyKE , HeilSH , SalisburyAL , CoyleMG , FischerG , et al. Prenatal exposure to methadone or buprenorphine: early childhood developmental outcomes. Drug and Alcohol Dependence2018;185:40-9. UngerA , JagschR , BäwertA , WinklbaurB , RohrmeisterK , MartinPR , et al. Are male neonates more vulnerable to neonatal abstinence syndrome than female neonates?Gender Medicine2011;8(6):355-64. Wilson-MurphyMM , ChisolmMS , LeoutsakosJS , KaltenbachK , HeilSH , MartinPR . Treatment completion in opioid-dependent pregnant patients randomised to agonist treatment: the role of intravenous drug use. In: 73rd Annual Scientific Meeting of the College on Problems of Drug Dependence. 2011:195, Abstract no: 778. Winklbaur-HausknostB , JagschR , Graf-RohrmeisterK , UngerA , BaewertA , LangerM , et al. Lessons learned from a comparison of evidence-based research in pregnant opioid-dependent women. Human Psychopharmacology2013;28(1):15-24. ">MOTHER study</a> is a multicentre, international study conducted in Austria, Canada and the USA. </p> <p>Three trials compared a methadone dose of between 20 and 140 mg/day with a buprenorphine dose of between 2 and 32 mg/day (<a href="./references#CD006318-bbs2-0002" title="FischerG , OrtnerR , RohrmeisterK , JagschR , BaewertA , LangerM , et al. Methadone versus buprenorphine in pregnant addicts: a double-blind, double dummy comparison study. Addiction2006;101(2):275-81. ">Fischer 2006</a>; <a href="./references#CD006318-bbs2-0003" title="JonesHE , JohnsonRE , JasinskiDR , O'GradyKE , ChisholmCA , ChooRE , et al. Buprenorphine versus methadone in the treatment of pregnant opioid-dependent patients: effects on the neonatal abstinence syndrome. Drug and Alcohol Dependence2005;79(1):1-10. ">Jones 2005</a>; <a href="./references#CD006318-bbs2-0004" title="ChisolmMS , FitzsimonsH , LeoutsakosJM , AcquavitaSP , HeilSH , Wilson-MurphyM , et al. A comparison of cigarette smoking profiles in opioid-dependent pregnant patients receiving methadone or buprenorphine. Nicotine Tobacco Research2013;15(7):1297-304. CoyleMG , SalisburyAL , LesterBM , JonesHE , LinH , Graf-RohrmeisterK , et al. Neonatal neurobehavior effects following buprenorphine versus methadone exposure. Addiction2012;107(Suppl 1):63-73. GaalemaDE , ScottTL , HeilSH , CoyleMG , KaltenbachK , BadgerGJ , et al. Differences in the profile of neonatal abstinence syndrome signs in methadone- versus buprenorphine-exposed neonates. Addiction2012;107(Suppl 1):53-62. HolbrookAM , BaxterJK , JonesHE , HeilSH , CoyleMG , MartinPR , et al. Infections and obstetric outcomes in opioid-dependent pregnant women maintained on methadone or buprenorphine. Addiction2012;107(Suppl 1):83-90. HolbrookAM , JonesHE , HeilSH , MartinPR , StineSM , FischerG , et al. Induction of pregnant women onto opioid-agonist maintenance medication: an analysis of withdrawal symptoms and study retention. Drug and Alcohol Dependence2013;132(0):329-34. JanssonLM , DipietroJA , VelezM , ElkoA , WilliamsE , MilioL , et al. Fetal neurobehavioral effects of exposure to methadone or buprenorphine. Neurotoxicology and Teratology2011;33(2):240-3. JonesHE , DenglerE , GarrisondA , O'GradyeKE , SeashoreC , HortonE , et al. Neonatal outcomes and their relationship to maternal buprenorphine dose during pregnancy. Drug and Alcohol Dependence2014;134:414-7. JonesHE , FischerG , HeilSH , KaltenbachK , MartinPR , CoyleMG , et al. Maternal Opioid Treatment: Human Experimental Research (MOTHER) - approach, issues and lessons learned. Addiction2012;107(Suppl 1):28-35. JonesHE , JanssonLM , O’GradycKE , KaltenbachK . The relationship between maternal methadone dose at delivery and neonatal outcome: methodological and design considerations. Neurotoxicology and Teratology2013:110-5. [DOI: 10.1016/j.ntt.2013.05.003]JonesHE , JohnsonRE , JasinskiDR , TutenM , MilioL . Dosing pre to postpartum with either buprenorphine or methadone. In: 69th Annual Scientific Meeting of the College on Problems of Drug Dependence. Quebec City, Canada, 2007:16-21. JonesHE , JohnsonRE , O'GradyKE , JasinskiDR , TutenM , MilioL . Dosing adjustments in postpartum patients maintained on buprenorphine or methadone. Journal of Addiction Medicine2008;2(2):103-7. JonesHE , KaltenbachK , HeilSH , StineSM , CoyleMG , ArriaAM , et al. Neonatal abstinence syndrome after methadone or buprenorphine exposure. New England Journal of Medicine2010;363:2320-31. KaltenbachK , O’GradyKE , HeilSH , SalisburyAL , CoyleMG , FischerG , et al. Prenatal exposure to methadone or buprenorphine: early childhood developmental outcomes. Drug and Alcohol Dependence2018;185:40-9. UngerA , JagschR , BäwertA , WinklbaurB , RohrmeisterK , MartinPR , et al. Are male neonates more vulnerable to neonatal abstinence syndrome than female neonates?Gender Medicine2011;8(6):355-64. Wilson-MurphyMM , ChisolmMS , LeoutsakosJS , KaltenbachK , HeilSH , MartinPR . Treatment completion in opioid-dependent pregnant patients randomised to agonist treatment: the role of intravenous drug use. In: 73rd Annual Scientific Meeting of the College on Problems of Drug Dependence. 2011:195, Abstract no: 778. Winklbaur-HausknostB , JagschR , Graf-RohrmeisterK , UngerA , BaewertA , LangerM , et al. Lessons learned from a comparison of evidence-based research in pregnant opioid-dependent women. Human Psychopharmacology2013;28(1):15-24. ">MOTHER Study</a>). One trial compared methadone (mean dose at delivery 53.48 mg) with oral slow‐release morphine (mean dose at delivery 300.43 mg) (<a href="./references#CD006318-bbs2-0001" title="FischerG , JagschR , EderH , GombasW , EtzerdorferP , Schmidl-MohlK , et al. Comparison of methadone and slow-release morphine maintenance in pregnant addicts. Addiction1999;94(2):231-9. ">Fischer 1999</a>). </p> <p>Three studies were conducted in an outpatient setting (<a href="./references#CD006318-bbs2-0001" title="FischerG , JagschR , EderH , GombasW , EtzerdorferP , Schmidl-MohlK , et al. Comparison of methadone and slow-release morphine maintenance in pregnant addicts. Addiction1999;94(2):231-9. ">Fischer 1999</a>; <a href="./references#CD006318-bbs2-0002" title="FischerG , OrtnerR , RohrmeisterK , JagschR , BaewertA , LangerM , et al. Methadone versus buprenorphine in pregnant addicts: a double-blind, double dummy comparison study. Addiction2006;101(2):275-81. ">Fischer 2006</a>; <a href="./references#CD006318-bbs2-0004" title="ChisolmMS , FitzsimonsH , LeoutsakosJM , AcquavitaSP , HeilSH , Wilson-MurphyM , et al. A comparison of cigarette smoking profiles in opioid-dependent pregnant patients receiving methadone or buprenorphine. Nicotine Tobacco Research2013;15(7):1297-304. CoyleMG , SalisburyAL , LesterBM , JonesHE , LinH , Graf-RohrmeisterK , et al. Neonatal neurobehavior effects following buprenorphine versus methadone exposure. Addiction2012;107(Suppl 1):63-73. GaalemaDE , ScottTL , HeilSH , CoyleMG , KaltenbachK , BadgerGJ , et al. Differences in the profile of neonatal abstinence syndrome signs in methadone- versus buprenorphine-exposed neonates. Addiction2012;107(Suppl 1):53-62. HolbrookAM , BaxterJK , JonesHE , HeilSH , CoyleMG , MartinPR , et al. Infections and obstetric outcomes in opioid-dependent pregnant women maintained on methadone or buprenorphine. Addiction2012;107(Suppl 1):83-90. HolbrookAM , JonesHE , HeilSH , MartinPR , StineSM , FischerG , et al. Induction of pregnant women onto opioid-agonist maintenance medication: an analysis of withdrawal symptoms and study retention. Drug and Alcohol Dependence2013;132(0):329-34. JanssonLM , DipietroJA , VelezM , ElkoA , WilliamsE , MilioL , et al. Fetal neurobehavioral effects of exposure to methadone or buprenorphine. Neurotoxicology and Teratology2011;33(2):240-3. JonesHE , DenglerE , GarrisondA , O'GradyeKE , SeashoreC , HortonE , et al. Neonatal outcomes and their relationship to maternal buprenorphine dose during pregnancy. Drug and Alcohol Dependence2014;134:414-7. JonesHE , FischerG , HeilSH , KaltenbachK , MartinPR , CoyleMG , et al. Maternal Opioid Treatment: Human Experimental Research (MOTHER) - approach, issues and lessons learned. Addiction2012;107(Suppl 1):28-35. JonesHE , JanssonLM , O’GradycKE , KaltenbachK . The relationship between maternal methadone dose at delivery and neonatal outcome: methodological and design considerations. Neurotoxicology and Teratology2013:110-5. [DOI: 10.1016/j.ntt.2013.05.003]JonesHE , JohnsonRE , JasinskiDR , TutenM , MilioL . Dosing pre to postpartum with either buprenorphine or methadone. In: 69th Annual Scientific Meeting of the College on Problems of Drug Dependence. Quebec City, Canada, 2007:16-21. JonesHE , JohnsonRE , O'GradyKE , JasinskiDR , TutenM , MilioL . Dosing adjustments in postpartum patients maintained on buprenorphine or methadone. Journal of Addiction Medicine2008;2(2):103-7. JonesHE , KaltenbachK , HeilSH , StineSM , CoyleMG , ArriaAM , et al. Neonatal abstinence syndrome after methadone or buprenorphine exposure. New England Journal of Medicine2010;363:2320-31. KaltenbachK , O’GradyKE , HeilSH , SalisburyAL , CoyleMG , FischerG , et al. Prenatal exposure to methadone or buprenorphine: early childhood developmental outcomes. Drug and Alcohol Dependence2018;185:40-9. UngerA , JagschR , BäwertA , WinklbaurB , RohrmeisterK , MartinPR , et al. Are male neonates more vulnerable to neonatal abstinence syndrome than female neonates?Gender Medicine2011;8(6):355-64. Wilson-MurphyMM , ChisolmMS , LeoutsakosJS , KaltenbachK , HeilSH , MartinPR . Treatment completion in opioid-dependent pregnant patients randomised to agonist treatment: the role of intravenous drug use. In: 73rd Annual Scientific Meeting of the College on Problems of Drug Dependence. 2011:195, Abstract no: 778. Winklbaur-HausknostB , JagschR , Graf-RohrmeisterK , UngerA , BaewertA , LangerM , et al. Lessons learned from a comparison of evidence-based research in pregnant opioid-dependent women. Human Psychopharmacology2013;28(1):15-24. ">MOTHER Study</a>) and one in an inpatient setting (<a href="./references#CD006318-bbs2-0003" title="JonesHE , JohnsonRE , JasinskiDR , O'GradyKE , ChisholmCA , ChooRE , et al. Buprenorphine versus methadone in the treatment of pregnant opioid-dependent patients: effects on the neonatal abstinence syndrome. Drug and Alcohol Dependence2005;79(1):1-10. ">Jones 2005</a>). </p> </section> <section id="CD006318-sec-0048"> <h5 class="title">Participants</h5> <p>Two hundred seventy‐one opiate‐dependent pregnant women meeting the DSM‐IV criteria were included in the studies. The mean age of participants was 27.3 years. The mean gestational age was 22 weeks. Nicotine use during pregnancy was reported only in one trial (<a href="./references#CD006318-bbs2-0001" title="FischerG , JagschR , EderH , GombasW , EtzerdorferP , Schmidl-MohlK , et al. Comparison of methadone and slow-release morphine maintenance in pregnant addicts. Addiction1999;94(2):231-9. ">Fischer 1999</a>) as a mean number of cigarettes per day: it was 27.56 (SD 26.28) for the methadone group and 31.30 (SD 22.56) for the morphine group. </p> </section> <section id="CD006318-sec-0049"> <h5 class="title">Rating instruments utilised in the studies</h5> <p>All the included studies measured neonatal abstinence syndrome using the Finnegan scale (<a href="./references#CD006318-bbs2-0040" title="FinneganLP , KaltenbachK . Neonatal abstinence syndrome. In: Primary Pediatric Care. 2nd edition. St Louis: CV Mosby, 1992.">Finnegan 1992</a>), but the <a href="./references#CD006318-bbs2-0004" title="ChisolmMS , FitzsimonsH , LeoutsakosJM , AcquavitaSP , HeilSH , Wilson-MurphyM , et al. A comparison of cigarette smoking profiles in opioid-dependent pregnant patients receiving methadone or buprenorphine. Nicotine Tobacco Research2013;15(7):1297-304. CoyleMG , SalisburyAL , LesterBM , JonesHE , LinH , Graf-RohrmeisterK , et al. Neonatal neurobehavior effects following buprenorphine versus methadone exposure. Addiction2012;107(Suppl 1):63-73. GaalemaDE , ScottTL , HeilSH , CoyleMG , KaltenbachK , BadgerGJ , et al. Differences in the profile of neonatal abstinence syndrome signs in methadone- versus buprenorphine-exposed neonates. Addiction2012;107(Suppl 1):53-62. HolbrookAM , BaxterJK , JonesHE , HeilSH , CoyleMG , MartinPR , et al. Infections and obstetric outcomes in opioid-dependent pregnant women maintained on methadone or buprenorphine. Addiction2012;107(Suppl 1):83-90. HolbrookAM , JonesHE , HeilSH , MartinPR , StineSM , FischerG , et al. Induction of pregnant women onto opioid-agonist maintenance medication: an analysis of withdrawal symptoms and study retention. Drug and Alcohol Dependence2013;132(0):329-34. JanssonLM , DipietroJA , VelezM , ElkoA , WilliamsE , MilioL , et al. Fetal neurobehavioral effects of exposure to methadone or buprenorphine. Neurotoxicology and Teratology2011;33(2):240-3. JonesHE , DenglerE , GarrisondA , O'GradyeKE , SeashoreC , HortonE , et al. Neonatal outcomes and their relationship to maternal buprenorphine dose during pregnancy. Drug and Alcohol Dependence2014;134:414-7. JonesHE , FischerG , HeilSH , KaltenbachK , MartinPR , CoyleMG , et al. Maternal Opioid Treatment: Human Experimental Research (MOTHER) - approach, issues and lessons learned. Addiction2012;107(Suppl 1):28-35. JonesHE , JanssonLM , O’GradycKE , KaltenbachK . The relationship between maternal methadone dose at delivery and neonatal outcome: methodological and design considerations. Neurotoxicology and Teratology2013:110-5. [DOI: 10.1016/j.ntt.2013.05.003]JonesHE , JohnsonRE , JasinskiDR , TutenM , MilioL . Dosing pre to postpartum with either buprenorphine or methadone. In: 69th Annual Scientific Meeting of the College on Problems of Drug Dependence. Quebec City, Canada, 2007:16-21. JonesHE , JohnsonRE , O'GradyKE , JasinskiDR , TutenM , MilioL . Dosing adjustments in postpartum patients maintained on buprenorphine or methadone. Journal of Addiction Medicine2008;2(2):103-7. JonesHE , KaltenbachK , HeilSH , StineSM , CoyleMG , ArriaAM , et al. Neonatal abstinence syndrome after methadone or buprenorphine exposure. New England Journal of Medicine2010;363:2320-31. KaltenbachK , O’GradyKE , HeilSH , SalisburyAL , CoyleMG , FischerG , et al. Prenatal exposure to methadone or buprenorphine: early childhood developmental outcomes. Drug and Alcohol Dependence2018;185:40-9. UngerA , JagschR , BäwertA , WinklbaurB , RohrmeisterK , MartinPR , et al. Are male neonates more vulnerable to neonatal abstinence syndrome than female neonates?Gender Medicine2011;8(6):355-64. Wilson-MurphyMM , ChisolmMS , LeoutsakosJS , KaltenbachK , HeilSH , MartinPR . Treatment completion in opioid-dependent pregnant patients randomised to agonist treatment: the role of intravenous drug use. In: 73rd Annual Scientific Meeting of the College on Problems of Drug Dependence. 2011:195, Abstract no: 778. Winklbaur-HausknostB , JagschR , Graf-RohrmeisterK , UngerA , BaewertA , LangerM , et al. Lessons learned from a comparison of evidence-based research in pregnant opioid-dependent women. Human Psychopharmacology2013;28(1):15-24. ">MOTHER Study</a> used a modified Finnegan scale (called the MOTHER neonatal abstinence syndrome scale), which includes 28 items with 19 items used for scoring and medication decisions. Scores on the modified scale range from 0 to 42, with higher scores indicating more severe withdrawal. Original neonatal abstinence syndrome item definitions, as well as the morphine medication protocol, were refined before data collection. </p> </section> <section id="CD006318-sec-0050"> <h5 class="title">Comparisons</h5> <section id="CD006318-sec-0051"> <h6 class="title">Comparison 1</h6> <p>Methadone versus buprenorphine was compared in three trials with 223 participants (<a href="./references#CD006318-bbs2-0002" title="FischerG , OrtnerR , RohrmeisterK , JagschR , BaewertA , LangerM , et al. Methadone versus buprenorphine in pregnant addicts: a double-blind, double dummy comparison study. Addiction2006;101(2):275-81. ">Fischer 2006</a>; <a href="./references#CD006318-bbs2-0003" title="JonesHE , JohnsonRE , JasinskiDR , O'GradyKE , ChisholmCA , ChooRE , et al. Buprenorphine versus methadone in the treatment of pregnant opioid-dependent patients: effects on the neonatal abstinence syndrome. Drug and Alcohol Dependence2005;79(1):1-10. ">Jones 2005</a>; <a href="./references#CD006318-bbs2-0004" title="ChisolmMS , FitzsimonsH , LeoutsakosJM , AcquavitaSP , HeilSH , Wilson-MurphyM , et al. A comparison of cigarette smoking profiles in opioid-dependent pregnant patients receiving methadone or buprenorphine. Nicotine Tobacco Research2013;15(7):1297-304. CoyleMG , SalisburyAL , LesterBM , JonesHE , LinH , Graf-RohrmeisterK , et al. Neonatal neurobehavior effects following buprenorphine versus methadone exposure. Addiction2012;107(Suppl 1):63-73. GaalemaDE , ScottTL , HeilSH , CoyleMG , KaltenbachK , BadgerGJ , et al. Differences in the profile of neonatal abstinence syndrome signs in methadone- versus buprenorphine-exposed neonates. Addiction2012;107(Suppl 1):53-62. HolbrookAM , BaxterJK , JonesHE , HeilSH , CoyleMG , MartinPR , et al. Infections and obstetric outcomes in opioid-dependent pregnant women maintained on methadone or buprenorphine. Addiction2012;107(Suppl 1):83-90. HolbrookAM , JonesHE , HeilSH , MartinPR , StineSM , FischerG , et al. Induction of pregnant women onto opioid-agonist maintenance medication: an analysis of withdrawal symptoms and study retention. Drug and Alcohol Dependence2013;132(0):329-34. JanssonLM , DipietroJA , VelezM , ElkoA , WilliamsE , MilioL , et al. Fetal neurobehavioral effects of exposure to methadone or buprenorphine. Neurotoxicology and Teratology2011;33(2):240-3. JonesHE , DenglerE , GarrisondA , O'GradyeKE , SeashoreC , HortonE , et al. Neonatal outcomes and their relationship to maternal buprenorphine dose during pregnancy. Drug and Alcohol Dependence2014;134:414-7. JonesHE , FischerG , HeilSH , KaltenbachK , MartinPR , CoyleMG , et al. Maternal Opioid Treatment: Human Experimental Research (MOTHER) - approach, issues and lessons learned. Addiction2012;107(Suppl 1):28-35. JonesHE , JanssonLM , O’GradycKE , KaltenbachK . The relationship between maternal methadone dose at delivery and neonatal outcome: methodological and design considerations. Neurotoxicology and Teratology2013:110-5. [DOI: 10.1016/j.ntt.2013.05.003]JonesHE , JohnsonRE , JasinskiDR , TutenM , MilioL . Dosing pre to postpartum with either buprenorphine or methadone. In: 69th Annual Scientific Meeting of the College on Problems of Drug Dependence. Quebec City, Canada, 2007:16-21. JonesHE , JohnsonRE , O'GradyKE , JasinskiDR , TutenM , MilioL . Dosing adjustments in postpartum patients maintained on buprenorphine or methadone. Journal of Addiction Medicine2008;2(2):103-7. JonesHE , KaltenbachK , HeilSH , StineSM , CoyleMG , ArriaAM , et al. Neonatal abstinence syndrome after methadone or buprenorphine exposure. New England Journal of Medicine2010;363:2320-31. KaltenbachK , O’GradyKE , HeilSH , SalisburyAL , CoyleMG , FischerG , et al. Prenatal exposure to methadone or buprenorphine: early childhood developmental outcomes. Drug and Alcohol Dependence2018;185:40-9. UngerA , JagschR , BäwertA , WinklbaurB , RohrmeisterK , MartinPR , et al. Are male neonates more vulnerable to neonatal abstinence syndrome than female neonates?Gender Medicine2011;8(6):355-64. Wilson-MurphyMM , ChisolmMS , LeoutsakosJS , KaltenbachK , HeilSH , MartinPR . Treatment completion in opioid-dependent pregnant patients randomised to agonist treatment: the role of intravenous drug use. In: 73rd Annual Scientific Meeting of the College on Problems of Drug Dependence. 2011:195, Abstract no: 778. Winklbaur-HausknostB , JagschR , Graf-RohrmeisterK , UngerA , BaewertA , LangerM , et al. Lessons learned from a comparison of evidence-based research in pregnant opioid-dependent women. Human Psychopharmacology2013;28(1):15-24. ">MOTHER Study</a>). </p> </section> <section id="CD006318-sec-0052"> <h6 class="title">Comparison 2</h6> <p>Methadone versus slow‐release morphine was compared in one trial with 48 participants (<a href="./references#CD006318-bbs2-0001" title="FischerG , JagschR , EderH , GombasW , EtzerdorferP , Schmidl-MohlK , et al. Comparison of methadone and slow-release morphine maintenance in pregnant addicts. Addiction1999;94(2):231-9. ">Fischer 1999</a>). </p> </section> </section> </section> <section id="CD006318-sec-0053"> <h4 class="title">Excluded studies</h4> <p>Twenty‐one studies did not meet the criteria for inclusion in this review. The grounds for exclusion were: study design (13 studies) (<a href="./references#CD006318-bbs2-0005" title="Bandstra, EmmaleeS . Maternal Opioid Treatment: Human Experimental Research (MOTHER) study: maternal, fetal and neonatal outcomes from secondary analyses. Addiction2012;107(Suppl 1):1-4. ">Bandstra 2012</a>; <a href="./references#CD006318-bbs2-0007" title="BinderT , VavrinkovaB . Prospective randomised comparative study of the effect of buprenorphine, methadone and heroin on the course of pregnancy, birthweight of newborns, early postpartum adaptation and course of the neonatal abstinence syndrome (NAS) in women followed up in the outpatient department. Neuro Endocrinology Letters2008;29(1):80-6. ">Binder 2008</a>; <a href="./references#CD006318-bbs2-0011" title="EbnerN , RohrmeisterK , WinklbaurB , BaewertA , JagschR , PeternellA , et al. Management of neonatal abstinence syndrome in neonates born to opioid maintained women. Drug and Alcohol Dependence2007;87:131-8. ">Ebner 2007</a>; <a href="./references#CD006318-bbs2-0012" title="FisherG , EtzersdorferP , EderH , JagschR , LangerM , WeningerM . Buprenorphine maintenance in pregnant opiate addicts. European Addiction Research1998;1:32-6. ">Fisher 1998</a>; <a href="./references#CD006318-bbs2-0013" title="GordonAL , StaceyH , PearsonV , HaslamRR , LopatkoOV , WhiteJM . Buprenorphine and methadone in pregnancy: effects on the mother and fetus/neonate. In: Sixty-Sixth Annual Scientific Meeting of the College on Problems of Drug Dependence. 2004. ">Gordon 2004</a>; <a href="./references#CD006318-bbs2-0014" title="HulseGK , O'NeilG , Arnold-ReedDE . Methadone maintenance vs. implantable naltrexone treatment in the pregnant heroin user. International Journal of Gynaecology &amp; Obstetrics2004;85(2):170-1. ">Hulse 2004</a>; <a href="./references#CD006318-bbs2-0018" title="Keyser-MarcusL , MilesD , JanssonL , JonesH , SvikisD . Perinatal opiate dependence: methadone and birth outcomes. In: Drug and Alcohol Dependence. Vol. 66 Suppl 1. 2002. ">Keyser‐Marcus 2002</a>; <a href="./references#CD006318-bbs2-0016" title="JonesHE , MartinPR , HeilSH , KaltenbachK , SelbyP , CoyleMG , et al. Treatment of opioid-dependent pregnant women: clinical and research issues. Journal of Substance Abuse Treatment2008;35(3):245-59. ">Jones 2008</a>; <a href="./references#CD006318-bbs2-0019" title="LacroixI , BerrebiA , GaripuyD , SchmittL , HammouY , ChaumerliacC , et al. Buprenorphine versus methadone in pregnant opioid-dependent women: a prospective multicenter study. European Journal of Clinical Pharmacology2011;67(10):1053-9. ">Lacroix 2011</a>; <a href="./references#CD006318-bbs2-0020" title="LakenMP , McComishJF , AgerJ . Predictors of prenatal substance use and birth weight during outpatient treatment. Journal of Substance Abuse Treatment1997;14(4):359-66. ">Laken 1997</a>; <a href="./references#CD006318-bbs2-0021" title="MartinPR . Opioid dependence during pregnancy: balancing risk versus benefit. Klinik Psikofarmakoloji Bülteni2011;21:S35. ">Martin 2011</a>; <a href="./references#CD006318-bbs2-0022" title='NewmanR . Response to "Methadone maintenance vs. methadone taper during pregnancy" paper. American Journal on Addictions2009;18(3):250; author reply 251. '>Newman 2009</a>; <a href="./references#CD006318-bbs2-0023" title="StineSM , HeilSH , KaltenbachK , MartinPR , CoyleMG , FischerG , et al. Characteristics of opioid-using pregnant women who accept or refuse participation in a clinical trial: screening results from the MOTHER study. American Journal of Drug and Alcohol Abuse2009;35(6):429-33. ">Stine 2009</a>), type of participants (four studies) (<a href="./references#CD006318-bbs2-0006" title="BellJ , ZadorD . Dihydrocodeine as effective as methadone for maintenance of treatment for opiate dependence?Evidence Based Mental Health2007;10(3):88. ">Bell 2007</a>; <a href="./references#CD006318-bbs2-0010" title="DaweS , HarnettP . Reducing potential for child abuse among methadone-maintained parents: results from a randomized controlled trial. Journal of Substance Abuse Treatment2007;32(4):381-90. ">Dawe 2007</a>; <a href="./references#CD006318-bbs2-0015" title="JacksonL , TingA , MckayS , GaleaP , SkeochC . A randomised controlled trial of morphine versus phenobarbitone for neonatal abstinence syndrome. Archives of Disease in Childhood. Fetal and Neonatal Edition2004;89:300-4. ">Jackson 2004</a>; <a href="./references#CD006318-bbs2-0024" title="SuchmanNE , RounsavilleB , DeCosteC , LutharS . Parental control, parental warmth, and psychosocial adjustment in a sample of substance-abusing mothers and their school-aged and adolescent children. 2007 Journal of Substance Abuse Treatment;32(1):1-10. ">Suchman 2007</a>), type of experimental intervention (two studies) (<a href="./references#CD006318-bbs2-0008" title="CarrollKM , ChangG , BehrH , ClintonB , KostenTR . Improving treatment outcome in pregnant, methadone-maintained women. American Journal on Addictions1995;4(1):56-9. ">Carroll 1995</a>; <a href="./references#CD006318-bbs2-0009" title="CochranG , SmidMC , KransEE , BryanMA , GordonAJ , LundahlB , et al. A pilot multisite study of patient navigation for pregnant women with opioid use disorder. Contemporary Clinical Trials2019;87:1-8. ">Cochran 2019</a>) and type of control intervention (two studies) (<a href="./references#CD006318-bbs2-0017" title="JonesHE , O'GradyKE , TutenM . Reinforcement-based treatment improves the maternal treatment and neonatal outcomes of pregnant patients enrolled in comprehensive care treatment. American Journal on Addictions2011;20(3):196-204. ">Jones 2011</a>; <a href="./references#CD006318-bbs2-0025" title="TutenM , SvikisDS , Keyser-MarcusL , O'GradyKE , JonesHE . Lessons learned from a randomized trial of fixed and escalating contingency management schedules in opioid-dependent pregnant women. American Journal of Drug and Alcohol Abuse2012;38(4):286-92. ">Tuten 2012</a>). </p> </section> </section> <section id="CD006318-sec-0054"> <h3 class="title">Risk of bias in included studies</h3> <p>See <a href="#CD006318-fig-0003">Figure 3</a> and <a href="#CD006318-fig-0004">Figure 4</a>. All of the studies were randomised controlled trials. </p> <div class="figure" id="CD006318-fig-0003"> <div class="figure-caption-wrapper-top"> <nav class="inline-nav-list has-dividers"> <ul> <li><a class="open-in-figure-viewer" href="#0">Open in figure viewer</a></li> </ul> </nav> <div class="figure-label">Figure 3</div> </div> <hr class="top"/><img alt="'Risk of bias' graph: review authors' judgements about each risk of bias item presented as percentages across all included studies." data-id="CD006318-fig-0003" src="/cdsr/doi/10.1002/14651858.CD006318.pub4/media/CDSR/CD006318/image_n/nCD006318-FIG-03.svg"/><hr class="bottom"/> <div class="figure-caption-wrapper-bottom"> <div class="figure-caption"> <p>'Risk of bias' graph: review authors' judgements about each risk of bias item presented as percentages across all included studies. </p> </div> </div> </div> <div class="figure" id="CD006318-fig-0004"> <div class="figure-caption-wrapper-top"> <nav class="inline-nav-list has-dividers"> <ul> <li><a class="open-in-figure-viewer" href="#0">Open in figure viewer</a></li> </ul> </nav> <div class="figure-label">Figure 4</div> </div> <hr class="top"/><img alt="'Risk of bias' summary: review authors' judgements about each risk of bias item for each included study." data-id="CD006318-fig-0004" src="/cdsr/doi/10.1002/14651858.CD006318.pub4/media/CDSR/CD006318/image_n/nCD006318-FIG-04.svg"/><hr class="bottom"/> <div class="figure-caption-wrapper-bottom"> <div class="figure-caption"> <p>'Risk of bias' summary: review authors' judgements about each risk of bias item for each included study. </p> </div> </div> </div> <section id="CD006318-sec-0055"> <h4 class="title">Allocation</h4> <section id="CD006318-sec-0056"> <h5 class="title">Random sequence generation</h5> <p>Only one study (<a href="./references#CD006318-bbs2-0003" title="JonesHE , JohnsonRE , JasinskiDR , O'GradyKE , ChisholmCA , ChooRE , et al. Buprenorphine versus methadone in the treatment of pregnant opioid-dependent patients: effects on the neonatal abstinence syndrome. Drug and Alcohol Dependence2005;79(1):1-10. ">Jones 2005</a>) used a random sequence generation method and was at low risk of selection bias. We judged all the other studies to be at unclear risk of bias. </p> </section> <section id="CD006318-sec-0057"> <h5 class="title">Allocation concealment</h5> <p>There was a low risk of bias for allocation concealment in three studies (<a href="./references#CD006318-bbs2-0002" title="FischerG , OrtnerR , RohrmeisterK , JagschR , BaewertA , LangerM , et al. Methadone versus buprenorphine in pregnant addicts: a double-blind, double dummy comparison study. Addiction2006;101(2):275-81. ">Fischer 2006</a>; <a href="./references#CD006318-bbs2-0003" title="JonesHE , JohnsonRE , JasinskiDR , O'GradyKE , ChisholmCA , ChooRE , et al. Buprenorphine versus methadone in the treatment of pregnant opioid-dependent patients: effects on the neonatal abstinence syndrome. Drug and Alcohol Dependence2005;79(1):1-10. ">Jones 2005</a>; <a href="./references#CD006318-bbs2-0004" title="ChisolmMS , FitzsimonsH , LeoutsakosJM , AcquavitaSP , HeilSH , Wilson-MurphyM , et al. A comparison of cigarette smoking profiles in opioid-dependent pregnant patients receiving methadone or buprenorphine. Nicotine Tobacco Research2013;15(7):1297-304. CoyleMG , SalisburyAL , LesterBM , JonesHE , LinH , Graf-RohrmeisterK , et al. Neonatal neurobehavior effects following buprenorphine versus methadone exposure. Addiction2012;107(Suppl 1):63-73. GaalemaDE , ScottTL , HeilSH , CoyleMG , KaltenbachK , BadgerGJ , et al. Differences in the profile of neonatal abstinence syndrome signs in methadone- versus buprenorphine-exposed neonates. Addiction2012;107(Suppl 1):53-62. HolbrookAM , BaxterJK , JonesHE , HeilSH , CoyleMG , MartinPR , et al. Infections and obstetric outcomes in opioid-dependent pregnant women maintained on methadone or buprenorphine. Addiction2012;107(Suppl 1):83-90. HolbrookAM , JonesHE , HeilSH , MartinPR , StineSM , FischerG , et al. Induction of pregnant women onto opioid-agonist maintenance medication: an analysis of withdrawal symptoms and study retention. Drug and Alcohol Dependence2013;132(0):329-34. JanssonLM , DipietroJA , VelezM , ElkoA , WilliamsE , MilioL , et al. Fetal neurobehavioral effects of exposure to methadone or buprenorphine. Neurotoxicology and Teratology2011;33(2):240-3. JonesHE , DenglerE , GarrisondA , O'GradyeKE , SeashoreC , HortonE , et al. Neonatal outcomes and their relationship to maternal buprenorphine dose during pregnancy. Drug and Alcohol Dependence2014;134:414-7. JonesHE , FischerG , HeilSH , KaltenbachK , MartinPR , CoyleMG , et al. Maternal Opioid Treatment: Human Experimental Research (MOTHER) - approach, issues and lessons learned. Addiction2012;107(Suppl 1):28-35. JonesHE , JanssonLM , O’GradycKE , KaltenbachK . The relationship between maternal methadone dose at delivery and neonatal outcome: methodological and design considerations. Neurotoxicology and Teratology2013:110-5. [DOI: 10.1016/j.ntt.2013.05.003]JonesHE , JohnsonRE , JasinskiDR , TutenM , MilioL . Dosing pre to postpartum with either buprenorphine or methadone. In: 69th Annual Scientific Meeting of the College on Problems of Drug Dependence. Quebec City, Canada, 2007:16-21. JonesHE , JohnsonRE , O'GradyKE , JasinskiDR , TutenM , MilioL . Dosing adjustments in postpartum patients maintained on buprenorphine or methadone. Journal of Addiction Medicine2008;2(2):103-7. JonesHE , KaltenbachK , HeilSH , StineSM , CoyleMG , ArriaAM , et al. Neonatal abstinence syndrome after methadone or buprenorphine exposure. New England Journal of Medicine2010;363:2320-31. KaltenbachK , O’GradyKE , HeilSH , SalisburyAL , CoyleMG , FischerG , et al. Prenatal exposure to methadone or buprenorphine: early childhood developmental outcomes. Drug and Alcohol Dependence2018;185:40-9. UngerA , JagschR , BäwertA , WinklbaurB , RohrmeisterK , MartinPR , et al. Are male neonates more vulnerable to neonatal abstinence syndrome than female neonates?Gender Medicine2011;8(6):355-64. Wilson-MurphyMM , ChisolmMS , LeoutsakosJS , KaltenbachK , HeilSH , MartinPR . Treatment completion in opioid-dependent pregnant patients randomised to agonist treatment: the role of intravenous drug use. In: 73rd Annual Scientific Meeting of the College on Problems of Drug Dependence. 2011:195, Abstract no: 778. Winklbaur-HausknostB , JagschR , Graf-RohrmeisterK , UngerA , BaewertA , LangerM , et al. Lessons learned from a comparison of evidence-based research in pregnant opioid-dependent women. Human Psychopharmacology2013;28(1):15-24. ">MOTHER Study</a>) and an unclear risk in the fourth study (<a href="./references#CD006318-bbs2-0001" title="FischerG , JagschR , EderH , GombasW , EtzerdorferP , Schmidl-MohlK , et al. Comparison of methadone and slow-release morphine maintenance in pregnant addicts. Addiction1999;94(2):231-9. ">Fischer 1999</a>). </p> </section> </section> <section id="CD006318-sec-0058"> <h4 class="title">Blinding</h4> <section id="CD006318-sec-0059"> <h5 class="title">Subjective outcomes</h5> <p>We judged one study (<a href="./references#CD006318-bbs2-0001" title="FischerG , JagschR , EderH , GombasW , EtzerdorferP , Schmidl-MohlK , et al. Comparison of methadone and slow-release morphine maintenance in pregnant addicts. Addiction1999;94(2):231-9. ">Fischer 1999</a>) to be at a high risk of performance and detection bias because it was an open‐label study. All the other studies were double‐blind, and we judged them to be at a low risk of bias. </p> </section> <section id="CD006318-sec-0060"> <h5 class="title">Objective outcomes</h5> <p>We judged all four studies to be at a low risk of performance and detection bias.</p> </section> </section> <section id="CD006318-sec-0061"> <h4 class="title">Incomplete outcome data</h4> <p>Only one study had no attrition (<a href="./references#CD006318-bbs2-0001" title="FischerG , JagschR , EderH , GombasW , EtzerdorferP , Schmidl-MohlK , et al. Comparison of methadone and slow-release morphine maintenance in pregnant addicts. Addiction1999;94(2):231-9. ">Fischer 1999</a>). We judged the other three to be at high risk of attrition bias because the attrition rate was high and unbalanced between groups. </p> </section> <section id="CD006318-sec-0062"> <h4 class="title">Selective reporting</h4> <p>Only one study (<a href="./references#CD006318-bbs2-0004" title="ChisolmMS , FitzsimonsH , LeoutsakosJM , AcquavitaSP , HeilSH , Wilson-MurphyM , et al. A comparison of cigarette smoking profiles in opioid-dependent pregnant patients receiving methadone or buprenorphine. Nicotine Tobacco Research2013;15(7):1297-304. CoyleMG , SalisburyAL , LesterBM , JonesHE , LinH , Graf-RohrmeisterK , et al. Neonatal neurobehavior effects following buprenorphine versus methadone exposure. Addiction2012;107(Suppl 1):63-73. GaalemaDE , ScottTL , HeilSH , CoyleMG , KaltenbachK , BadgerGJ , et al. Differences in the profile of neonatal abstinence syndrome signs in methadone- versus buprenorphine-exposed neonates. Addiction2012;107(Suppl 1):53-62. HolbrookAM , BaxterJK , JonesHE , HeilSH , CoyleMG , MartinPR , et al. Infections and obstetric outcomes in opioid-dependent pregnant women maintained on methadone or buprenorphine. Addiction2012;107(Suppl 1):83-90. HolbrookAM , JonesHE , HeilSH , MartinPR , StineSM , FischerG , et al. Induction of pregnant women onto opioid-agonist maintenance medication: an analysis of withdrawal symptoms and study retention. Drug and Alcohol Dependence2013;132(0):329-34. JanssonLM , DipietroJA , VelezM , ElkoA , WilliamsE , MilioL , et al. Fetal neurobehavioral effects of exposure to methadone or buprenorphine. Neurotoxicology and Teratology2011;33(2):240-3. JonesHE , DenglerE , GarrisondA , O'GradyeKE , SeashoreC , HortonE , et al. Neonatal outcomes and their relationship to maternal buprenorphine dose during pregnancy. Drug and Alcohol Dependence2014;134:414-7. JonesHE , FischerG , HeilSH , KaltenbachK , MartinPR , CoyleMG , et al. Maternal Opioid Treatment: Human Experimental Research (MOTHER) - approach, issues and lessons learned. Addiction2012;107(Suppl 1):28-35. JonesHE , JanssonLM , O’GradycKE , KaltenbachK . The relationship between maternal methadone dose at delivery and neonatal outcome: methodological and design considerations. Neurotoxicology and Teratology2013:110-5. [DOI: 10.1016/j.ntt.2013.05.003]JonesHE , JohnsonRE , JasinskiDR , TutenM , MilioL . Dosing pre to postpartum with either buprenorphine or methadone. In: 69th Annual Scientific Meeting of the College on Problems of Drug Dependence. Quebec City, Canada, 2007:16-21. JonesHE , JohnsonRE , O'GradyKE , JasinskiDR , TutenM , MilioL . Dosing adjustments in postpartum patients maintained on buprenorphine or methadone. Journal of Addiction Medicine2008;2(2):103-7. JonesHE , KaltenbachK , HeilSH , StineSM , CoyleMG , ArriaAM , et al. Neonatal abstinence syndrome after methadone or buprenorphine exposure. New England Journal of Medicine2010;363:2320-31. KaltenbachK , O’GradyKE , HeilSH , SalisburyAL , CoyleMG , FischerG , et al. Prenatal exposure to methadone or buprenorphine: early childhood developmental outcomes. Drug and Alcohol Dependence2018;185:40-9. UngerA , JagschR , BäwertA , WinklbaurB , RohrmeisterK , MartinPR , et al. Are male neonates more vulnerable to neonatal abstinence syndrome than female neonates?Gender Medicine2011;8(6):355-64. Wilson-MurphyMM , ChisolmMS , LeoutsakosJS , KaltenbachK , HeilSH , MartinPR . Treatment completion in opioid-dependent pregnant patients randomised to agonist treatment: the role of intravenous drug use. In: 73rd Annual Scientific Meeting of the College on Problems of Drug Dependence. 2011:195, Abstract no: 778. Winklbaur-HausknostB , JagschR , Graf-RohrmeisterK , UngerA , BaewertA , LangerM , et al. Lessons learned from a comparison of evidence-based research in pregnant opioid-dependent women. Human Psychopharmacology2013;28(1):15-24. ">MOTHER Study</a>) had a protocol published before the completion of the study; it was judged at low risk of selective reporting because the results of all the predefined outcomes were reported. The other studies were judged to be at unclear risk because no protocol was available </p> </section> </section> <section id="CD006318-sec-0063"> <h3 class="title" id="CD006318-sec-0063">Effects of interventions</h3> <p>See: <a href="./full#CD006318-tbl-0001"><b>Summary of findings 1</b> Methadone compared to buprenorphine for opiate‐dependent pregnant women</a>; <a href="./full#CD006318-tbl-0002"><b>Summary of findings 2</b> Methadone compared to oral slow‐release morphine for opiate‐dependent pregnant women</a> </p> <section id="CD006318-sec-0064"> <h4 class="title">Comparison 1: Methadone versus buprenorphine</h4> <p>See <a href="./full#CD006318-tbl-0001">summary of findings Table 1</a>. </p> <section id="CD006318-sec-0065"> <h5 class="title">Primary outcomes: for the woman</h5> <section id="CD006318-sec-0066"> <h6 class="title">1. Dropouts from treatment</h6> <p>We analysed the number of participants who did not complete the treatment (<a href="./references#CD006318-bbs2-0002" title="FischerG , OrtnerR , RohrmeisterK , JagschR , BaewertA , LangerM , et al. Methadone versus buprenorphine in pregnant addicts: a double-blind, double dummy comparison study. Addiction2006;101(2):275-81. ">Fischer 2006</a>; <a href="./references#CD006318-bbs2-0003" title="JonesHE , JohnsonRE , JasinskiDR , O'GradyKE , ChisholmCA , ChooRE , et al. Buprenorphine versus methadone in the treatment of pregnant opioid-dependent patients: effects on the neonatal abstinence syndrome. Drug and Alcohol Dependence2005;79(1):1-10. ">Jones 2005</a>; <a href="./references#CD006318-bbs2-0004" title="ChisolmMS , FitzsimonsH , LeoutsakosJM , AcquavitaSP , HeilSH , Wilson-MurphyM , et al. A comparison of cigarette smoking profiles in opioid-dependent pregnant patients receiving methadone or buprenorphine. Nicotine Tobacco Research2013;15(7):1297-304. CoyleMG , SalisburyAL , LesterBM , JonesHE , LinH , Graf-RohrmeisterK , et al. Neonatal neurobehavior effects following buprenorphine versus methadone exposure. Addiction2012;107(Suppl 1):63-73. GaalemaDE , ScottTL , HeilSH , CoyleMG , KaltenbachK , BadgerGJ , et al. Differences in the profile of neonatal abstinence syndrome signs in methadone- versus buprenorphine-exposed neonates. Addiction2012;107(Suppl 1):53-62. HolbrookAM , BaxterJK , JonesHE , HeilSH , CoyleMG , MartinPR , et al. Infections and obstetric outcomes in opioid-dependent pregnant women maintained on methadone or buprenorphine. Addiction2012;107(Suppl 1):83-90. HolbrookAM , JonesHE , HeilSH , MartinPR , StineSM , FischerG , et al. Induction of pregnant women onto opioid-agonist maintenance medication: an analysis of withdrawal symptoms and study retention. Drug and Alcohol Dependence2013;132(0):329-34. JanssonLM , DipietroJA , VelezM , ElkoA , WilliamsE , MilioL , et al. Fetal neurobehavioral effects of exposure to methadone or buprenorphine. Neurotoxicology and Teratology2011;33(2):240-3. JonesHE , DenglerE , GarrisondA , O'GradyeKE , SeashoreC , HortonE , et al. Neonatal outcomes and their relationship to maternal buprenorphine dose during pregnancy. Drug and Alcohol Dependence2014;134:414-7. JonesHE , FischerG , HeilSH , KaltenbachK , MartinPR , CoyleMG , et al. Maternal Opioid Treatment: Human Experimental Research (MOTHER) - approach, issues and lessons learned. Addiction2012;107(Suppl 1):28-35. JonesHE , JanssonLM , O’GradycKE , KaltenbachK . The relationship between maternal methadone dose at delivery and neonatal outcome: methodological and design considerations. Neurotoxicology and Teratology2013:110-5. [DOI: 10.1016/j.ntt.2013.05.003]JonesHE , JohnsonRE , JasinskiDR , TutenM , MilioL . Dosing pre to postpartum with either buprenorphine or methadone. In: 69th Annual Scientific Meeting of the College on Problems of Drug Dependence. Quebec City, Canada, 2007:16-21. JonesHE , JohnsonRE , O'GradyKE , JasinskiDR , TutenM , MilioL . Dosing adjustments in postpartum patients maintained on buprenorphine or methadone. Journal of Addiction Medicine2008;2(2):103-7. JonesHE , KaltenbachK , HeilSH , StineSM , CoyleMG , ArriaAM , et al. Neonatal abstinence syndrome after methadone or buprenorphine exposure. New England Journal of Medicine2010;363:2320-31. KaltenbachK , O’GradyKE , HeilSH , SalisburyAL , CoyleMG , FischerG , et al. Prenatal exposure to methadone or buprenorphine: early childhood developmental outcomes. Drug and Alcohol Dependence2018;185:40-9. UngerA , JagschR , BäwertA , WinklbaurB , RohrmeisterK , MartinPR , et al. Are male neonates more vulnerable to neonatal abstinence syndrome than female neonates?Gender Medicine2011;8(6):355-64. Wilson-MurphyMM , ChisolmMS , LeoutsakosJS , KaltenbachK , HeilSH , MartinPR . Treatment completion in opioid-dependent pregnant patients randomised to agonist treatment: the role of intravenous drug use. In: 73rd Annual Scientific Meeting of the College on Problems of Drug Dependence. 2011:195, Abstract no: 778. Winklbaur-HausknostB , JagschR , Graf-RohrmeisterK , UngerA , BaewertA , LangerM , et al. Lessons learned from a comparison of evidence-based research in pregnant opioid-dependent women. Human Psychopharmacology2013;28(1):15-24. ">MOTHER Study</a>): There was no evidence of a difference between treatments (RR 0.66, 95% confidence interval (CI) 0.37 to 1.20, 223 participants, three studies, moderate quality evidence). (<a href="./references#CD006318-fig-0005" title="">Analysis 1.1</a>). </p> </section> <section id="CD006318-sec-0067"> <h6 class="title">2. Use of primary substance of abuse</h6> <section id="CD006318-sec-0068"> <p><b>2.1 During or at the end of treatment</b></p> <p>We pooled two trials (<a href="./references#CD006318-bbs2-0003" title="JonesHE , JohnsonRE , JasinskiDR , O'GradyKE , ChisholmCA , ChooRE , et al. Buprenorphine versus methadone in the treatment of pregnant opioid-dependent patients: effects on the neonatal abstinence syndrome. Drug and Alcohol Dependence2005;79(1):1-10. ">Jones 2005</a>, <a href="./references#CD006318-bbs2-0004" title="ChisolmMS , FitzsimonsH , LeoutsakosJM , AcquavitaSP , HeilSH , Wilson-MurphyM , et al. A comparison of cigarette smoking profiles in opioid-dependent pregnant patients receiving methadone or buprenorphine. Nicotine Tobacco Research2013;15(7):1297-304. CoyleMG , SalisburyAL , LesterBM , JonesHE , LinH , Graf-RohrmeisterK , et al. Neonatal neurobehavior effects following buprenorphine versus methadone exposure. Addiction2012;107(Suppl 1):63-73. GaalemaDE , ScottTL , HeilSH , CoyleMG , KaltenbachK , BadgerGJ , et al. Differences in the profile of neonatal abstinence syndrome signs in methadone- versus buprenorphine-exposed neonates. Addiction2012;107(Suppl 1):53-62. HolbrookAM , BaxterJK , JonesHE , HeilSH , CoyleMG , MartinPR , et al. Infections and obstetric outcomes in opioid-dependent pregnant women maintained on methadone or buprenorphine. Addiction2012;107(Suppl 1):83-90. HolbrookAM , JonesHE , HeilSH , MartinPR , StineSM , FischerG , et al. Induction of pregnant women onto opioid-agonist maintenance medication: an analysis of withdrawal symptoms and study retention. Drug and Alcohol Dependence2013;132(0):329-34. JanssonLM , DipietroJA , VelezM , ElkoA , WilliamsE , MilioL , et al. Fetal neurobehavioral effects of exposure to methadone or buprenorphine. Neurotoxicology and Teratology2011;33(2):240-3. JonesHE , DenglerE , GarrisondA , O'GradyeKE , SeashoreC , HortonE , et al. Neonatal outcomes and their relationship to maternal buprenorphine dose during pregnancy. Drug and Alcohol Dependence2014;134:414-7. JonesHE , FischerG , HeilSH , KaltenbachK , MartinPR , CoyleMG , et al. Maternal Opioid Treatment: Human Experimental Research (MOTHER) - approach, issues and lessons learned. Addiction2012;107(Suppl 1):28-35. JonesHE , JanssonLM , O’GradycKE , KaltenbachK . The relationship between maternal methadone dose at delivery and neonatal outcome: methodological and design considerations. Neurotoxicology and Teratology2013:110-5. [DOI: 10.1016/j.ntt.2013.05.003]JonesHE , JohnsonRE , JasinskiDR , TutenM , MilioL . Dosing pre to postpartum with either buprenorphine or methadone. In: 69th Annual Scientific Meeting of the College on Problems of Drug Dependence. Quebec City, Canada, 2007:16-21. JonesHE , JohnsonRE , O'GradyKE , JasinskiDR , TutenM , MilioL . Dosing adjustments in postpartum patients maintained on buprenorphine or methadone. Journal of Addiction Medicine2008;2(2):103-7. JonesHE , KaltenbachK , HeilSH , StineSM , CoyleMG , ArriaAM , et al. Neonatal abstinence syndrome after methadone or buprenorphine exposure. New England Journal of Medicine2010;363:2320-31. KaltenbachK , O’GradyKE , HeilSH , SalisburyAL , CoyleMG , FischerG , et al. Prenatal exposure to methadone or buprenorphine: early childhood developmental outcomes. Drug and Alcohol Dependence2018;185:40-9. UngerA , JagschR , BäwertA , WinklbaurB , RohrmeisterK , MartinPR , et al. Are male neonates more vulnerable to neonatal abstinence syndrome than female neonates?Gender Medicine2011;8(6):355-64. Wilson-MurphyMM , ChisolmMS , LeoutsakosJS , KaltenbachK , HeilSH , MartinPR . Treatment completion in opioid-dependent pregnant patients randomised to agonist treatment: the role of intravenous drug use. In: 73rd Annual Scientific Meeting of the College on Problems of Drug Dependence. 2011:195, Abstract no: 778. Winklbaur-HausknostB , JagschR , Graf-RohrmeisterK , UngerA , BaewertA , LangerM , et al. Lessons learned from a comparison of evidence-based research in pregnant opioid-dependent women. Human Psychopharmacology2013;28(1):15-24. ">MOTHER Study</a>) with 151 participants. There was no evidence of a difference between treatments (RR 1.81, 95% CI 0.70 to 4.68, low quality evidence) (<a href="./references#CD006318-fig-0006" title="">Analysis 1.2</a>). </p> </section> <section id="CD006318-sec-0069"> <p><b>2.2 At follow‐up</b></p> <p>None of the studies considered this outcome.</p> </section> </section> <section id="CD006318-sec-0070"> <h6 class="title">3. Obstetric outcomes</h6> <section id="CD006318-sec-0071"> <p><b>3.1 Third trimester bleeding</b></p> <p>Data for this outcome were not reported in any of the included studies.</p> </section> <section id="CD006318-sec-0072"> <p><b>3.2 Preterm delivery</b></p> <p>In <a href="./references#CD006318-bbs2-0002" title="FischerG , OrtnerR , RohrmeisterK , JagschR , BaewertA , LangerM , et al. Methadone versus buprenorphine in pregnant addicts: a double-blind, double dummy comparison study. Addiction2006;101(2):275-81. ">Fischer 2006</a>, three children were delivered prematurely in the methadone group and two in the buprenorphine group (one at week 34, one at week 35 and three at week 36). In <a href="./references#CD006318-bbs2-0003" title="JonesHE , JohnsonRE , JasinskiDR , O'GradyKE , ChisholmCA , ChooRE , et al. Buprenorphine versus methadone in the treatment of pregnant opioid-dependent patients: effects on the neonatal abstinence syndrome. Drug and Alcohol Dependence2005;79(1):1-10. ">Jones 2005</a>, there was one preterm birth in the methadone group (week not reported). In the <a href="./references#CD006318-bbs2-0004" title="ChisolmMS , FitzsimonsH , LeoutsakosJM , AcquavitaSP , HeilSH , Wilson-MurphyM , et al. A comparison of cigarette smoking profiles in opioid-dependent pregnant patients receiving methadone or buprenorphine. Nicotine Tobacco Research2013;15(7):1297-304. CoyleMG , SalisburyAL , LesterBM , JonesHE , LinH , Graf-RohrmeisterK , et al. Neonatal neurobehavior effects following buprenorphine versus methadone exposure. Addiction2012;107(Suppl 1):63-73. GaalemaDE , ScottTL , HeilSH , CoyleMG , KaltenbachK , BadgerGJ , et al. Differences in the profile of neonatal abstinence syndrome signs in methadone- versus buprenorphine-exposed neonates. Addiction2012;107(Suppl 1):53-62. HolbrookAM , BaxterJK , JonesHE , HeilSH , CoyleMG , MartinPR , et al. Infections and obstetric outcomes in opioid-dependent pregnant women maintained on methadone or buprenorphine. Addiction2012;107(Suppl 1):83-90. HolbrookAM , JonesHE , HeilSH , MartinPR , StineSM , FischerG , et al. Induction of pregnant women onto opioid-agonist maintenance medication: an analysis of withdrawal symptoms and study retention. Drug and Alcohol Dependence2013;132(0):329-34. JanssonLM , DipietroJA , VelezM , ElkoA , WilliamsE , MilioL , et al. Fetal neurobehavioral effects of exposure to methadone or buprenorphine. Neurotoxicology and Teratology2011;33(2):240-3. JonesHE , DenglerE , GarrisondA , O'GradyeKE , SeashoreC , HortonE , et al. Neonatal outcomes and their relationship to maternal buprenorphine dose during pregnancy. Drug and Alcohol Dependence2014;134:414-7. JonesHE , FischerG , HeilSH , KaltenbachK , MartinPR , CoyleMG , et al. Maternal Opioid Treatment: Human Experimental Research (MOTHER) - approach, issues and lessons learned. Addiction2012;107(Suppl 1):28-35. JonesHE , JanssonLM , O’GradycKE , KaltenbachK . The relationship between maternal methadone dose at delivery and neonatal outcome: methodological and design considerations. Neurotoxicology and Teratology2013:110-5. [DOI: 10.1016/j.ntt.2013.05.003]JonesHE , JohnsonRE , JasinskiDR , TutenM , MilioL . Dosing pre to postpartum with either buprenorphine or methadone. In: 69th Annual Scientific Meeting of the College on Problems of Drug Dependence. Quebec City, Canada, 2007:16-21. JonesHE , JohnsonRE , O'GradyKE , JasinskiDR , TutenM , MilioL . Dosing adjustments in postpartum patients maintained on buprenorphine or methadone. Journal of Addiction Medicine2008;2(2):103-7. JonesHE , KaltenbachK , HeilSH , StineSM , CoyleMG , ArriaAM , et al. Neonatal abstinence syndrome after methadone or buprenorphine exposure. New England Journal of Medicine2010;363:2320-31. KaltenbachK , O’GradyKE , HeilSH , SalisburyAL , CoyleMG , FischerG , et al. Prenatal exposure to methadone or buprenorphine: early childhood developmental outcomes. Drug and Alcohol Dependence2018;185:40-9. UngerA , JagschR , BäwertA , WinklbaurB , RohrmeisterK , MartinPR , et al. Are male neonates more vulnerable to neonatal abstinence syndrome than female neonates?Gender Medicine2011;8(6):355-64. Wilson-MurphyMM , ChisolmMS , LeoutsakosJS , KaltenbachK , HeilSH , MartinPR . Treatment completion in opioid-dependent pregnant patients randomised to agonist treatment: the role of intravenous drug use. In: 73rd Annual Scientific Meeting of the College on Problems of Drug Dependence. 2011:195, Abstract no: 778. Winklbaur-HausknostB , JagschR , Graf-RohrmeisterK , UngerA , BaewertA , LangerM , et al. Lessons learned from a comparison of evidence-based research in pregnant opioid-dependent women. Human Psychopharmacology2013;28(1):15-24. ">MOTHER Study</a>, there were 19% preterm deliveries in the methadone group and 7% in the buprenorphine group. There was no evidence of a difference between treatments. </p> </section> <section id="CD006318-sec-0073"> <p><b>3.3 Fetal distress and meconium aspiration</b></p> <p>Data for this outcome were not reported in <a href="./references#CD006318-bbs2-0003" title="JonesHE , JohnsonRE , JasinskiDR , O'GradyKE , ChisholmCA , ChooRE , et al. Buprenorphine versus methadone in the treatment of pregnant opioid-dependent patients: effects on the neonatal abstinence syndrome. Drug and Alcohol Dependence2005;79(1):1-10. ">Jones 2005</a> and <a href="./references#CD006318-bbs2-0002" title="FischerG , OrtnerR , RohrmeisterK , JagschR , BaewertA , LangerM , et al. Methadone versus buprenorphine in pregnant addicts: a double-blind, double dummy comparison study. Addiction2006;101(2):275-81. ">Fischer 2006</a>. In the <a href="./references#CD006318-bbs2-0004" title="ChisolmMS , FitzsimonsH , LeoutsakosJM , AcquavitaSP , HeilSH , Wilson-MurphyM , et al. A comparison of cigarette smoking profiles in opioid-dependent pregnant patients receiving methadone or buprenorphine. Nicotine Tobacco Research2013;15(7):1297-304. CoyleMG , SalisburyAL , LesterBM , JonesHE , LinH , Graf-RohrmeisterK , et al. Neonatal neurobehavior effects following buprenorphine versus methadone exposure. Addiction2012;107(Suppl 1):63-73. GaalemaDE , ScottTL , HeilSH , CoyleMG , KaltenbachK , BadgerGJ , et al. Differences in the profile of neonatal abstinence syndrome signs in methadone- versus buprenorphine-exposed neonates. Addiction2012;107(Suppl 1):53-62. HolbrookAM , BaxterJK , JonesHE , HeilSH , CoyleMG , MartinPR , et al. Infections and obstetric outcomes in opioid-dependent pregnant women maintained on methadone or buprenorphine. Addiction2012;107(Suppl 1):83-90. HolbrookAM , JonesHE , HeilSH , MartinPR , StineSM , FischerG , et al. Induction of pregnant women onto opioid-agonist maintenance medication: an analysis of withdrawal symptoms and study retention. Drug and Alcohol Dependence2013;132(0):329-34. JanssonLM , DipietroJA , VelezM , ElkoA , WilliamsE , MilioL , et al. Fetal neurobehavioral effects of exposure to methadone or buprenorphine. Neurotoxicology and Teratology2011;33(2):240-3. JonesHE , DenglerE , GarrisondA , O'GradyeKE , SeashoreC , HortonE , et al. Neonatal outcomes and their relationship to maternal buprenorphine dose during pregnancy. Drug and Alcohol Dependence2014;134:414-7. JonesHE , FischerG , HeilSH , KaltenbachK , MartinPR , CoyleMG , et al. Maternal Opioid Treatment: Human Experimental Research (MOTHER) - approach, issues and lessons learned. Addiction2012;107(Suppl 1):28-35. JonesHE , JanssonLM , O’GradycKE , KaltenbachK . The relationship between maternal methadone dose at delivery and neonatal outcome: methodological and design considerations. Neurotoxicology and Teratology2013:110-5. [DOI: 10.1016/j.ntt.2013.05.003]JonesHE , JohnsonRE , JasinskiDR , TutenM , MilioL . Dosing pre to postpartum with either buprenorphine or methadone. In: 69th Annual Scientific Meeting of the College on Problems of Drug Dependence. Quebec City, Canada, 2007:16-21. JonesHE , JohnsonRE , O'GradyKE , JasinskiDR , TutenM , MilioL . Dosing adjustments in postpartum patients maintained on buprenorphine or methadone. Journal of Addiction Medicine2008;2(2):103-7. JonesHE , KaltenbachK , HeilSH , StineSM , CoyleMG , ArriaAM , et al. Neonatal abstinence syndrome after methadone or buprenorphine exposure. New England Journal of Medicine2010;363:2320-31. KaltenbachK , O’GradyKE , HeilSH , SalisburyAL , CoyleMG , FischerG , et al. Prenatal exposure to methadone or buprenorphine: early childhood developmental outcomes. Drug and Alcohol Dependence2018;185:40-9. UngerA , JagschR , BäwertA , WinklbaurB , RohrmeisterK , MartinPR , et al. Are male neonates more vulnerable to neonatal abstinence syndrome than female neonates?Gender Medicine2011;8(6):355-64. Wilson-MurphyMM , ChisolmMS , LeoutsakosJS , KaltenbachK , HeilSH , MartinPR . Treatment completion in opioid-dependent pregnant patients randomised to agonist treatment: the role of intravenous drug use. In: 73rd Annual Scientific Meeting of the College on Problems of Drug Dependence. 2011:195, Abstract no: 778. Winklbaur-HausknostB , JagschR , Graf-RohrmeisterK , UngerA , BaewertA , LangerM , et al. Lessons learned from a comparison of evidence-based research in pregnant opioid-dependent women. Human Psychopharmacology2013;28(1):15-24. ">MOTHER Study</a>, there was one case of meconium aspiration in the buprenorphine group. </p> </section> <section id="CD006318-sec-0074"> <p><b>3.4 Caesarean section</b></p> <p>In <a href="./references#CD006318-bbs2-0003" title="JonesHE , JohnsonRE , JasinskiDR , O'GradyKE , ChisholmCA , ChooRE , et al. Buprenorphine versus methadone in the treatment of pregnant opioid-dependent patients: effects on the neonatal abstinence syndrome. Drug and Alcohol Dependence2005;79(1):1-10. ">Jones 2005</a>, all but one birth in each group were vaginal. In <a href="./references#CD006318-bbs2-0002" title="FischerG , OrtnerR , RohrmeisterK , JagschR , BaewertA , LangerM , et al. Methadone versus buprenorphine in pregnant addicts: a double-blind, double dummy comparison study. Addiction2006;101(2):275-81. ">Fischer 2006</a>, two women maintained on buprenorphine were delivered by planned caesarean section at week 40. In the <a href="./references#CD006318-bbs2-0004" title="ChisolmMS , FitzsimonsH , LeoutsakosJM , AcquavitaSP , HeilSH , Wilson-MurphyM , et al. A comparison of cigarette smoking profiles in opioid-dependent pregnant patients receiving methadone or buprenorphine. Nicotine Tobacco Research2013;15(7):1297-304. CoyleMG , SalisburyAL , LesterBM , JonesHE , LinH , Graf-RohrmeisterK , et al. Neonatal neurobehavior effects following buprenorphine versus methadone exposure. Addiction2012;107(Suppl 1):63-73. GaalemaDE , ScottTL , HeilSH , CoyleMG , KaltenbachK , BadgerGJ , et al. Differences in the profile of neonatal abstinence syndrome signs in methadone- versus buprenorphine-exposed neonates. Addiction2012;107(Suppl 1):53-62. HolbrookAM , BaxterJK , JonesHE , HeilSH , CoyleMG , MartinPR , et al. Infections and obstetric outcomes in opioid-dependent pregnant women maintained on methadone or buprenorphine. Addiction2012;107(Suppl 1):83-90. HolbrookAM , JonesHE , HeilSH , MartinPR , StineSM , FischerG , et al. Induction of pregnant women onto opioid-agonist maintenance medication: an analysis of withdrawal symptoms and study retention. Drug and Alcohol Dependence2013;132(0):329-34. JanssonLM , DipietroJA , VelezM , ElkoA , WilliamsE , MilioL , et al. Fetal neurobehavioral effects of exposure to methadone or buprenorphine. Neurotoxicology and Teratology2011;33(2):240-3. JonesHE , DenglerE , GarrisondA , O'GradyeKE , SeashoreC , HortonE , et al. Neonatal outcomes and their relationship to maternal buprenorphine dose during pregnancy. Drug and Alcohol Dependence2014;134:414-7. JonesHE , FischerG , HeilSH , KaltenbachK , MartinPR , CoyleMG , et al. Maternal Opioid Treatment: Human Experimental Research (MOTHER) - approach, issues and lessons learned. Addiction2012;107(Suppl 1):28-35. JonesHE , JanssonLM , O’GradycKE , KaltenbachK . The relationship between maternal methadone dose at delivery and neonatal outcome: methodological and design considerations. Neurotoxicology and Teratology2013:110-5. [DOI: 10.1016/j.ntt.2013.05.003]JonesHE , JohnsonRE , JasinskiDR , TutenM , MilioL . Dosing pre to postpartum with either buprenorphine or methadone. In: 69th Annual Scientific Meeting of the College on Problems of Drug Dependence. Quebec City, Canada, 2007:16-21. JonesHE , JohnsonRE , O'GradyKE , JasinskiDR , TutenM , MilioL . Dosing adjustments in postpartum patients maintained on buprenorphine or methadone. Journal of Addiction Medicine2008;2(2):103-7. JonesHE , KaltenbachK , HeilSH , StineSM , CoyleMG , ArriaAM , et al. Neonatal abstinence syndrome after methadone or buprenorphine exposure. New England Journal of Medicine2010;363:2320-31. KaltenbachK , O’GradyKE , HeilSH , SalisburyAL , CoyleMG , FischerG , et al. Prenatal exposure to methadone or buprenorphine: early childhood developmental outcomes. Drug and Alcohol Dependence2018;185:40-9. UngerA , JagschR , BäwertA , WinklbaurB , RohrmeisterK , MartinPR , et al. Are male neonates more vulnerable to neonatal abstinence syndrome than female neonates?Gender Medicine2011;8(6):355-64. Wilson-MurphyMM , ChisolmMS , LeoutsakosJS , KaltenbachK , HeilSH , MartinPR . Treatment completion in opioid-dependent pregnant patients randomised to agonist treatment: the role of intravenous drug use. In: 73rd Annual Scientific Meeting of the College on Problems of Drug Dependence. 2011:195, Abstract no: 778. Winklbaur-HausknostB , JagschR , Graf-RohrmeisterK , UngerA , BaewertA , LangerM , et al. Lessons learned from a comparison of evidence-based research in pregnant opioid-dependent women. Human Psychopharmacology2013;28(1):15-24. ">MOTHER Study</a>, there were 37% of caesarean sections in the methadone group and 29% in the buprenorphine group. There was no evidence of a difference between treatments. </p> </section> <section id="CD006318-sec-0075"> <p><b>3.5 Abnormal presentation</b></p> <p>In <a href="./references#CD006318-bbs2-0003" title="JonesHE , JohnsonRE , JasinskiDR , O'GradyKE , ChisholmCA , ChooRE , et al. Buprenorphine versus methadone in the treatment of pregnant opioid-dependent patients: effects on the neonatal abstinence syndrome. Drug and Alcohol Dependence2005;79(1):1-10. ">Jones 2005</a>, all births were normal presentation. Data were not reported in <a href="./references#CD006318-bbs2-0002" title="FischerG , OrtnerR , RohrmeisterK , JagschR , BaewertA , LangerM , et al. Methadone versus buprenorphine in pregnant addicts: a double-blind, double dummy comparison study. Addiction2006;101(2):275-81. ">Fischer 2006</a>. In the <a href="./references#CD006318-bbs2-0004" title="ChisolmMS , FitzsimonsH , LeoutsakosJM , AcquavitaSP , HeilSH , Wilson-MurphyM , et al. A comparison of cigarette smoking profiles in opioid-dependent pregnant patients receiving methadone or buprenorphine. Nicotine Tobacco Research2013;15(7):1297-304. CoyleMG , SalisburyAL , LesterBM , JonesHE , LinH , Graf-RohrmeisterK , et al. Neonatal neurobehavior effects following buprenorphine versus methadone exposure. Addiction2012;107(Suppl 1):63-73. GaalemaDE , ScottTL , HeilSH , CoyleMG , KaltenbachK , BadgerGJ , et al. Differences in the profile of neonatal abstinence syndrome signs in methadone- versus buprenorphine-exposed neonates. Addiction2012;107(Suppl 1):53-62. HolbrookAM , BaxterJK , JonesHE , HeilSH , CoyleMG , MartinPR , et al. Infections and obstetric outcomes in opioid-dependent pregnant women maintained on methadone or buprenorphine. Addiction2012;107(Suppl 1):83-90. HolbrookAM , JonesHE , HeilSH , MartinPR , StineSM , FischerG , et al. Induction of pregnant women onto opioid-agonist maintenance medication: an analysis of withdrawal symptoms and study retention. Drug and Alcohol Dependence2013;132(0):329-34. JanssonLM , DipietroJA , VelezM , ElkoA , WilliamsE , MilioL , et al. Fetal neurobehavioral effects of exposure to methadone or buprenorphine. Neurotoxicology and Teratology2011;33(2):240-3. JonesHE , DenglerE , GarrisondA , O'GradyeKE , SeashoreC , HortonE , et al. Neonatal outcomes and their relationship to maternal buprenorphine dose during pregnancy. Drug and Alcohol Dependence2014;134:414-7. JonesHE , FischerG , HeilSH , KaltenbachK , MartinPR , CoyleMG , et al. Maternal Opioid Treatment: Human Experimental Research (MOTHER) - approach, issues and lessons learned. Addiction2012;107(Suppl 1):28-35. JonesHE , JanssonLM , O’GradycKE , KaltenbachK . The relationship between maternal methadone dose at delivery and neonatal outcome: methodological and design considerations. Neurotoxicology and Teratology2013:110-5. [DOI: 10.1016/j.ntt.2013.05.003]JonesHE , JohnsonRE , JasinskiDR , TutenM , MilioL . Dosing pre to postpartum with either buprenorphine or methadone. In: 69th Annual Scientific Meeting of the College on Problems of Drug Dependence. Quebec City, Canada, 2007:16-21. JonesHE , JohnsonRE , O'GradyKE , JasinskiDR , TutenM , MilioL . Dosing adjustments in postpartum patients maintained on buprenorphine or methadone. Journal of Addiction Medicine2008;2(2):103-7. JonesHE , KaltenbachK , HeilSH , StineSM , CoyleMG , ArriaAM , et al. Neonatal abstinence syndrome after methadone or buprenorphine exposure. New England Journal of Medicine2010;363:2320-31. KaltenbachK , O’GradyKE , HeilSH , SalisburyAL , CoyleMG , FischerG , et al. Prenatal exposure to methadone or buprenorphine: early childhood developmental outcomes. Drug and Alcohol Dependence2018;185:40-9. UngerA , JagschR , BäwertA , WinklbaurB , RohrmeisterK , MartinPR , et al. Are male neonates more vulnerable to neonatal abstinence syndrome than female neonates?Gender Medicine2011;8(6):355-64. Wilson-MurphyMM , ChisolmMS , LeoutsakosJS , KaltenbachK , HeilSH , MartinPR . Treatment completion in opioid-dependent pregnant patients randomised to agonist treatment: the role of intravenous drug use. In: 73rd Annual Scientific Meeting of the College on Problems of Drug Dependence. 2011:195, Abstract no: 778. Winklbaur-HausknostB , JagschR , Graf-RohrmeisterK , UngerA , BaewertA , LangerM , et al. Lessons learned from a comparison of evidence-based research in pregnant opioid-dependent women. Human Psychopharmacology2013;28(1):15-24. ">MOTHER Study</a>, there were 14% abnormal fetal presentations in the methadone group and 5% in the buprenorphine group. There was no evidence of a difference between treatments. </p> </section> <section id="CD006318-sec-0076"> <p><b>3.6 Medical complications at delivery</b></p> <p>In <a href="./references#CD006318-bbs2-0002" title="FischerG , OrtnerR , RohrmeisterK , JagschR , BaewertA , LangerM , et al. Methadone versus buprenorphine in pregnant addicts: a double-blind, double dummy comparison study. Addiction2006;101(2):275-81. ">Fischer 2006</a>, one woman in the methadone group required vacuum extraction due to a prolonged delivery. No medical complications occurred in <a href="./references#CD006318-bbs2-0003" title="JonesHE , JohnsonRE , JasinskiDR , O'GradyKE , ChisholmCA , ChooRE , et al. Buprenorphine versus methadone in the treatment of pregnant opioid-dependent patients: effects on the neonatal abstinence syndrome. Drug and Alcohol Dependence2005;79(1):1-10. ">Jones 2005</a>. In the <a href="./references#CD006318-bbs2-0004" title="ChisolmMS , FitzsimonsH , LeoutsakosJM , AcquavitaSP , HeilSH , Wilson-MurphyM , et al. A comparison of cigarette smoking profiles in opioid-dependent pregnant patients receiving methadone or buprenorphine. Nicotine Tobacco Research2013;15(7):1297-304. CoyleMG , SalisburyAL , LesterBM , JonesHE , LinH , Graf-RohrmeisterK , et al. Neonatal neurobehavior effects following buprenorphine versus methadone exposure. Addiction2012;107(Suppl 1):63-73. GaalemaDE , ScottTL , HeilSH , CoyleMG , KaltenbachK , BadgerGJ , et al. Differences in the profile of neonatal abstinence syndrome signs in methadone- versus buprenorphine-exposed neonates. Addiction2012;107(Suppl 1):53-62. HolbrookAM , BaxterJK , JonesHE , HeilSH , CoyleMG , MartinPR , et al. Infections and obstetric outcomes in opioid-dependent pregnant women maintained on methadone or buprenorphine. Addiction2012;107(Suppl 1):83-90. HolbrookAM , JonesHE , HeilSH , MartinPR , StineSM , FischerG , et al. Induction of pregnant women onto opioid-agonist maintenance medication: an analysis of withdrawal symptoms and study retention. Drug and Alcohol Dependence2013;132(0):329-34. JanssonLM , DipietroJA , VelezM , ElkoA , WilliamsE , MilioL , et al. Fetal neurobehavioral effects of exposure to methadone or buprenorphine. Neurotoxicology and Teratology2011;33(2):240-3. JonesHE , DenglerE , GarrisondA , O'GradyeKE , SeashoreC , HortonE , et al. Neonatal outcomes and their relationship to maternal buprenorphine dose during pregnancy. Drug and Alcohol Dependence2014;134:414-7. JonesHE , FischerG , HeilSH , KaltenbachK , MartinPR , CoyleMG , et al. Maternal Opioid Treatment: Human Experimental Research (MOTHER) - approach, issues and lessons learned. Addiction2012;107(Suppl 1):28-35. JonesHE , JanssonLM , O’GradycKE , KaltenbachK . The relationship between maternal methadone dose at delivery and neonatal outcome: methodological and design considerations. Neurotoxicology and Teratology2013:110-5. [DOI: 10.1016/j.ntt.2013.05.003]JonesHE , JohnsonRE , JasinskiDR , TutenM , MilioL . Dosing pre to postpartum with either buprenorphine or methadone. In: 69th Annual Scientific Meeting of the College on Problems of Drug Dependence. Quebec City, Canada, 2007:16-21. JonesHE , JohnsonRE , O'GradyKE , JasinskiDR , TutenM , MilioL . Dosing adjustments in postpartum patients maintained on buprenorphine or methadone. Journal of Addiction Medicine2008;2(2):103-7. JonesHE , KaltenbachK , HeilSH , StineSM , CoyleMG , ArriaAM , et al. Neonatal abstinence syndrome after methadone or buprenorphine exposure. New England Journal of Medicine2010;363:2320-31. KaltenbachK , O’GradyKE , HeilSH , SalisburyAL , CoyleMG , FischerG , et al. Prenatal exposure to methadone or buprenorphine: early childhood developmental outcomes. Drug and Alcohol Dependence2018;185:40-9. UngerA , JagschR , BäwertA , WinklbaurB , RohrmeisterK , MartinPR , et al. Are male neonates more vulnerable to neonatal abstinence syndrome than female neonates?Gender Medicine2011;8(6):355-64. Wilson-MurphyMM , ChisolmMS , LeoutsakosJS , KaltenbachK , HeilSH , MartinPR . Treatment completion in opioid-dependent pregnant patients randomised to agonist treatment: the role of intravenous drug use. In: 73rd Annual Scientific Meeting of the College on Problems of Drug Dependence. 2011:195, Abstract no: 778. Winklbaur-HausknostB , JagschR , Graf-RohrmeisterK , UngerA , BaewertA , LangerM , et al. Lessons learned from a comparison of evidence-based research in pregnant opioid-dependent women. Human Psychopharmacology2013;28(1):15-24. ">MOTHER Study</a>, there were 51% medical complications at delivery in the methadone group and 31% in the buprenorphine group (P = 0.03). </p> </section> <section id="CD006318-sec-0077"> <p><b>3.7 Breastfeeding following delivery</b></p> <p>Data were not reported in any of the included studies.</p> </section> <section id="CD006318-sec-0078"> <p><b>3.8 Puerperal morbidity</b></p> <p>No cases of puerperal morbidity were observed in <a href="./references#CD006318-bbs2-0003" title="JonesHE , JohnsonRE , JasinskiDR , O'GradyKE , ChisholmCA , ChooRE , et al. Buprenorphine versus methadone in the treatment of pregnant opioid-dependent patients: effects on the neonatal abstinence syndrome. Drug and Alcohol Dependence2005;79(1):1-10. ">Jones 2005</a> or in the <a href="./references#CD006318-bbs2-0004" title="ChisolmMS , FitzsimonsH , LeoutsakosJM , AcquavitaSP , HeilSH , Wilson-MurphyM , et al. A comparison of cigarette smoking profiles in opioid-dependent pregnant patients receiving methadone or buprenorphine. Nicotine Tobacco Research2013;15(7):1297-304. CoyleMG , SalisburyAL , LesterBM , JonesHE , LinH , Graf-RohrmeisterK , et al. Neonatal neurobehavior effects following buprenorphine versus methadone exposure. Addiction2012;107(Suppl 1):63-73. GaalemaDE , ScottTL , HeilSH , CoyleMG , KaltenbachK , BadgerGJ , et al. Differences in the profile of neonatal abstinence syndrome signs in methadone- versus buprenorphine-exposed neonates. Addiction2012;107(Suppl 1):53-62. HolbrookAM , BaxterJK , JonesHE , HeilSH , CoyleMG , MartinPR , et al. Infections and obstetric outcomes in opioid-dependent pregnant women maintained on methadone or buprenorphine. Addiction2012;107(Suppl 1):83-90. HolbrookAM , JonesHE , HeilSH , MartinPR , StineSM , FischerG , et al. Induction of pregnant women onto opioid-agonist maintenance medication: an analysis of withdrawal symptoms and study retention. Drug and Alcohol Dependence2013;132(0):329-34. JanssonLM , DipietroJA , VelezM , ElkoA , WilliamsE , MilioL , et al. Fetal neurobehavioral effects of exposure to methadone or buprenorphine. Neurotoxicology and Teratology2011;33(2):240-3. JonesHE , DenglerE , GarrisondA , O'GradyeKE , SeashoreC , HortonE , et al. Neonatal outcomes and their relationship to maternal buprenorphine dose during pregnancy. Drug and Alcohol Dependence2014;134:414-7. JonesHE , FischerG , HeilSH , KaltenbachK , MartinPR , CoyleMG , et al. Maternal Opioid Treatment: Human Experimental Research (MOTHER) - approach, issues and lessons learned. Addiction2012;107(Suppl 1):28-35. JonesHE , JanssonLM , O’GradycKE , KaltenbachK . The relationship between maternal methadone dose at delivery and neonatal outcome: methodological and design considerations. Neurotoxicology and Teratology2013:110-5. [DOI: 10.1016/j.ntt.2013.05.003]JonesHE , JohnsonRE , JasinskiDR , TutenM , MilioL . Dosing pre to postpartum with either buprenorphine or methadone. In: 69th Annual Scientific Meeting of the College on Problems of Drug Dependence. Quebec City, Canada, 2007:16-21. JonesHE , JohnsonRE , O'GradyKE , JasinskiDR , TutenM , MilioL . Dosing adjustments in postpartum patients maintained on buprenorphine or methadone. Journal of Addiction Medicine2008;2(2):103-7. JonesHE , KaltenbachK , HeilSH , StineSM , CoyleMG , ArriaAM , et al. Neonatal abstinence syndrome after methadone or buprenorphine exposure. New England Journal of Medicine2010;363:2320-31. KaltenbachK , O’GradyKE , HeilSH , SalisburyAL , CoyleMG , FischerG , et al. Prenatal exposure to methadone or buprenorphine: early childhood developmental outcomes. Drug and Alcohol Dependence2018;185:40-9. UngerA , JagschR , BäwertA , WinklbaurB , RohrmeisterK , MartinPR , et al. Are male neonates more vulnerable to neonatal abstinence syndrome than female neonates?Gender Medicine2011;8(6):355-64. Wilson-MurphyMM , ChisolmMS , LeoutsakosJS , KaltenbachK , HeilSH , MartinPR . Treatment completion in opioid-dependent pregnant patients randomised to agonist treatment: the role of intravenous drug use. In: 73rd Annual Scientific Meeting of the College on Problems of Drug Dependence. 2011:195, Abstract no: 778. Winklbaur-HausknostB , JagschR , Graf-RohrmeisterK , UngerA , BaewertA , LangerM , et al. Lessons learned from a comparison of evidence-based research in pregnant opioid-dependent women. Human Psychopharmacology2013;28(1):15-24. ">MOTHER Study</a>. Data were not reported in <a href="./references#CD006318-bbs2-0002" title="FischerG , OrtnerR , RohrmeisterK , JagschR , BaewertA , LangerM , et al. Methadone versus buprenorphine in pregnant addicts: a double-blind, double dummy comparison study. Addiction2006;101(2):275-81. ">Fischer 2006</a>. </p> </section> </section> </section> <section id="CD006318-sec-0079"> <h5 class="title">Primary outcomes: for the child</h5> <section id="CD006318-sec-0080"> <h6 class="title">4. Health status</h6> <section id="CD006318-sec-0081"> <p><b>4.1 Birth weight</b></p> <p>Two studies (<a href="./references#CD006318-bbs2-0003" title="JonesHE , JohnsonRE , JasinskiDR , O'GradyKE , ChisholmCA , ChooRE , et al. Buprenorphine versus methadone in the treatment of pregnant opioid-dependent patients: effects on the neonatal abstinence syndrome. Drug and Alcohol Dependence2005;79(1):1-10. ">Jones 2005</a>; <a href="./references#CD006318-bbs2-0004" title="ChisolmMS , FitzsimonsH , LeoutsakosJM , AcquavitaSP , HeilSH , Wilson-MurphyM , et al. A comparison of cigarette smoking profiles in opioid-dependent pregnant patients receiving methadone or buprenorphine. Nicotine Tobacco Research2013;15(7):1297-304. CoyleMG , SalisburyAL , LesterBM , JonesHE , LinH , Graf-RohrmeisterK , et al. Neonatal neurobehavior effects following buprenorphine versus methadone exposure. Addiction2012;107(Suppl 1):63-73. GaalemaDE , ScottTL , HeilSH , CoyleMG , KaltenbachK , BadgerGJ , et al. Differences in the profile of neonatal abstinence syndrome signs in methadone- versus buprenorphine-exposed neonates. Addiction2012;107(Suppl 1):53-62. HolbrookAM , BaxterJK , JonesHE , HeilSH , CoyleMG , MartinPR , et al. Infections and obstetric outcomes in opioid-dependent pregnant women maintained on methadone or buprenorphine. Addiction2012;107(Suppl 1):83-90. HolbrookAM , JonesHE , HeilSH , MartinPR , StineSM , FischerG , et al. Induction of pregnant women onto opioid-agonist maintenance medication: an analysis of withdrawal symptoms and study retention. Drug and Alcohol Dependence2013;132(0):329-34. JanssonLM , DipietroJA , VelezM , ElkoA , WilliamsE , MilioL , et al. Fetal neurobehavioral effects of exposure to methadone or buprenorphine. Neurotoxicology and Teratology2011;33(2):240-3. JonesHE , DenglerE , GarrisondA , O'GradyeKE , SeashoreC , HortonE , et al. Neonatal outcomes and their relationship to maternal buprenorphine dose during pregnancy. Drug and Alcohol Dependence2014;134:414-7. JonesHE , FischerG , HeilSH , KaltenbachK , MartinPR , CoyleMG , et al. Maternal Opioid Treatment: Human Experimental Research (MOTHER) - approach, issues and lessons learned. Addiction2012;107(Suppl 1):28-35. JonesHE , JanssonLM , O’GradycKE , KaltenbachK . The relationship between maternal methadone dose at delivery and neonatal outcome: methodological and design considerations. Neurotoxicology and Teratology2013:110-5. [DOI: 10.1016/j.ntt.2013.05.003]JonesHE , JohnsonRE , JasinskiDR , TutenM , MilioL . Dosing pre to postpartum with either buprenorphine or methadone. In: 69th Annual Scientific Meeting of the College on Problems of Drug Dependence. Quebec City, Canada, 2007:16-21. JonesHE , JohnsonRE , O'GradyKE , JasinskiDR , TutenM , MilioL . Dosing adjustments in postpartum patients maintained on buprenorphine or methadone. Journal of Addiction Medicine2008;2(2):103-7. JonesHE , KaltenbachK , HeilSH , StineSM , CoyleMG , ArriaAM , et al. Neonatal abstinence syndrome after methadone or buprenorphine exposure. New England Journal of Medicine2010;363:2320-31. KaltenbachK , O’GradyKE , HeilSH , SalisburyAL , CoyleMG , FischerG , et al. Prenatal exposure to methadone or buprenorphine: early childhood developmental outcomes. Drug and Alcohol Dependence2018;185:40-9. UngerA , JagschR , BäwertA , WinklbaurB , RohrmeisterK , MartinPR , et al. Are male neonates more vulnerable to neonatal abstinence syndrome than female neonates?Gender Medicine2011;8(6):355-64. Wilson-MurphyMM , ChisolmMS , LeoutsakosJS , KaltenbachK , HeilSH , MartinPR . Treatment completion in opioid-dependent pregnant patients randomised to agonist treatment: the role of intravenous drug use. In: 73rd Annual Scientific Meeting of the College on Problems of Drug Dependence. 2011:195, Abstract no: 778. Winklbaur-HausknostB , JagschR , Graf-RohrmeisterK , UngerA , BaewertA , LangerM , et al. Lessons learned from a comparison of evidence-based research in pregnant opioid-dependent women. Human Psychopharmacology2013;28(1):15-24. ">MOTHER Study</a>) with 150 participants reported data for this outcome (one mother in the buprenorphine group delivered twins; twin data were not considered for this outcome because it could be altered by twin status). The results were in favour of buprenorhine in both studies: MD; ‐530.00 g (95%CI ‐662.78 to ‐397.22) in <a href="./references#CD006318-bbs2-0003" title="JonesHE , JohnsonRE , JasinskiDR , O'GradyKE , ChisholmCA , ChooRE , et al. Buprenorphine versus methadone in the treatment of pregnant opioid-dependent patients: effects on the neonatal abstinence syndrome. Drug and Alcohol Dependence2005;79(1):1-10. ">Jones 2005</a> and MD: ‐215.00 g (95%CI ‐238.93 to ‐191.07) in the <a href="./references#CD006318-bbs2-0004" title="ChisolmMS , FitzsimonsH , LeoutsakosJM , AcquavitaSP , HeilSH , Wilson-MurphyM , et al. A comparison of cigarette smoking profiles in opioid-dependent pregnant patients receiving methadone or buprenorphine. Nicotine Tobacco Research2013;15(7):1297-304. CoyleMG , SalisburyAL , LesterBM , JonesHE , LinH , Graf-RohrmeisterK , et al. Neonatal neurobehavior effects following buprenorphine versus methadone exposure. Addiction2012;107(Suppl 1):63-73. GaalemaDE , ScottTL , HeilSH , CoyleMG , KaltenbachK , BadgerGJ , et al. Differences in the profile of neonatal abstinence syndrome signs in methadone- versus buprenorphine-exposed neonates. Addiction2012;107(Suppl 1):53-62. HolbrookAM , BaxterJK , JonesHE , HeilSH , CoyleMG , MartinPR , et al. Infections and obstetric outcomes in opioid-dependent pregnant women maintained on methadone or buprenorphine. Addiction2012;107(Suppl 1):83-90. HolbrookAM , JonesHE , HeilSH , MartinPR , StineSM , FischerG , et al. Induction of pregnant women onto opioid-agonist maintenance medication: an analysis of withdrawal symptoms and study retention. Drug and Alcohol Dependence2013;132(0):329-34. JanssonLM , DipietroJA , VelezM , ElkoA , WilliamsE , MilioL , et al. Fetal neurobehavioral effects of exposure to methadone or buprenorphine. Neurotoxicology and Teratology2011;33(2):240-3. JonesHE , DenglerE , GarrisondA , O'GradyeKE , SeashoreC , HortonE , et al. Neonatal outcomes and their relationship to maternal buprenorphine dose during pregnancy. Drug and Alcohol Dependence2014;134:414-7. JonesHE , FischerG , HeilSH , KaltenbachK , MartinPR , CoyleMG , et al. Maternal Opioid Treatment: Human Experimental Research (MOTHER) - approach, issues and lessons learned. Addiction2012;107(Suppl 1):28-35. JonesHE , JanssonLM , O’GradycKE , KaltenbachK . The relationship between maternal methadone dose at delivery and neonatal outcome: methodological and design considerations. Neurotoxicology and Teratology2013:110-5. [DOI: 10.1016/j.ntt.2013.05.003]JonesHE , JohnsonRE , JasinskiDR , TutenM , MilioL . Dosing pre to postpartum with either buprenorphine or methadone. In: 69th Annual Scientific Meeting of the College on Problems of Drug Dependence. Quebec City, Canada, 2007:16-21. JonesHE , JohnsonRE , O'GradyKE , JasinskiDR , TutenM , MilioL . Dosing adjustments in postpartum patients maintained on buprenorphine or methadone. Journal of Addiction Medicine2008;2(2):103-7. JonesHE , KaltenbachK , HeilSH , StineSM , CoyleMG , ArriaAM , et al. Neonatal abstinence syndrome after methadone or buprenorphine exposure. New England Journal of Medicine2010;363:2320-31. KaltenbachK , O’GradyKE , HeilSH , SalisburyAL , CoyleMG , FischerG , et al. Prenatal exposure to methadone or buprenorphine: early childhood developmental outcomes. Drug and Alcohol Dependence2018;185:40-9. UngerA , JagschR , BäwertA , WinklbaurB , RohrmeisterK , MartinPR , et al. Are male neonates more vulnerable to neonatal abstinence syndrome than female neonates?Gender Medicine2011;8(6):355-64. Wilson-MurphyMM , ChisolmMS , LeoutsakosJS , KaltenbachK , HeilSH , MartinPR . Treatment completion in opioid-dependent pregnant patients randomised to agonist treatment: the role of intravenous drug use. In: 73rd Annual Scientific Meeting of the College on Problems of Drug Dependence. 2011:195, Abstract no: 778. Winklbaur-HausknostB , JagschR , Graf-RohrmeisterK , UngerA , BaewertA , LangerM , et al. Lessons learned from a comparison of evidence-based research in pregnant opioid-dependent women. Human Psychopharmacology2013;28(1):15-24. ">MOTHER Study</a>; data were not pooled due to high heterogeneity ( P &lt; 0.00001, I<sup>2</sup> = 95%). Quality of evidence was judged as very low.The third study (<a href="./references#CD006318-bbs2-0002" title="FischerG , OrtnerR , RohrmeisterK , JagschR , BaewertA , LangerM , et al. Methadone versus buprenorphine in pregnant addicts: a double-blind, double dummy comparison study. Addiction2006;101(2):275-81. ">Fischer 2006</a>) did not report data but stated that there was no evidence of a difference between treatments in birth weight (mean 2820 g). </p> <p><i>4.2 APGAR score (Activity, Pulse, Grimace, Appearance and Respiration score) at five minutes</i> </p> <p>We pooled two studies (<a href="./references#CD006318-bbs2-0003" title="JonesHE , JohnsonRE , JasinskiDR , O'GradyKE , ChisholmCA , ChooRE , et al. Buprenorphine versus methadone in the treatment of pregnant opioid-dependent patients: effects on the neonatal abstinence syndrome. Drug and Alcohol Dependence2005;79(1):1-10. ">Jones 2005</a>; <a href="./references#CD006318-bbs2-0004" title="ChisolmMS , FitzsimonsH , LeoutsakosJM , AcquavitaSP , HeilSH , Wilson-MurphyM , et al. A comparison of cigarette smoking profiles in opioid-dependent pregnant patients receiving methadone or buprenorphine. Nicotine Tobacco Research2013;15(7):1297-304. CoyleMG , SalisburyAL , LesterBM , JonesHE , LinH , Graf-RohrmeisterK , et al. Neonatal neurobehavior effects following buprenorphine versus methadone exposure. Addiction2012;107(Suppl 1):63-73. GaalemaDE , ScottTL , HeilSH , CoyleMG , KaltenbachK , BadgerGJ , et al. Differences in the profile of neonatal abstinence syndrome signs in methadone- versus buprenorphine-exposed neonates. Addiction2012;107(Suppl 1):53-62. HolbrookAM , BaxterJK , JonesHE , HeilSH , CoyleMG , MartinPR , et al. Infections and obstetric outcomes in opioid-dependent pregnant women maintained on methadone or buprenorphine. Addiction2012;107(Suppl 1):83-90. HolbrookAM , JonesHE , HeilSH , MartinPR , StineSM , FischerG , et al. Induction of pregnant women onto opioid-agonist maintenance medication: an analysis of withdrawal symptoms and study retention. Drug and Alcohol Dependence2013;132(0):329-34. JanssonLM , DipietroJA , VelezM , ElkoA , WilliamsE , MilioL , et al. Fetal neurobehavioral effects of exposure to methadone or buprenorphine. Neurotoxicology and Teratology2011;33(2):240-3. JonesHE , DenglerE , GarrisondA , O'GradyeKE , SeashoreC , HortonE , et al. Neonatal outcomes and their relationship to maternal buprenorphine dose during pregnancy. Drug and Alcohol Dependence2014;134:414-7. JonesHE , FischerG , HeilSH , KaltenbachK , MartinPR , CoyleMG , et al. Maternal Opioid Treatment: Human Experimental Research (MOTHER) - approach, issues and lessons learned. Addiction2012;107(Suppl 1):28-35. JonesHE , JanssonLM , O’GradycKE , KaltenbachK . The relationship between maternal methadone dose at delivery and neonatal outcome: methodological and design considerations. Neurotoxicology and Teratology2013:110-5. [DOI: 10.1016/j.ntt.2013.05.003]JonesHE , JohnsonRE , JasinskiDR , TutenM , MilioL . Dosing pre to postpartum with either buprenorphine or methadone. In: 69th Annual Scientific Meeting of the College on Problems of Drug Dependence. Quebec City, Canada, 2007:16-21. JonesHE , JohnsonRE , O'GradyKE , JasinskiDR , TutenM , MilioL . Dosing adjustments in postpartum patients maintained on buprenorphine or methadone. Journal of Addiction Medicine2008;2(2):103-7. JonesHE , KaltenbachK , HeilSH , StineSM , CoyleMG , ArriaAM , et al. Neonatal abstinence syndrome after methadone or buprenorphine exposure. New England Journal of Medicine2010;363:2320-31. KaltenbachK , O’GradyKE , HeilSH , SalisburyAL , CoyleMG , FischerG , et al. Prenatal exposure to methadone or buprenorphine: early childhood developmental outcomes. Drug and Alcohol Dependence2018;185:40-9. UngerA , JagschR , BäwertA , WinklbaurB , RohrmeisterK , MartinPR , et al. Are male neonates more vulnerable to neonatal abstinence syndrome than female neonates?Gender Medicine2011;8(6):355-64. Wilson-MurphyMM , ChisolmMS , LeoutsakosJS , KaltenbachK , HeilSH , MartinPR . Treatment completion in opioid-dependent pregnant patients randomised to agonist treatment: the role of intravenous drug use. In: 73rd Annual Scientific Meeting of the College on Problems of Drug Dependence. 2011:195, Abstract no: 778. Winklbaur-HausknostB , JagschR , Graf-RohrmeisterK , UngerA , BaewertA , LangerM , et al. Lessons learned from a comparison of evidence-based research in pregnant opioid-dependent women. Human Psychopharmacology2013;28(1):15-24. ">MOTHER Study</a>) with 163 participants. There was no evidence of a difference between treatments (MD 0.00, 95% CI ‐0.03 to 0.03, low quality evidence) (<a href="./references#CD006318-fig-0008" title="">Analysis 1.4</a>;). The third study (<a href="./references#CD006318-bbs2-0002" title="FischerG , OrtnerR , RohrmeisterK , JagschR , BaewertA , LangerM , et al. Methadone versus buprenorphine in pregnant addicts: a double-blind, double dummy comparison study. Addiction2006;101(2):275-81. ">Fischer 2006</a>) did not report data but stated that there was no evidence of a difference between treatments in the APGAR score between groups. </p> </section> <section id="CD006318-sec-0082"> <p><b>4.3 Neonatal abstinence syndrome</b></p> <p>We pooled the number of newborns treated for neonatal abstinence syndrome from three studies with 166 participants (<a href="./references#CD006318-bbs2-0002" title="FischerG , OrtnerR , RohrmeisterK , JagschR , BaewertA , LangerM , et al. Methadone versus buprenorphine in pregnant addicts: a double-blind, double dummy comparison study. Addiction2006;101(2):275-81. ">Fischer 2006</a>; <a href="./references#CD006318-bbs2-0003" title="JonesHE , JohnsonRE , JasinskiDR , O'GradyKE , ChisholmCA , ChooRE , et al. Buprenorphine versus methadone in the treatment of pregnant opioid-dependent patients: effects on the neonatal abstinence syndrome. Drug and Alcohol Dependence2005;79(1):1-10. ">Jones 2005</a>; <a href="./references#CD006318-bbs2-0004" title="ChisolmMS , FitzsimonsH , LeoutsakosJM , AcquavitaSP , HeilSH , Wilson-MurphyM , et al. A comparison of cigarette smoking profiles in opioid-dependent pregnant patients receiving methadone or buprenorphine. Nicotine Tobacco Research2013;15(7):1297-304. CoyleMG , SalisburyAL , LesterBM , JonesHE , LinH , Graf-RohrmeisterK , et al. Neonatal neurobehavior effects following buprenorphine versus methadone exposure. Addiction2012;107(Suppl 1):63-73. GaalemaDE , ScottTL , HeilSH , CoyleMG , KaltenbachK , BadgerGJ , et al. Differences in the profile of neonatal abstinence syndrome signs in methadone- versus buprenorphine-exposed neonates. Addiction2012;107(Suppl 1):53-62. HolbrookAM , BaxterJK , JonesHE , HeilSH , CoyleMG , MartinPR , et al. Infections and obstetric outcomes in opioid-dependent pregnant women maintained on methadone or buprenorphine. Addiction2012;107(Suppl 1):83-90. HolbrookAM , JonesHE , HeilSH , MartinPR , StineSM , FischerG , et al. Induction of pregnant women onto opioid-agonist maintenance medication: an analysis of withdrawal symptoms and study retention. Drug and Alcohol Dependence2013;132(0):329-34. JanssonLM , DipietroJA , VelezM , ElkoA , WilliamsE , MilioL , et al. Fetal neurobehavioral effects of exposure to methadone or buprenorphine. Neurotoxicology and Teratology2011;33(2):240-3. JonesHE , DenglerE , GarrisondA , O'GradyeKE , SeashoreC , HortonE , et al. Neonatal outcomes and their relationship to maternal buprenorphine dose during pregnancy. Drug and Alcohol Dependence2014;134:414-7. JonesHE , FischerG , HeilSH , KaltenbachK , MartinPR , CoyleMG , et al. Maternal Opioid Treatment: Human Experimental Research (MOTHER) - approach, issues and lessons learned. Addiction2012;107(Suppl 1):28-35. JonesHE , JanssonLM , O’GradycKE , KaltenbachK . The relationship between maternal methadone dose at delivery and neonatal outcome: methodological and design considerations. Neurotoxicology and Teratology2013:110-5. [DOI: 10.1016/j.ntt.2013.05.003]JonesHE , JohnsonRE , JasinskiDR , TutenM , MilioL . Dosing pre to postpartum with either buprenorphine or methadone. In: 69th Annual Scientific Meeting of the College on Problems of Drug Dependence. Quebec City, Canada, 2007:16-21. JonesHE , JohnsonRE , O'GradyKE , JasinskiDR , TutenM , MilioL . Dosing adjustments in postpartum patients maintained on buprenorphine or methadone. Journal of Addiction Medicine2008;2(2):103-7. JonesHE , KaltenbachK , HeilSH , StineSM , CoyleMG , ArriaAM , et al. Neonatal abstinence syndrome after methadone or buprenorphine exposure. New England Journal of Medicine2010;363:2320-31. KaltenbachK , O’GradyKE , HeilSH , SalisburyAL , CoyleMG , FischerG , et al. Prenatal exposure to methadone or buprenorphine: early childhood developmental outcomes. Drug and Alcohol Dependence2018;185:40-9. UngerA , JagschR , BäwertA , WinklbaurB , RohrmeisterK , MartinPR , et al. Are male neonates more vulnerable to neonatal abstinence syndrome than female neonates?Gender Medicine2011;8(6):355-64. Wilson-MurphyMM , ChisolmMS , LeoutsakosJS , KaltenbachK , HeilSH , MartinPR . Treatment completion in opioid-dependent pregnant patients randomised to agonist treatment: the role of intravenous drug use. In: 73rd Annual Scientific Meeting of the College on Problems of Drug Dependence. 2011:195, Abstract no: 778. Winklbaur-HausknostB , JagschR , Graf-RohrmeisterK , UngerA , BaewertA , LangerM , et al. Lessons learned from a comparison of evidence-based research in pregnant opioid-dependent women. Human Psychopharmacology2013;28(1):15-24. ">MOTHER Study</a>). There was no evidence of a difference between treatments (RR 1.19; 95% CI 0.87 to 1.66, low quality evidence) (<a href="./references#CD006318-fig-0009" title="">Analysis 1.5</a>). </p> <p>Neonatal abstinence syndrome peak score during the overall observation days were measured in two studies (<a href="./references#CD006318-bbs2-0003" title="JonesHE , JohnsonRE , JasinskiDR , O'GradyKE , ChisholmCA , ChooRE , et al. Buprenorphine versus methadone in the treatment of pregnant opioid-dependent patients: effects on the neonatal abstinence syndrome. Drug and Alcohol Dependence2005;79(1):1-10. ">Jones 2005</a>; <a href="./references#CD006318-bbs2-0004" title="ChisolmMS , FitzsimonsH , LeoutsakosJM , AcquavitaSP , HeilSH , Wilson-MurphyM , et al. A comparison of cigarette smoking profiles in opioid-dependent pregnant patients receiving methadone or buprenorphine. Nicotine Tobacco Research2013;15(7):1297-304. CoyleMG , SalisburyAL , LesterBM , JonesHE , LinH , Graf-RohrmeisterK , et al. Neonatal neurobehavior effects following buprenorphine versus methadone exposure. Addiction2012;107(Suppl 1):63-73. GaalemaDE , ScottTL , HeilSH , CoyleMG , KaltenbachK , BadgerGJ , et al. Differences in the profile of neonatal abstinence syndrome signs in methadone- versus buprenorphine-exposed neonates. Addiction2012;107(Suppl 1):53-62. HolbrookAM , BaxterJK , JonesHE , HeilSH , CoyleMG , MartinPR , et al. Infections and obstetric outcomes in opioid-dependent pregnant women maintained on methadone or buprenorphine. Addiction2012;107(Suppl 1):83-90. HolbrookAM , JonesHE , HeilSH , MartinPR , StineSM , FischerG , et al. Induction of pregnant women onto opioid-agonist maintenance medication: an analysis of withdrawal symptoms and study retention. Drug and Alcohol Dependence2013;132(0):329-34. JanssonLM , DipietroJA , VelezM , ElkoA , WilliamsE , MilioL , et al. Fetal neurobehavioral effects of exposure to methadone or buprenorphine. Neurotoxicology and Teratology2011;33(2):240-3. JonesHE , DenglerE , GarrisondA , O'GradyeKE , SeashoreC , HortonE , et al. Neonatal outcomes and their relationship to maternal buprenorphine dose during pregnancy. Drug and Alcohol Dependence2014;134:414-7. JonesHE , FischerG , HeilSH , KaltenbachK , MartinPR , CoyleMG , et al. Maternal Opioid Treatment: Human Experimental Research (MOTHER) - approach, issues and lessons learned. Addiction2012;107(Suppl 1):28-35. JonesHE , JanssonLM , O’GradycKE , KaltenbachK . The relationship between maternal methadone dose at delivery and neonatal outcome: methodological and design considerations. Neurotoxicology and Teratology2013:110-5. [DOI: 10.1016/j.ntt.2013.05.003]JonesHE , JohnsonRE , JasinskiDR , TutenM , MilioL . Dosing pre to postpartum with either buprenorphine or methadone. In: 69th Annual Scientific Meeting of the College on Problems of Drug Dependence. Quebec City, Canada, 2007:16-21. JonesHE , JohnsonRE , O'GradyKE , JasinskiDR , TutenM , MilioL . Dosing adjustments in postpartum patients maintained on buprenorphine or methadone. Journal of Addiction Medicine2008;2(2):103-7. JonesHE , KaltenbachK , HeilSH , StineSM , CoyleMG , ArriaAM , et al. Neonatal abstinence syndrome after methadone or buprenorphine exposure. New England Journal of Medicine2010;363:2320-31. KaltenbachK , O’GradyKE , HeilSH , SalisburyAL , CoyleMG , FischerG , et al. Prenatal exposure to methadone or buprenorphine: early childhood developmental outcomes. Drug and Alcohol Dependence2018;185:40-9. UngerA , JagschR , BäwertA , WinklbaurB , RohrmeisterK , MartinPR , et al. Are male neonates more vulnerable to neonatal abstinence syndrome than female neonates?Gender Medicine2011;8(6):355-64. Wilson-MurphyMM , ChisolmMS , LeoutsakosJS , KaltenbachK , HeilSH , MartinPR . Treatment completion in opioid-dependent pregnant patients randomised to agonist treatment: the role of intravenous drug use. In: 73rd Annual Scientific Meeting of the College on Problems of Drug Dependence. 2011:195, Abstract no: 778. Winklbaur-HausknostB , JagschR , Graf-RohrmeisterK , UngerA , BaewertA , LangerM , et al. Lessons learned from a comparison of evidence-based research in pregnant opioid-dependent women. Human Psychopharmacology2013;28(1):15-24. ">MOTHER Study</a>). In <a href="./references#CD006318-bbs2-0003" title="JonesHE , JohnsonRE , JasinskiDR , O'GradyKE , ChisholmCA , ChooRE , et al. Buprenorphine versus methadone in the treatment of pregnant opioid-dependent patients: effects on the neonatal abstinence syndrome. Drug and Alcohol Dependence2005;79(1):1-10. ">Jones 2005</a> (21 participants), the results were methadone: 4.9, buprenorphine: 6.8 (SDs not provided); There was no evidence of a difference between treatments. In the <a href="./references#CD006318-bbs2-0004" title="ChisolmMS , FitzsimonsH , LeoutsakosJM , AcquavitaSP , HeilSH , Wilson-MurphyM , et al. A comparison of cigarette smoking profiles in opioid-dependent pregnant patients receiving methadone or buprenorphine. Nicotine Tobacco Research2013;15(7):1297-304. CoyleMG , SalisburyAL , LesterBM , JonesHE , LinH , Graf-RohrmeisterK , et al. Neonatal neurobehavior effects following buprenorphine versus methadone exposure. Addiction2012;107(Suppl 1):63-73. GaalemaDE , ScottTL , HeilSH , CoyleMG , KaltenbachK , BadgerGJ , et al. Differences in the profile of neonatal abstinence syndrome signs in methadone- versus buprenorphine-exposed neonates. Addiction2012;107(Suppl 1):53-62. HolbrookAM , BaxterJK , JonesHE , HeilSH , CoyleMG , MartinPR , et al. Infections and obstetric outcomes in opioid-dependent pregnant women maintained on methadone or buprenorphine. Addiction2012;107(Suppl 1):83-90. HolbrookAM , JonesHE , HeilSH , MartinPR , StineSM , FischerG , et al. Induction of pregnant women onto opioid-agonist maintenance medication: an analysis of withdrawal symptoms and study retention. Drug and Alcohol Dependence2013;132(0):329-34. JanssonLM , DipietroJA , VelezM , ElkoA , WilliamsE , MilioL , et al. Fetal neurobehavioral effects of exposure to methadone or buprenorphine. Neurotoxicology and Teratology2011;33(2):240-3. JonesHE , DenglerE , GarrisondA , O'GradyeKE , SeashoreC , HortonE , et al. Neonatal outcomes and their relationship to maternal buprenorphine dose during pregnancy. Drug and Alcohol Dependence2014;134:414-7. JonesHE , FischerG , HeilSH , KaltenbachK , MartinPR , CoyleMG , et al. Maternal Opioid Treatment: Human Experimental Research (MOTHER) - approach, issues and lessons learned. Addiction2012;107(Suppl 1):28-35. JonesHE , JanssonLM , O’GradycKE , KaltenbachK . The relationship between maternal methadone dose at delivery and neonatal outcome: methodological and design considerations. Neurotoxicology and Teratology2013:110-5. [DOI: 10.1016/j.ntt.2013.05.003]JonesHE , JohnsonRE , JasinskiDR , TutenM , MilioL . Dosing pre to postpartum with either buprenorphine or methadone. In: 69th Annual Scientific Meeting of the College on Problems of Drug Dependence. Quebec City, Canada, 2007:16-21. JonesHE , JohnsonRE , O'GradyKE , JasinskiDR , TutenM , MilioL . Dosing adjustments in postpartum patients maintained on buprenorphine or methadone. Journal of Addiction Medicine2008;2(2):103-7. JonesHE , KaltenbachK , HeilSH , StineSM , CoyleMG , ArriaAM , et al. Neonatal abstinence syndrome after methadone or buprenorphine exposure. New England Journal of Medicine2010;363:2320-31. KaltenbachK , O’GradyKE , HeilSH , SalisburyAL , CoyleMG , FischerG , et al. Prenatal exposure to methadone or buprenorphine: early childhood developmental outcomes. Drug and Alcohol Dependence2018;185:40-9. UngerA , JagschR , BäwertA , WinklbaurB , RohrmeisterK , MartinPR , et al. Are male neonates more vulnerable to neonatal abstinence syndrome than female neonates?Gender Medicine2011;8(6):355-64. Wilson-MurphyMM , ChisolmMS , LeoutsakosJS , KaltenbachK , HeilSH , MartinPR . Treatment completion in opioid-dependent pregnant patients randomised to agonist treatment: the role of intravenous drug use. In: 73rd Annual Scientific Meeting of the College on Problems of Drug Dependence. 2011:195, Abstract no: 778. Winklbaur-HausknostB , JagschR , Graf-RohrmeisterK , UngerA , BaewertA , LangerM , et al. Lessons learned from a comparison of evidence-based research in pregnant opioid-dependent women. Human Psychopharmacology2013;28(1):15-24. ">MOTHER Study</a> (131 participants), the results were methadone: 12.8 ± 0.6, buprenorphine: 11.0 ± 0.6 (P = 0.04), which is in favour of buprenorphine. </p> <p>We pooled the mean duration of treatment for neonatal abstinence syndrome results from two studies (<a href="./references#CD006318-bbs2-0002" title="FischerG , OrtnerR , RohrmeisterK , JagschR , BaewertA , LangerM , et al. Methadone versus buprenorphine in pregnant addicts: a double-blind, double dummy comparison study. Addiction2006;101(2):275-81. ">Fischer 2006</a>; <a href="./references#CD006318-bbs2-0004" title="ChisolmMS , FitzsimonsH , LeoutsakosJM , AcquavitaSP , HeilSH , Wilson-MurphyM , et al. A comparison of cigarette smoking profiles in opioid-dependent pregnant patients receiving methadone or buprenorphine. Nicotine Tobacco Research2013;15(7):1297-304. CoyleMG , SalisburyAL , LesterBM , JonesHE , LinH , Graf-RohrmeisterK , et al. Neonatal neurobehavior effects following buprenorphine versus methadone exposure. Addiction2012;107(Suppl 1):63-73. GaalemaDE , ScottTL , HeilSH , CoyleMG , KaltenbachK , BadgerGJ , et al. Differences in the profile of neonatal abstinence syndrome signs in methadone- versus buprenorphine-exposed neonates. Addiction2012;107(Suppl 1):53-62. HolbrookAM , BaxterJK , JonesHE , HeilSH , CoyleMG , MartinPR , et al. Infections and obstetric outcomes in opioid-dependent pregnant women maintained on methadone or buprenorphine. Addiction2012;107(Suppl 1):83-90. HolbrookAM , JonesHE , HeilSH , MartinPR , StineSM , FischerG , et al. Induction of pregnant women onto opioid-agonist maintenance medication: an analysis of withdrawal symptoms and study retention. Drug and Alcohol Dependence2013;132(0):329-34. JanssonLM , DipietroJA , VelezM , ElkoA , WilliamsE , MilioL , et al. Fetal neurobehavioral effects of exposure to methadone or buprenorphine. Neurotoxicology and Teratology2011;33(2):240-3. JonesHE , DenglerE , GarrisondA , O'GradyeKE , SeashoreC , HortonE , et al. Neonatal outcomes and their relationship to maternal buprenorphine dose during pregnancy. Drug and Alcohol Dependence2014;134:414-7. JonesHE , FischerG , HeilSH , KaltenbachK , MartinPR , CoyleMG , et al. Maternal Opioid Treatment: Human Experimental Research (MOTHER) - approach, issues and lessons learned. Addiction2012;107(Suppl 1):28-35. JonesHE , JanssonLM , O’GradycKE , KaltenbachK . The relationship between maternal methadone dose at delivery and neonatal outcome: methodological and design considerations. Neurotoxicology and Teratology2013:110-5. [DOI: 10.1016/j.ntt.2013.05.003]JonesHE , JohnsonRE , JasinskiDR , TutenM , MilioL . Dosing pre to postpartum with either buprenorphine or methadone. In: 69th Annual Scientific Meeting of the College on Problems of Drug Dependence. Quebec City, Canada, 2007:16-21. JonesHE , JohnsonRE , O'GradyKE , JasinskiDR , TutenM , MilioL . Dosing adjustments in postpartum patients maintained on buprenorphine or methadone. Journal of Addiction Medicine2008;2(2):103-7. JonesHE , KaltenbachK , HeilSH , StineSM , CoyleMG , ArriaAM , et al. Neonatal abstinence syndrome after methadone or buprenorphine exposure. New England Journal of Medicine2010;363:2320-31. KaltenbachK , O’GradyKE , HeilSH , SalisburyAL , CoyleMG , FischerG , et al. Prenatal exposure to methadone or buprenorphine: early childhood developmental outcomes. Drug and Alcohol Dependence2018;185:40-9. UngerA , JagschR , BäwertA , WinklbaurB , RohrmeisterK , MartinPR , et al. Are male neonates more vulnerable to neonatal abstinence syndrome than female neonates?Gender Medicine2011;8(6):355-64. Wilson-MurphyMM , ChisolmMS , LeoutsakosJS , KaltenbachK , HeilSH , MartinPR . Treatment completion in opioid-dependent pregnant patients randomised to agonist treatment: the role of intravenous drug use. In: 73rd Annual Scientific Meeting of the College on Problems of Drug Dependence. 2011:195, Abstract no: 778. Winklbaur-HausknostB , JagschR , Graf-RohrmeisterK , UngerA , BaewertA , LangerM , et al. Lessons learned from a comparison of evidence-based research in pregnant opioid-dependent women. Human Psychopharmacology2013;28(1):15-24. ">MOTHER Study</a>) (145 participants). There was no evidence of a difference between treatments (MD 0.00; 95% CI ‐0.03 to 0.03) (<a href="./references#CD006318-fig-0010" title="">Analysis 1.6</a>). </p> <p>The total number of morphine drops administered was measured in one study with 21 participants (<a href="./references#CD006318-bbs2-0003" title="JonesHE , JohnsonRE , JasinskiDR , O'GradyKE , ChisholmCA , ChooRE , et al. Buprenorphine versus methadone in the treatment of pregnant opioid-dependent patients: effects on the neonatal abstinence syndrome. Drug and Alcohol Dependence2005;79(1):1-10. ">Jones 2005</a>). The results were methadone: 93.1, buprenorphine: 23.6; There was no evidence of a difference between treatments. </p> <p>Length of hospital stay was reported by two studies (<a href="./references#CD006318-bbs2-0003" title="JonesHE , JohnsonRE , JasinskiDR , O'GradyKE , ChisholmCA , ChooRE , et al. Buprenorphine versus methadone in the treatment of pregnant opioid-dependent patients: effects on the neonatal abstinence syndrome. Drug and Alcohol Dependence2005;79(1):1-10. ">Jones 2005</a>; <a href="./references#CD006318-bbs2-0004" title="ChisolmMS , FitzsimonsH , LeoutsakosJM , AcquavitaSP , HeilSH , Wilson-MurphyM , et al. A comparison of cigarette smoking profiles in opioid-dependent pregnant patients receiving methadone or buprenorphine. Nicotine Tobacco Research2013;15(7):1297-304. CoyleMG , SalisburyAL , LesterBM , JonesHE , LinH , Graf-RohrmeisterK , et al. Neonatal neurobehavior effects following buprenorphine versus methadone exposure. Addiction2012;107(Suppl 1):63-73. GaalemaDE , ScottTL , HeilSH , CoyleMG , KaltenbachK , BadgerGJ , et al. Differences in the profile of neonatal abstinence syndrome signs in methadone- versus buprenorphine-exposed neonates. Addiction2012;107(Suppl 1):53-62. HolbrookAM , BaxterJK , JonesHE , HeilSH , CoyleMG , MartinPR , et al. Infections and obstetric outcomes in opioid-dependent pregnant women maintained on methadone or buprenorphine. Addiction2012;107(Suppl 1):83-90. HolbrookAM , JonesHE , HeilSH , MartinPR , StineSM , FischerG , et al. Induction of pregnant women onto opioid-agonist maintenance medication: an analysis of withdrawal symptoms and study retention. Drug and Alcohol Dependence2013;132(0):329-34. JanssonLM , DipietroJA , VelezM , ElkoA , WilliamsE , MilioL , et al. Fetal neurobehavioral effects of exposure to methadone or buprenorphine. Neurotoxicology and Teratology2011;33(2):240-3. JonesHE , DenglerE , GarrisondA , O'GradyeKE , SeashoreC , HortonE , et al. Neonatal outcomes and their relationship to maternal buprenorphine dose during pregnancy. Drug and Alcohol Dependence2014;134:414-7. JonesHE , FischerG , HeilSH , KaltenbachK , MartinPR , CoyleMG , et al. Maternal Opioid Treatment: Human Experimental Research (MOTHER) - approach, issues and lessons learned. Addiction2012;107(Suppl 1):28-35. JonesHE , JanssonLM , O’GradycKE , KaltenbachK . The relationship between maternal methadone dose at delivery and neonatal outcome: methodological and design considerations. Neurotoxicology and Teratology2013:110-5. [DOI: 10.1016/j.ntt.2013.05.003]JonesHE , JohnsonRE , JasinskiDR , TutenM , MilioL . Dosing pre to postpartum with either buprenorphine or methadone. In: 69th Annual Scientific Meeting of the College on Problems of Drug Dependence. Quebec City, Canada, 2007:16-21. JonesHE , JohnsonRE , O'GradyKE , JasinskiDR , TutenM , MilioL . Dosing adjustments in postpartum patients maintained on buprenorphine or methadone. Journal of Addiction Medicine2008;2(2):103-7. JonesHE , KaltenbachK , HeilSH , StineSM , CoyleMG , ArriaAM , et al. Neonatal abstinence syndrome after methadone or buprenorphine exposure. New England Journal of Medicine2010;363:2320-31. KaltenbachK , O’GradyKE , HeilSH , SalisburyAL , CoyleMG , FischerG , et al. Prenatal exposure to methadone or buprenorphine: early childhood developmental outcomes. Drug and Alcohol Dependence2018;185:40-9. UngerA , JagschR , BäwertA , WinklbaurB , RohrmeisterK , MartinPR , et al. Are male neonates more vulnerable to neonatal abstinence syndrome than female neonates?Gender Medicine2011;8(6):355-64. Wilson-MurphyMM , ChisolmMS , LeoutsakosJS , KaltenbachK , HeilSH , MartinPR . Treatment completion in opioid-dependent pregnant patients randomised to agonist treatment: the role of intravenous drug use. In: 73rd Annual Scientific Meeting of the College on Problems of Drug Dependence. 2011:195, Abstract no: 778. Winklbaur-HausknostB , JagschR , Graf-RohrmeisterK , UngerA , BaewertA , LangerM , et al. Lessons learned from a comparison of evidence-based research in pregnant opioid-dependent women. Human Psychopharmacology2013;28(1):15-24. ">MOTHER Study</a>) (152 participants). One study (<a href="./references#CD006318-bbs2-0003" title="JonesHE , JohnsonRE , JasinskiDR , O'GradyKE , ChisholmCA , ChooRE , et al. Buprenorphine versus methadone in the treatment of pregnant opioid-dependent patients: effects on the neonatal abstinence syndrome. Drug and Alcohol Dependence2005;79(1):1-10. ">Jones 2005</a>) did not found signficant difference (MD 1.30,days, 95%CI 0.60, to 2.00), while the <a href="./references#CD006318-bbs2-0004" title="ChisolmMS , FitzsimonsH , LeoutsakosJM , AcquavitaSP , HeilSH , Wilson-MurphyM , et al. A comparison of cigarette smoking profiles in opioid-dependent pregnant patients receiving methadone or buprenorphine. Nicotine Tobacco Research2013;15(7):1297-304. CoyleMG , SalisburyAL , LesterBM , JonesHE , LinH , Graf-RohrmeisterK , et al. Neonatal neurobehavior effects following buprenorphine versus methadone exposure. Addiction2012;107(Suppl 1):63-73. GaalemaDE , ScottTL , HeilSH , CoyleMG , KaltenbachK , BadgerGJ , et al. Differences in the profile of neonatal abstinence syndrome signs in methadone- versus buprenorphine-exposed neonates. Addiction2012;107(Suppl 1):53-62. HolbrookAM , BaxterJK , JonesHE , HeilSH , CoyleMG , MartinPR , et al. Infections and obstetric outcomes in opioid-dependent pregnant women maintained on methadone or buprenorphine. Addiction2012;107(Suppl 1):83-90. HolbrookAM , JonesHE , HeilSH , MartinPR , StineSM , FischerG , et al. Induction of pregnant women onto opioid-agonist maintenance medication: an analysis of withdrawal symptoms and study retention. Drug and Alcohol Dependence2013;132(0):329-34. JanssonLM , DipietroJA , VelezM , ElkoA , WilliamsE , MilioL , et al. Fetal neurobehavioral effects of exposure to methadone or buprenorphine. Neurotoxicology and Teratology2011;33(2):240-3. JonesHE , DenglerE , GarrisondA , O'GradyeKE , SeashoreC , HortonE , et al. Neonatal outcomes and their relationship to maternal buprenorphine dose during pregnancy. Drug and Alcohol Dependence2014;134:414-7. JonesHE , FischerG , HeilSH , KaltenbachK , MartinPR , CoyleMG , et al. Maternal Opioid Treatment: Human Experimental Research (MOTHER) - approach, issues and lessons learned. Addiction2012;107(Suppl 1):28-35. JonesHE , JanssonLM , O’GradycKE , KaltenbachK . The relationship between maternal methadone dose at delivery and neonatal outcome: methodological and design considerations. Neurotoxicology and Teratology2013:110-5. [DOI: 10.1016/j.ntt.2013.05.003]JonesHE , JohnsonRE , JasinskiDR , TutenM , MilioL . Dosing pre to postpartum with either buprenorphine or methadone. In: 69th Annual Scientific Meeting of the College on Problems of Drug Dependence. Quebec City, Canada, 2007:16-21. JonesHE , JohnsonRE , O'GradyKE , JasinskiDR , TutenM , MilioL . Dosing adjustments in postpartum patients maintained on buprenorphine or methadone. Journal of Addiction Medicine2008;2(2):103-7. JonesHE , KaltenbachK , HeilSH , StineSM , CoyleMG , ArriaAM , et al. Neonatal abstinence syndrome after methadone or buprenorphine exposure. New England Journal of Medicine2010;363:2320-31. KaltenbachK , O’GradyKE , HeilSH , SalisburyAL , CoyleMG , FischerG , et al. Prenatal exposure to methadone or buprenorphine: early childhood developmental outcomes. Drug and Alcohol Dependence2018;185:40-9. UngerA , JagschR , BäwertA , WinklbaurB , RohrmeisterK , MartinPR , et al. Are male neonates more vulnerable to neonatal abstinence syndrome than female neonates?Gender Medicine2011;8(6):355-64. Wilson-MurphyMM , ChisolmMS , LeoutsakosJS , KaltenbachK , HeilSH , MartinPR . Treatment completion in opioid-dependent pregnant patients randomised to agonist treatment: the role of intravenous drug use. In: 73rd Annual Scientific Meeting of the College on Problems of Drug Dependence. 2011:195, Abstract no: 778. Winklbaur-HausknostB , JagschR , Graf-RohrmeisterK , UngerA , BaewertA , LangerM , et al. Lessons learned from a comparison of evidence-based research in pregnant opioid-dependent women. Human Psychopharmacology2013;28(1):15-24. ">MOTHER Study</a> repoted shorter hospital stay in the buprenorphin group: MD 6.70 days, 95%CI 6.24 to 7.16). Data were not pooled to very high heterogeneity (P &lt; 0.00001, I<sup>2</sup> = 99%) (<a href="./references#CD006318-fig-0011" title="">Analysis 1.7</a>). </p> <p>Total amount of morphine required to manage neonatal abstinence syndrome was reported in two studies (<a href="./references#CD006318-bbs2-0002" title="FischerG , OrtnerR , RohrmeisterK , JagschR , BaewertA , LangerM , et al. Methadone versus buprenorphine in pregnant addicts: a double-blind, double dummy comparison study. Addiction2006;101(2):275-81. ">Fischer 2006</a>; <a href="./references#CD006318-bbs2-0004" title="ChisolmMS , FitzsimonsH , LeoutsakosJM , AcquavitaSP , HeilSH , Wilson-MurphyM , et al. A comparison of cigarette smoking profiles in opioid-dependent pregnant patients receiving methadone or buprenorphine. Nicotine Tobacco Research2013;15(7):1297-304. CoyleMG , SalisburyAL , LesterBM , JonesHE , LinH , Graf-RohrmeisterK , et al. Neonatal neurobehavior effects following buprenorphine versus methadone exposure. Addiction2012;107(Suppl 1):63-73. GaalemaDE , ScottTL , HeilSH , CoyleMG , KaltenbachK , BadgerGJ , et al. Differences in the profile of neonatal abstinence syndrome signs in methadone- versus buprenorphine-exposed neonates. Addiction2012;107(Suppl 1):53-62. HolbrookAM , BaxterJK , JonesHE , HeilSH , CoyleMG , MartinPR , et al. Infections and obstetric outcomes in opioid-dependent pregnant women maintained on methadone or buprenorphine. Addiction2012;107(Suppl 1):83-90. HolbrookAM , JonesHE , HeilSH , MartinPR , StineSM , FischerG , et al. Induction of pregnant women onto opioid-agonist maintenance medication: an analysis of withdrawal symptoms and study retention. Drug and Alcohol Dependence2013;132(0):329-34. JanssonLM , DipietroJA , VelezM , ElkoA , WilliamsE , MilioL , et al. Fetal neurobehavioral effects of exposure to methadone or buprenorphine. Neurotoxicology and Teratology2011;33(2):240-3. JonesHE , DenglerE , GarrisondA , O'GradyeKE , SeashoreC , HortonE , et al. Neonatal outcomes and their relationship to maternal buprenorphine dose during pregnancy. Drug and Alcohol Dependence2014;134:414-7. JonesHE , FischerG , HeilSH , KaltenbachK , MartinPR , CoyleMG , et al. Maternal Opioid Treatment: Human Experimental Research (MOTHER) - approach, issues and lessons learned. Addiction2012;107(Suppl 1):28-35. JonesHE , JanssonLM , O’GradycKE , KaltenbachK . The relationship between maternal methadone dose at delivery and neonatal outcome: methodological and design considerations. Neurotoxicology and Teratology2013:110-5. [DOI: 10.1016/j.ntt.2013.05.003]JonesHE , JohnsonRE , JasinskiDR , TutenM , MilioL . Dosing pre to postpartum with either buprenorphine or methadone. In: 69th Annual Scientific Meeting of the College on Problems of Drug Dependence. Quebec City, Canada, 2007:16-21. JonesHE , JohnsonRE , O'GradyKE , JasinskiDR , TutenM , MilioL . Dosing adjustments in postpartum patients maintained on buprenorphine or methadone. Journal of Addiction Medicine2008;2(2):103-7. JonesHE , KaltenbachK , HeilSH , StineSM , CoyleMG , ArriaAM , et al. Neonatal abstinence syndrome after methadone or buprenorphine exposure. New England Journal of Medicine2010;363:2320-31. KaltenbachK , O’GradyKE , HeilSH , SalisburyAL , CoyleMG , FischerG , et al. Prenatal exposure to methadone or buprenorphine: early childhood developmental outcomes. Drug and Alcohol Dependence2018;185:40-9. UngerA , JagschR , BäwertA , WinklbaurB , RohrmeisterK , MartinPR , et al. Are male neonates more vulnerable to neonatal abstinence syndrome than female neonates?Gender Medicine2011;8(6):355-64. Wilson-MurphyMM , ChisolmMS , LeoutsakosJS , KaltenbachK , HeilSH , MartinPR . Treatment completion in opioid-dependent pregnant patients randomised to agonist treatment: the role of intravenous drug use. In: 73rd Annual Scientific Meeting of the College on Problems of Drug Dependence. 2011:195, Abstract no: 778. Winklbaur-HausknostB , JagschR , Graf-RohrmeisterK , UngerA , BaewertA , LangerM , et al. Lessons learned from a comparison of evidence-based research in pregnant opioid-dependent women. Human Psychopharmacology2013;28(1):15-24. ">MOTHER Study</a>) (145 participants). One study (<a href="./references#CD006318-bbs2-0002" title="FischerG , OrtnerR , RohrmeisterK , JagschR , BaewertA , LangerM , et al. Methadone versus buprenorphine in pregnant addicts: a double-blind, double dummy comparison study. Addiction2006;101(2):275-81. ">Fischer 2006</a>) did not found signficant diference (MD: 0.71mg, 95%CI ‐1.22,to 2.64), while the <a href="./references#CD006318-bbs2-0004" title="ChisolmMS , FitzsimonsH , LeoutsakosJM , AcquavitaSP , HeilSH , Wilson-MurphyM , et al. A comparison of cigarette smoking profiles in opioid-dependent pregnant patients receiving methadone or buprenorphine. Nicotine Tobacco Research2013;15(7):1297-304. CoyleMG , SalisburyAL , LesterBM , JonesHE , LinH , Graf-RohrmeisterK , et al. Neonatal neurobehavior effects following buprenorphine versus methadone exposure. Addiction2012;107(Suppl 1):63-73. GaalemaDE , ScottTL , HeilSH , CoyleMG , KaltenbachK , BadgerGJ , et al. Differences in the profile of neonatal abstinence syndrome signs in methadone- versus buprenorphine-exposed neonates. Addiction2012;107(Suppl 1):53-62. HolbrookAM , BaxterJK , JonesHE , HeilSH , CoyleMG , MartinPR , et al. Infections and obstetric outcomes in opioid-dependent pregnant women maintained on methadone or buprenorphine. Addiction2012;107(Suppl 1):83-90. HolbrookAM , JonesHE , HeilSH , MartinPR , StineSM , FischerG , et al. Induction of pregnant women onto opioid-agonist maintenance medication: an analysis of withdrawal symptoms and study retention. Drug and Alcohol Dependence2013;132(0):329-34. JanssonLM , DipietroJA , VelezM , ElkoA , WilliamsE , MilioL , et al. Fetal neurobehavioral effects of exposure to methadone or buprenorphine. Neurotoxicology and Teratology2011;33(2):240-3. JonesHE , DenglerE , GarrisondA , O'GradyeKE , SeashoreC , HortonE , et al. Neonatal outcomes and their relationship to maternal buprenorphine dose during pregnancy. Drug and Alcohol Dependence2014;134:414-7. JonesHE , FischerG , HeilSH , KaltenbachK , MartinPR , CoyleMG , et al. Maternal Opioid Treatment: Human Experimental Research (MOTHER) - approach, issues and lessons learned. Addiction2012;107(Suppl 1):28-35. JonesHE , JanssonLM , O’GradycKE , KaltenbachK . The relationship between maternal methadone dose at delivery and neonatal outcome: methodological and design considerations. Neurotoxicology and Teratology2013:110-5. [DOI: 10.1016/j.ntt.2013.05.003]JonesHE , JohnsonRE , JasinskiDR , TutenM , MilioL . Dosing pre to postpartum with either buprenorphine or methadone. In: 69th Annual Scientific Meeting of the College on Problems of Drug Dependence. Quebec City, Canada, 2007:16-21. JonesHE , JohnsonRE , O'GradyKE , JasinskiDR , TutenM , MilioL . Dosing adjustments in postpartum patients maintained on buprenorphine or methadone. Journal of Addiction Medicine2008;2(2):103-7. JonesHE , KaltenbachK , HeilSH , StineSM , CoyleMG , ArriaAM , et al. Neonatal abstinence syndrome after methadone or buprenorphine exposure. New England Journal of Medicine2010;363:2320-31. KaltenbachK , O’GradyKE , HeilSH , SalisburyAL , CoyleMG , FischerG , et al. Prenatal exposure to methadone or buprenorphine: early childhood developmental outcomes. Drug and Alcohol Dependence2018;185:40-9. UngerA , JagschR , BäwertA , WinklbaurB , RohrmeisterK , MartinPR , et al. Are male neonates more vulnerable to neonatal abstinence syndrome than female neonates?Gender Medicine2011;8(6):355-64. Wilson-MurphyMM , ChisolmMS , LeoutsakosJS , KaltenbachK , HeilSH , MartinPR . Treatment completion in opioid-dependent pregnant patients randomised to agonist treatment: the role of intravenous drug use. In: 73rd Annual Scientific Meeting of the College on Problems of Drug Dependence. 2011:195, Abstract no: 778. Winklbaur-HausknostB , JagschR , Graf-RohrmeisterK , UngerA , BaewertA , LangerM , et al. Lessons learned from a comparison of evidence-based research in pregnant opioid-dependent women. Human Psychopharmacology2013;28(1):15-24. ">MOTHER Study</a> reported significant less morphine required in the buprenorphine group (MD:9.30 mg, 95%CI 8.68 to 9.92) Data were not pooled to very high heterogeneity (P &lt; 0.00001, I<sup>2</sup> = 99%) (<a href="./references#CD006318-fig-0012" title="">Analysis 1.8</a>). </p> </section> <section id="CD006318-sec-0083"> <p><b>4.4 Prenatal and neonatal mortality</b></p> <p>In one study (<a href="./references#CD006318-bbs2-0002" title="FischerG , OrtnerR , RohrmeisterK , JagschR , BaewertA , LangerM , et al. Methadone versus buprenorphine in pregnant addicts: a double-blind, double dummy comparison study. Addiction2006;101(2):275-81. ">Fischer 2006</a>), there was one sudden intrauterine death at 38 weeks of pregnancy and one late abortion at 28 weeks of pregnancy, both in the methadone group. In the first woman, urine toxicology revealed 66% opioid‐positive results, 48% cocaine‐positive results and 16% benzodiazepine‐positive results over the study period. Cigarette consumption was a mean of 35 per day. In the second woman, all urine toxicology results were negative. </p> </section> </section> </section> <section id="CD006318-sec-0084"> <h5 class="title">Secondary outcomes</h5> <section id="CD006318-sec-0085"> <h6 class="title">5. Nicotine consumption</h6> <p>Smoking data were available from 124 (methadone n = 67 and buprenorphine n = 57) of the patients enrolled in the <a href="./references#CD006318-bbs2-0004" title="ChisolmMS , FitzsimonsH , LeoutsakosJM , AcquavitaSP , HeilSH , Wilson-MurphyM , et al. A comparison of cigarette smoking profiles in opioid-dependent pregnant patients receiving methadone or buprenorphine. Nicotine Tobacco Research2013;15(7):1297-304. CoyleMG , SalisburyAL , LesterBM , JonesHE , LinH , Graf-RohrmeisterK , et al. Neonatal neurobehavior effects following buprenorphine versus methadone exposure. Addiction2012;107(Suppl 1):63-73. GaalemaDE , ScottTL , HeilSH , CoyleMG , KaltenbachK , BadgerGJ , et al. Differences in the profile of neonatal abstinence syndrome signs in methadone- versus buprenorphine-exposed neonates. Addiction2012;107(Suppl 1):53-62. HolbrookAM , BaxterJK , JonesHE , HeilSH , CoyleMG , MartinPR , et al. Infections and obstetric outcomes in opioid-dependent pregnant women maintained on methadone or buprenorphine. Addiction2012;107(Suppl 1):83-90. HolbrookAM , JonesHE , HeilSH , MartinPR , StineSM , FischerG , et al. Induction of pregnant women onto opioid-agonist maintenance medication: an analysis of withdrawal symptoms and study retention. Drug and Alcohol Dependence2013;132(0):329-34. JanssonLM , DipietroJA , VelezM , ElkoA , WilliamsE , MilioL , et al. Fetal neurobehavioral effects of exposure to methadone or buprenorphine. Neurotoxicology and Teratology2011;33(2):240-3. JonesHE , DenglerE , GarrisondA , O'GradyeKE , SeashoreC , HortonE , et al. Neonatal outcomes and their relationship to maternal buprenorphine dose during pregnancy. Drug and Alcohol Dependence2014;134:414-7. JonesHE , FischerG , HeilSH , KaltenbachK , MartinPR , CoyleMG , et al. Maternal Opioid Treatment: Human Experimental Research (MOTHER) - approach, issues and lessons learned. Addiction2012;107(Suppl 1):28-35. JonesHE , JanssonLM , O’GradycKE , KaltenbachK . The relationship between maternal methadone dose at delivery and neonatal outcome: methodological and design considerations. Neurotoxicology and Teratology2013:110-5. [DOI: 10.1016/j.ntt.2013.05.003]JonesHE , JohnsonRE , JasinskiDR , TutenM , MilioL . Dosing pre to postpartum with either buprenorphine or methadone. In: 69th Annual Scientific Meeting of the College on Problems of Drug Dependence. Quebec City, Canada, 2007:16-21. JonesHE , JohnsonRE , O'GradyKE , JasinskiDR , TutenM , MilioL . Dosing adjustments in postpartum patients maintained on buprenorphine or methadone. Journal of Addiction Medicine2008;2(2):103-7. JonesHE , KaltenbachK , HeilSH , StineSM , CoyleMG , ArriaAM , et al. Neonatal abstinence syndrome after methadone or buprenorphine exposure. New England Journal of Medicine2010;363:2320-31. KaltenbachK , O’GradyKE , HeilSH , SalisburyAL , CoyleMG , FischerG , et al. Prenatal exposure to methadone or buprenorphine: early childhood developmental outcomes. Drug and Alcohol Dependence2018;185:40-9. UngerA , JagschR , BäwertA , WinklbaurB , RohrmeisterK , MartinPR , et al. Are male neonates more vulnerable to neonatal abstinence syndrome than female neonates?Gender Medicine2011;8(6):355-64. Wilson-MurphyMM , ChisolmMS , LeoutsakosJS , KaltenbachK , HeilSH , MartinPR . Treatment completion in opioid-dependent pregnant patients randomised to agonist treatment: the role of intravenous drug use. In: 73rd Annual Scientific Meeting of the College on Problems of Drug Dependence. 2011:195, Abstract no: 778. Winklbaur-HausknostB , JagschR , Graf-RohrmeisterK , UngerA , BaewertA , LangerM , et al. Lessons learned from a comparison of evidence-based research in pregnant opioid-dependent women. Human Psychopharmacology2013;28(1):15-24. ">MOTHER Study</a>. Among the sample, 95% reported cigarette smoking at treatment entry. Participants in the two medication conditions were similar for pretreatment characteristics, including smoking rates and daily cigarette amounts. Throughout the pregnancy, no meaningful changes in cigarette smoking were observed for either medication condition. The fitted difference in change in adjusted cigarettes per day between the two conditions was small and non‐significant (â = 0.08, standard error (SE) = 0.05, P = 0.132). </p> <p><b>6. Use of other substances</b><br/><a href="./references#CD006318-bbs2-0003" title="JonesHE , JohnsonRE , JasinskiDR , O'GradyKE , ChisholmCA , ChooRE , et al. Buprenorphine versus methadone in the treatment of pregnant opioid-dependent patients: effects on the neonatal abstinence syndrome. Drug and Alcohol Dependence2005;79(1):1-10. ">Jones 2005</a> reported the percentage of results that were urine positive for each substance during the study period for the methadone and buprenorphine group, respectively. The results were cocaine: 15.6% and 16.7%; benzodiazepines: 0.4% and 2.5%; amphetamine: 0% and 0%; and marijuana 7.5% and 0%. The <a href="./references#CD006318-bbs2-0002" title="FischerG , OrtnerR , RohrmeisterK , JagschR , BaewertA , LangerM , et al. Methadone versus buprenorphine in pregnant addicts: a double-blind, double dummy comparison study. Addiction2006;101(2):275-81. ">Fischer 2006</a> study reported the median number of urine samples positive for methadone and buprenorphine, respectively: cocaine: 0.00 and 0.00; benzodiazepines: 7.82 and 5.36. No data were reported in the <a href="./references#CD006318-bbs2-0004" title="ChisolmMS , FitzsimonsH , LeoutsakosJM , AcquavitaSP , HeilSH , Wilson-MurphyM , et al. A comparison of cigarette smoking profiles in opioid-dependent pregnant patients receiving methadone or buprenorphine. Nicotine Tobacco Research2013;15(7):1297-304. CoyleMG , SalisburyAL , LesterBM , JonesHE , LinH , Graf-RohrmeisterK , et al. Neonatal neurobehavior effects following buprenorphine versus methadone exposure. Addiction2012;107(Suppl 1):63-73. GaalemaDE , ScottTL , HeilSH , CoyleMG , KaltenbachK , BadgerGJ , et al. Differences in the profile of neonatal abstinence syndrome signs in methadone- versus buprenorphine-exposed neonates. Addiction2012;107(Suppl 1):53-62. HolbrookAM , BaxterJK , JonesHE , HeilSH , CoyleMG , MartinPR , et al. Infections and obstetric outcomes in opioid-dependent pregnant women maintained on methadone or buprenorphine. Addiction2012;107(Suppl 1):83-90. HolbrookAM , JonesHE , HeilSH , MartinPR , StineSM , FischerG , et al. Induction of pregnant women onto opioid-agonist maintenance medication: an analysis of withdrawal symptoms and study retention. Drug and Alcohol Dependence2013;132(0):329-34. JanssonLM , DipietroJA , VelezM , ElkoA , WilliamsE , MilioL , et al. Fetal neurobehavioral effects of exposure to methadone or buprenorphine. Neurotoxicology and Teratology2011;33(2):240-3. JonesHE , DenglerE , GarrisondA , O'GradyeKE , SeashoreC , HortonE , et al. Neonatal outcomes and their relationship to maternal buprenorphine dose during pregnancy. Drug and Alcohol Dependence2014;134:414-7. JonesHE , FischerG , HeilSH , KaltenbachK , MartinPR , CoyleMG , et al. Maternal Opioid Treatment: Human Experimental Research (MOTHER) - approach, issues and lessons learned. Addiction2012;107(Suppl 1):28-35. JonesHE , JanssonLM , O’GradycKE , KaltenbachK . The relationship between maternal methadone dose at delivery and neonatal outcome: methodological and design considerations. Neurotoxicology and Teratology2013:110-5. [DOI: 10.1016/j.ntt.2013.05.003]JonesHE , JohnsonRE , JasinskiDR , TutenM , MilioL . Dosing pre to postpartum with either buprenorphine or methadone. In: 69th Annual Scientific Meeting of the College on Problems of Drug Dependence. Quebec City, Canada, 2007:16-21. JonesHE , JohnsonRE , O'GradyKE , JasinskiDR , TutenM , MilioL . Dosing adjustments in postpartum patients maintained on buprenorphine or methadone. Journal of Addiction Medicine2008;2(2):103-7. JonesHE , KaltenbachK , HeilSH , StineSM , CoyleMG , ArriaAM , et al. Neonatal abstinence syndrome after methadone or buprenorphine exposure. New England Journal of Medicine2010;363:2320-31. KaltenbachK , O’GradyKE , HeilSH , SalisburyAL , CoyleMG , FischerG , et al. Prenatal exposure to methadone or buprenorphine: early childhood developmental outcomes. Drug and Alcohol Dependence2018;185:40-9. UngerA , JagschR , BäwertA , WinklbaurB , RohrmeisterK , MartinPR , et al. Are male neonates more vulnerable to neonatal abstinence syndrome than female neonates?Gender Medicine2011;8(6):355-64. Wilson-MurphyMM , ChisolmMS , LeoutsakosJS , KaltenbachK , HeilSH , MartinPR . Treatment completion in opioid-dependent pregnant patients randomised to agonist treatment: the role of intravenous drug use. In: 73rd Annual Scientific Meeting of the College on Problems of Drug Dependence. 2011:195, Abstract no: 778. Winklbaur-HausknostB , JagschR , Graf-RohrmeisterK , UngerA , BaewertA , LangerM , et al. Lessons learned from a comparison of evidence-based research in pregnant opioid-dependent women. Human Psychopharmacology2013;28(1):15-24. ">MOTHER Study</a>. </p> <p><b>7. Side effects for the mother</b><br/>No side effects for the mothers were reported in the <a href="./references#CD006318-bbs2-0003" title="JonesHE , JohnsonRE , JasinskiDR , O'GradyKE , ChisholmCA , ChooRE , et al. Buprenorphine versus methadone in the treatment of pregnant opioid-dependent patients: effects on the neonatal abstinence syndrome. Drug and Alcohol Dependence2005;79(1):1-10. ">Jones 2005</a> and <a href="./references#CD006318-bbs2-0002" title="FischerG , OrtnerR , RohrmeisterK , JagschR , BaewertA , LangerM , et al. Methadone versus buprenorphine in pregnant addicts: a double-blind, double dummy comparison study. Addiction2006;101(2):275-81. ">Fischer 2006</a> studies. In the <a href="./references#CD006318-bbs2-0004" title="ChisolmMS , FitzsimonsH , LeoutsakosJM , AcquavitaSP , HeilSH , Wilson-MurphyM , et al. A comparison of cigarette smoking profiles in opioid-dependent pregnant patients receiving methadone or buprenorphine. Nicotine Tobacco Research2013;15(7):1297-304. CoyleMG , SalisburyAL , LesterBM , JonesHE , LinH , Graf-RohrmeisterK , et al. Neonatal neurobehavior effects following buprenorphine versus methadone exposure. Addiction2012;107(Suppl 1):63-73. GaalemaDE , ScottTL , HeilSH , CoyleMG , KaltenbachK , BadgerGJ , et al. Differences in the profile of neonatal abstinence syndrome signs in methadone- versus buprenorphine-exposed neonates. Addiction2012;107(Suppl 1):53-62. HolbrookAM , BaxterJK , JonesHE , HeilSH , CoyleMG , MartinPR , et al. Infections and obstetric outcomes in opioid-dependent pregnant women maintained on methadone or buprenorphine. Addiction2012;107(Suppl 1):83-90. HolbrookAM , JonesHE , HeilSH , MartinPR , StineSM , FischerG , et al. Induction of pregnant women onto opioid-agonist maintenance medication: an analysis of withdrawal symptoms and study retention. Drug and Alcohol Dependence2013;132(0):329-34. JanssonLM , DipietroJA , VelezM , ElkoA , WilliamsE , MilioL , et al. Fetal neurobehavioral effects of exposure to methadone or buprenorphine. Neurotoxicology and Teratology2011;33(2):240-3. JonesHE , DenglerE , GarrisondA , O'GradyeKE , SeashoreC , HortonE , et al. Neonatal outcomes and their relationship to maternal buprenorphine dose during pregnancy. Drug and Alcohol Dependence2014;134:414-7. JonesHE , FischerG , HeilSH , KaltenbachK , MartinPR , CoyleMG , et al. Maternal Opioid Treatment: Human Experimental Research (MOTHER) - approach, issues and lessons learned. Addiction2012;107(Suppl 1):28-35. JonesHE , JanssonLM , O’GradycKE , KaltenbachK . The relationship between maternal methadone dose at delivery and neonatal outcome: methodological and design considerations. Neurotoxicology and Teratology2013:110-5. [DOI: 10.1016/j.ntt.2013.05.003]JonesHE , JohnsonRE , JasinskiDR , TutenM , MilioL . Dosing pre to postpartum with either buprenorphine or methadone. In: 69th Annual Scientific Meeting of the College on Problems of Drug Dependence. Quebec City, Canada, 2007:16-21. JonesHE , JohnsonRE , O'GradyKE , JasinskiDR , TutenM , MilioL . Dosing adjustments in postpartum patients maintained on buprenorphine or methadone. Journal of Addiction Medicine2008;2(2):103-7. JonesHE , KaltenbachK , HeilSH , StineSM , CoyleMG , ArriaAM , et al. Neonatal abstinence syndrome after methadone or buprenorphine exposure. New England Journal of Medicine2010;363:2320-31. KaltenbachK , O’GradyKE , HeilSH , SalisburyAL , CoyleMG , FischerG , et al. Prenatal exposure to methadone or buprenorphine: early childhood developmental outcomes. Drug and Alcohol Dependence2018;185:40-9. UngerA , JagschR , BäwertA , WinklbaurB , RohrmeisterK , MartinPR , et al. Are male neonates more vulnerable to neonatal abstinence syndrome than female neonates?Gender Medicine2011;8(6):355-64. Wilson-MurphyMM , ChisolmMS , LeoutsakosJS , KaltenbachK , HeilSH , MartinPR . Treatment completion in opioid-dependent pregnant patients randomised to agonist treatment: the role of intravenous drug use. In: 73rd Annual Scientific Meeting of the College on Problems of Drug Dependence. 2011:195, Abstract no: 778. Winklbaur-HausknostB , JagschR , Graf-RohrmeisterK , UngerA , BaewertA , LangerM , et al. Lessons learned from a comparison of evidence-based research in pregnant opioid-dependent women. Human Psychopharmacology2013;28(1):15-24. ">MOTHER Study</a>, there were 14/89 (16%) serious adverse events in the methadone group and 8/86 (9%) in the buprenorphine group (RR 1.69, 95% CI 0.75 to 3.83) (<a href="./references#CD006318-fig-0013" title="">Analysis 1.9</a>). There were fewer non‐serious adverse events in the buprenorphine group (66/86; 77%) compared to methadone (83/89; 93%) (RR 1.22, 95% CI 1.07 to 1.38, low quality evidence) (<a href="./references#CD006318-fig-0014" title="">Analysis 1.10</a>). </p> <p><b>8. Side effects for the child</b><br/>No side effects for the child were reported in the <a href="./references#CD006318-bbs2-0003" title="JonesHE , JohnsonRE , JasinskiDR , O'GradyKE , ChisholmCA , ChooRE , et al. Buprenorphine versus methadone in the treatment of pregnant opioid-dependent patients: effects on the neonatal abstinence syndrome. Drug and Alcohol Dependence2005;79(1):1-10. ">Jones 2005</a> and <a href="./references#CD006318-bbs2-0002" title="FischerG , OrtnerR , RohrmeisterK , JagschR , BaewertA , LangerM , et al. Methadone versus buprenorphine in pregnant addicts: a double-blind, double dummy comparison study. Addiction2006;101(2):275-81. ">Fischer 2006</a> studies. In the <a href="./references#CD006318-bbs2-0004" title="ChisolmMS , FitzsimonsH , LeoutsakosJM , AcquavitaSP , HeilSH , Wilson-MurphyM , et al. A comparison of cigarette smoking profiles in opioid-dependent pregnant patients receiving methadone or buprenorphine. Nicotine Tobacco Research2013;15(7):1297-304. CoyleMG , SalisburyAL , LesterBM , JonesHE , LinH , Graf-RohrmeisterK , et al. Neonatal neurobehavior effects following buprenorphine versus methadone exposure. Addiction2012;107(Suppl 1):63-73. GaalemaDE , ScottTL , HeilSH , CoyleMG , KaltenbachK , BadgerGJ , et al. Differences in the profile of neonatal abstinence syndrome signs in methadone- versus buprenorphine-exposed neonates. Addiction2012;107(Suppl 1):53-62. HolbrookAM , BaxterJK , JonesHE , HeilSH , CoyleMG , MartinPR , et al. Infections and obstetric outcomes in opioid-dependent pregnant women maintained on methadone or buprenorphine. Addiction2012;107(Suppl 1):83-90. HolbrookAM , JonesHE , HeilSH , MartinPR , StineSM , FischerG , et al. Induction of pregnant women onto opioid-agonist maintenance medication: an analysis of withdrawal symptoms and study retention. Drug and Alcohol Dependence2013;132(0):329-34. JanssonLM , DipietroJA , VelezM , ElkoA , WilliamsE , MilioL , et al. Fetal neurobehavioral effects of exposure to methadone or buprenorphine. Neurotoxicology and Teratology2011;33(2):240-3. JonesHE , DenglerE , GarrisondA , O'GradyeKE , SeashoreC , HortonE , et al. Neonatal outcomes and their relationship to maternal buprenorphine dose during pregnancy. Drug and Alcohol Dependence2014;134:414-7. JonesHE , FischerG , HeilSH , KaltenbachK , MartinPR , CoyleMG , et al. Maternal Opioid Treatment: Human Experimental Research (MOTHER) - approach, issues and lessons learned. Addiction2012;107(Suppl 1):28-35. JonesHE , JanssonLM , O’GradycKE , KaltenbachK . The relationship between maternal methadone dose at delivery and neonatal outcome: methodological and design considerations. Neurotoxicology and Teratology2013:110-5. [DOI: 10.1016/j.ntt.2013.05.003]JonesHE , JohnsonRE , JasinskiDR , TutenM , MilioL . Dosing pre to postpartum with either buprenorphine or methadone. In: 69th Annual Scientific Meeting of the College on Problems of Drug Dependence. Quebec City, Canada, 2007:16-21. JonesHE , JohnsonRE , O'GradyKE , JasinskiDR , TutenM , MilioL . Dosing adjustments in postpartum patients maintained on buprenorphine or methadone. Journal of Addiction Medicine2008;2(2):103-7. JonesHE , KaltenbachK , HeilSH , StineSM , CoyleMG , ArriaAM , et al. Neonatal abstinence syndrome after methadone or buprenorphine exposure. New England Journal of Medicine2010;363:2320-31. KaltenbachK , O’GradyKE , HeilSH , SalisburyAL , CoyleMG , FischerG , et al. Prenatal exposure to methadone or buprenorphine: early childhood developmental outcomes. Drug and Alcohol Dependence2018;185:40-9. UngerA , JagschR , BäwertA , WinklbaurB , RohrmeisterK , MartinPR , et al. Are male neonates more vulnerable to neonatal abstinence syndrome than female neonates?Gender Medicine2011;8(6):355-64. Wilson-MurphyMM , ChisolmMS , LeoutsakosJS , KaltenbachK , HeilSH , MartinPR . Treatment completion in opioid-dependent pregnant patients randomised to agonist treatment: the role of intravenous drug use. In: 73rd Annual Scientific Meeting of the College on Problems of Drug Dependence. 2011:195, Abstract no: 778. Winklbaur-HausknostB , JagschR , Graf-RohrmeisterK , UngerA , BaewertA , LangerM , et al. Lessons learned from a comparison of evidence-based research in pregnant opioid-dependent women. Human Psychopharmacology2013;28(1):15-24. ">MOTHER Study</a>, there were more serious adverse events (6/73; 8%) in the methadone group than in the buprenorphine group (1/58; 2%) (RR 1.22, 95% CI 1.07 to 1.38) (<a href="./references#CD006318-fig-0015" title="">Analysis 1.11</a>). There was no significant difference in the frequency of non‐serious adverse events: 34/73 (47%) in the methadone group and 29/58 (50%) in the buprenorphine group (RR 1.08, 95% CI 0.74 to 1.59, low quality evidence). There was no evidence of a difference between treatments. </p> </section> </section> </section> <section id="CD006318-sec-0086"> <h4 class="title">Comparison 2: Methadone versus oral slow‐release morphine</h4> <p>See <a href="./full#CD006318-tbl-0002">summary of findings Table 2</a>. This comparison included one study (<a href="./references#CD006318-bbs2-0001" title="FischerG , JagschR , EderH , GombasW , EtzerdorferP , Schmidl-MohlK , et al. Comparison of methadone and slow-release morphine maintenance in pregnant addicts. Addiction1999;94(2):231-9. ">Fischer 1999</a>) with 48 participants. </p> <section id="CD006318-sec-0087"> <h5 class="title">Primary outcomes: for the woman</h5> <section id="CD006318-sec-0088"> <h6 class="title">1. Dropouts from treatment</h6> <p>No participants dropped out from either group, low quality evidence.</p> </section> <section id="CD006318-sec-0089"> <h6 class="title">2. Use of primary substance of abuse</h6> <section id="CD006318-sec-0090"> <p><b>2.1 During or at the end of treatment</b></p> <p>The result for the number of participants who used heroin in the third trimester was RR 2.40 (95% CI 1.00 to 5.77) low quality evidence, in favour of oral slow‐release morphine (<a href="./references#CD006318-fig-0017" title="">Analysis 2.1</a>). </p> </section> <section id="CD006318-sec-0091"> <p><b>2.2 At follow‐up</b></p> <p>The study did not consider this outcome.</p> <p><b>3. Obstetric outcomes</b> </p> </section> <section id="CD006318-sec-0092"> <p><b>3.1 Third trimester bleeding</b></p> <p>Data were not reported.</p> </section> <section id="CD006318-sec-0093"> <p><b>3.2 Preterm delivery</b></p> <p>One woman delivered at 31 weeks due to early amniotic rupture, but it was not reported to which group she was allocated. No other gynaecological problems occurred during the study period. The mean week of delivery was as follows: methadone: 38.92 (SD 1.74), morphine: 37.79 (SD 2.55). There was no evidence of a difference between treatments. </p> </section> <section id="CD006318-sec-0094"> <p><b>3.3 Fetal distress and meconium aspiration</b></p> <p>Data were not reported.</p> </section> <section id="CD006318-sec-0095"> <p><b>3.4 Caesarean section</b></p> <p>The percentage of caesarean sections was 25% in both groups.</p> </section> <section id="CD006318-sec-0096"> <p><b>3.5 Abnormal presentation</b></p> <p>Data were not reported.</p> </section> <section id="CD006318-sec-0097"> <p><b>3.6 Medical complications at delivery</b></p> <p>The percentage of vacuum extractions was 8.3% in both groups.</p> </section> <section id="CD006318-sec-0098"> <p><b>3.7 Breastfeeding following delivery</b></p> <p>Data were not reported.</p> </section> <section id="CD006318-sec-0099"> <p><b>3.8 Puerperal morbidity</b></p> <p>Data were not reported.</p> </section> </section> </section> <section id="CD006318-sec-0100"> <h5 class="title">Primary outcomes: for the child</h5> <p><b>4. Health status</b> </p> <section id="CD006318-sec-0101"> <h6 class="title">4.1 Birth weight</h6> <p>There was no evidence of a difference between treatments (MD 124 g, 95% CI ‐186 to 434, low quality evidence) (<a href="./references#CD006318-fig-0018" title="">Analysis 2.2</a>). </p> </section> <section id="CD006318-sec-0102"> <h6 class="title">4.2 APGAR score</h6> <p>The study did not consider this outcome.</p> </section> <section id="CD006318-sec-0103"> <h6 class="title">4.3 Neonatal abstinence syndrome</h6> <p>There was no evidence of a difference between treatments in the mean duration of neonatal abstinence syndrome (MD ‐5.00, 95% CI ‐10.97 to 0.97, low quality evidence) (<a href="./references#CD006318-fig-0019" title="">Analysis 2.3</a>). </p> </section> <section id="CD006318-sec-0104"> <h6 class="title">4.4 Prenatal and neonatal mortality</h6> <p>There was no prenatal or neonatal mortality in either group.</p> </section> </section> <section id="CD006318-sec-0105"> <h5 class="title">Secondary outcomes</h5> <section id="CD006318-sec-0106"> <h6 class="title">5. Nicotine consumption</h6> <p><a href="./references#CD006318-bbs2-0001" title="FischerG , JagschR , EderH , GombasW , EtzerdorferP , Schmidl-MohlK , et al. Comparison of methadone and slow-release morphine maintenance in pregnant addicts. Addiction1999;94(2):231-9. ">Fischer 1999</a> measured the difference in the mean number of cigarettes smoked per day before and at the end of treatment. At the start of the trial, the mean number of cigarettes smoked per day was 27.56 (SD 16.28) and 31.30 (SD 22.56) for the methadone and morphine group, respectively. At delivery, it was 15.89 (SD 12.24) and 15.20 (SD 8.24), respectively (MD ‐4.43, 95% CI ‐1.47 to 10.33); There was no evidence of a difference between treatments (<a href="./references#CD006318-fig-0020" title="">Analysis 2.4</a>). </p> </section> <section id="CD006318-sec-0107"> <h6 class="title">6. Use of other substances</h6> <p>The study only reported the percentage of negative urine testing during each week of treatment for methadone and slow‐release morphine in a graph: the mean percentages for the whole study period were about 95% and 90%, respectively, for cocaine and 54% and 89% for benzodiazepines. </p> </section> <section id="CD006318-sec-0108"> <h6 class="title">7. Side effects for the mother</h6> <p>No side effects for the mother were reported;(low quality evidence) .</p> </section> <section id="CD006318-sec-0109"> <h6 class="title">8. Side effects for the child</h6> <p>No severe complications were noted in any of the neonates as monitored by polysomnography, although one child in the methadone group had central apnoea, and one child in the morphine group had obstructive apnoea; (low quality evidence) . </p> </section> </section> </section> <section id="CD006318-sec-0110"> <h4 class="title">Sensitivity analysis</h4> <p>The only difference among the trials in terms of risk of bias was in random sequence generation (we judged one as at low risk and two as at unclear risk of bias). No differences were found in the results when studies were stratified for risk of bias for random sequence generation. Therefore, we did not perform sensitivity analyses. </p> </section> <section id="CD006318-sec-0111"> <h4 class="title">Assessment of reporting bias</h4> <p>We did not use a funnel plot to explore publication bias because only four studies were included, all with small sample sizes. In fact, the power of this method is very limited when meta‐analysis comprises only a few small studies (<a href="./references#CD006318-bbs2-0042" title="HigginsJPT , GreenS , editors. Cochrane Handbook for Systematic Reviews of Interventions 5.1.0 [updated March 2011]. The Cochrane Collaboration, 2011. Available from handbook.cochrane.org.">Higgins 2011</a>). </p> </section> </section> </section> </section> <section class="discussion"> <div class="section-header section-collapse-header" id="CD006318-sec-0112" lang="en"> <h2 class="title section-collapse-title"> Discussion <i aria-hidden="true" class="fa fa-caret-up section-collapse-icon"></i> </h2> </div> <section class="discussion" lang="en"> <div class="section-header" id="CD006318-sec-0112"></div> <section id="CD006318-sec-0113"> <h3 class="title" id="CD006318-sec-0113">Summary of main results</h3> <p>Only four trials with 271 pregnant women satisfied the criteria for inclusion in the review. Three (<a href="./references#CD006318-bbs2-0002" title="FischerG , OrtnerR , RohrmeisterK , JagschR , BaewertA , LangerM , et al. Methadone versus buprenorphine in pregnant addicts: a double-blind, double dummy comparison study. Addiction2006;101(2):275-81. ">Fischer 2006</a>; <a href="./references#CD006318-bbs2-0003" title="JonesHE , JohnsonRE , JasinskiDR , O'GradyKE , ChisholmCA , ChooRE , et al. Buprenorphine versus methadone in the treatment of pregnant opioid-dependent patients: effects on the neonatal abstinence syndrome. Drug and Alcohol Dependence2005;79(1):1-10. ">Jones 2005</a>; <a href="./references#CD006318-bbs2-0004" title="ChisolmMS , FitzsimonsH , LeoutsakosJM , AcquavitaSP , HeilSH , Wilson-MurphyM , et al. A comparison of cigarette smoking profiles in opioid-dependent pregnant patients receiving methadone or buprenorphine. Nicotine Tobacco Research2013;15(7):1297-304. CoyleMG , SalisburyAL , LesterBM , JonesHE , LinH , Graf-RohrmeisterK , et al. Neonatal neurobehavior effects following buprenorphine versus methadone exposure. Addiction2012;107(Suppl 1):63-73. GaalemaDE , ScottTL , HeilSH , CoyleMG , KaltenbachK , BadgerGJ , et al. Differences in the profile of neonatal abstinence syndrome signs in methadone- versus buprenorphine-exposed neonates. Addiction2012;107(Suppl 1):53-62. HolbrookAM , BaxterJK , JonesHE , HeilSH , CoyleMG , MartinPR , et al. Infections and obstetric outcomes in opioid-dependent pregnant women maintained on methadone or buprenorphine. Addiction2012;107(Suppl 1):83-90. HolbrookAM , JonesHE , HeilSH , MartinPR , StineSM , FischerG , et al. Induction of pregnant women onto opioid-agonist maintenance medication: an analysis of withdrawal symptoms and study retention. Drug and Alcohol Dependence2013;132(0):329-34. JanssonLM , DipietroJA , VelezM , ElkoA , WilliamsE , MilioL , et al. Fetal neurobehavioral effects of exposure to methadone or buprenorphine. Neurotoxicology and Teratology2011;33(2):240-3. JonesHE , DenglerE , GarrisondA , O'GradyeKE , SeashoreC , HortonE , et al. Neonatal outcomes and their relationship to maternal buprenorphine dose during pregnancy. Drug and Alcohol Dependence2014;134:414-7. JonesHE , FischerG , HeilSH , KaltenbachK , MartinPR , CoyleMG , et al. Maternal Opioid Treatment: Human Experimental Research (MOTHER) - approach, issues and lessons learned. Addiction2012;107(Suppl 1):28-35. JonesHE , JanssonLM , O’GradycKE , KaltenbachK . The relationship between maternal methadone dose at delivery and neonatal outcome: methodological and design considerations. Neurotoxicology and Teratology2013:110-5. [DOI: 10.1016/j.ntt.2013.05.003]JonesHE , JohnsonRE , JasinskiDR , TutenM , MilioL . Dosing pre to postpartum with either buprenorphine or methadone. In: 69th Annual Scientific Meeting of the College on Problems of Drug Dependence. Quebec City, Canada, 2007:16-21. JonesHE , JohnsonRE , O'GradyKE , JasinskiDR , TutenM , MilioL . Dosing adjustments in postpartum patients maintained on buprenorphine or methadone. Journal of Addiction Medicine2008;2(2):103-7. JonesHE , KaltenbachK , HeilSH , StineSM , CoyleMG , ArriaAM , et al. Neonatal abstinence syndrome after methadone or buprenorphine exposure. New England Journal of Medicine2010;363:2320-31. KaltenbachK , O’GradyKE , HeilSH , SalisburyAL , CoyleMG , FischerG , et al. Prenatal exposure to methadone or buprenorphine: early childhood developmental outcomes. Drug and Alcohol Dependence2018;185:40-9. UngerA , JagschR , BäwertA , WinklbaurB , RohrmeisterK , MartinPR , et al. Are male neonates more vulnerable to neonatal abstinence syndrome than female neonates?Gender Medicine2011;8(6):355-64. Wilson-MurphyMM , ChisolmMS , LeoutsakosJS , KaltenbachK , HeilSH , MartinPR . Treatment completion in opioid-dependent pregnant patients randomised to agonist treatment: the role of intravenous drug use. In: 73rd Annual Scientific Meeting of the College on Problems of Drug Dependence. 2011:195, Abstract no: 778. Winklbaur-HausknostB , JagschR , Graf-RohrmeisterK , UngerA , BaewertA , LangerM , et al. Lessons learned from a comparison of evidence-based research in pregnant opioid-dependent women. Human Psychopharmacology2013;28(1):15-24. ">MOTHER Study</a>) compared methadone with buprenorphine (223 participants), and one (<a href="./references#CD006318-bbs2-0001" title="FischerG , JagschR , EderH , GombasW , EtzerdorferP , Schmidl-MohlK , et al. Comparison of methadone and slow-release morphine maintenance in pregnant addicts. Addiction1999;94(2):231-9. ">Fischer 1999</a>) compared methadone with oral slow‐release morphine (48 participants). </p> <p>In the comparison of methadone versus buprenorphine, we found moderate‐quality evidence of little or no difference in the dropout rate of the mothers. We also found low‐quality evidence of no difference in the use of the primary substance between the methadone and buprenorphine groups. Birth weight was higher in the buprenorphine group in the two trials that repoterd data, but the quality of evidence is very low. The third study reported that there was no evidence of a difference between treatments. For the APGAR score, none of the studies found a significant difference, with low‐quality evidence. Many measures were used in the studies to assess neonatal abstinence syndrome. For the number of newborns treated for neonatal abstinence syndrome, the most critical outcome, we found low‐quality evidence of no significant difference. </p> <p>In the comparison of methadone versus oral slow‐release morphine, we found no difference in the dropout rate, whereas slow‐release morphine seemed to be superior to methadone for abstinence of women from the use of heroin. The study did not find evidence of a difference between treatments in birth weight or mean duration of neonatal abstinence syndrome. The APGAR score was not considered in the study. We judged the quality of evidence to be low for all outcomes. </p> <p>Only one study which compared methadone with buprenorphine reported side effects. For the mother, there was no significant difference between groups in the frequency of serious adverse events, while the non‐serious adverse events were fewer in the buprenorphine groups. There were no significant differences in the frequency of severe or non‐severe adverse events for the newborn. The quality of evidence was low. </p> <p>In the comparison of methadone versus slow‐release morphine, no side effects were reported for the mother, whereas one child in the methadone group had central apnoea, and one child in the morphine group had obstructive apnoea. </p> <p>The difficulty of determining whether the opioid substitution is associated with better outcomes for newborns always needs to be considered in relation to the direct effects of cigarette smoking. Only one study (<a href="./references#CD006318-bbs2-0001" title="FischerG , JagschR , EderH , GombasW , EtzerdorferP , Schmidl-MohlK , et al. Comparison of methadone and slow-release morphine maintenance in pregnant addicts. Addiction1999;94(2):231-9. ">Fischer 1999</a>) reported data on cigarette consumption at the start of the study and at delivery. Women smoked a mean of 29 cigarettes per day at enrollment in the study and a mean of 14 cigarettes per day at delivery. There was no statistically significant difference between groups in the reduction of cigarettes smoked. This seems to be a relevant outcome and was not considered by the majority of the included studies. The level of nicotine exposure during pregnancy does affect birth weight and could affect neonatal abstinence syndrome. </p> </section> <section id="CD006318-sec-0114"> <h3 class="title" id="CD006318-sec-0114">Overall completeness and applicability of evidence</h3> <p>The number of included studies and participants is too small to allow definite conclusions. Although, from a clinical point of view, it is well recognised that, for both women opiate addicts and their infants, agonist treatment during pregnancy is protective, but many questions remain unanswered. Which is the most effective drug treatment and at what dosage? What is the most appropriate type of setting? In particular, is it useful or not to associate any type of psychosocial intervention with pharmacological treatment? </p> <p>Furthermore, it would be useful to know, both for maternal and child health, whether the mothers continued to use maintenance treatments after their delivery. </p> </section> <section id="CD006318-sec-0115"> <h3 class="title" id="CD006318-sec-0115">Quality of the evidence</h3> <p>Three out of four studies had adequate allocation concealment and were double‐blind. The major flaw of the studies was attrition bias: three out of four had a high dropout rate (30% to 40%), and this was unbalanced between groups. In the comparison of methadone versus buprenorphine, quality of the evidence ranged from moderate to very low and was downgraded for risk of attrition bias, inconsistency and imprecision of the estimate. In the comparison of methadone versus slow‐release morphine, quality of the evidence was low and was downgraded for imprecision in the estimate due to a very small sample size. </p> </section> <section id="CD006318-sec-0116"> <h3 class="title" id="CD006318-sec-0116">Potential biases in the review process</h3> <p>To lower the risk of bias in the review process, two review authors independently screened abstracts, assessed full texts, rated risk of bias for included studies and extracted data from primary studies. None of the review authors has any personal, scientific or financial conflicts of interest or expected advantages from significant results in terms of reviewer decisions or raising funds, We could not inspect funnel plots for risk of possible publication bias due to the small number of studies included in the meta‐analyses; however, we did not find any unpublished studies, despite contacting all of the first authors of the included studies and searching conference proceedings.so the likelihood of publication bias can be considered low" . </p> </section> <section id="CD006318-sec-0117"> <h3 class="title" id="CD006318-sec-0117">Agreements and disagreements with other studies or reviews</h3> <p>We did not find any other systematic reviews on this topic. One narrative review published in 2008 (<a href="./references#CD006318-bbs2-0068" title="WinklbaurB , KopfN , EbnerN , JungE , ThauK , FischerG . Treating pregnant women dependent on opioids is not the same as treating pregnancy and opioid dependence: a knowledge synthesis for better treatment for women and neonates. Addiction2008;103(9):1429-40.">Winklbaur 2008</a>) considered all types of treatment for pregnant opioid‐dependent women and included both randomised and non‐randomised studies. This review cited the three randomised controlled trials (RCTs) published before 2006 and concluded that buprenorphine and methadone are substantially equivalent but may attenuate neonatal abstinence syndrome. A mixed‐method systematic review of interventional and observational systematic reviews identified 3 RCTs (n = 223), and 15 cohort observational (OBS) (n = 1923) studies to assess the safety of buprenorphine compared with methadone to treat pregnant women with opioid use disorder (<a href="./references#CD006318-bbs2-0069" title="ZedlerBK , MannAL , KimMM , AmickHR , JoyceAR , MurrelleEL , et al. Buprenorphine compared with methadone to treat pregnant women with opioid use disorder: a systematic review and meta-analysis of safety in the mother, fetus and child. Addiction2016;11:2115-28.">Zedler 2016</a>). Considering methadone as comparator, buprenorphine was found to be associated with lower risk of preterm birth (RCT risk ratio (RR) 0.40, 95% CI 0.18 to 0.91; OBS RR 0.67, 95% CI 0.50 to 0.90), and greater birth weight (RCT weighted mean difference (MD) 277 g, 95% CI 104 to 450; OBS MD 265 g, 95% CI 196 to 335). Authors concluded that methadone presents with a lower risk of preterm birth, and greater birth weight compared with buprenorphine treatment of maternal opioid use disorder during pregnancy. </p> <p>An older published narrative review (<a href="./references#CD006318-bbs2-0047" title="JonesHE , HeilSH , BaewertA , ArriaAM , KaltenbachK , MartinPR , et al. Buprenorphine treatment of opioid-dependent pregnant women: a comprehensive review. Addiction2012;107(Suppl 1):5-27.">Jones 2012</a>) compared buprenorphine with methadone and included the same three RCTs together with observational studies but did not pool the data in a meta‐analysis. This review reached the same conclusions, reporting that there was no significant difference between methadone and buprenorphine for maternal outcomes, whereas buprenorphine "...results in a clinically significant less severe neonatal abstinence syndrome (NAS) than treatment with methadone". They also stated, "...concluding that buprenorphine is an effective treatment for opioid dependence during pregnancy does not mean that methadone should no longer be considered a useful and effective medication for opioid dependence, nor does it mean that all opioid‐dependent pregnant women should be treated with buprenorphine without regard to their preferences and life circumstances." </p> </section> </section> </section> <div class="figures-list"> <div class="figure" id="CD006318-fig-0001"> <div> <p><a class="external" href="/cdsr/doi/10.1002/14651858.CD006318.pub4/media/CDSR/CD006318/urn:x-wiley:14651858:media:CD006318:CD006318-FIG-01" target="_blank"><b></b></a></p> </div><img alt="Study flow diagram September 2013." data-id="CD006318-fig-0001" src="/cdsr/doi/10.1002/14651858.CD006318.pub4/media/CDSR/CD006318/image_n/nCD006318-FIG-01.png"/><div> <p><a class="external" href="/cdsr/doi/10.1002/14651858.CD006318.pub4/media/CDSR/CD006318/image_t/tCD006318-FIG-01.png" target="_blank"><b></b></a></p> </div> <div class="scolaris-modal-title">Figures and Tables - </div> <div class="figure-viewer-caption"> <div class="figure-label">Figure 1</div> <div class="figure-caption"> <p>Study flow diagram September 2013.</p> </div> </div> <div class="tools"><a class="scolaris-systematic-reviews" href="https://training.cochrane.org/essentials/module-4-understanding-using-systematic-reviews" target="_blank">Using systematic reviews (free)</a><a class="figureList" href="/cdsr/doi/10.1002/14651858.CD006318.pub4/full#CD006318-fig-0001">Navigate to figure in review</a><button class="print-figure" href="#">Print figure</button><a class="figure-viewer-isolate" href="/cdsr/doi/10.1002/14651858.CD006318.pub4/media/CDSR/CD006318/image_n/nCD006318-FIG-01.png" target="_blank">Open in new tab</a></div> </div> <div class="figure" id="CD006318-fig-0002"> <div> <p><a class="external" href="/cdsr/doi/10.1002/14651858.CD006318.pub4/media/CDSR/CD006318/urn:x-wiley:14651858:media:CD006318:CD006318-FIG-02" target="_blank"><b></b></a></p> </div><img alt="Study flow diagram February 2020." data-id="CD006318-fig-0002" src="/cdsr/doi/10.1002/14651858.CD006318.pub4/media/CDSR/CD006318/image_n/nCD006318-FIG-02.png"/><div> <p><a class="external" href="/cdsr/doi/10.1002/14651858.CD006318.pub4/media/CDSR/CD006318/image_t/tCD006318-FIG-02.png" target="_blank"><b></b></a></p> </div> <div class="scolaris-modal-title">Figures and Tables - </div> <div class="figure-viewer-caption"> <div class="figure-label">Figure 2</div> <div class="figure-caption"> <p>Study flow diagram February 2020.</p> </div> </div> <div class="tools"><a class="scolaris-systematic-reviews" href="https://training.cochrane.org/essentials/module-4-understanding-using-systematic-reviews" target="_blank">Using systematic reviews (free)</a><a class="figureList" href="/cdsr/doi/10.1002/14651858.CD006318.pub4/full#CD006318-fig-0002">Navigate to figure in review</a><button class="print-figure" href="#">Print figure</button><a class="figure-viewer-isolate" href="/cdsr/doi/10.1002/14651858.CD006318.pub4/media/CDSR/CD006318/image_n/nCD006318-FIG-02.png" target="_blank">Open in new tab</a></div> </div> <div class="figure" id="CD006318-fig-0003"> <div> <p><a class="external" href="/cdsr/doi/10.1002/14651858.CD006318.pub4/media/CDSR/CD006318/urn:x-wiley:14651858:media:CD006318:CD006318-FIG-03" target="_blank"><b></b></a></p> </div><img alt="'Risk of bias' graph: review authors' judgements about each risk of bias item presented as percentages across all included studies." data-id="CD006318-fig-0003" src="/cdsr/doi/10.1002/14651858.CD006318.pub4/media/CDSR/CD006318/image_n/nCD006318-FIG-03.svg"/><div> <p><a class="external" href="/cdsr/doi/10.1002/14651858.CD006318.pub4/media/CDSR/CD006318/image_t/tCD006318-FIG-03.png" target="_blank"><b></b></a></p> </div> <div class="scolaris-modal-title">Figures and Tables - </div> <div class="figure-viewer-caption"> <div class="figure-label">Figure 3</div> <div class="figure-caption"> <p>'Risk of bias' graph: review authors' judgements about each risk of bias item presented as percentages across all included studies. </p> </div> </div> <div class="tools"><a class="scolaris-systematic-reviews" href="https://training.cochrane.org/essentials/module-4-understanding-using-systematic-reviews" target="_blank">Using systematic reviews (free)</a><a class="figureList" href="/cdsr/doi/10.1002/14651858.CD006318.pub4/full#CD006318-fig-0003">Navigate to figure in review</a><button class="print-figure" href="#">Print figure</button><a class="figure-viewer-isolate" href="/cdsr/doi/10.1002/14651858.CD006318.pub4/media/CDSR/CD006318/image_n/nCD006318-FIG-03.svg" target="_blank">Open in new tab</a></div> </div> <div class="figure" id="CD006318-fig-0004"> <div> <p><a class="external" href="/cdsr/doi/10.1002/14651858.CD006318.pub4/media/CDSR/CD006318/urn:x-wiley:14651858:media:CD006318:CD006318-FIG-04" target="_blank"><b></b></a></p> </div><img alt="'Risk of bias' summary: review authors' judgements about each risk of bias item for each included study." data-id="CD006318-fig-0004" src="/cdsr/doi/10.1002/14651858.CD006318.pub4/media/CDSR/CD006318/image_n/nCD006318-FIG-04.svg"/><div> <p><a class="external" href="/cdsr/doi/10.1002/14651858.CD006318.pub4/media/CDSR/CD006318/image_t/tCD006318-FIG-04.png" target="_blank"><b></b></a></p> </div> <div class="scolaris-modal-title">Figures and Tables - </div> <div class="figure-viewer-caption"> <div class="figure-label">Figure 4</div> <div class="figure-caption"> <p>'Risk of bias' summary: review authors' judgements about each risk of bias item for each included study. </p> </div> </div> <div class="tools"><a class="scolaris-systematic-reviews" href="https://training.cochrane.org/essentials/module-4-understanding-using-systematic-reviews" target="_blank">Using systematic reviews (free)</a><a class="figureList" href="/cdsr/doi/10.1002/14651858.CD006318.pub4/full#CD006318-fig-0004">Navigate to figure in review</a><button class="print-figure" href="#">Print figure</button><a class="figure-viewer-isolate" href="/cdsr/doi/10.1002/14651858.CD006318.pub4/media/CDSR/CD006318/image_n/nCD006318-FIG-04.svg" target="_blank">Open in new tab</a></div> </div> <div class="figure" id="CD006318-fig-0005"> <div> <p><a class="external" href="/cdsr/doi/10.1002/14651858.CD006318.pub4/media/CDSR/CD006318/urn:x-wiley:14651858:media:CD006318:CD006318-CMP-001.01" target="_blank"><b></b></a></p> </div><img alt="Comparison 1: Methadone versus buprenorphine, Outcome 1: Dropout rate" data-id="CD006318-fig-0005" src="/cdsr/doi/10.1002/14651858.CD006318.pub4/media/CDSR/CD006318/image_n/nCD006318-CMP-001.01.svg"/><div> <p><a class="external" href="/cdsr/doi/10.1002/14651858.CD006318.pub4/media/CDSR/CD006318/image_t/tCD006318-CMP-001.01.png" target="_blank"><b></b></a></p> </div> <div class="scolaris-modal-title">Figures and Tables - </div> <div class="figure-viewer-caption"> <div class="figure-label">Analysis 1.1</div> <div class="figure-caption"> <p>Comparison 1: Methadone versus buprenorphine, Outcome 1: Dropout rate</p> </div> </div> <div class="tools"><a class="scolaris-systematic-reviews" href="https://training.cochrane.org/essentials/module-4-understanding-using-systematic-reviews" target="_blank">Using systematic reviews (free)</a><a class="figureList" href="/cdsr/doi/10.1002/14651858.CD006318.pub4/references#CD006318-fig-0005">Navigate to figure in review</a><button class="print-figure" href="#">Print figure</button><a class="figure-viewer-isolate" href="/cdsr/doi/10.1002/14651858.CD006318.pub4/media/CDSR/CD006318/image_n/nCD006318-CMP-001.01.svg" target="_blank">Open in new tab</a></div> </div> <div class="figure" id="CD006318-fig-0006"> <div> <p><a class="external" href="/cdsr/doi/10.1002/14651858.CD006318.pub4/media/CDSR/CD006318/urn:x-wiley:14651858:media:CD006318:CD006318-CMP-001.02" target="_blank"><b></b></a></p> </div><img alt="Comparison 1: Methadone versus buprenorphine, Outcome 2: Use of primary substance" data-id="CD006318-fig-0006" src="/cdsr/doi/10.1002/14651858.CD006318.pub4/media/CDSR/CD006318/image_n/nCD006318-CMP-001.02.svg"/><div> <p><a class="external" href="/cdsr/doi/10.1002/14651858.CD006318.pub4/media/CDSR/CD006318/image_t/tCD006318-CMP-001.02.png" target="_blank"><b></b></a></p> </div> <div class="scolaris-modal-title">Figures and Tables - </div> <div class="figure-viewer-caption"> <div class="figure-label">Analysis 1.2</div> <div class="figure-caption"> <p>Comparison 1: Methadone versus buprenorphine, Outcome 2: Use of primary substance</p> </div> </div> <div class="tools"><a class="scolaris-systematic-reviews" href="https://training.cochrane.org/essentials/module-4-understanding-using-systematic-reviews" target="_blank">Using systematic reviews (free)</a><a class="figureList" href="/cdsr/doi/10.1002/14651858.CD006318.pub4/references#CD006318-fig-0006">Navigate to figure in review</a><button class="print-figure" href="#">Print figure</button><a class="figure-viewer-isolate" href="/cdsr/doi/10.1002/14651858.CD006318.pub4/media/CDSR/CD006318/image_n/nCD006318-CMP-001.02.svg" target="_blank">Open in new tab</a></div> </div> <div class="figure" id="CD006318-fig-0007"> <div> <p><a class="external" href="/cdsr/doi/10.1002/14651858.CD006318.pub4/media/CDSR/CD006318/urn:x-wiley:14651858:media:CD006318:CD006318-CMP-001.03" target="_blank"><b></b></a></p> </div><img alt="Comparison 1: Methadone versus buprenorphine, Outcome 3: Birth weight" data-id="CD006318-fig-0007" src="/cdsr/doi/10.1002/14651858.CD006318.pub4/media/CDSR/CD006318/image_n/nCD006318-CMP-001.03.svg"/><div> <p><a class="external" href="/cdsr/doi/10.1002/14651858.CD006318.pub4/media/CDSR/CD006318/image_t/tCD006318-CMP-001.03.png" target="_blank"><b></b></a></p> </div> <div class="scolaris-modal-title">Figures and Tables - </div> <div class="figure-viewer-caption"> <div class="figure-label">Analysis 1.3</div> <div class="figure-caption"> <p>Comparison 1: Methadone versus buprenorphine, Outcome 3: Birth weight</p> </div> </div> <div class="tools"><a class="scolaris-systematic-reviews" href="https://training.cochrane.org/essentials/module-4-understanding-using-systematic-reviews" target="_blank">Using systematic reviews (free)</a><a class="figureList" href="/cdsr/doi/10.1002/14651858.CD006318.pub4/references#CD006318-fig-0007">Navigate to figure in review</a><button class="print-figure" href="#">Print figure</button><a class="figure-viewer-isolate" href="/cdsr/doi/10.1002/14651858.CD006318.pub4/media/CDSR/CD006318/image_n/nCD006318-CMP-001.03.svg" target="_blank">Open in new tab</a></div> </div> <div class="figure" id="CD006318-fig-0008"> <div> <p><a class="external" href="/cdsr/doi/10.1002/14651858.CD006318.pub4/media/CDSR/CD006318/urn:x-wiley:14651858:media:CD006318:CD006318-CMP-001.04" target="_blank"><b></b></a></p> </div><img alt="Comparison 1: Methadone versus buprenorphine, Outcome 4: APGAR score" data-id="CD006318-fig-0008" src="/cdsr/doi/10.1002/14651858.CD006318.pub4/media/CDSR/CD006318/image_n/nCD006318-CMP-001.04.svg"/><div> <p><a class="external" href="/cdsr/doi/10.1002/14651858.CD006318.pub4/media/CDSR/CD006318/image_t/tCD006318-CMP-001.04.png" target="_blank"><b></b></a></p> </div> <div class="scolaris-modal-title">Figures and Tables - </div> <div class="figure-viewer-caption"> <div class="figure-label">Analysis 1.4</div> <div class="figure-caption"> <p>Comparison 1: Methadone versus buprenorphine, Outcome 4: APGAR score</p> </div> </div> <div class="tools"><a class="scolaris-systematic-reviews" href="https://training.cochrane.org/essentials/module-4-understanding-using-systematic-reviews" target="_blank">Using systematic reviews (free)</a><a class="figureList" href="/cdsr/doi/10.1002/14651858.CD006318.pub4/references#CD006318-fig-0008">Navigate to figure in review</a><button class="print-figure" href="#">Print figure</button><a class="figure-viewer-isolate" href="/cdsr/doi/10.1002/14651858.CD006318.pub4/media/CDSR/CD006318/image_n/nCD006318-CMP-001.04.svg" target="_blank">Open in new tab</a></div> </div> <div class="figure" id="CD006318-fig-0009"> <div> <p><a class="external" href="/cdsr/doi/10.1002/14651858.CD006318.pub4/media/CDSR/CD006318/urn:x-wiley:14651858:media:CD006318:CD006318-CMP-001.05" target="_blank"><b></b></a></p> </div><img alt="Comparison 1: Methadone versus buprenorphine, Outcome 5: Number treated for NAS" data-id="CD006318-fig-0009" src="/cdsr/doi/10.1002/14651858.CD006318.pub4/media/CDSR/CD006318/image_n/nCD006318-CMP-001.05.svg"/><div> <p><a class="external" href="/cdsr/doi/10.1002/14651858.CD006318.pub4/media/CDSR/CD006318/image_t/tCD006318-CMP-001.05.png" target="_blank"><b></b></a></p> </div> <div class="scolaris-modal-title">Figures and Tables - </div> <div class="figure-viewer-caption"> <div class="figure-label">Analysis 1.5</div> <div class="figure-caption"> <p>Comparison 1: Methadone versus buprenorphine, Outcome 5: Number treated for NAS</p> </div> </div> <div class="tools"><a class="scolaris-systematic-reviews" href="https://training.cochrane.org/essentials/module-4-understanding-using-systematic-reviews" target="_blank">Using systematic reviews (free)</a><a class="figureList" href="/cdsr/doi/10.1002/14651858.CD006318.pub4/references#CD006318-fig-0009">Navigate to figure in review</a><button class="print-figure" href="#">Print figure</button><a class="figure-viewer-isolate" href="/cdsr/doi/10.1002/14651858.CD006318.pub4/media/CDSR/CD006318/image_n/nCD006318-CMP-001.05.svg" target="_blank">Open in new tab</a></div> </div> <div class="figure" id="CD006318-fig-0010"> <div> <p><a class="external" href="/cdsr/doi/10.1002/14651858.CD006318.pub4/media/CDSR/CD006318/urn:x-wiley:14651858:media:CD006318:CD006318-CMP-001.06" target="_blank"><b></b></a></p> </div><img alt="Comparison 1: Methadone versus buprenorphine, Outcome 6: Mean duration of NAS treatment" data-id="CD006318-fig-0010" src="/cdsr/doi/10.1002/14651858.CD006318.pub4/media/CDSR/CD006318/image_n/nCD006318-CMP-001.06.svg"/><div> <p><a class="external" href="/cdsr/doi/10.1002/14651858.CD006318.pub4/media/CDSR/CD006318/image_t/tCD006318-CMP-001.06.png" target="_blank"><b></b></a></p> </div> <div class="scolaris-modal-title">Figures and Tables - </div> <div class="figure-viewer-caption"> <div class="figure-label">Analysis 1.6</div> <div class="figure-caption"> <p>Comparison 1: Methadone versus buprenorphine, Outcome 6: Mean duration of NAS treatment</p> </div> </div> <div class="tools"><a class="scolaris-systematic-reviews" href="https://training.cochrane.org/essentials/module-4-understanding-using-systematic-reviews" target="_blank">Using systematic reviews (free)</a><a class="figureList" href="/cdsr/doi/10.1002/14651858.CD006318.pub4/references#CD006318-fig-0010">Navigate to figure in review</a><button class="print-figure" href="#">Print figure</button><a class="figure-viewer-isolate" href="/cdsr/doi/10.1002/14651858.CD006318.pub4/media/CDSR/CD006318/image_n/nCD006318-CMP-001.06.svg" target="_blank">Open in new tab</a></div> </div> <div class="figure" id="CD006318-fig-0011"> <div> <p><a class="external" href="/cdsr/doi/10.1002/14651858.CD006318.pub4/media/CDSR/CD006318/urn:x-wiley:14651858:media:CD006318:CD006318-CMP-001.07" target="_blank"><b></b></a></p> </div><img alt="Comparison 1: Methadone versus buprenorphine, Outcome 7: Length of hospital stay" data-id="CD006318-fig-0011" src="/cdsr/doi/10.1002/14651858.CD006318.pub4/media/CDSR/CD006318/image_n/nCD006318-CMP-001.07.svg"/><div> <p><a class="external" href="/cdsr/doi/10.1002/14651858.CD006318.pub4/media/CDSR/CD006318/image_t/tCD006318-CMP-001.07.png" target="_blank"><b></b></a></p> </div> <div class="scolaris-modal-title">Figures and Tables - </div> <div class="figure-viewer-caption"> <div class="figure-label">Analysis 1.7</div> <div class="figure-caption"> <p>Comparison 1: Methadone versus buprenorphine, Outcome 7: Length of hospital stay</p> </div> </div> <div class="tools"><a class="scolaris-systematic-reviews" href="https://training.cochrane.org/essentials/module-4-understanding-using-systematic-reviews" target="_blank">Using systematic reviews (free)</a><a class="figureList" href="/cdsr/doi/10.1002/14651858.CD006318.pub4/references#CD006318-fig-0011">Navigate to figure in review</a><button class="print-figure" href="#">Print figure</button><a class="figure-viewer-isolate" href="/cdsr/doi/10.1002/14651858.CD006318.pub4/media/CDSR/CD006318/image_n/nCD006318-CMP-001.07.svg" target="_blank">Open in new tab</a></div> </div> <div class="figure" id="CD006318-fig-0012"> <div> <p><a class="external" href="/cdsr/doi/10.1002/14651858.CD006318.pub4/media/CDSR/CD006318/urn:x-wiley:14651858:media:CD006318:CD006318-CMP-001.08" target="_blank"><b></b></a></p> </div><img alt="Comparison 1: Methadone versus buprenorphine, Outcome 8: Total amount of morphine for NAS" data-id="CD006318-fig-0012" src="/cdsr/doi/10.1002/14651858.CD006318.pub4/media/CDSR/CD006318/image_n/nCD006318-CMP-001.08.svg"/><div> <p><a class="external" href="/cdsr/doi/10.1002/14651858.CD006318.pub4/media/CDSR/CD006318/image_t/tCD006318-CMP-001.08.png" target="_blank"><b></b></a></p> </div> <div class="scolaris-modal-title">Figures and Tables - </div> <div class="figure-viewer-caption"> <div class="figure-label">Analysis 1.8</div> <div class="figure-caption"> <p>Comparison 1: Methadone versus buprenorphine, Outcome 8: Total amount of morphine for NAS </p> </div> </div> <div class="tools"><a class="scolaris-systematic-reviews" href="https://training.cochrane.org/essentials/module-4-understanding-using-systematic-reviews" target="_blank">Using systematic reviews (free)</a><a class="figureList" href="/cdsr/doi/10.1002/14651858.CD006318.pub4/references#CD006318-fig-0012">Navigate to figure in review</a><button class="print-figure" href="#">Print figure</button><a class="figure-viewer-isolate" href="/cdsr/doi/10.1002/14651858.CD006318.pub4/media/CDSR/CD006318/image_n/nCD006318-CMP-001.08.svg" target="_blank">Open in new tab</a></div> </div> <div class="figure" id="CD006318-fig-0013"> <div> <p><a class="external" href="/cdsr/doi/10.1002/14651858.CD006318.pub4/media/CDSR/CD006318/urn:x-wiley:14651858:media:CD006318:CD006318-CMP-001.09" target="_blank"><b></b></a></p> </div><img alt="Comparison 1: Methadone versus buprenorphine, Outcome 9: Serious AE for the mother" data-id="CD006318-fig-0013" src="/cdsr/doi/10.1002/14651858.CD006318.pub4/media/CDSR/CD006318/image_n/nCD006318-CMP-001.09.svg"/><div> <p><a class="external" href="/cdsr/doi/10.1002/14651858.CD006318.pub4/media/CDSR/CD006318/image_t/tCD006318-CMP-001.09.png" target="_blank"><b></b></a></p> </div> <div class="scolaris-modal-title">Figures and Tables - </div> <div class="figure-viewer-caption"> <div class="figure-label">Analysis 1.9</div> <div class="figure-caption"> <p>Comparison 1: Methadone versus buprenorphine, Outcome 9: Serious AE for the mother</p> </div> </div> <div class="tools"><a class="scolaris-systematic-reviews" href="https://training.cochrane.org/essentials/module-4-understanding-using-systematic-reviews" target="_blank">Using systematic reviews (free)</a><a class="figureList" href="/cdsr/doi/10.1002/14651858.CD006318.pub4/references#CD006318-fig-0013">Navigate to figure in review</a><button class="print-figure" href="#">Print figure</button><a class="figure-viewer-isolate" href="/cdsr/doi/10.1002/14651858.CD006318.pub4/media/CDSR/CD006318/image_n/nCD006318-CMP-001.09.svg" target="_blank">Open in new tab</a></div> </div> <div class="figure" id="CD006318-fig-0014"> <div> <p><a class="external" href="/cdsr/doi/10.1002/14651858.CD006318.pub4/media/CDSR/CD006318/urn:x-wiley:14651858:media:CD006318:CD006318-CMP-001.10" target="_blank"><b></b></a></p> </div><img alt="Comparison 1: Methadone versus buprenorphine, Outcome 10: Serious AE for the child" data-id="CD006318-fig-0014" src="/cdsr/doi/10.1002/14651858.CD006318.pub4/media/CDSR/CD006318/image_n/nCD006318-CMP-001.10.svg"/><div> <p><a class="external" href="/cdsr/doi/10.1002/14651858.CD006318.pub4/media/CDSR/CD006318/image_t/tCD006318-CMP-001.10.png" target="_blank"><b></b></a></p> </div> <div class="scolaris-modal-title">Figures and Tables - </div> <div class="figure-viewer-caption"> <div class="figure-label">Analysis 1.10</div> <div class="figure-caption"> <p>Comparison 1: Methadone versus buprenorphine, Outcome 10: Serious AE for the child</p> </div> </div> <div class="tools"><a class="scolaris-systematic-reviews" href="https://training.cochrane.org/essentials/module-4-understanding-using-systematic-reviews" target="_blank">Using systematic reviews (free)</a><a class="figureList" href="/cdsr/doi/10.1002/14651858.CD006318.pub4/references#CD006318-fig-0014">Navigate to figure in review</a><button class="print-figure" href="#">Print figure</button><a class="figure-viewer-isolate" href="/cdsr/doi/10.1002/14651858.CD006318.pub4/media/CDSR/CD006318/image_n/nCD006318-CMP-001.10.svg" target="_blank">Open in new tab</a></div> </div> <div class="figure" id="CD006318-fig-0015"> <div> <p><a class="external" href="/cdsr/doi/10.1002/14651858.CD006318.pub4/media/CDSR/CD006318/urn:x-wiley:14651858:media:CD006318:CD006318-CMP-001.11" target="_blank"><b></b></a></p> </div><img alt="Comparison 1: Methadone versus buprenorphine, Outcome 11: Non‐serious AE for the mother" data-id="CD006318-fig-0015" src="/cdsr/doi/10.1002/14651858.CD006318.pub4/media/CDSR/CD006318/image_n/nCD006318-CMP-001.11.svg"/><div> <p><a class="external" href="/cdsr/doi/10.1002/14651858.CD006318.pub4/media/CDSR/CD006318/image_t/tCD006318-CMP-001.11.png" target="_blank"><b></b></a></p> </div> <div class="scolaris-modal-title">Figures and Tables - </div> <div class="figure-viewer-caption"> <div class="figure-label">Analysis 1.11</div> <div class="figure-caption"> <p>Comparison 1: Methadone versus buprenorphine, Outcome 11: Non‐serious AE for the mother</p> </div> </div> <div class="tools"><a class="scolaris-systematic-reviews" href="https://training.cochrane.org/essentials/module-4-understanding-using-systematic-reviews" target="_blank">Using systematic reviews (free)</a><a class="figureList" href="/cdsr/doi/10.1002/14651858.CD006318.pub4/references#CD006318-fig-0015">Navigate to figure in review</a><button class="print-figure" href="#">Print figure</button><a class="figure-viewer-isolate" href="/cdsr/doi/10.1002/14651858.CD006318.pub4/media/CDSR/CD006318/image_n/nCD006318-CMP-001.11.svg" target="_blank">Open in new tab</a></div> </div> <div class="figure" id="CD006318-fig-0016"> <div> <p><a class="external" href="/cdsr/doi/10.1002/14651858.CD006318.pub4/media/CDSR/CD006318/urn:x-wiley:14651858:media:CD006318:CD006318-CMP-001.12" target="_blank"><b></b></a></p> </div><img alt="Comparison 1: Methadone versus buprenorphine, Outcome 12: Non‐serious AE for the child" data-id="CD006318-fig-0016" src="/cdsr/doi/10.1002/14651858.CD006318.pub4/media/CDSR/CD006318/image_n/nCD006318-CMP-001.12.svg"/><div> <p><a class="external" href="/cdsr/doi/10.1002/14651858.CD006318.pub4/media/CDSR/CD006318/image_t/tCD006318-CMP-001.12.png" target="_blank"><b></b></a></p> </div> <div class="scolaris-modal-title">Figures and Tables - </div> <div class="figure-viewer-caption"> <div class="figure-label">Analysis 1.12</div> <div class="figure-caption"> <p>Comparison 1: Methadone versus buprenorphine, Outcome 12: Non‐serious AE for the child</p> </div> </div> <div class="tools"><a class="scolaris-systematic-reviews" href="https://training.cochrane.org/essentials/module-4-understanding-using-systematic-reviews" target="_blank">Using systematic reviews (free)</a><a class="figureList" href="/cdsr/doi/10.1002/14651858.CD006318.pub4/references#CD006318-fig-0016">Navigate to figure in review</a><button class="print-figure" href="#">Print figure</button><a class="figure-viewer-isolate" href="/cdsr/doi/10.1002/14651858.CD006318.pub4/media/CDSR/CD006318/image_n/nCD006318-CMP-001.12.svg" target="_blank">Open in new tab</a></div> </div> <div class="figure" id="CD006318-fig-0017"> <div> <p><a class="external" href="/cdsr/doi/10.1002/14651858.CD006318.pub4/media/CDSR/CD006318/urn:x-wiley:14651858:media:CD006318:CD006318-CMP-002.01" target="_blank"><b></b></a></p> </div><img alt="Comparison 2: Methadone versus oral slow‐release morphine, Outcome 1: Use of primary substance" data-id="CD006318-fig-0017" src="/cdsr/doi/10.1002/14651858.CD006318.pub4/media/CDSR/CD006318/image_n/nCD006318-CMP-002.01.svg"/><div> <p><a class="external" href="/cdsr/doi/10.1002/14651858.CD006318.pub4/media/CDSR/CD006318/image_t/tCD006318-CMP-002.01.png" target="_blank"><b></b></a></p> </div> <div class="scolaris-modal-title">Figures and Tables - </div> <div class="figure-viewer-caption"> <div class="figure-label">Analysis 2.1</div> <div class="figure-caption"> <p>Comparison 2: Methadone versus oral slow‐release morphine, Outcome 1: Use of primary substance </p> </div> </div> <div class="tools"><a class="scolaris-systematic-reviews" href="https://training.cochrane.org/essentials/module-4-understanding-using-systematic-reviews" target="_blank">Using systematic reviews (free)</a><a class="figureList" href="/cdsr/doi/10.1002/14651858.CD006318.pub4/references#CD006318-fig-0017">Navigate to figure in review</a><button class="print-figure" href="#">Print figure</button><a class="figure-viewer-isolate" href="/cdsr/doi/10.1002/14651858.CD006318.pub4/media/CDSR/CD006318/image_n/nCD006318-CMP-002.01.svg" target="_blank">Open in new tab</a></div> </div> <div class="figure" id="CD006318-fig-0018"> <div> <p><a class="external" href="/cdsr/doi/10.1002/14651858.CD006318.pub4/media/CDSR/CD006318/urn:x-wiley:14651858:media:CD006318:CD006318-CMP-002.02" target="_blank"><b></b></a></p> </div><img alt="Comparison 2: Methadone versus oral slow‐release morphine, Outcome 2: Birth weight" data-id="CD006318-fig-0018" src="/cdsr/doi/10.1002/14651858.CD006318.pub4/media/CDSR/CD006318/image_n/nCD006318-CMP-002.02.svg"/><div> <p><a class="external" href="/cdsr/doi/10.1002/14651858.CD006318.pub4/media/CDSR/CD006318/image_t/tCD006318-CMP-002.02.png" target="_blank"><b></b></a></p> </div> <div class="scolaris-modal-title">Figures and Tables - </div> <div class="figure-viewer-caption"> <div class="figure-label">Analysis 2.2</div> <div class="figure-caption"> <p>Comparison 2: Methadone versus oral slow‐release morphine, Outcome 2: Birth weight</p> </div> </div> <div class="tools"><a class="scolaris-systematic-reviews" href="https://training.cochrane.org/essentials/module-4-understanding-using-systematic-reviews" target="_blank">Using systematic reviews (free)</a><a class="figureList" href="/cdsr/doi/10.1002/14651858.CD006318.pub4/references#CD006318-fig-0018">Navigate to figure in review</a><button class="print-figure" href="#">Print figure</button><a class="figure-viewer-isolate" href="/cdsr/doi/10.1002/14651858.CD006318.pub4/media/CDSR/CD006318/image_n/nCD006318-CMP-002.02.svg" target="_blank">Open in new tab</a></div> </div> <div class="figure" id="CD006318-fig-0019"> <div> <p><a class="external" href="/cdsr/doi/10.1002/14651858.CD006318.pub4/media/CDSR/CD006318/urn:x-wiley:14651858:media:CD006318:CD006318-CMP-002.03" target="_blank"><b></b></a></p> </div><img alt="Comparison 2: Methadone versus oral slow‐release morphine, Outcome 3: NAS mean duration" data-id="CD006318-fig-0019" src="/cdsr/doi/10.1002/14651858.CD006318.pub4/media/CDSR/CD006318/image_n/nCD006318-CMP-002.03.svg"/><div> <p><a class="external" href="/cdsr/doi/10.1002/14651858.CD006318.pub4/media/CDSR/CD006318/image_t/tCD006318-CMP-002.03.png" target="_blank"><b></b></a></p> </div> <div class="scolaris-modal-title">Figures and Tables - </div> <div class="figure-viewer-caption"> <div class="figure-label">Analysis 2.3</div> <div class="figure-caption"> <p>Comparison 2: Methadone versus oral slow‐release morphine, Outcome 3: NAS mean duration</p> </div> </div> <div class="tools"><a class="scolaris-systematic-reviews" href="https://training.cochrane.org/essentials/module-4-understanding-using-systematic-reviews" target="_blank">Using systematic reviews (free)</a><a class="figureList" href="/cdsr/doi/10.1002/14651858.CD006318.pub4/references#CD006318-fig-0019">Navigate to figure in review</a><button class="print-figure" href="#">Print figure</button><a class="figure-viewer-isolate" href="/cdsr/doi/10.1002/14651858.CD006318.pub4/media/CDSR/CD006318/image_n/nCD006318-CMP-002.03.svg" target="_blank">Open in new tab</a></div> </div> <div class="figure" id="CD006318-fig-0020"> <div> <p><a class="external" href="/cdsr/doi/10.1002/14651858.CD006318.pub4/media/CDSR/CD006318/urn:x-wiley:14651858:media:CD006318:CD006318-CMP-002.04" target="_blank"><b></b></a></p> </div><img alt="Comparison 2: Methadone versus oral slow‐release morphine, Outcome 4: Nicotine consumption" data-id="CD006318-fig-0020" src="/cdsr/doi/10.1002/14651858.CD006318.pub4/media/CDSR/CD006318/image_n/nCD006318-CMP-002.04.svg"/><div> <p><a class="external" href="/cdsr/doi/10.1002/14651858.CD006318.pub4/media/CDSR/CD006318/image_t/tCD006318-CMP-002.04.png" target="_blank"><b></b></a></p> </div> <div class="scolaris-modal-title">Figures and Tables - </div> <div class="figure-viewer-caption"> <div class="figure-label">Analysis 2.4</div> <div class="figure-caption"> <p>Comparison 2: Methadone versus oral slow‐release morphine, Outcome 4: Nicotine consumption</p> </div> </div> <div class="tools"><a class="scolaris-systematic-reviews" href="https://training.cochrane.org/essentials/module-4-understanding-using-systematic-reviews" target="_blank">Using systematic reviews (free)</a><a class="figureList" href="/cdsr/doi/10.1002/14651858.CD006318.pub4/references#CD006318-fig-0020">Navigate to figure in review</a><button class="print-figure" href="#">Print figure</button><a class="figure-viewer-isolate" href="/cdsr/doi/10.1002/14651858.CD006318.pub4/media/CDSR/CD006318/image_n/nCD006318-CMP-002.04.svg" target="_blank">Open in new tab</a></div> </div> </div> <div class="tables-list"> <div class="table"> <table class="summary-of-findings framed" data-id="CD006318-tbl-0001"> <div class="table-heading"><span class="table-label">Summary of findings 1.</span> <span class="table-title">Methadone compared to buprenorphine for opiate‐dependent pregnant women</span></div> <tbody> <tr class="separated"> <td align="left" bgcolor="#ffffff" colspan="7" rowspan="1" valign="top"> <p><b>Methadone compared to buprenorphine for opiate‐dependent pregnant women</b> </p> </td> </tr> <tr class="separated"> <td align="left" bgcolor="#ffffff" colspan="7" rowspan="1" valign="top"> <p><b>Patient or population:</b> opiate‐dependent pregnant women<br/><b>Setting:</b> outpatients<br/><b>Intervention:</b> methadone<br/><b>Comparison:</b> buprenorphine </p> </td> </tr> <tr class="separated"> <th align="left" class="headercell" colspan="1" rowspan="2" scope="col" valign="top"> <p><b>Outcomes</b> </p> </th> <th align="left" class="headercell table-tint" colspan="2" rowspan="1" scope="col" valign="top"> <p><b>Anticipated absolute effects<sup>*</sup> (95% CI)</b> </p> </th> <th align="left" class="headercell" colspan="1" rowspan="2" scope="col" valign="top"> <p><b>Relative effect<br/>(95% CI)</b> </p> </th> <th align="left" class="headercell" colspan="1" rowspan="2" scope="col" valign="top"> <p><b>№ of participants<br/>(studies)</b> </p> </th> <th align="left" class="headercell" colspan="1" rowspan="2" scope="col" valign="top"> <p><b>Certainty of the evidence<br/>(GRADE)</b> </p> </th> <th align="left" class="headercell" colspan="1" rowspan="2" scope="col" valign="top"> <p><b>Comments</b> </p> </th> </tr> <tr class="separated"> <th align="left" class="headercell table-tint" colspan="1" rowspan="1" scope="col" valign="top"> <p><b>Risk with buprenorphine</b> </p> </th> <th align="left" class="headercell table-tint" colspan="1" rowspan="1" scope="col" valign="top"> <p><b>Risk with methadone</b> </p> </th> </tr> <tr class="separated"> <td align="left" bgcolor="#ffffff" colspan="1" rowspan="2" valign="top"> <p>Dropout rate<br/>follow‐up: range 15 weeks to 18 weeks </p> </td> <td align="left" class="table-tint table-highlight" colspan="2" rowspan="1" valign="top"> <p>Study population</p> </td> <td align="left" bgcolor="#ffffff" colspan="1" rowspan="2" valign="top"> <p>RR 0.66<br/>(0.37 to 1.20) </p> </td> <td align="left" bgcolor="#ffffff" colspan="1" rowspan="2" valign="top"> <p>223<br/>(3 RCTs) </p> </td> <td align="left" bgcolor="#ffffff" colspan="1" rowspan="2" valign="top"> <p>⊕⊕⊕⊝<br/>MODERATE <sup>1</sup> </p> </td> <td align="left" bgcolor="#ffffff" colspan="1" rowspan="2" valign="top"></td> </tr> <tr class="separated"> <td align="left" class="table-tint table-highlight" colspan="1" rowspan="1" valign="top"> <p>318 per 1000</p> </td> <td align="left" class="table-tint table-highlight" colspan="1" rowspan="1" valign="top"> <p>210 per 1000<br/>(118 to 382) </p> </td> </tr> <tr class="separated"> <td align="left" bgcolor="#ffffff" colspan="1" rowspan="2" valign="top"> <p>Use of primary substance<br/>follow‐up: range 15 weeks to 18 weeks </p> </td> <td align="left" class="table-tint table-highlight" colspan="2" rowspan="1" valign="top"> <p>Study population</p> </td> <td align="left" bgcolor="#ffffff" colspan="1" rowspan="2" valign="top"> <p>RR 1.81<br/>(0.70 to 4.68) </p> </td> <td align="left" bgcolor="#ffffff" colspan="1" rowspan="2" valign="top"> <p>151<br/>(2 RCTs) </p> </td> <td align="left" bgcolor="#ffffff" colspan="1" rowspan="2" valign="top"> <p>⊕⊕⊝⊝<br/>LOW <sup>1 2</sup> </p> </td> <td align="left" bgcolor="#ffffff" colspan="1" rowspan="2" valign="top"></td> </tr> <tr class="separated"> <td align="left" class="table-tint table-highlight" colspan="1" rowspan="1" valign="top"> <p>75 per 1000</p> </td> <td align="left" class="table-tint table-highlight" colspan="1" rowspan="1" valign="top"> <p>135 per 1000<br/>(52 to 349) </p> </td> </tr> <tr class="separated"> <td align="left" bgcolor="#ffffff" colspan="1" rowspan="1" valign="top"> <p>Birth weight<br/>follow‐up: mean 18 weeks </p> </td> <td align="left" class="table-tint table-highlight" colspan="1" rowspan="1" valign="top"> <p>The mean birth weight ranged from 3.093 g to 3530 gr</p> </td> <td align="left" class="table-tint table-highlight" colspan="1" rowspan="1" valign="top"> <p>MD ranged from ‐530.00 gr (662.78,lower to 397.22 lower) to ‐215.00 gr (238.93, lower to 191.07 lower) </p> </td> <td align="left" bgcolor="#ffffff" colspan="1" rowspan="1" valign="top"> <p>‐</p> </td> <td align="left" bgcolor="#ffffff" colspan="1" rowspan="1" valign="top"> <p>19 and 131 participants <br/>(2 RCTs) </p> </td> <td align="left" bgcolor="#ffffff" colspan="1" rowspan="1" valign="top"> <p>⊕⊝⊝⊝<br/>VERY LOW <sup>2 3 4</sup> </p> </td> <td align="left" bgcolor="#ffffff" colspan="1" rowspan="1" valign="top"></td> </tr> <tr class="separated"> <td align="left" bgcolor="#ffffff" colspan="1" rowspan="1" valign="top"> <p>APGAR score<br/>Scale from: 0 to 10<br/>follow‐up: mean 18 weeks </p> </td> <td align="left" class="table-tint table-highlight" colspan="1" rowspan="1" valign="top"> <p>The mean APGAR score was 8.95</p> </td> <td align="left" class="table-tint table-highlight" colspan="1" rowspan="1" valign="top"> <p>MD 0<br/>(0.03 lower to 0.03 higher) </p> </td> <td align="left" bgcolor="#ffffff" colspan="1" rowspan="1" valign="top"> <p>‐</p> </td> <td align="left" bgcolor="#ffffff" colspan="1" rowspan="1" valign="top"> <p>163<br/>(2 RCTs) </p> </td> <td align="left" bgcolor="#ffffff" colspan="1" rowspan="1" valign="top"> <p>⊕⊕⊝⊝<br/>LOW <sup>2 4</sup> </p> </td> <td align="left" bgcolor="#ffffff" colspan="1" rowspan="1" valign="top"></td> </tr> <tr class="separated"> <td align="left" bgcolor="#ffffff" colspan="1" rowspan="2" valign="top"> <p>Number treated for NAS<br/>follow‐up: range 15 weeks to 18 weeks </p> </td> <td align="left" class="table-tint table-highlight" colspan="2" rowspan="1" valign="top"> <p>Study population</p> </td> <td align="left" bgcolor="#ffffff" colspan="1" rowspan="2" valign="top"> <p>RR 1.19<br/>(0.87 to 1.63) </p> </td> <td align="left" bgcolor="#ffffff" colspan="1" rowspan="2" valign="top"> <p>166<br/>(3 RCTs) </p> </td> <td align="left" bgcolor="#ffffff" colspan="1" rowspan="2" valign="top"> <p>⊕⊕⊝⊝<br/>LOW <sup>1 2</sup> </p> </td> <td align="left" bgcolor="#ffffff" colspan="1" rowspan="2" valign="top"></td> </tr> <tr class="separated"> <td align="left" class="table-tint table-highlight" colspan="1" rowspan="1" valign="top"> <p>447 per 1000</p> </td> <td align="left" class="table-tint table-highlight" colspan="1" rowspan="1" valign="top"> <p>532 per 1000<br/>(389 to 729) </p> </td> </tr> <tr class="separated"> <td align="left" bgcolor="#ffffff" colspan="1" rowspan="2" valign="top"> <p>Serious adverse events for the mother</p> </td> <td align="left" class="table-tint table-highlight" colspan="2" rowspan="1" valign="top"> <p>Study population</p> </td> <td align="left" bgcolor="#ffffff" colspan="1" rowspan="2" valign="top"> <p>RR 1.69<br/>(0.75 to 3.83) </p> </td> <td align="left" bgcolor="#ffffff" colspan="1" rowspan="2" valign="top"> <p>175<br/>(1 RCT) </p> </td> <td align="left" bgcolor="#ffffff" colspan="1" rowspan="2" valign="top"> <p>⊕⊕⊝⊝<br/>LOW <sup>1 2</sup> </p> </td> <td align="left" bgcolor="#ffffff" colspan="1" rowspan="2" valign="top"></td> </tr> <tr class="separated"> <td align="left" class="table-tint table-highlight" colspan="1" rowspan="1" valign="top"> <p>93 per 1000</p> </td> <td align="left" class="table-tint table-highlight" colspan="1" rowspan="1" valign="top"> <p>157 per 1000<br/>(70 to 356) </p> </td> </tr> <tr class="separated"> <td align="left" bgcolor="#ffffff" colspan="1" rowspan="2" valign="top"> <p>Serious adverse events for the child</p> </td> <td align="left" class="table-tint table-highlight" colspan="2" rowspan="1" valign="top"> <p>Study population</p> </td> <td align="left" bgcolor="#ffffff" colspan="1" rowspan="2" valign="top"> <p>RR 4.77<br/>(0.59 to 38.49) </p> </td> <td align="left" bgcolor="#ffffff" colspan="1" rowspan="2" valign="top"> <p>131<br/>(1 RCT) </p> </td> <td align="left" bgcolor="#ffffff" colspan="1" rowspan="2" valign="top"> <p>⊕⊕⊝⊝<br/>LOW <sup>1 2</sup> </p> </td> <td align="left" bgcolor="#ffffff" colspan="1" rowspan="2" valign="top"></td> </tr> <tr class="separated"> <td align="left" class="table-tint table-highlight" colspan="1" rowspan="1" valign="top"> <p>17 per 1000</p> </td> <td align="left" class="table-tint table-highlight" colspan="1" rowspan="1" valign="top"> <p>82 per 1000<br/>(10 to 664) </p> </td> </tr> <tr class="separated"> <td align="" bgcolor="#ffffff" colspan="7" rowspan="1" valign=""> <p>*<b>The risk in the intervention group</b> (and its 95% confidence interval) is based on the assumed risk in the comparison group and the <b>relative effect</b> of the intervention (and its 95% CI).<br/><br/><b>CI:</b> Confidence interval; <b>RR:</b> Risk ratio; <b>OR:</b> Odds ratio; </p> </td> </tr> <tr class="separated"> <td align="" bgcolor="#ffffff" colspan="7" rowspan="1" valign=""> <p><b>GRADE Working Group grades of evidence</b> <br/><b>High certainty:</b> We are very confident that the true effect lies close to that of the estimate of the effect<br/><b>Moderate certainty:</b> We are moderately confident in the effect estimate: The true effect is likely to be close to the estimate of the effect, but there is a possibility that it is substantially different<br/><b>Low certainty:</b> Our confidence in the effect estimate is limited: The true effect may be substantially different from the estimate of the effect<br/><b>Very low certainty:</b> We have very little confidence in the effect estimate: The true effect is likely to be substantially different from the estimate of effect </p> </td> </tr> </tbody> <tfoot> <tr> <td colspan="7"> <div class="table-footnote"> <p><sup>1</sup> downgraded one level due to imprecision: optimal information size not met </p> <p><sup>2</sup> downgraded one level due to study limitations: high risk of attrition bias </p> <p><sup>3</sup> downgraded one level due to inconsistency: high heterogeneity: I<sup>2</sup> 95% </p> <p><sup>4</sup> downgraded one level due to imprecision: fewer than 400 participants </p> </div> </td> </tr> </tfoot> </table> <div class="scolaris-modal-title">Figures and Tables - </div> <div class="table-viewer-caption"> <div class="table-heading"><span class="table-label">Summary of findings 1.</span> <span class="table-title">Methadone compared to buprenorphine for opiate‐dependent pregnant women</span></div> </div> <div class="tools"><a class="tableList" href="/cdsr/doi/10.1002/14651858.CD006318.pub4/full#CD006318-tbl-0001">Navigate to table in review</a></div> </div> <div class="table"> <table class="summary-of-findings framed" data-id="CD006318-tbl-0002"> <div class="table-heading"><span class="table-label">Summary of findings 2.</span> <span class="table-title">Methadone compared to oral slow‐release morphine for opiate‐dependent pregnant women</span></div> <tbody> <tr class="separated"> <td align="left" bgcolor="#ffffff" colspan="7" rowspan="1" valign="top"> <p><b>Methadone compared to oral slow‐release morphine for opiate‐dependent pregnant women</b> </p> </td> </tr> <tr class="separated"> <td align="left" bgcolor="#ffffff" colspan="7" rowspan="1" valign="top"> <p><b>Patient or population:</b> opiate‐dependent pregnant women<br/><b>Setting:</b> <br/><b>Intervention:</b> methadone<br/><b>Comparison:</b> oral slow‐release morphine </p> </td> </tr> <tr class="separated"> <th align="left" class="headercell" colspan="1" rowspan="2" scope="col" valign="top"> <p><b>Outcomes</b> </p> </th> <th align="left" class="headercell table-tint" colspan="2" rowspan="1" scope="col" valign="top"> <p><b>Anticipated absolute effects<sup>*</sup> (95% CI)</b> </p> </th> <th align="left" class="headercell" colspan="1" rowspan="2" scope="col" valign="top"> <p><b>Relative effect<br/>(95% CI)</b> </p> </th> <th align="left" class="headercell" colspan="1" rowspan="2" scope="col" valign="top"> <p><b>№ of participants<br/>(studies)</b> </p> </th> <th align="left" class="headercell" colspan="1" rowspan="2" scope="col" valign="top"> <p><b>Certainty of the evidence<br/>(GRADE)</b> </p> </th> <th align="left" class="headercell" colspan="1" rowspan="2" scope="col" valign="top"> <p><b>Comments</b> </p> </th> </tr> <tr class="separated"> <th align="left" class="headercell table-tint" colspan="1" rowspan="1" scope="col" valign="top"> <p><b>Risk with oral slow‐release morphine</b> </p> </th> <th align="left" class="headercell table-tint" colspan="1" rowspan="1" scope="col" valign="top"> <p><b>Risk with methadone</b> </p> </th> </tr> <tr class="separated"> <td align="left" bgcolor="#ffffff" colspan="1" rowspan="1" valign="top"> <p>Dropout rate from treatment<br/>follow‐up: mean 15 weeks </p> </td> <td align="left" class="table-tint table-highlight" colspan="2" rowspan="1" valign="top"> <p>No dropouts from either group</p> </td> <td align="left" bgcolor="#ffffff" colspan="1" rowspan="1" valign="top"></td> <td align="left" bgcolor="#ffffff" colspan="1" rowspan="1" valign="top"> <p>48<br/>(1 RCT) </p> </td> <td align="left" bgcolor="#ffffff" colspan="1" rowspan="1" valign="top"> <p>⊕⊕⊝⊝<br/>LOW <sup>1 2</sup> </p> </td> <td align="left" bgcolor="#ffffff" colspan="1" rowspan="1" valign="top"></td> </tr> <tr class="separated"> <td align="left" bgcolor="#ffffff" colspan="1" rowspan="2" valign="top"> <p>Use of substance<br/>follow‐up: mean 15 weeks </p> </td> <td align="left" class="table-tint table-highlight" colspan="2" rowspan="1" valign="top"> <p>Study population</p> </td> <td align="left" bgcolor="#ffffff" colspan="1" rowspan="2" valign="top"> <p>RR 2.40<br/>(1.00 to 5.77) </p> </td> <td align="left" bgcolor="#ffffff" colspan="1" rowspan="2" valign="top"> <p>48<br/>(1 RCT) </p> </td> <td align="left" bgcolor="#ffffff" colspan="1" rowspan="2" valign="top"> <p>⊕⊕⊝⊝<br/>LOW <sup>1 3</sup> </p> </td> <td align="left" bgcolor="#ffffff" colspan="1" rowspan="2" valign="top"></td> </tr> <tr class="separated"> <td align="left" class="table-tint table-highlight" colspan="1" rowspan="1" valign="top"> <p>208 per 1000</p> </td> <td align="left" class="table-tint table-highlight" colspan="1" rowspan="1" valign="top"> <p>500 per 1000<br/>(208 to 1000) </p> </td> </tr> <tr class="separated"> <td align="left" bgcolor="#ffffff" colspan="1" rowspan="1" valign="top"> <p>Birth weight<br/>follow‐up: mean 15 weeks </p> </td> <td align="left" class="table-tint table-highlight" colspan="1" rowspan="1" valign="top"> <p>The mean birth weight was 2912 g</p> </td> <td align="left" class="table-tint table-highlight" colspan="1" rowspan="1" valign="top"> <p>MD 124 higher<br/>(186.94 lower to 434.94 higher) </p> </td> <td align="left" bgcolor="#ffffff" colspan="1" rowspan="1" valign="top"> <p>‐</p> </td> <td align="left" bgcolor="#ffffff" colspan="1" rowspan="1" valign="top"> <p>48<br/>(1 RCT) </p> </td> <td align="left" bgcolor="#ffffff" colspan="1" rowspan="1" valign="top"> <p>⊕⊕⊝⊝<br/>LOW <sup>1 2</sup> </p> </td> <td align="left" bgcolor="#ffffff" colspan="1" rowspan="1" valign="top"></td> </tr> <tr class="separated"> <td align="left" bgcolor="#ffffff" colspan="1" rowspan="1" valign="top"> <p>APGAR score (APGAR score )<br/>follow‐up: mean 15 weeks </p> </td> <td align="left" class="table-tint table-highlight" colspan="2" rowspan="1" valign="top"> <p>The study did not assess this outcome</p> </td> <td align="left" bgcolor="#ffffff" colspan="1" rowspan="1" valign="top"> <p>‐</p> </td> <td align="left" bgcolor="#ffffff" colspan="1" rowspan="1" valign="top"></td> <td align="left" bgcolor="#ffffff" colspan="1" rowspan="1" valign="top"></td> <td align="left" bgcolor="#ffffff" colspan="1" rowspan="1" valign="top"></td> </tr> <tr class="separated"> <td align="" bgcolor="#ffffff" colspan="1" rowspan="1" valign=""> <p>Adverse events for the mother</p> <p>follow‐up: mean 15 weeks</p> </td> <td align="" class="table-tint table-highlight" colspan="2" rowspan="1" valign=""> <p>No side effects for the mother were reported</p> </td> <td align="" bgcolor="#ffffff" colspan="1" rowspan="1" valign=""></td> <td align="" bgcolor="#ffffff" colspan="1" rowspan="1" valign=""> <p>48<br/>(1 RCT) </p> </td> <td align="" bgcolor="#ffffff" colspan="1" rowspan="1" valign=""> <p>⊕⊕⊝⊝<br/>LOW <sup>1 2</sup> </p> </td> <td align="" bgcolor="#ffffff" colspan="1" rowspan="1" valign=""></td> </tr> <tr class="separated"> <td align="" bgcolor="#ffffff" colspan="1" rowspan="1" valign=""> <p>Serious adverse events for the child</p> <p>follow‐up: mean 15 weeks</p> </td> <td align="" class="table-tint table-highlight" colspan="2" rowspan="1" valign=""> <p>No severe complications were noted in any of the neonates as monitored by polysomnography, although one child in the methadone group had central apnoea and one child in the morphine group had obstructive apnoea. </p> </td> <td align="" bgcolor="#ffffff" colspan="1" rowspan="1" valign=""></td> <td align="" bgcolor="#ffffff" colspan="1" rowspan="1" valign=""> <p>48<br/>(1 RCT) </p> </td> <td align="" bgcolor="#ffffff" colspan="1" rowspan="1" valign=""> <p>⊕⊕⊝⊝<br/>LOW <sup>1 2</sup> </p> </td> <td align="" bgcolor="#ffffff" colspan="1" rowspan="1" valign=""></td> </tr> <tr class="separated"> <td align="" bgcolor="#ffffff" colspan="7" rowspan="1" valign=""> <p>*<b>The risk in the intervention group</b> (and its 95% confidence interval) is based on the assumed risk in the comparison group and the <b>relative effect</b> of the intervention (and its 95% CI).<br/><br/><b>CI:</b> Confidence interval; <b>RR:</b> Risk ratio; <b>OR:</b> Odds ratio; </p> </td> </tr> <tr class="separated"> <td align="" bgcolor="#ffffff" colspan="7" rowspan="1" valign=""> <p><b>GRADE Working Group grades of evidence</b> <br/><b>High certainty:</b> We are very confident that the true effect lies close to that of the estimate of the effect<br/><b>Moderate certainty:</b> We are moderately confident in the effect estimate: The true effect is likely to be close to the estimate of the effect, but there is a possibility that it is substantially different<br/><b>Low certainty:</b> Our confidence in the effect estimate is limited: The true effect may be substantially different from the estimate of the effect<br/><b>Very low certainty:</b> We have very little confidence in the effect estimate: The true effect is likely to be substantially different from the estimate of effect </p> </td> </tr> </tbody> <tfoot> <tr> <td colspan="7"> <div class="table-footnote"> <p><sup>1</sup> not applicable </p> <p><sup>2</sup> downgraded two levels: fewer than 100 participants </p> <p><sup>3</sup> downgraded two level: optimal information size not met </p> </div> </td> </tr> </tfoot> </table> <div class="scolaris-modal-title">Figures and Tables - </div> <div class="table-viewer-caption"> <div class="table-heading"><span class="table-label">Summary of findings 2.</span> <span class="table-title">Methadone compared to oral slow‐release morphine for opiate‐dependent pregnant women</span></div> </div> <div class="tools"><a class="tableList" href="/cdsr/doi/10.1002/14651858.CD006318.pub4/full#CD006318-tbl-0002">Navigate to table in review</a></div> </div> <div class="table"> <table class="comparison" data-id="CD006318-tbl-0003"> <div class="table-heading"><span class="table-label">Comparison 1.</span> <span class="table-title">Methadone versus buprenorphine</span></div> <thead> <tr> <td align="" bgcolor="#ffffff" colspan="1" data-title="Outcome or subgroup title" rowspan="1" valign=""> <p>Outcome or subgroup title</p> </td> <td align="" bgcolor="#ffffff" colspan="1" data-title="No. of studies" rowspan="1" valign=""> <p>No. of studies</p> </td> <td align="" bgcolor="#ffffff" colspan="1" data-title="No. of participants" rowspan="1" valign=""> <p>No. of participants</p> </td> <td align="" bgcolor="#ffffff" colspan="1" data-title="Statistical method" rowspan="1" valign=""> <p>Statistical method</p> </td> <td align="" bgcolor="#ffffff" colspan="1" data-title="Effect size" rowspan="1" valign=""> <p>Effect size</p> </td> </tr> </thead> <tbody> <tr> <td align="" bgcolor="#ffffff" colspan="1" data-title="Outcome or subgroup title" rowspan="1" valign=""> <p class="subgroupTitle">1.1 Dropout rate <span class="subgroupLink"><b class="text-toggle-control">Show forest plot</b><i aria-hidden="true" class="fa fa-caret-down"></i></span></p> </td> <td align="" bgcolor="#ffffff" colspan="1" data-title="No. of studies" rowspan="1" valign=""> <p>3</p> </td> <td align="" bgcolor="#ffffff" colspan="1" data-title="No. of participants" rowspan="1" valign=""> <p>223</p> </td> <td align="" bgcolor="#ffffff" colspan="1" data-title="Statistical method" rowspan="1" valign=""> <p>Risk Ratio (M‐H, Random, 95% CI)</p> </td> <td align="" bgcolor="#ffffff" colspan="1" data-title="Effect size" rowspan="1" valign=""> <p>0.66 [0.37, 1.20]</p> </td> </tr> <tr class="figure-image"> <td colspan="5"></td> </tr> <tr> <td align="" bgcolor="#ffffff" colspan="1" data-title="Outcome or subgroup title" rowspan="1" valign=""> <p class="subgroupTitle">1.2 Use of primary substance <span class="subgroupLink"><b class="text-toggle-control">Show forest plot</b><i aria-hidden="true" class="fa fa-caret-down"></i></span></p> </td> <td align="" bgcolor="#ffffff" colspan="1" data-title="No. of studies" rowspan="1" valign=""> <p>2</p> </td> <td align="" bgcolor="#ffffff" colspan="1" data-title="No. of participants" rowspan="1" valign=""> <p>151</p> </td> <td align="" bgcolor="#ffffff" colspan="1" data-title="Statistical method" rowspan="1" valign=""> <p>Risk Ratio (M‐H, Random, 95% CI)</p> </td> <td align="" bgcolor="#ffffff" colspan="1" data-title="Effect size" rowspan="1" valign=""> <p>1.81 [0.70, 4.68]</p> </td> </tr> <tr class="figure-image"> <td colspan="5"></td> </tr> <tr> <td align="" bgcolor="#ffffff" colspan="1" data-title="Outcome or subgroup title" rowspan="1" valign=""> <p class="subgroupTitle">1.3 Birth weight <span class="subgroupLink"><b class="text-toggle-control">Show forest plot</b><i aria-hidden="true" class="fa fa-caret-down"></i></span></p> </td> <td align="" bgcolor="#ffffff" colspan="1" data-title="No. of studies" rowspan="1" valign=""> <p>2</p> </td> <td align="" bgcolor="#ffffff" colspan="1" data-title="No. of participants" rowspan="1" valign=""></td> <td align="" bgcolor="#ffffff" colspan="1" data-title="Statistical method" rowspan="1" valign=""> <p>Mean Difference (IV, Random, 95% CI)</p> </td> <td align="" bgcolor="#ffffff" colspan="1" data-title="Effect size" rowspan="1" valign=""> <p>Totals not selected</p> </td> </tr> <tr class="figure-image"> <td colspan="5"></td> </tr> <tr> <td align="" bgcolor="#ffffff" colspan="1" data-title="Outcome or subgroup title" rowspan="1" valign=""> <p class="subgroupTitle">1.4 APGAR score <span class="subgroupLink"><b class="text-toggle-control">Show forest plot</b><i aria-hidden="true" class="fa fa-caret-down"></i></span></p> </td> <td align="" bgcolor="#ffffff" colspan="1" data-title="No. of studies" rowspan="1" valign=""> <p>2</p> </td> <td align="" bgcolor="#ffffff" colspan="1" data-title="No. of participants" rowspan="1" valign=""> <p>163</p> </td> <td align="" bgcolor="#ffffff" colspan="1" data-title="Statistical method" rowspan="1" valign=""> <p>Mean Difference (IV, Random, 95% CI)</p> </td> <td align="" bgcolor="#ffffff" colspan="1" data-title="Effect size" rowspan="1" valign=""> <p>0.00 [‐0.03, 0.03]</p> </td> </tr> <tr class="figure-image"> <td colspan="5"></td> </tr> <tr> <td align="" bgcolor="#ffffff" colspan="1" data-title="Outcome or subgroup title" rowspan="1" valign=""> <p class="subgroupTitle">1.5 Number treated for NAS <span class="subgroupLink"><b class="text-toggle-control">Show forest plot</b><i aria-hidden="true" class="fa fa-caret-down"></i></span></p> </td> <td align="" bgcolor="#ffffff" colspan="1" data-title="No. of studies" rowspan="1" valign=""> <p>3</p> </td> <td align="" bgcolor="#ffffff" colspan="1" data-title="No. of participants" rowspan="1" valign=""> <p>166</p> </td> <td align="" bgcolor="#ffffff" colspan="1" data-title="Statistical method" rowspan="1" valign=""> <p>Risk Ratio (M‐H, Random, 95% CI)</p> </td> <td align="" bgcolor="#ffffff" colspan="1" data-title="Effect size" rowspan="1" valign=""> <p>1.19 [0.87, 1.63]</p> </td> </tr> <tr class="figure-image"> <td colspan="5"></td> </tr> <tr> <td align="" bgcolor="#ffffff" colspan="1" data-title="Outcome or subgroup title" rowspan="1" valign=""> <p class="subgroupTitle">1.6 Mean duration of NAS treatment <span class="subgroupLink"><b class="text-toggle-control">Show forest plot</b><i aria-hidden="true" class="fa fa-caret-down"></i></span></p> </td> <td align="" bgcolor="#ffffff" colspan="1" data-title="No. of studies" rowspan="1" valign=""> <p>2</p> </td> <td align="" bgcolor="#ffffff" colspan="1" data-title="No. of participants" rowspan="1" valign=""> <p>145</p> </td> <td align="" bgcolor="#ffffff" colspan="1" data-title="Statistical method" rowspan="1" valign=""> <p>Mean Difference (IV, Random, 95% CI)</p> </td> <td align="" bgcolor="#ffffff" colspan="1" data-title="Effect size" rowspan="1" valign=""> <p>0.00 [‐0.03, 0.03]</p> </td> </tr> <tr class="figure-image"> <td colspan="5"></td> </tr> <tr> <td align="" bgcolor="#ffffff" colspan="1" data-title="Outcome or subgroup title" rowspan="1" valign=""> <p class="subgroupTitle">1.7 Length of hospital stay <span class="subgroupLink"><b class="text-toggle-control">Show forest plot</b><i aria-hidden="true" class="fa fa-caret-down"></i></span></p> </td> <td align="" bgcolor="#ffffff" colspan="1" data-title="No. of studies" rowspan="1" valign=""> <p>2</p> </td> <td align="" bgcolor="#ffffff" colspan="1" data-title="No. of participants" rowspan="1" valign=""></td> <td align="" bgcolor="#ffffff" colspan="1" data-title="Statistical method" rowspan="1" valign=""> <p>Mean Difference (IV, Random, 95% CI)</p> </td> <td align="" bgcolor="#ffffff" colspan="1" data-title="Effect size" rowspan="1" valign=""> <p>Totals not selected</p> </td> </tr> <tr class="figure-image"> <td colspan="5"></td> </tr> <tr> <td align="" bgcolor="#ffffff" colspan="1" data-title="Outcome or subgroup title" rowspan="1" valign=""> <p class="subgroupTitle">1.8 Total amount of morphine for NAS <span class="subgroupLink"><b class="text-toggle-control">Show forest plot</b><i aria-hidden="true" class="fa fa-caret-down"></i></span></p> </td> <td align="" bgcolor="#ffffff" colspan="1" data-title="No. of studies" rowspan="1" valign=""> <p>2</p> </td> <td align="" bgcolor="#ffffff" colspan="1" data-title="No. of participants" rowspan="1" valign=""></td> <td align="" bgcolor="#ffffff" colspan="1" data-title="Statistical method" rowspan="1" valign=""> <p>Mean Difference (IV, Random, 95% CI)</p> </td> <td align="" bgcolor="#ffffff" colspan="1" data-title="Effect size" rowspan="1" valign=""> <p>Totals not selected</p> </td> </tr> <tr class="figure-image"> <td colspan="5"></td> </tr> <tr> <td align="" bgcolor="#ffffff" colspan="1" data-title="Outcome or subgroup title" rowspan="1" valign=""> <p class="subgroupTitle">1.9 Serious AE for the mother <span class="subgroupLink"><b class="text-toggle-control">Show forest plot</b><i aria-hidden="true" class="fa fa-caret-down"></i></span></p> </td> <td align="" bgcolor="#ffffff" colspan="1" data-title="No. of studies" rowspan="1" valign=""> <p>1</p> </td> <td align="" bgcolor="#ffffff" colspan="1" data-title="No. of participants" rowspan="1" valign=""> <p>175</p> </td> <td align="" bgcolor="#ffffff" colspan="1" data-title="Statistical method" rowspan="1" valign=""> <p>Risk Ratio (M‐H, Fixed, 95% CI)</p> </td> <td align="" bgcolor="#ffffff" colspan="1" data-title="Effect size" rowspan="1" valign=""> <p>1.69 [0.75, 3.83]</p> </td> </tr> <tr class="figure-image"> <td colspan="5"></td> </tr> <tr> <td align="" bgcolor="#ffffff" colspan="1" data-title="Outcome or subgroup title" rowspan="1" valign=""> <p class="subgroupTitle">1.10 Serious AE for the child <span class="subgroupLink"><b class="text-toggle-control">Show forest plot</b><i aria-hidden="true" class="fa fa-caret-down"></i></span></p> </td> <td align="" bgcolor="#ffffff" colspan="1" data-title="No. of studies" rowspan="1" valign=""> <p>1</p> </td> <td align="" bgcolor="#ffffff" colspan="1" data-title="No. of participants" rowspan="1" valign=""> <p>131</p> </td> <td align="" bgcolor="#ffffff" colspan="1" data-title="Statistical method" rowspan="1" valign=""> <p>Risk Ratio (M‐H, Fixed, 95% CI)</p> </td> <td align="" bgcolor="#ffffff" colspan="1" data-title="Effect size" rowspan="1" valign=""> <p>4.77 [0.59, 38.49]</p> </td> </tr> <tr class="figure-image"> <td colspan="5"></td> </tr> <tr> <td align="" bgcolor="#ffffff" colspan="1" data-title="Outcome or subgroup title" rowspan="1" valign=""> <p class="subgroupTitle">1.11 Non‐serious AE for the mother <span class="subgroupLink"><b class="text-toggle-control">Show forest plot</b><i aria-hidden="true" class="fa fa-caret-down"></i></span></p> </td> <td align="" bgcolor="#ffffff" colspan="1" data-title="No. of studies" rowspan="1" valign=""> <p>1</p> </td> <td align="" bgcolor="#ffffff" colspan="1" data-title="No. of participants" rowspan="1" valign=""> <p>175</p> </td> <td align="" bgcolor="#ffffff" colspan="1" data-title="Statistical method" rowspan="1" valign=""> <p>Risk Ratio (M‐H, Fixed, 95% CI)</p> </td> <td align="" bgcolor="#ffffff" colspan="1" data-title="Effect size" rowspan="1" valign=""> <p>1.22 [1.07, 1.38]</p> </td> </tr> <tr class="figure-image"> <td colspan="5"></td> </tr> <tr> <td align="" bgcolor="#ffffff" colspan="1" data-title="Outcome or subgroup title" rowspan="1" valign=""> <p class="subgroupTitle">1.12 Non‐serious AE for the child <span class="subgroupLink"><b class="text-toggle-control">Show forest plot</b><i aria-hidden="true" class="fa fa-caret-down"></i></span></p> </td> <td align="" bgcolor="#ffffff" colspan="1" data-title="No. of studies" rowspan="1" valign=""> <p>1</p> </td> <td align="" bgcolor="#ffffff" colspan="1" data-title="No. of participants" rowspan="1" valign=""> <p>131</p> </td> <td align="" bgcolor="#ffffff" colspan="1" data-title="Statistical method" rowspan="1" valign=""> <p>Risk Ratio (M‐H, Fixed, 95% CI)</p> </td> <td align="" bgcolor="#ffffff" colspan="1" data-title="Effect size" rowspan="1" valign=""> <p>1.08 [0.74, 1.59]</p> </td> </tr> <tr class="figure-image"> <td colspan="5"></td> </tr> </tbody> </table> <div class="scolaris-modal-title">Figures and Tables - </div> <div class="table-viewer-caption"> <div class="table-heading"><span class="table-label">Comparison 1.</span> <span class="table-title">Methadone versus buprenorphine</span></div> </div> <div class="tools"><a class="tableList" href="/cdsr/doi/10.1002/14651858.CD006318.pub4/references#CD006318-tbl-0003">Navigate to table in review</a></div> </div> <div class="table"> <table class="comparison" data-id="CD006318-tbl-0004"> <div class="table-heading"><span class="table-label">Comparison 2.</span> <span class="table-title">Methadone versus oral slow‐release morphine</span></div> <thead> <tr> <td align="" bgcolor="#ffffff" colspan="1" data-title="Outcome or subgroup title" rowspan="1" valign=""> <p>Outcome or subgroup title</p> </td> <td align="" bgcolor="#ffffff" colspan="1" data-title="No. of studies" rowspan="1" valign=""> <p>No. of studies</p> </td> <td align="" bgcolor="#ffffff" colspan="1" data-title="No. of participants" rowspan="1" valign=""> <p>No. of participants</p> </td> <td align="" bgcolor="#ffffff" colspan="1" data-title="Statistical method" rowspan="1" valign=""> <p>Statistical method</p> </td> <td align="" bgcolor="#ffffff" colspan="1" data-title="Effect size" rowspan="1" valign=""> <p>Effect size</p> </td> </tr> </thead> <tbody> <tr> <td align="" bgcolor="#ffffff" colspan="1" data-title="Outcome or subgroup title" rowspan="1" valign=""> <p class="subgroupTitle">2.1 Use of primary substance <span class="subgroupLink"><b class="text-toggle-control">Show forest plot</b><i aria-hidden="true" class="fa fa-caret-down"></i></span></p> </td> <td align="" bgcolor="#ffffff" colspan="1" data-title="No. of studies" rowspan="1" valign=""> <p>1</p> </td> <td align="" bgcolor="#ffffff" colspan="1" data-title="No. of participants" rowspan="1" valign=""> <p>48</p> </td> <td align="" bgcolor="#ffffff" colspan="1" data-title="Statistical method" rowspan="1" valign=""> <p>Risk Ratio (M‐H, Fixed, 95% CI)</p> </td> <td align="" bgcolor="#ffffff" colspan="1" data-title="Effect size" rowspan="1" valign=""> <p>2.40 [1.00, 5.77]</p> </td> </tr> <tr class="figure-image"> <td colspan="5"></td> </tr> <tr> <td align="" bgcolor="#ffffff" colspan="1" data-title="Outcome or subgroup title" rowspan="1" valign=""> <p class="subgroupTitle">2.2 Birth weight <span class="subgroupLink"><b class="text-toggle-control">Show forest plot</b><i aria-hidden="true" class="fa fa-caret-down"></i></span></p> </td> <td align="" bgcolor="#ffffff" colspan="1" data-title="No. of studies" rowspan="1" valign=""> <p>1</p> </td> <td align="" bgcolor="#ffffff" colspan="1" data-title="No. of participants" rowspan="1" valign=""> <p>48</p> </td> <td align="" bgcolor="#ffffff" colspan="1" data-title="Statistical method" rowspan="1" valign=""> <p>Mean Difference (IV, Fixed, 95% CI)</p> </td> <td align="" bgcolor="#ffffff" colspan="1" data-title="Effect size" rowspan="1" valign=""> <p>124.00 [‐186.94, 434.94]</p> </td> </tr> <tr class="figure-image"> <td colspan="5"></td> </tr> <tr> <td align="" bgcolor="#ffffff" colspan="1" data-title="Outcome or subgroup title" rowspan="1" valign=""> <p class="subgroupTitle">2.3 NAS mean duration <span class="subgroupLink"><b class="text-toggle-control">Show forest plot</b><i aria-hidden="true" class="fa fa-caret-down"></i></span></p> </td> <td align="" bgcolor="#ffffff" colspan="1" data-title="No. of studies" rowspan="1" valign=""> <p>1</p> </td> <td align="" bgcolor="#ffffff" colspan="1" data-title="No. of participants" rowspan="1" valign=""> <p>48</p> </td> <td align="" bgcolor="#ffffff" colspan="1" data-title="Statistical method" rowspan="1" valign=""> <p>Mean Difference (IV, Fixed, 95% CI)</p> </td> <td align="" bgcolor="#ffffff" colspan="1" data-title="Effect size" rowspan="1" valign=""> <p>‐5.00 [‐10.97, 0.97]</p> </td> </tr> <tr class="figure-image"> <td colspan="5"></td> </tr> <tr> <td align="" bgcolor="#ffffff" colspan="1" data-title="Outcome or subgroup title" rowspan="1" valign=""> <p class="subgroupTitle">2.4 Nicotine consumption <span class="subgroupLink"><b class="text-toggle-control">Show forest plot</b><i aria-hidden="true" class="fa fa-caret-down"></i></span></p> </td> <td align="" bgcolor="#ffffff" colspan="1" data-title="No. of studies" rowspan="1" valign=""> <p>1</p> </td> <td align="" bgcolor="#ffffff" colspan="1" data-title="No. of participants" rowspan="1" valign=""> <p>48</p> </td> <td align="" bgcolor="#ffffff" colspan="1" data-title="Statistical method" rowspan="1" valign=""> <p>Mean Difference (IV, Fixed, 95% CI)</p> </td> <td align="" bgcolor="#ffffff" colspan="1" data-title="Effect size" rowspan="1" valign=""> <p>4.43 [‐1.47, 10.33]</p> </td> </tr> <tr class="figure-image"> <td colspan="5"></td> </tr> </tbody> </table> <div class="scolaris-modal-title">Figures and Tables - </div> <div class="table-viewer-caption"> <div class="table-heading"><span class="table-label">Comparison 2.</span> <span class="table-title">Methadone versus oral slow‐release morphine</span></div> </div> <div class="tools"><a class="tableList" href="/cdsr/doi/10.1002/14651858.CD006318.pub4/references#CD006318-tbl-0004">Navigate to table in review</a></div> </div> </div> <noscript> <img height="1" src="/scolaris-auth/report/nonjs/fulltexthtmlreg?doi=10.1002%2F14651858.CD006318.pub4&amp;rf=&amp;articleType=CDSR" style="display:none" width="1"> </img></noscript> <section class="translation-notes-modal" data-modal-class="translation-notes" data-modal-title="Translation notes" data-ok-btn-selector=".ok-btn" style="display: none"> <div class="translation-notes"> <div class="section-language-toggles"> <nav class="section-languages"> <ul> <li class="section-languages-legend">Available in</li> <li class="section-language"> <a class="" href="de#CD006318-note-0005">Deutsch</a> </li> <li class="section-language"> <a class="" href="es#CD006318-note-0014">Español</a> </li> <li class="section-language"> <a class="" href="fa#CD006318-note-0011">فارسی</a> </li> <li class="section-language"> <a class="" href="fr#CD006318-note-0012">Français</a> </li> <li class="section-language"> <a class="" href="ja#CD006318-note-0010">日本語</a> </li> <li class="section-language"> <a class="" href="ko#CD006318-note-0008">한국어</a> </li> <li class="section-language"> <a class="" href="ms#CD006318-note-0009">Bahasa Malaysia</a> </li> <li class="section-language"> <a class="" href="pl#CD006318-note-0013">Polski</a> </li> <li class="section-language"> <a class="" href="ru#CD006318-note-0007">Русский</a> </li> <li class="section-language"> <a class="" href="zh_HANS#CD006318-note-0004">简体中文</a> </li> <li class="section-language"> <a class="" href="zh_HANT#CD006318-note-0006">繁體中文</a> </li> </ul> </nav> </div> <section class="translation-notes-content"> </section> <button class="btn primary ok-btn pull-right" type="button">Close</button> </div> </section></article> </div> <div class="citation-modal" style="display: none"> <div class="export-citation-header"> <p class="inset-message" data-load-error="Unable to load citation data" id="citeProcText"></p> </div> <div class="export-citation-body row-fluid"> <div class="span12"> <div class="addthis_toolbox addthis_default_style addthis_16x16_style"> <nav class="inline-nav-list is-bordered"> <li> <h4 class="heading">Save citation to:</h4> </li> <li><a class="citation-btn-refworks at300b btn btn-link" href="#" id="refWorksCitationBtn"><span class="citation-icon refworks"></span>RefWorks</a></li> <li><a class="citation-btn-sciwheel at300b btn btn-link disabled" href="#" id="sciWheelCitationBtn" target="_blank"><span class="citation-icon sciwheel"></span>SciWheel</a></li> </nav> </div> </div> </div> <div class="row-fluid"> <div class="span12"> <div class="citation-format"> <h4>Copy or download citation</h4> <a href="/en/help/exporting-search-results" rel="noopener noreferrer" target="_blank">Export help</a> </div> <nav class="inline-nav-list has-dividers"> <li class="citation-option" data-option="plain"><button class="btn btn-link" type="button">Plain text</button></li> <li class="citation-option" data-option="endnote"><button class="btn btn-link" type="button">EndNote</button></li> <li class="citation-option" data-option="refmanager"><button class="btn btn-link" type="button">Reference Manager</button></li> <li class="citation-option" data-option="procite"><button class="btn btn-link" type="button">ProCite</button></li> <li class="citation-option" data-option="bibtex"><button class="btn btn-link" type="button">BibteX</button></li> <li class="citation-option" data-option="csv"><button class="btn btn-link" type="button">CSV (Excel)</button></li> </nav> <div class="citation-content"> <pre data-load-error="Unable to load citation data" id="citationContent" tabindex="0"></pre> </div> <div class="clearfix"> <form class="download-citation-form" data-citation-citeproc-url="https://www.cochranelibrary.com/en/content?p_p_id=scolariscontentdisplay_WAR_scolariscontentdisplay&amp;p_p_lifecycle=2&amp;p_p_state=normal&amp;p_p_mode=view&amp;p_p_resource_id=citation-citeproc&amp;p_p_cacheability=cacheLevelPage&amp;p_p_col_id=column-1&amp;p_p_col_count=1" method="GET" target="citation-download-iframe"> <input id="siteId" name="siteId" type="hidden" value=""> <input id="downloadType" name="downloadType" type="hidden" value=""> <input id="style" name="style" type="hidden" value=""> <input id="articleId" name="articleId" type="hidden" value=""> <input name="p_p_id" type="hidden" value="scolariscontentdisplay_WAR_scolariscontentdisplay"><input name="p_p_lifecycle" type="hidden" value="2"><input name="p_p_state" type="hidden" value="normal"><input name="p_p_mode" type="hidden" value="view"/><input name="p_p_resource_id" type="hidden" value="citation-download"/><input name="p_p_cacheability" type="hidden" value="cacheLevelPage"/><input name="p_p_col_id" type="hidden" value="column-1"/><input name="p_p_col_count" type="hidden" value="1"/> <button class="btn primary wide pull-right" type="submit">Download</button> <div class="inline-checkbox pull-right"> <label title=" for=" withabstract"=""> <input checked="" class="checkbox" name="withAbstract" type="checkbox"/> <span class="checkbox-label">Include abstract</span> </label> </div> </input></input></input></input></input></input></input></form> <iframe aria-hidden="true" name="citation-download-iframe" src="" style="display: none; visibility: hidden" title="Citation download frame"></iframe> </div> </div> </div> </div> <div class="print-modal" data-modal-title="Print this review" style="display: none;"> <div class="print-options-wrapper"> <p><strong>All sections are selected by default</strong>, please select the sections you do not wish to print or use the select or deselect all button to add or remove sections.</p> <div class="print-options-controls"> <input checked="checked" class="print-options-select-all" title="Select/deselect all" type="checkbox"/> <span class="checkbox-label">Select/deselect all</span> </div> <ul class="print-options checkbox-list"> </ul> <button class="btn primary print-article pull-right"><i aria-hidden="true" class="fa fa-print"></i> Print</button> </div> </div> <div class="download-stats-data-modal" data-modal-title="Download data package" style="display: none;"> <div> <p> The data available are protected by copyright and may only be used in accordance with the <a class="external" href="/about/data-download" target="_blank">Terms and Conditions.</a> </p> <div class="hide-for-zip"> <p> <a class="external" href="https://revman.cochrane.org/#/rm5Converter" target="_blank">RevMan 5 files</a> can be converted to a <a class="external" href="https://links.cochrane.org/review-datapack-userguide" target="_blank">data package.</a> </p> </div> <p> Files in the data package can be imported to <a class="external" href="https://revman.cochrane.org/info" target="_blank">Review Manager software</a> or opened in other tools that support CSV and RIS. </p> <form class="download-stats-data-form" method="GET" target="_blank"> <input name="content-disposition" type="hidden" value="attachment"/> <input name="mime-type" type="hidden" value="application/octet-stream"/> <p class="print-options-controls"> <input aria-label="I agree to these terms and conditions" class="download-stats-data-toc-check-box" type="checkbox"/> <span aria-hidden="true" class="checkbox-label">I agree to these terms and conditions</span> <button class="btn primary download-stats-data pull-right" disabled=""><i aria-hidden="true" class="fa fa-download"></i> Download data</button> </p> </form> </div> </div> <div class="share-modal" data-modal-title="Share this review" style="display:none;"> </div> <div class="viewer-thumbnail-pane-html" style="display:none;"> <div class="figure-viewer-options"> <nav class="inline-nav-list"> <li class="figure-options-btn-container"><button class="btn btn-link" id="figureOptionBtn" type="button">Figures</button></li> <li class="table-options-btn-container"><button class="btn btn-link" id="tableOptionBtn" type="button">Tables</button></li> </nav> </div> <div class="figure-viewer-thumbnails"> <div class="figure-thumbnails is-visible" id="figureThumbnails"></div> <div class="table-thumbnails" id="tableThumbnails"></div> </div> </div> <div class="utilities-html" style="display:none;"> <div class="figure-viewer-utilities"> <a class="figure-viewer-menu-toggle" href="#"> <i class="fa fa-chevron-left"></i><span class="toggle-label" data-figure-hide-text="Hide thumbnails" data-figure-show-text="Show thumbnails" data-table-hide-text="Hide table list" data-table-show-text="Show table list">Hide thumbnails</span> </a> <a class="figure-viewer-navigateback" href="#"> <i class="fa fa-chevron-left"></i> </a> <a class="figure-viewer-rotate" href="#"> <i class="fa fa-undo"></i> </a> <a class="figure-viewer-download" href="#"> <i class="fa fa-download"></i> </a> <a class="figure-viewer-share" href="#"> <i class="fa fa-share-alt"></i> </a> <a class="figure-viewer-zoomin" href="#"> <i class="fa fa-plus"></i><span>zoom in</span> </a> <a class="figure-viewer-zoomout" href="#"> <i class="fa fa-minus"></i><span>zoom out</span> </a> </div> </div> <div class="controls-html" style="display:none;"> <div class="figure-viewer-navigation"> <a class="figure-viewer-nav previous" href="#"> <i class="fa fa-chevron-left"></i><span>left</span> </a> <a class="figure-viewer-nav next" href="#"> <i class="fa fa-chevron-right"></i><span>right</span> </a> </div> </div> <div class="mobile-thumbnail-selector-html" style="display:none;"> <div class="figure-viewer-mobile-thumbnails"> <select class="figure-selection"> <option>Figures</option> </select> <select class="table-selection"> <option>Tables</option> </select> </div> </div> </div> </div> </div> <div style="display:none"> <input id="freelabel" name="freelabel" type="hidden" value="Free access"/>
<input id="openlabel" name="openlabel" type="hidden" value="Open access"/>
</div>
</section>
</div>
</div>
</div>
</div>
</div>
<div class="portlet-boundary portlet-boundary_1_WAR_kaleodesignerportlet_ portlet-static portlet-static-end kaleo-designer-portlet" id="p_p_id_1_WAR_kaleodesignerportlet_">
<span id="p_1_WAR_kaleodesignerportlet"></span>
</div>
<form action="#" id="hrefFm" method="post" name="hrefFm">
<span></span>
</form>
</div>
<footer class="footer">
<div class="main-footer">
<div class="main-footer-wrapper container">
<div class="brand">
<p class="brand-name">Cochrane</p>
<a href="http://www.cochrane.org/" title="Cochrane logo">
<img alt="Cochrane logo" class="footer-logo logo-part-1" src="https://www.cochranelibrary.com/cochrane-theme/images/footer-logo-part-1.png"> <img alt="" class="footer-logo logo-part-2" src="https://www.cochranelibrary.com/cochrane-theme/images/footer-logo-part-2.png"> </img></img></a> </div> </div> </div> <div class="aux-footer"> <div class="aux-footer-nav-container container"> <nav class="aux-footer-nav"> <ul class="aux-footer-nav-list"> <li><a class="aux-footer-nav-link" href="https://onlinelibrary.wiley.com/">Browse Publications</a></li> <li><a class="aux-footer-nav-link" href="https://onlinelibrary.wiley.com/">Browse by Subject</a></li> </ul> <ul class="aux-footer-nav-list"> <li><a class="aux-footer-nav-link" href="https://onlinelibrary.wiley.com/advertisers">Advertisers &amp; Agents</a></li> <li><a class="aux-footer-nav-link" href="https://hub.wiley.com/community/support/cochrane-library">Contact Us</a></li> </ul> <ul class="aux-footer-nav-list"> <li><a class="aux-footer-nav-link" href="https://hub.wiley.com/community/support/cochrane-library">Help &amp; Support</a></li> <li><a class="aux-footer-nav-link" href="https://onlinelibrary.wiley.com/terms-and-conditions">Terms &amp; Conditions</a></li> </ul> </nav> </div> <div class="brand"> <div class="brand-container container"> <p class="copyright"> Copyright © 2000 - 2025 by <a class="" href="http://www.wiley.com">John Wiley &amp; Sons, Inc.</a> All Rights Reserved <br> Review our <a href="https://www.wiley.com/privacy"><strong>Privacy Policy</strong></a> <a href="https://www.wiley.com/cookies"><strong>Cookie Policy</strong></a> <a href="#" onclick="Osano.cm.showDrawer('osano-cm-dom-info-dialog-open')"><strong>Cookie Preferences</strong></a> </br></p> <a href="http://eu.wiley.com/"><img alt="Wiley logo" class="logo" src="https://www.cochranelibrary.com/cochrane-theme/images/en-US_wiley-footer-logo.png"/></a> </div> </div> <span class="wiley-semi-circle"></span> </div> <!--BEGIN QUALTRICS WEBSITE FEEDBACK SNIPPET--> <script type="text/javascript"> (function(){var g=function(e,h,f,g){ this.get=function(a){for(var a=a+"=",c=document.cookie.split(";"),b=0,e=c.length;b<e;b++){for(var d=c[b];" "==d.charAt(0);)d=d.substring(1,d.length);if(0==d.indexOf(a))return d.substring(a.length,d.length)}return null}; this.set=function(a,c){var b="",b=new Date;b.setTime(b.getTime()+6048E5);b="; expires="+b.toGMTString();document.cookie=a+"="+c+b+"; path=/; "}; this.check=function(){var a=this.get(f);if(a)a=a.split(":");else if(100!=e)"v"==h&&(e=Math.random()>=e/100?0:100),a=[h,e,0],this.set(f,a.join(":"));else return!0;var c=a[1];if(100==c)return!0;switch(a[0]){case "v":return!1;case "r":return c=a[2]%Math.floor(100/c),a[2]++,this.set(f,a.join(":")),!c}return!0}; this.go=function(){if(this.check()){var a=document.createElement("script");a.type="text/javascript";a.src=g;document.body&&document.body.appendChild(a)}}; this.start=function(){var t=this;"complete"!==document.readyState?window.addEventListener?window.addEventListener("load",function(){t.go()},!1):window.attachEvent&&window.attachEvent("onload",function(){t.go()}):t.go()};}; try{(new g(100,"r","QSI_S_ZN_cGCHHvWNpnJb1zf","https://zncgchhvwnpnjb1zf-wiley.siteintercept.qualtrics.com/SIE/?Q_ZID=ZN_cGCHHvWNpnJb1zf")).start()}catch(i){}})(); </script><div id="ZN_cGCHHvWNpnJb1zf"><!--DO NOT REMOVE-CONTENTS PLACED HERE--></div> <!--END WEBSITE FEEDBACK SNIPPET--> </footer> <div class="scolaris-modal-overlay"></div> <div class="scolaris-modal"> <div class="scolaris-modal-titlebar clearfix"> <p class="scolaris-modal-title"></p> <a class="scolaris-modal-close" href="#"><span>close</span><span class="icon fa fa-times"></span></a> <div class="scolaris-modal-ui"></div> </div> <!-- Static injection of addtoAny as dynamic injection not working properly--> <div class="scolaris-share-modal-content clearfix"> <div class="scolaris-modal-ui clearfix"> <div class="a2a_kit a2a_kit_size_32 a2a_default_style"> <a class="a2a_button_facebook share-button">  Facebook</a> <a class="a2a_button_x share-button">  X(Twitter)</a> <a class="a2a_button_whatsapp share-button">  WhatsApp</a> <a class="a2a_dd share-button">  View more</a> </div> </div> </div> <div class="scolaris-modal-content clearfix"> <div class="scolaris-modal-ui clearfix"></div> </div> <div class="scolaris-modal-ui clearfix"></div> </div> <div class="english-only-modal-wrapper" data-modal-class="english-only-modal" data-modal-title="Feature in English only" style="display: none"> <div class="english-only-modal"> <p class="message"></p> <button class="btn primary ok-btn pull-right" type="button">OK</button> <button class="btn primary border-only cancel-btn pull-right" type="button">Cancel</button> </div> </div> <!--[if gte IE 9]><!--> <script src="/cochrane-theme/vendor/ie9.js?t=1738734064000" type="text/javascript"></script> <!--<![endif]--> <script src="https://www.cochranelibrary.com/cochrane-theme/js/theme.js?t=1738734064000" type="text/javascript"></script> <script src="https://content.readcube.com/cochrane/checkout.js"></script> <script src="https://content.readcube.com/cochrane/epdf_linker.js" type="text/javascript"></script> <script src="https://crossmark-cdn.crossref.org/widget/v2.0/widget.js" type="text/javascript"></script> <script src="https://d1bxh8uas1mnw7.cloudfront.net/assets/embed.js" type="text/javascript"></script> <script src="https://www.cochranelibrary.com/scolaris-content-display/js/hit-highlighting.js?browserId=other&amp;minifierType=js&amp;languageId=en_US&amp;b=6210&amp;t=1739772750000" type="text/javascript"></script> <script src="https://www.cochranelibrary.com/scolaris-content-display/js/topics-lookup.js?browserId=other&amp;minifierType=js&amp;languageId=en_US&amp;b=6210&amp;t=1739772750000" type="text/javascript"></script> <script src="https://www.cochranelibrary.com/scolaris-content-display/js/institution.js?browserId=other&amp;minifierType=js&amp;languageId=en_US&amp;b=6210&amp;t=1739772750000" type="text/javascript"></script> <script src="https://www.cochranelibrary.com/scolaris-content-display/js/api-manager.js?browserId=other&amp;minifierType=js&amp;languageId=en_US&amp;b=6210&amp;t=1739772750000" type="text/javascript"></script> <script src="https://www.cochranelibrary.com/scolaris-content-display/js/pico.js?browserId=other&amp;minifierType=js&amp;languageId=en_US&amp;b=6210&amp;t=1739772750000" type="text/javascript"></script> <script src="https://www.cochranelibrary.com/scolaris-content-display/js/reference-linking.js?browserId=other&amp;minifierType=js&amp;languageId=en_US&amp;b=6210&amp;t=1739772750000" type="text/javascript"></script> <script src="https://www.cochranelibrary.com/scolaris-content-display/js/rightsLink.js?browserId=other&amp;minifierType=js&amp;languageId=en_US&amp;b=6210&amp;t=1739772750000" type="text/javascript"></script> <script src="https://www.cochranelibrary.com/scolaris-content-display/js/ui.submit.failed.js?browserId=other&amp;minifierType=js&amp;languageId=en_US&amp;b=6210&amp;t=1739772750000" type="text/javascript"></script> <script src="https://www.cochranelibrary.com/scolaris-content-display/js/ui.comment.form.js?browserId=other&amp;minifierType=js&amp;languageId=en_US&amp;b=6210&amp;t=1739772750000" type="text/javascript"></script> <script src="https://www.cochranelibrary.com/scolaris-content-display/js/safety-alerts.js?browserId=other&amp;minifierType=js&amp;languageId=en_US&amp;b=6210&amp;t=1739772750000" type="text/javascript"></script> <script src="https://www.cochranelibrary.com/scolaris-content-display/js/ui.translation-notes-modal.js?browserId=other&amp;minifierType=js&amp;languageId=en_US&amp;b=6210&amp;t=1739772750000" type="text/javascript"></script> <script src="https://www.cochranelibrary.com/scolaris-content-display/js/main.js?browserId=other&amp;minifierType=js&amp;languageId=en_US&amp;b=6210&amp;t=1739772750000" type="text/javascript"></script> <script src="https://www.cochranelibrary.com/notifications-portlet/notifications/js/main.js?browserId=other&amp;minifierType=js&amp;languageId=en_US&amp;b=6210&amp;t=1739772751000" type="text/javascript"></script> <script src="https://www.cochranelibrary.com/scolaris-search/js/main.js?browserId=other&amp;minifierType=js&amp;languageId=en_US&amp;b=6210&amp;t=1739772894000" type="text/javascript"></script> <script src="https://www.cochranelibrary.com/scolaris-topics/js/main.js?browserId=other&amp;minifierType=js&amp;languageId=en_US&amp;b=6210&amp;t=1739772894000" type="text/javascript"></script> <script src="https://www.cochranelibrary.com/scolaris-language-portlet/js/main.js?browserId=other&amp;minifierType=js&amp;languageId=en_US&amp;b=6210&amp;t=1739772746000" type="text/javascript"></script> <script type="text/javascript">Liferay.Util.addInputFocus();</script> <script type="text/javascript">Liferay.Portlet.register("scolarislanguageselector_WAR_scolarislanguageportlet_INSTANCE_header");Liferay.Portlet.onLoad({canEditTitle:false,columnPos:0,isStatic:"end",namespacedId:"p_p_id_scolarislanguageselector_WAR_scolarislanguageportlet_INSTANCE_header_",portletId:"scolarislanguageselector_WAR_scolarislanguageportlet_INSTANCE_header",refreshURL:"\x2fen\x2fc\x2fportal\x2frender_portlet\x3fp_l_id\x3d20757\x26p_p_id\x3dscolarislanguageselector_WAR_scolarislanguageportlet_INSTANCE_header\x26p_p_lifecycle\x3d0\x26p_t_lifecycle\x3d0\x26p_p_state\x3dnormal\x26p_p_mode\x3dview\x26p_p_col_id\x3dnull\x26p_p_col_pos\x3dnull\x26p_p_col_count\x3dnull\x26p_p_static\x3d1\x26p_p_isolated\x3d1\x26currentURL\x3d\x252Fweb\x252Fcochrane\x252Fcontent\x253FtemplateType\x253Dfull\x2526urlTitle\x253D\x252Fcdsr\x252Fdoi\x252F10\x2e1002\x252F14651858\x2eCD006318\x2epub4\x2526doi\x253D10\x2e1002\x252F14651858\x2eCD006318\x2epub4\x2526type\x253Dcdsr\x2526contentLanguage\x253D\x26templateType\x3dfull\x26urlTitle\x3d\x252Fcdsr\x252Fdoi\x252F10\x2e1002\x252F14651858\x2eCD006318\x2epub4\x26contentLanguage\x3d\x26type\x3dcdsr\x26doi\x3d10\x2e1002\x252F14651858\x2eCD006318\x2epub4"});Liferay.Portlet.register("scolariscontentdisplay_WAR_scolariscontentdisplay");Liferay.Portlet.onLoad({canEditTitle:false,columnPos:0,isStatic:"end",namespacedId:"p_p_id_scolariscontentdisplay_WAR_scolariscontentdisplay_",portletId:"scolariscontentdisplay_WAR_scolariscontentdisplay",refreshURL:"\x2fen\x2fc\x2fportal\x2frender_portlet\x3fp_l_id\x3d20757\x26p_p_id\x3dscolariscontentdisplay_WAR_scolariscontentdisplay\x26p_p_lifecycle\x3d0\x26p_t_lifecycle\x3d0\x26p_p_state\x3dnormal\x26p_p_mode\x3dview\x26p_p_col_id\x3dcolumn-1\x26p_p_col_pos\x3d0\x26p_p_col_count\x3d1\x26p_p_isolated\x3d1\x26currentURL\x3d\x252Fweb\x252Fcochrane\x252Fcontent\x253FtemplateType\x253Dfull\x2526urlTitle\x253D\x252Fcdsr\x252Fdoi\x252F10\x2e1002\x252F14651858\x2eCD006318\x2epub4\x2526doi\x253D10\x2e1002\x252F14651858\x2eCD006318\x2epub4\x2526type\x253Dcdsr\x2526contentLanguage\x253D"});Liferay.provide(Liferay.Util,"openKaleoDesignerPortlet",function(c){var b=AUI();var e=Liferay.PortletURL.createURL("https://www.cochranelibrary.com/en/content?p_p_id=2_WAR_kaleodesignerportlet&p_p_lifecycle=0");e.setParameter("mvcPath","/designer/edit_kaleo_draft_definition.jsp");e.setParameter("availableFields",c.availableFields);e.setParameter("availablePropertyModels",c.availablePropertyModels);e.setParameter("ddmStructureId",c.ddmStructureId);e.setParameter("draftVersion",c.draftVersion);e.setParameter("kaleoProcessId",c.kaleoProcessId);e.setParameter("name",c.name);e.setParameter("openerWindowName",c.openerWindowName);e.setParameter("portletResourceNamespace",c.portletResourceNamespace);e.setParameter("propertiesSaveCallback",c.propertiesSaveCallback);e.setParameter("refreshOpenerOnClose",c.refreshOpenerOnClose);e.setParameter("saveCallback",c.saveCallback);e.setParameter("version",c.version);e.setWindowState("pop_up");c.uri=e.toString();var d=c.dialog;if(!d){var f=b.one(Liferay.Util.getOpener()).get("region");d={destroyOnHide:true};c.dialog=d}if(!("align" in d)){d.align=Liferay.Util.Window.ALIGN_CENTER}var a=c.dialogIframe;if(!a){a={closeOnEscape:false};c.dialogIframe=a}Liferay.Util.openWindow(c)},["liferay-portlet-url"]);Liferay.Portlet.register("1_WAR_kaleodesignerportlet");Liferay.Portlet.onLoad({canEditTitle:false,columnPos:0,isStatic:"end",namespacedId:"p_p_id_1_WAR_kaleodesignerportlet_",portletId:"1_WAR_kaleodesignerportlet",refreshURL:"\x2fen\x2fc\x2fportal\x2frender_portlet\x3fp_l_id\x3d20757\x26p_p_id\x3d1_WAR_kaleodesignerportlet\x26p_p_lifecycle\x3d0\x26p_t_lifecycle\x3d0\x26p_p_state\x3dnormal\x26p_p_mode\x3dview\x26p_p_col_id\x3dnull\x26p_p_col_pos\x3dnull\x26p_p_col_count\x3dnull\x26p_p_static\x3d1\x26p_p_isolated\x3d1\x26currentURL\x3d\x252Fweb\x252Fcochrane\x252Fcontent\x253FtemplateType\x253Dfull\x2526urlTitle\x253D\x252Fcdsr\x252Fdoi\x252F10\x2e1002\x252F14651858\x2eCD006318\x2epub4\x2526doi\x253D10\x2e1002\x252F14651858\x2eCD006318\x2epub4\x2526type\x253Dcdsr\x2526contentLanguage\x253D\x26templateType\x3dfull\x26urlTitle\x3d\x252Fcdsr\x252Fdoi\x252F10\x2e1002\x252F14651858\x2eCD006318\x2epub4\x26contentLanguage\x3d\x26type\x3dcdsr\x26doi\x3d10\x2e1002\x252F14651858\x2eCD006318\x2epub4"});Liferay.Portlet.register("scolarissearchportlet_WAR_scolarissearch");Liferay.Portlet.onLoad({canEditTitle:false,columnPos:0,isStatic:"end",namespacedId:"p_p_id_scolarissearchportlet_WAR_scolarissearch_",portletId:"scolarissearchportlet_WAR_scolarissearch",refreshURL:"\x2fen\x2fc\x2fportal\x2frender_portlet\x3fp_l_id\x3d20757\x26p_p_id\x3dscolarissearchportlet_WAR_scolarissearch\x26p_p_lifecycle\x3d0\x26p_t_lifecycle\x3d0\x26p_p_state\x3dnormal\x26p_p_mode\x3dview\x26p_p_col_id\x3dnull\x26p_p_col_pos\x3dnull\x26p_p_col_count\x3dnull\x26p_p_static\x3d1\x26p_p_isolated\x3d1\x26currentURL\x3d\x252Fweb\x252Fcochrane\x252Fcontent\x253FtemplateType\x253Dfull\x2526urlTitle\x253D\x252Fcdsr\x252Fdoi\x252F10\x2e1002\x252F14651858\x2eCD006318\x2epub4\x2526doi\x253D10\x2e1002\x252F14651858\x2eCD006318\x2epub4\x2526type\x253Dcdsr\x2526contentLanguage\x253D\x26templateType\x3dfull\x26urlTitle\x3d\x252Fcdsr\x252Fdoi\x252F10\x2e1002\x252F14651858\x2eCD006318\x2epub4\x26contentLanguage\x3d\x26type\x3dcdsr\x26doi\x3d10\x2e1002\x252F14651858\x2eCD006318\x2epub4"});Liferay.Portlet.register("scolariscontentlanguagebanner_WAR_scolarislanguageportlet");Liferay.Portlet.onLoad({canEditTitle:false,columnPos:0,isStatic:"end",namespacedId:"p_p_id_scolariscontentlanguagebanner_WAR_scolarislanguageportlet_",portletId:"scolariscontentlanguagebanner_WAR_scolarislanguageportlet",refreshURL:"\x2fen\x2fc\x2fportal\x2frender_portlet\x3fp_l_id\x3d20757\x26p_p_id\x3dscolariscontentlanguagebanner_WAR_scolarislanguageportlet\x26p_p_lifecycle\x3d0\x26p_t_lifecycle\x3d0\x26p_p_state\x3dnormal\x26p_p_mode\x3dview\x26p_p_col_id\x3dnull\x26p_p_col_pos\x3dnull\x26p_p_col_count\x3dnull\x26p_p_static\x3d1\x26p_p_isolated\x3d1\x26currentURL\x3d\x252Fweb\x252Fcochrane\x252Fcontent\x253FtemplateType\x253Dfull\x2526urlTitle\x253D\x252Fcdsr\x252Fdoi\x252F10\x2e1002\x252F14651858\x2eCD006318\x2epub4\x2526doi\x253D10\x2e1002\x252F14651858\x2eCD006318\x2epub4\x2526type\x253Dcdsr\x2526contentLanguage\x253D\x26templateType\x3dfull\x26urlTitle\x3d\x252Fcdsr\x252Fdoi\x252F10\x2e1002\x252F14651858\x2eCD006318\x2epub4\x26contentLanguage\x3d\x26type\x3dcdsr\x26doi\x3d10\x2e1002\x252F14651858\x2eCD006318\x2epub4"});AUI().use("aui-base","liferay-menu","liferay-notice","liferay-poller","liferay-session",function(a){(function(){Liferay.Util.addInputType();Liferay.Portlet.ready(function(b,c){Liferay.Util.addInputType(c)});if(a.UA.mobile){Liferay.Util.addInputCancel()}})();(function(){new Liferay.Menu();var b=Liferay.Data.notices;for(var c=1;c<b.length;c++){new Liferay.Notice(b[c])}})();(function(){Liferay.Session=new Liferay.SessionBase({autoExtend:true,sessionLength:1800,redirectOnExpire:false,redirectUrl:"https\x3a\x2f\x2fwww\x2ecochranelibrary\x2ecom\x2fweb\x2fcochrane",warningLength:0})})()});</script> <script src="https://www.cochranelibrary.com/cochrane-theme/js/main.js?browserId=other&amp;minifierType=js&amp;languageId=en_US&amp;b=6210&amp;t=1738734064000" type="text/javascript"></script> <script type="text/javascript"></script> <div class="mobile-righthand-nav"> <a class="rh-nav-close-btn" href="#"> <span>Close</span> <span class="fa fa-chevron-down"></span> </a> <div class="wrapper"> </div> <a class="rh-nav-open-btn" href="#"> <span>Review tools &amp; navigation</span> </a> </div> <iframe aria-hidden="true" id="printframe" name="printframe" style="position: absolute; left: -2000px; top: 0;" title="Print frame"></iframe> <iframe aria-hidden="true" id="citationExportFrame" name="citationExportFrame" style="position: absolute; left: -2000px; top: 0;" title="scolaris.citation.export.frame"></iframe> <nav> <div class="mobile-navigation"> <div class="close-container"> <a aria-label="Navigate back" class="main-nav-back-btn" href="#"><i class="fa fa-chevron-left"></i></a> <a class="main-nav-close-btn" href="#" title="Close menu">Close menu <i class="fa fa-times"></i></a> </div> <div class="mobile-search basic-search-container"> <div class="portlet-boundary portlet-boundary_scolarissearchportlet_WAR_scolarissearch_ portlet-static portlet-static-end" id="p_p_id_scolarissearchportlet_WAR_scolarissearch_"> <span id="p_scolarissearchportlet_WAR_scolarissearch"></span> <section class="portlet" id="portlet_scolarissearchportlet_WAR_scolarissearch"> <header class="portlet-topper"> <h1 class="portlet-title"> <span class="" onmouseover="Liferay.Portal.ToolTip.show(this, 'Scolaris\x20Search\x20Portlet')"> <img alt="" id="ymag__null__null" src="/scolaris-search/icon.png"> <span class="taglib-text hide-accessible">Scolaris Search Portlet</span> </img></span> <span class="portlet-title-text">Scolaris Search Portlet</span> </h1> <menu class="portlet-topper-toolbar" id="portlet-topper-toolbar_scolarissearchportlet_WAR_scolarissearch" type="toolbar"> </menu> </header> <div class="portlet-content"> <div class="portlet-content-container"> <div class="portlet-body"> <div class="header-search"> <form action="https://www.cochranelibrary.com/en/content?p_auth=Xx9QLps0&amp;p_p_id=scolarissearchportlet_WAR_scolarissearch&amp;p_p_lifecycle=1&amp;p_p_state=normal&amp;p_p_mode=view&amp;_scolarissearchportlet_WAR_scolarissearch_scolarisAction=redirectSearchResult" method="post"> <input name="searchType" type="hidden" value="basic"> <input name="facetDisplayName" type="hidden" value=""> <input name="facetQueryTerm" type="hidden" value=""/> <input name="facetQueryField" type="hidden" value=""/> <input name="facetCategory" type="hidden" value=""/> <fieldset class="fieldset"> <legend class="sr-only">Basic Search</legend> <div class="select search-by"> <select aria-label="Search by options" class="custom-select-enabled search-type" name="searchBy" title="Search by options"> <option value="1">Title Abstract Keyword</option> <option value="2">Record Title</option> <option value="3">Abstract</option> <option value="4">Author</option> <option value="5">Keyword</option> <option value="6">All Text</option> <option value="7">Publication Type</option> <option value="8">Source</option> <option value="9">DOI</option> <option value="14">Language</option> <option value="10">Accession Number</option> <option value="11">Trial Registry Number</option> <option value="12">Cochrane Group</option> <option value="13">Cochrane Topic</option> </select> </div> <div class="search-select-crg-container select" style="display: none;"> <select class="search-select-crg-list"></select> </div> <div class="search-select-topic-container select" data-topic-list-url="https://www.cochranelibrary.com/en/content?p_p_id=scolaristopics_WAR_scolaristopics&amp;p_p_lifecycle=2&amp;p_p_state=normal&amp;p_p_mode=view&amp;p_p_resource_id=topics-list&amp;p_p_cacheability=cacheLevelPage" style="display: none;"> <select class="search-select-topic-list"></select> </div> <div class="search-select-cl-container select" style="display: none;"> <select class="search-select-cl-list"></select> </div> <div class="search-text-container"> <div class="control-group control-group-inline search-input-wrapper"> <input aria-label="Enter search term" class="field browser-search search-text ui-autocomplete-input" id="searchText" name="searchText" placeholder="Search" size="30" type="text" value=""/>
<div id="autocomplete-results"></div>
</div>
<div class="control-group control-group-inline search-button-wrapper">
<button aria-label="Search" class="searchByBtn" type="submit">
<i aria-hidden="true" class="fa fa-search"></i>
</button>
</div>
</div>
</fieldset>
</input></input></form>
</div>
<script>
    window.displayResultURL = 'https://www.cochranelibrary.com/en/content?p_p_id=scolarissearchportlet_WAR_scolarissearch&p_p_lifecycle=2&p_p_state=normal&p_p_mode=view&p_p_resource_id=getSuggestions&p_p_cacheability=cacheLevelPage&_scolarissearchportlet_WAR_scolarissearch_templateType=full&_scolarissearchportlet_WAR_scolarissearch_urlTitle=%2Fcdsr%2Fdoi%2F10.1002%2F14651858.CD006318.pub4&_scolarissearchportlet_WAR_scolarissearch_contentLanguage=&_scolarissearchportlet_WAR_scolarissearch_type=cdsr&_scolarissearchportlet_WAR_scolarissearch_doi=10.1002%2F14651858.CD006318.pub4';
    window.searchByOption = '';
</script>
</div>
</div>
</div>
<div style="display:none">
<input id="freelabel" name="freelabel" type="hidden" value="Free access"/>
<input id="openlabel" name="openlabel" type="hidden" value="Open access"/>
</div>
</section>
</div>
<a class="btn secondary" href="/en/browse-by-topic">Browse </a>
<a class="btn secondary advanced-search-button" href="/en/advanced-search">Advanced search</a>
</div>
<div class="menu-items parent">
<div>
<div class="nav-root-item parent">
<a class="language-selection-title-link" href="#" title="Select language">
<span class="mobile-nav-language-title">Select your preferred language </span></a> <span class="icon fa fa-caret-down"></span>
<div class="mob-child">
<div class="portlet-boundary portlet-boundary_scolarislanguageselector_WAR_scolarislanguageportlet_ portlet-static portlet-static-end" id="p_p_id_scolarislanguageselector_WAR_scolarislanguageportlet_INSTANCE_mobilenav_">
<span id="p_scolarislanguageselector_WAR_scolarislanguageportlet_INSTANCE_mobilenav"></span>
<section class="portlet" id="portlet_scolarislanguageselector_WAR_scolarislanguageportlet_INSTANCE_mobilenav">
<header class="portlet-topper">
<h1 class="portlet-title">
<span class="" onmouseover="Liferay.Portal.ToolTip.show(this, 'Scolaris\x20Language\x20Selector')">
<img alt="" id="fdkn__null__null" src="/scolaris-language-portlet/icon.png"> <span class="taglib-text hide-accessible">Scolaris Language Selector</span> </img></span> <span class="portlet-title-text">Scolaris Language Selector</span> </h1> <menu class="portlet-topper-toolbar" id="portlet-topper-toolbar_scolarislanguageselector_WAR_scolarislanguageportlet_INSTANCE_mobilenav" type="toolbar"> </menu> </header> <div class="portlet-content"> <div class="portlet-content-container"> <div class="portlet-body"> <div class="language-display" data-content-languages="[de, en, es, fa, fr, hi, hr, id, ja, ko, hu, ms, nl, pl, pt, ru, ro, ta, th, zh_HANT, zh_HANS]"> <a class="language-select-mobile" href="#" title="Select your preferred language"> <i class="fa fa-file-text"></i> English </a> <a class="language-select-mobile" href="#" title="Select your preferred language"> <i class="fa fa-globe"></i> English </a> </div> <div class="form-content language-selector-modal child"> <div class="row-fluid"> <h3><i class="fa fa-file-text"></i> Cochrane review language</h3> <p>Select your preferred language for Cochrane reviews and other content. Sections without translation will be in English.</p> <div class="dropdown-trigger" id="active-content-language"> <span>English</span> <i aria-hidden="true" class="fa fa-caret-down"></i> </div> <div class="language-selector-dropdown"> <a class="content-language-selector" data-languagecode="de" href="https://www.cochranelibrary.com/en/content?p_p_id=scolariscontentlanguagebanner_WAR_scolarislanguageportlet&amp;p_p_lifecycle=2&amp;p_p_state=normal&amp;p_p_mode=view&amp;p_p_resource_id=set-content-language&amp;p_p_cacheability=cacheLevelPage&amp;_scolariscontentlanguagebanner_WAR_scolarislanguageportlet_contentLanguage=de">Deutsch</a> <a class="content-language-selector is-active" data-languagecode="en" href="https://www.cochranelibrary.com/en/content?p_p_id=scolariscontentlanguagebanner_WAR_scolarislanguageportlet&amp;p_p_lifecycle=2&amp;p_p_state=normal&amp;p_p_mode=view&amp;p_p_resource_id=set-content-language&amp;p_p_cacheability=cacheLevelPage&amp;_scolariscontentlanguagebanner_WAR_scolarislanguageportlet_contentLanguage=en">English</a> <a class="content-language-selector" data-languagecode="es" href="https://www.cochranelibrary.com/en/content?p_p_id=scolariscontentlanguagebanner_WAR_scolarislanguageportlet&amp;p_p_lifecycle=2&amp;p_p_state=normal&amp;p_p_mode=view&amp;p_p_resource_id=set-content-language&amp;p_p_cacheability=cacheLevelPage&amp;_scolariscontentlanguagebanner_WAR_scolarislanguageportlet_contentLanguage=es">Español</a> <a class="content-language-selector" data-languagecode="fa" href="https://www.cochranelibrary.com/en/content?p_p_id=scolariscontentlanguagebanner_WAR_scolarislanguageportlet&amp;p_p_lifecycle=2&amp;p_p_state=normal&amp;p_p_mode=view&amp;p_p_resource_id=set-content-language&amp;p_p_cacheability=cacheLevelPage&amp;_scolariscontentlanguagebanner_WAR_scolarislanguageportlet_contentLanguage=fa">فارسی</a> <a class="content-language-selector" data-languagecode="fr" href="https://www.cochranelibrary.com/en/content?p_p_id=scolariscontentlanguagebanner_WAR_scolarislanguageportlet&amp;p_p_lifecycle=2&amp;p_p_state=normal&amp;p_p_mode=view&amp;p_p_resource_id=set-content-language&amp;p_p_cacheability=cacheLevelPage&amp;_scolariscontentlanguagebanner_WAR_scolarislanguageportlet_contentLanguage=fr">Français</a> <a class="content-language-selector" data-languagecode="hi" href="https://www.cochranelibrary.com/en/content?p_p_id=scolariscontentlanguagebanner_WAR_scolarislanguageportlet&amp;p_p_lifecycle=2&amp;p_p_state=normal&amp;p_p_mode=view&amp;p_p_resource_id=set-content-language&amp;p_p_cacheability=cacheLevelPage&amp;_scolariscontentlanguagebanner_WAR_scolarislanguageportlet_contentLanguage=hi">हिन्दी</a> <a class="content-language-selector" data-languagecode="hr" href="https://www.cochranelibrary.com/en/content?p_p_id=scolariscontentlanguagebanner_WAR_scolarislanguageportlet&amp;p_p_lifecycle=2&amp;p_p_state=normal&amp;p_p_mode=view&amp;p_p_resource_id=set-content-language&amp;p_p_cacheability=cacheLevelPage&amp;_scolariscontentlanguagebanner_WAR_scolarislanguageportlet_contentLanguage=hr">Hrvatski</a> <a class="content-language-selector" data-languagecode="id" href="https://www.cochranelibrary.com/en/content?p_p_id=scolariscontentlanguagebanner_WAR_scolarislanguageportlet&amp;p_p_lifecycle=2&amp;p_p_state=normal&amp;p_p_mode=view&amp;p_p_resource_id=set-content-language&amp;p_p_cacheability=cacheLevelPage&amp;_scolariscontentlanguagebanner_WAR_scolarislanguageportlet_contentLanguage=id">Bahasa Indonesia</a> <a class="content-language-selector" data-languagecode="ja" href="https://www.cochranelibrary.com/en/content?p_p_id=scolariscontentlanguagebanner_WAR_scolarislanguageportlet&amp;p_p_lifecycle=2&amp;p_p_state=normal&amp;p_p_mode=view&amp;p_p_resource_id=set-content-language&amp;p_p_cacheability=cacheLevelPage&amp;_scolariscontentlanguagebanner_WAR_scolarislanguageportlet_contentLanguage=ja">日本語</a> <a class="content-language-selector" data-languagecode="ko" href="https://www.cochranelibrary.com/en/content?p_p_id=scolariscontentlanguagebanner_WAR_scolarislanguageportlet&amp;p_p_lifecycle=2&amp;p_p_state=normal&amp;p_p_mode=view&amp;p_p_resource_id=set-content-language&amp;p_p_cacheability=cacheLevelPage&amp;_scolariscontentlanguagebanner_WAR_scolarislanguageportlet_contentLanguage=ko">한국어</a> <a class="content-language-selector" data-languagecode="hu" href="https://www.cochranelibrary.com/en/content?p_p_id=scolariscontentlanguagebanner_WAR_scolarislanguageportlet&amp;p_p_lifecycle=2&amp;p_p_state=normal&amp;p_p_mode=view&amp;p_p_resource_id=set-content-language&amp;p_p_cacheability=cacheLevelPage&amp;_scolariscontentlanguagebanner_WAR_scolarislanguageportlet_contentLanguage=hu">Magyar</a> <a class="content-language-selector" data-languagecode="ms" href="https://www.cochranelibrary.com/en/content?p_p_id=scolariscontentlanguagebanner_WAR_scolarislanguageportlet&amp;p_p_lifecycle=2&amp;p_p_state=normal&amp;p_p_mode=view&amp;p_p_resource_id=set-content-language&amp;p_p_cacheability=cacheLevelPage&amp;_scolariscontentlanguagebanner_WAR_scolarislanguageportlet_contentLanguage=ms">Bahasa Malaysia</a> <a class="content-language-selector" data-languagecode="nl" href="https://www.cochranelibrary.com/en/content?p_p_id=scolariscontentlanguagebanner_WAR_scolarislanguageportlet&amp;p_p_lifecycle=2&amp;p_p_state=normal&amp;p_p_mode=view&amp;p_p_resource_id=set-content-language&amp;p_p_cacheability=cacheLevelPage&amp;_scolariscontentlanguagebanner_WAR_scolarislanguageportlet_contentLanguage=nl">Nederlands</a> <a class="content-language-selector" data-languagecode="pl" href="https://www.cochranelibrary.com/en/content?p_p_id=scolariscontentlanguagebanner_WAR_scolarislanguageportlet&amp;p_p_lifecycle=2&amp;p_p_state=normal&amp;p_p_mode=view&amp;p_p_resource_id=set-content-language&amp;p_p_cacheability=cacheLevelPage&amp;_scolariscontentlanguagebanner_WAR_scolarislanguageportlet_contentLanguage=pl">Polski</a> <a class="content-language-selector" data-languagecode="pt" href="https://www.cochranelibrary.com/en/content?p_p_id=scolariscontentlanguagebanner_WAR_scolarislanguageportlet&amp;p_p_lifecycle=2&amp;p_p_state=normal&amp;p_p_mode=view&amp;p_p_resource_id=set-content-language&amp;p_p_cacheability=cacheLevelPage&amp;_scolariscontentlanguagebanner_WAR_scolarislanguageportlet_contentLanguage=pt">Português</a> <a class="content-language-selector" data-languagecode="ru" href="https://www.cochranelibrary.com/en/content?p_p_id=scolariscontentlanguagebanner_WAR_scolarislanguageportlet&amp;p_p_lifecycle=2&amp;p_p_state=normal&amp;p_p_mode=view&amp;p_p_resource_id=set-content-language&amp;p_p_cacheability=cacheLevelPage&amp;_scolariscontentlanguagebanner_WAR_scolarislanguageportlet_contentLanguage=ru">Русский</a> <a class="content-language-selector" data-languagecode="ro" href="https://www.cochranelibrary.com/en/content?p_p_id=scolariscontentlanguagebanner_WAR_scolarislanguageportlet&amp;p_p_lifecycle=2&amp;p_p_state=normal&amp;p_p_mode=view&amp;p_p_resource_id=set-content-language&amp;p_p_cacheability=cacheLevelPage&amp;_scolariscontentlanguagebanner_WAR_scolarislanguageportlet_contentLanguage=ro">Română</a> <a class="content-language-selector" data-languagecode="ta" href="https://www.cochranelibrary.com/en/content?p_p_id=scolariscontentlanguagebanner_WAR_scolarislanguageportlet&amp;p_p_lifecycle=2&amp;p_p_state=normal&amp;p_p_mode=view&amp;p_p_resource_id=set-content-language&amp;p_p_cacheability=cacheLevelPage&amp;_scolariscontentlanguagebanner_WAR_scolarislanguageportlet_contentLanguage=ta">தமிழ்</a> <a class="content-language-selector" data-languagecode="th" href="https://www.cochranelibrary.com/en/content?p_p_id=scolariscontentlanguagebanner_WAR_scolarislanguageportlet&amp;p_p_lifecycle=2&amp;p_p_state=normal&amp;p_p_mode=view&amp;p_p_resource_id=set-content-language&amp;p_p_cacheability=cacheLevelPage&amp;_scolariscontentlanguagebanner_WAR_scolarislanguageportlet_contentLanguage=th">ภาษาไทย</a> <a class="content-language-selector" data-languagecode="zh_HANT" href="https://www.cochranelibrary.com/en/content?p_p_id=scolariscontentlanguagebanner_WAR_scolarislanguageportlet&amp;p_p_lifecycle=2&amp;p_p_state=normal&amp;p_p_mode=view&amp;p_p_resource_id=set-content-language&amp;p_p_cacheability=cacheLevelPage&amp;_scolariscontentlanguagebanner_WAR_scolarislanguageportlet_contentLanguage=zh_HANT">繁體中文</a> <a class="content-language-selector" data-languagecode="zh_HANS" href="https://www.cochranelibrary.com/en/content?p_p_id=scolariscontentlanguagebanner_WAR_scolarislanguageportlet&amp;p_p_lifecycle=2&amp;p_p_state=normal&amp;p_p_mode=view&amp;p_p_resource_id=set-content-language&amp;p_p_cacheability=cacheLevelPage&amp;_scolariscontentlanguagebanner_WAR_scolarislanguageportlet_contentLanguage=zh_HANS">简体中文</a> </div> </div> <div class="row-fluid"> <h3 class="portal-language-header"><i class="fa fa-globe"></i> Website language</h3> <p>Select your preferred language for the Cochrane Library website.</p> <div class="dropdown-trigger" id="active-portal-language"> <span>English</span> <i aria-hidden="true" class="fa fa-caret-down"></i> </div> <div class="language-selector-dropdown"> <a class="portal-language-selector is-active" data-portallanguage="en" href="/en/cdsr/doi/10.1002/14651858.CD006318.pub4/full/en">English</a> <a class="portal-language-selector" data-portallanguage="es" href="/es/cdsr/doi/10.1002/14651858.CD006318.pub4/full/es">Español</a> </div> </div> <a class="btn secondary ok-btn pull-right" href="https://www.cochranelibrary.com/en/content?p_p_id=scolariscontentlanguagebanner_WAR_scolarislanguageportlet&amp;p_p_lifecycle=2&amp;p_p_state=normal&amp;p_p_mode=view&amp;p_p_resource_id=set-content-language&amp;p_p_cacheability=cacheLevelPage">Save</a> </div> </div> </div> </div> <div style="display:none"> <input id="freelabel" name="freelabel" type="hidden" value="Free access"/>
<input id="openlabel" name="openlabel" type="hidden" value="Open access"/>
</div>
</section>
</div>
</div>
</div>
<div class="parent">
<a class="mobile-link signin" data-redirect="false" href="https://www.cochranelibrary.com/c/portal/login?p_l_id=20757&amp;redirect=%2Fcdsr%2Fdoi%2F10.1002%2F14651858.CD006318.pub4%2Ffull" rel="nofollow">
                        Sign In
                    </a>
</div>
</div>
<div class="menu-items-footer">
<div class="utility-links">
<a class="cochrane-link" href="http://www.cochrane.org/" target="_blank">Visit Cochrane.org</a>
</div>
</div>
</div>
<div class="menu-items child"></div>
</div>
</nav><div class="basic-login-form-content" data-modal-title="Sign in" style="display: none;">
<div class="form-content">
<div class="row-fluid">
<div class="span12">
<div class="portlet-boundary portlet-boundary_58_ portlet-static portlet-static-end portlet-login" id="p_p_id_58_INSTANCE_MODAL_">
<span id="p_58_INSTANCE_MODAL"></span>
<section class="portlet" id="portlet_58_INSTANCE_MODAL">
<header class="portlet-topper">
<h1 class="portlet-title">
<span class="" onmouseover="Liferay.Portal.ToolTip.show(this, 'Sign\x20In')">
<img alt="" id="dbam__null__null" src="https://www.cochranelibrary.com/cochrane-theme/images/spacer.png" style="background-image: url('https://www.cochranelibrary.com/sprite/html/icons/_sprite.png'); background-position: 50% -592px; background-repeat: no-repeat; height: 16px; width: 16px;"> <span class="taglib-text hide-accessible">Sign In</span> </img></span> <span class="portlet-title-text">Sign In</span> </h1> <menu class="portlet-topper-toolbar" id="portlet-topper-toolbar_58_INSTANCE_MODAL" type="toolbar"> </menu> </header> <div class="portlet-content"> <div class="portlet-content-container"> <div class="portlet-body"> <form action="https://www.cochranelibrary.com/en/content?p_p_id=58_INSTANCE_MODAL&amp;p_p_lifecycle=1&amp;p_p_state=normal&amp;p_p_mode=view&amp;_58_INSTANCE_MODAL_struts_action=%2Flogin%2Flogin" autocomplete="on" class="form sign-in-form" id="_58_INSTANCE_MODAL_fm" method="post" name="_58_INSTANCE_MODAL_fm"> <fieldset class="input-container" disabled="disabled"> <legend class="sr-only">Cochrane Login</legend> <input name="_58_INSTANCE_MODAL_formDate" type="hidden" value="1740715435458"> <input class="field" id="_58_INSTANCE_MODAL_saveLastPath" name="_58_INSTANCE_MODAL_saveLastPath" type="hidden" value="false"> <input class="field" id="_58_INSTANCE_MODAL_redirect" name="_58_INSTANCE_MODAL_redirect" type="hidden" value="/cdsr/doi/10.1002/14651858.CD006318.pub4/full"> <input class="field" id="_58_INSTANCE_MODAL_doActionAfterLogin" name="_58_INSTANCE_MODAL_doActionAfterLogin" type="hidden" value="false"> <div class="control-group input-text-wrapper"> <label class="control-label" for="_58_INSTANCE_MODAL_login"> Email Address </label> <input class="field clearable" id="_58_INSTANCE_MODAL_login" name="_58_INSTANCE_MODAL_login" type="text" value=""> </input></div> <div class="control-group input-text-wrapper"> <label class="control-label" for="_58_INSTANCE_MODAL_password"> Password </label> <input class="field" id="_58_INSTANCE_MODAL_password" name="_58_INSTANCE_MODAL_password" type="password" value=""/> </div> <span id="_58_INSTANCE_MODAL_passwordCapsLockSpan" style="display: none;"> Caps Lock is on. </span> <div class="clearfix"> <div class="checkbox-list pull-left"> <div class="checkbox-list-item"> <div class="control-group form-inline input-checkbox-wrapper"> <label for="_58_INSTANCE_MODAL_rememberMeCheckbox"> <input id="_58_INSTANCE_MODAL_rememberMe" name="_58_INSTANCE_MODAL_rememberMe" type="hidden" value="true"/> <input checked="" class="field" id="_58_INSTANCE_MODAL_rememberMeCheckbox" name="_58_INSTANCE_MODAL_rememberMeCheckbox" onclick="Liferay.Util.updateCheckboxValue(this); " type="checkbox" value="true"/> Remember Me </label> </div> </div> </div> <div class="pull-right"> <a href="https://onlinelibrary.wiley.com/user/forgottenpassword" target="_blank">Forgotten password?</a> </div> </div> <div class="login-form-footer clearfix"> <div class="pull-left"> <button class="btn primary" type="submit">Sign in</button> <a class="btn secondary" href="https://onlinelibrary.wiley.com/user-registration" target="_blank">Register</a> </div> <div class="pull-right"> <a class="institutional-login-form-button" href="https://www.cochranelibrary.com/en/content?p_p_id=scolariscontentdisplay_WAR_scolariscontentdisplay&amp;p_p_lifecycle=0&amp;p_p_state=normal&amp;p_p_mode=view&amp;_scolariscontentdisplay_WAR_scolariscontentdisplay_action=institution-access">Institutional login</a> </div> </div> </input></input></input></input></fieldset> </form> </div> </div> </div> <div style="display:none"> <input id="freelabel" name="freelabel" type="hidden" value="Free access"/>
<input id="openlabel" name="openlabel" type="hidden" value="Open access"/>
</div>
</section>
</div>
</div>
</div>
</div></div>
<div class="institution-login-form-content" data-modal-title="Institutional login" style="display: none;">
<div class="form-content">
<div class="row-fluid access-content-wrapper">
<div class="span12">
<div class="section">
<div class="portlet-boundary portlet-boundary_scolariscontentdisplay_WAR_scolariscontentdisplay_ portlet-static portlet-static-end scolaris-content-display-portlet" id="p_p_id_scolariscontentdisplay_WAR_scolariscontentdisplay_INSTANCE_combinedloginform_">
<span id="p_scolariscontentdisplay_WAR_scolariscontentdisplay_INSTANCE_combinedloginform"></span>
<section class="portlet" id="portlet_scolariscontentdisplay_WAR_scolariscontentdisplay_INSTANCE_combinedloginform">
<header class="portlet-topper">
<h1 class="portlet-title">
<span class="" onmouseover="Liferay.Portal.ToolTip.show(this, 'Scolaris\x20Content\x20Display')">
<img alt="" id="obft__null__null" src="/scolaris-content-display/icon.png"> <span class="taglib-text hide-accessible">Scolaris Content Display</span> </img></span> <span class="portlet-title-text">Scolaris Content Display</span> </h1> <menu class="portlet-topper-toolbar" id="portlet-topper-toolbar_scolariscontentdisplay_WAR_scolariscontentdisplay_INSTANCE_combinedloginform" type="toolbar"> </menu> </header> <div class="portlet-content"> <div class="portlet-content-container"> <div class="portlet-body"> <div class="access-content-section"> <div class="section-content"> <p>Search for your institution's name below to login via Shibboleth</p> <form action="/shibboleth" id="institutionLoginForm" method="post"> <div class="fieldset"> <div class="form-group access-input-wrapper"> <div class="ui-widget ui-front"> <label class="sr-only" for="institutionName">Institution name</label> <input class="field" id="institutionName" name="institutionName" type="text" value=""/>
</div>
<button class="btn primary" name="button" type="submit">Go</button>
</div>
<div class="message error" id="institutionLookupErrorDiv" style="display:none">
                        '<span id="enteredInstitionNameSpan"></span>' is not set up for this type of access on Wiley Online Library. Please contact your institution's administrator to ask about access.
                    </div>
</div>
<input id="entityId" name="entityId" type="hidden" value=""/>
</form>
<h4>Previously accessed institutions</h4>
<ul class="plain" id="previousInstitutions">
<li>(none)</li>
</ul>
</div>
<div class="section-content">
<div class="open-athens-login">
                Login using <a href="/openathens">OpenAthens</a>
</div>
</div>
</div>
</div>
</div>
</div>
<div style="display:none">
<input id="freelabel" name="freelabel" type="hidden" value="Free access"/>
<input id="openlabel" name="openlabel" type="hidden" value="Open access"/>
</div>
</section>
</div>
<div class="portlet-boundary portlet-boundary_58_ portlet-static portlet-static-end portlet-login" id="p_p_id_58_INSTANCE_4_">
<span id="p_58_INSTANCE_4"></span>
<section class="portlet" id="portlet_58_INSTANCE_4">
<header class="portlet-topper">
<h1 class="portlet-title">
<span class="" onmouseover="Liferay.Portal.ToolTip.show(this, 'Sign\x20In')">
<img alt="" id="joiu__null__null" src="https://www.cochranelibrary.com/cochrane-theme/images/spacer.png" style="background-image: url('https://www.cochranelibrary.com/sprite/html/icons/_sprite.png'); background-position: 50% -592px; background-repeat: no-repeat; height: 16px; width: 16px;"> <span class="taglib-text hide-accessible">Sign In</span> </img></span> <span class="portlet-title-text">Sign In</span> </h1> <menu class="portlet-topper-toolbar" id="portlet-topper-toolbar_58_INSTANCE_4" type="toolbar"> </menu> </header> <div class="portlet-content"> <div class="portlet-content-container"> <div class="portlet-body"> <p>If you have a <strong>Wiley Online Library</strong> institutional username and password, enter them here.</p> <form action="https://www.cochranelibrary.com/en/content?p_p_id=58_INSTANCE_4&amp;p_p_lifecycle=1&amp;p_p_state=normal&amp;p_p_mode=view&amp;_58_INSTANCE_4_struts_action=%2Flogin%2Flogin" autocomplete="on" class="form sign-in-form" id="_58_INSTANCE_4_fm" method="post" name="_58_INSTANCE_4_fm"> <fieldset class="input-container" disabled="disabled"> <legend class="sr-only">Cochrane Login</legend> <input name="_58_INSTANCE_4_formDate" type="hidden" value="1740715435462"> <input class="field" id="_58_INSTANCE_4_saveLastPath" name="_58_INSTANCE_4_saveLastPath" type="hidden" value="false"> <input class="field" id="_58_INSTANCE_4_redirect" name="_58_INSTANCE_4_redirect" type="hidden" value="/cdsr/doi/10.1002/14651858.CD006318.pub4/full"> <input class="field" id="_58_INSTANCE_4_doActionAfterLogin" name="_58_INSTANCE_4_doActionAfterLogin" type="hidden" value="false"> <div class="control-group input-text-wrapper"> <label class="control-label" for="_58_INSTANCE_4_login"> Username </label> <input class="field clearable" id="_58_INSTANCE_4_login" name="_58_INSTANCE_4_login" type="text" value=""> </input></div> <div class="control-group input-text-wrapper"> <label class="control-label" for="_58_INSTANCE_4_password"> Password </label> <input class="field" id="_58_INSTANCE_4_password" name="_58_INSTANCE_4_password" type="password" value=""> </input></div> <input class="field" id="_58_INSTANCE_4_institutionalLogin" name="_58_INSTANCE_4_institutionalLogin" type="hidden" value="true"/> <span id="_58_INSTANCE_4_passwordCapsLockSpan" style="display: none;"> Caps Lock is on. </span> <div class="login-form-footer clearfix"> <div class="pull-left"> <button class="btn primary" type="submit">Sign in</button> </div> </div> </input></input></input></input></fieldset> </form> </div> </div> </div> <div style="display:none"> <input id="freelabel" name="freelabel" type="hidden" value="Free access"/>
<input id="openlabel" name="openlabel" type="hidden" value="Open access"/>
</div>
</section>
</div>
</div>
</div>
</div>
</div></div>
<div class="get-access-form-content" data-modal-title="Unlock gold-standard Cochrane evidence" style="display: none;">
<div class="portlet-boundary portlet-boundary_scolariscontentdisplay_WAR_scolariscontentdisplay_ portlet-static portlet-static-end scolaris-content-display-portlet" id="p_p_id_scolariscontentdisplay_WAR_scolariscontentdisplay_INSTANCE_getaccessform_">
<span id="p_scolariscontentdisplay_WAR_scolariscontentdisplay_INSTANCE_getaccessform"></span>
<section class="portlet" id="portlet_scolariscontentdisplay_WAR_scolariscontentdisplay_INSTANCE_getaccessform">
<header class="portlet-topper">
<h1 class="portlet-title">
<span class="" onmouseover="Liferay.Portal.ToolTip.show(this, 'Scolaris\x20Content\x20Display')">
<img alt="" id="wpdq__null__null" src="/scolaris-content-display/icon.png"> <span class="taglib-text hide-accessible">Scolaris Content Display</span> </img></span> <span class="portlet-title-text">Scolaris Content Display</span> </h1> <menu class="portlet-topper-toolbar" id="portlet-topper-toolbar_scolariscontentdisplay_WAR_scolariscontentdisplay_INSTANCE_getaccessform" type="toolbar"> </menu> </header> <div class="portlet-content"> <div class="portlet-content-container"> <div class="portlet-body"> <div class="readcube-checkout-container-outer"> <div class="row-fluid access-content-wrapper"> <div class="span6 access-left-content"> <div class="section"> <div class="section-content"> <p>Improve your health decisions with access to trusted, independent evidence from the Cochrane Library. Unlock this review for uninterrupted access.</p> <p>Still deciding? <a href="https://m.info.wiley.com/webApp/cochranenewsletter"> Sign up to our newsletter to learn more </a> </p> </div> </div> <div class="section"> <div class="access-content-section"> <h3 class="title">Institutional users</h3> <div class="section-content"> <p>Search for your institution's name below to login via Shibboleth</p> <form action="/shibboleth" id="institutionLoginForm" method="post"> <div class="fieldset"> <div class="form-group access-input-wrapper"> <div class="ui-widget ui-front"> <label class="sr-only" for="institutionName">Institution name</label> <input class="field" id="institutionName" name="institutionName" type="text" value=""/> </div> <button class="btn primary" name="button" type="submit">Go</button> </div> <div class="message error" id="institutionLookupErrorDiv" style="display:none"> '<span id="enteredInstitionNameSpan"></span>' is not set up for this type of access on Wiley Online Library. Please contact your institution's administrator to ask about access. </div> </div> <input id="entityId" name="entityId" type="hidden" value=""/> </form> <h4>Previously accessed institutions</h4> <ul class="plain" id="previousInstitutions"> <li>(none)</li> </ul> </div> <div class="section-content"> <div class="open-athens-login"> Login using <a href="/openathens">OpenAthens</a> </div> </div> </div> </div> <div class="section"> <div class="access-content-section"> <h3 class="title"> Other access options </h3> <div class="section-content"> <ul class="plain"> <li> <a class="get-access-individual-login-button" href="/c/portal/login"> Individual access - via Wiley Online Library </a> </li> </ul> </div> </div> </div> </div> <div class="span6 access-right-content readcube-checkout-container"> <div class="section"> </div> </div> </div> </div> </div> </div> </div> <div style="display:none"> <input id="freelabel" name="freelabel" type="hidden" value="Free access"/> <input id="openlabel" name="openlabel" type="hidden" value="Open access"/> </div> </section> </div> </div> <!-- Scolaris Version: --> <script type="text/javascript">if(window._satellite){_satellite.pageBottom()};</script> </div> <script>(function(){function c(){var b=a.contentDocument||a.contentWindow.document;if(b){var d=b.createElement('script');d.innerHTML="window.__CF$cv$params={r:'918d87089cf39374',t:'MTc0MDcxNTQzNS4wMDAwMDA='};var a=document.createElement('script');a.nonce='';a.src='/cdn-cgi/challenge-platform/scripts/jsd/main.js';document.getElementsByTagName('head')[0].appendChild(a);";b.getElementsByTagName('head')[0].appendChild(d)}}if(document.body){var a=document.createElement('iframe');a.height=1;a.width=1;a.style.position='absolute';a.style.top=0;a.style.left=0;a.style.border='none';a.style.visibility='hidden';document.body.appendChild(a);if('loading'!==document.readyState)c();else if(window.addEventListener)document.addEventListener('DOMContentLoaded',c);else{var e=document.onreadystatechange||function(){};document.onreadystatechange=function(b){e(b);'loading'!==document.readyState&&(document.onreadystatechange=e,c())}}}})();</script></body> </html> 